{
    "clinical": {
        "clinical_0": {
            "question": "Does the compound ADA improve cognitive function in a model of Alzheimer's disease?",
            "answer": "The answer is UNRELATED because none of the provided contextual information mentions or discusses the compound ADA in relation to cognitive function in Alzheimer's disease models.\n\nUNRELATED",
            "pmid": [
                "pmid21606627",
                "pmid35782939",
                "pmid27767993",
                "pmid28939187",
                "pmid38185066",
                "pmid34294612",
                "pmid30807987",
                "pmid11110737",
                "pmid18037281",
                "pmid25443284"
            ]
        },
        "clinical_1": {
            "question": "Did the patient experience symptoms resembling delirium after receiving low-dose cyclophosphamide chemotherapy?",
            "answer": "B. No",
            "pmid": [
                "pmid19079356",
                "pmid22949902",
                "pmid39958332",
                "pmid38409802",
                "pmid37133446",
                "pmid18585545",
                "pmid20204907",
                "pmid34123673",
                "pmid18577171",
                "pmid37566435"
            ]
        },
        "clinical_2": {
            "question": "Does pNaktide have potential therapeutic effects for Alzheimer's disease by mitigating neuroinflammation and oxidative stress?",
            "answer": "A. Yes",
            "pmid": [
                "pmid36689848",
                "pmid36820018",
                "pmid12453679",
                "pmid26696494",
                "pmid36533331",
                "pmid32739157",
                "pmid31945778",
                "pmid11487523",
                "pmid21683531",
                "pmid27352979"
            ]
        },
        "clinical_3": {
            "question": "Does the regulation of PSMC5 expression have potential therapeutic implications for Alzheimer's disease-associated cognitive deficits?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid25443284",
                "pmid36139423",
                "pmid27072684",
                "pmid36508924",
                "pmid24886239",
                "pmid38577889",
                "pmid12881482",
                "pmid21069780",
                "pmid33420799",
                "pmid35350668"
            ]
        },
        "clinical_4": {
            "question": "Does low-intensity pulsed ultrasound (LIPUS) reduce memory impairment in a model simulating Alzheimer's disease?",
            "answer": "A",
            "pmid": [
                "pmid30873554",
                "pmid29857968",
                "pmid31410223",
                "pmid37620888",
                "pmid18003341",
                "pmid39588954",
                "pmid37569786",
                "pmid33132889",
                "pmid34499614",
                "pmid17349923"
            ]
        },
        "clinical_5": {
            "question": "Does loading quercetin into nanoparticles improve its efficacy in preventing neuroinflammation associated with Alzheimer's disease?",
            "answer": "The new context discusses the benefits of quercetin and mentions challenges with bioavailability, suggesting that nanoformulations could help. It also cites a study using resveratrol and OPC nanoparticles for AD treatment. However, it doesn't specifically mention quercetin in nanoparticles. Therefore, based on the provided context, the answer isn't directly supported.\n\n**Answer: C. UNRELATED**",
            "pmid": [
                "pmid32464160",
                "pmid39824363",
                "pmid24802026",
                "pmid27591943",
                "pmid18602817",
                "pmid35594435",
                "pmid35031260",
                "pmid33405649",
                "pmid39858545",
                "pmid37206236"
            ]
        },
        "clinical_6": {
            "question": "Does apigenin treatment restore cognitive function in a model of MTX-induced neurotoxicity similar to Alzheimer's disease?",
            "answer": "The provided context discusses two studies involving compounds used to treat Alzheimer's disease (AD) models. The first study evaluates apigenin's effects on MTX-induced neurotoxicity, showing it restores cognitive function through behavioral tests. The second study is unrelated as it focuses on PNS and oxidative stress mitigation.\n\n**Answer: A. Yes**\n\nNew Answer: \n\nA. Yes",
            "pmid": [
                "pmid23966081",
                "pmid36943623",
                "pmid36817510",
                "pmid25443284",
                "pmid14648600",
                "pmid20555131",
                "pmid29120942",
                "pmid23783773",
                "pmid38575939",
                "pmid25445365"
            ]
        },
        "clinical_7": {
            "question": "Does antithrombotic therapy show significant cognitive benefits in people with small vessel disease without Alzheimer's?",
            "answer": "**Answer: B. No**\n\nBased on the contextual information provided, antithrombotic therapy does not show significant cognitive benefits in people with small vessel disease without Alzheimer's.",
            "pmid": [
                "pmid35833913",
                "pmid37897809",
                "pmid26727124",
                "pmid33613260",
                "pmid27567825",
                "pmid17664404",
                "pmid27767993",
                "pmid23224755",
                "pmid15582745",
                "pmid19805638"
            ]
        },
        "clinical_8": {
            "question": "Does the combination of osthole and notopterol exhibit a synergistic anti-Alzheimer's effect in the zebrafish model?",
            "answer": "The combination of osthole and notopterol does exhibit a synergistic anti-Alzheimer's effect in the zebrafish model.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid39053867",
                "pmid38827230",
                "pmid32173426",
                "pmid30392874",
                "pmid38228217",
                "pmid39039682",
                "pmid20888863",
                "pmid33687726",
                "pmid34207381",
                "pmid39281976"
            ]
        },
        "clinical_9": {
            "question": "Does Ashwagandha have neuroprotective effects in Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe provided context indicates that Ashwagandha exhibits neuroprotective effects in Alzheimer's disease by protecting against amyloid-beta toxicity and improving cognitive function in animal models.",
            "pmid": [
                "pmid32305638",
                "pmid25789768",
                "pmid20538052",
                "pmid29112116",
                "pmid38355004",
                "pmid18037281",
                "pmid29238386",
                "pmid35910833",
                "pmid21606627",
                "pmid35204177"
            ]
        },
        "clinical_10": {
            "question": "Does activation of alpha7nAChR by GTS-21 improve cognitive deficits in a model of Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe provided context indicates that activation of alpha7 nicotinic acetylcholine receptors (alpha7nAChR) with agonists such as galantamine and PNU282987 improves cognitive deficits in Alzheimer's disease models by reducing neurotoxicity, enhancing memory, and promoting protective mechanisms. Since GTS-21 is another alpha7nAChR agonist, it is reasonable to conclude that its activation would similarly benefit cognitive function in AD models.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid25443284",
                "pmid1647485",
                "pmid8242380",
                "pmid34297968",
                "pmid12960778",
                "pmid31823156",
                "pmid24136196",
                "pmid39116785",
                "pmid38577889",
                "pmid25637481"
            ]
        },
        "clinical_11": {
            "question": "Does alogliptin treatment alleviate cognitive impairment in a model of Alzheimer's disease?",
            "answer": "The provided context does not mention alogliptin. The only DPP-4 inhibitor discussed is sitagliptin in pmid30186862, but no information on alogliptin's effect on Alzheimer's cognitive impairment exists here.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid30186862",
                "pmid8997426",
                "pmid26638900",
                "pmid27767993",
                "pmid35815283",
                "pmid19805638",
                "pmid11110737",
                "pmid27567825",
                "pmid37897809",
                "pmid30354809"
            ]
        },
        "clinical_12": {
            "question": "Does Memantine improve cognitive performance in Alzheimer's disease by regulating NGF signaling?",
            "answer": "A: Yes",
            "pmid": [
                "pmid24846616",
                "pmid34120588",
                "pmid19642202",
                "pmid18615702",
                "pmid15192085",
                "pmid20042680",
                "pmid19948208",
                "pmid28167259",
                "pmid28917837",
                "pmid16354790"
            ]
        },
        "clinical_13": {
            "question": "Does Berula erecta improve cognitive functioning in a model of Parkinson's disease, which is related to Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe study demonstrates that Berula erecta improves cognitive functioning in a Parkinson's disease model. Given the potential overlap in cognitive symptoms between Parkinson's and Alzheimer's diseases, this suggests a possible benefit for models related to Alzheimer's as well.\n\nFinal Answer: 0",
            "pmid": [
                "pmid39546440",
                "pmid28279707",
                "pmid29080453",
                "pmid21116051",
                "pmid35204177",
                "pmid30844489",
                "pmid33432644",
                "pmid28643520",
                "pmid35599481",
                "pmid36777330"
            ]
        },
        "clinical_14": {
            "question": "Is pimavanserin approved for the treatment of psychosis in Alzheimer's disease?",
            "answer": "B. No",
            "pmid": [
                "pmid32695312",
                "pmid31920655",
                "pmid32618483",
                "pmid39623197",
                "pmid23293526",
                "pmid39648108",
                "pmid16315159",
                "pmid12671528",
                "pmid16505133",
                "pmid21492498"
            ]
        },
        "clinical_15": {
            "question": "Does the combination therapy with TSA and LEV improve outcomes in delirium post-TBI?",
            "answer": "The combination therapy with TSA and LEV does not improve outcomes in delirium post-TBI. \n\n**Answer:** B. No",
            "pmid": [
                "pmid37762352",
                "pmid24259659",
                "pmid37133446",
                "pmid28243098",
                "pmid39554848",
                "pmid31046593",
                "pmid20471115",
                "pmid31896448",
                "pmid26674479",
                "pmid25143737"
            ]
        },
        "clinical_17": {
            "question": "Does gossypitrin have potential therapeutic applications for Alzheimer's disease by mitigating iron-induced oxidative stress and mitochondrial damage?",
            "answer": "A",
            "pmid": [
                "pmid34199597",
                "pmid38924927",
                "pmid35204177",
                "pmid37673021",
                "pmid22666518",
                "pmid31232699",
                "pmid36068400",
                "pmid27588088",
                "pmid32784451",
                "pmid17886039"
            ]
        },
        "clinical_18": {
            "question": "Does dexmedetomidine reduce neuronal hyperactivity and overactive behaviors caused by esketamine, which could be relevant to delirium?",
            "answer": "**Answer: A. Yes**\n\nDexmedetomidine reduces neuronal hyperactivity and overactive behaviors caused by esketamine in mice, as shown by reduced c-Fos expression and decreased agitation-related behaviors. This effect is relevant to delirium, which often involves similar symptoms like confusion and agitation.\n\n---\n\n### Final Answer\n\n**A. Yes**\n\nDexmedetomidine can reduce neuronal hyperactivity and overactive behaviors caused by esketamine, which are relevant to delirium.",
            "pmid": [
                "pmid36077505",
                "pmid22683080",
                "pmid38911008",
                "pmid34807273",
                "pmid39541802",
                "pmid32018069",
                "pmid34712126",
                "pmid39210294",
                "pmid37993790",
                "pmid29958125"
            ]
        },
        "clinical_19": {
            "question": "Does NXP031 reduce Abeta accumulation and improve memory function in Alzheimer's disease models?",
            "answer": "A. Yes",
            "pmid": [
                "pmid39521153",
                "pmid25443284",
                "pmid17008108",
                "pmid12203047",
                "pmid20634578",
                "pmid24278306",
                "pmid17261088",
                "pmid21799251",
                "pmid17055782",
                "pmid39891801"
            ]
        },
        "clinical_20": {
            "question": "Does meloxicam improve memory loss in Alzheimer's disease by inhibiting neuronal apoptosis?",
            "answer": "**Answer: A. Yes**\n\nMeloxicam improves memory loss in Alzheimer's disease by inhibiting neuronal apoptosis through mechanisms such as deactivating TNFRSF25 and reducing inflammation, as supported by studies on its effects in relevant models.",
            "pmid": [
                "pmid36279100",
                "pmid20476569",
                "pmid20877425",
                "pmid36232612",
                "pmid39521153",
                "pmid25102327",
                "pmid39574131",
                "pmid29081887",
                "pmid30922179",
                "pmid24975829"
            ]
        },
        "clinical_21": {
            "question": "Does Cudraflavone B have potential therapeutic effects for Alzheimer's disease?",
            "answer": "**Answer:**\n\nBased on the context provided, Cudraflavone B has demonstrated neuroprotective effects in vitro by mitigating glutamate-induced damage through mechanisms involving Nrf2 and PI3K/Akt signaling pathways. This suggests it has potential therapeutic effects against oxidative stress-related neuronal damage, which is relevant to Alzheimer's disease.\n\n**A. Yes**",
            "pmid": [
                "pmid24328060",
                "pmid36071869",
                "pmid34569961",
                "pmid32168835",
                "pmid38441013",
                "pmid28854504",
                "pmid25061726",
                "pmid38106662",
                "pmid26529297",
                "pmid25229015"
            ]
        },
        "clinical_22": {
            "question": "Does carbenoxolone supplementation improve cognitive decline associated with Alzheimer's disease?",
            "answer": "The context provided does not mention carbenoxolone, so we cannot determine its effect on cognitive decline in Alzheimer's disease from the given information.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid26638900",
                "pmid27567825",
                "pmid31560162",
                "pmid31606373",
                "pmid37508010",
                "pmid23224755",
                "pmid21606627",
                "pmid37701892",
                "pmid21035308",
                "pmid8997426"
            ]
        },
        "clinical_23": {
            "question": "Do antipsychotics like haloperidol and risperidone, which are used to treat delirium in cancer patients, enhance the effectiveness of doxorubicin in resistant uterine sarcoma cells?",
            "answer": "Based on the provided context, there is no direct evidence regarding the use of haloperidol or risperidone in enhancing doxorubicin's effectiveness in resistant uterine sarcoma cells. The studies mentioned focus on other aspects and drugs.\n\nAnswer: B. No",
            "pmid": [
                "pmid26122223",
                "pmid32162816",
                "pmid34944601",
                "pmid17381385",
                "pmid38409802",
                "pmid23859663",
                "pmid33322363",
                "pmid36671340",
                "pmid35053377",
                "pmid31191825"
            ]
        },
        "clinical_24": {
            "question": "Does dexmedetomidine reduce the risk of delirium by inhibiting proinflammatory factors through the beta2 adrenergic receptor pathway?",
            "answer": "I'm sorry, an unexpected error occurred while processing your question. Please try again later.",
            "pmid": null
        },
        "clinical_25": {
            "question": "Does remimazolam reduce the incidence of delirium in clinical reports?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid38911008",
                "pmid23859663",
                "pmid17381385",
                "pmid38409802",
                "pmid37133446",
                "pmid24815757",
                "pmid22949902",
                "pmid38135802",
                "pmid26674479",
                "pmid32329703"
            ]
        },
        "clinical_26": {
            "question": "Does the CDK4/6 inhibitor abemaciclib mesylate improve cognitive function in Alzheimer's disease models?",
            "answer": "The study by PMID36907286 demonstrates that abemaciclib mesylate improves cognitive function in Alzheimer's disease models.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid36907286",
                "pmid36586644",
                "pmid34856907",
                "pmid20555131",
                "pmid36508924",
                "pmid22033930",
                "pmid23783773",
                "pmid31076196",
                "pmid17008108",
                "pmid8997426"
            ]
        },
        "clinical_27": {
            "question": "Does kinetin show protective effects against cognitive impairment in an Alzheimer's disease model induced by aluminum chloride and D-galactose?",
            "answer": "Based on the context provided, the study with pmid28867383 indicates that kinetin does have protective effects against cognitive impairment in an Alzheimer's disease model induced by aluminum chloride and D-galactose.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid28867383",
                "pmid28930532",
                "pmid23219964",
                "pmid33582452",
                "pmid38827230",
                "pmid38448794",
                "pmid18625454",
                "pmid34354404",
                "pmid31945778",
                "pmid37823115"
            ]
        },
        "clinical_28": {
            "question": "Does Torin2 have potential therapeutic implications for Alzheimer's disease based on its anti-inflammatory effects in macrophages?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid35874059",
                "pmid35153729",
                "pmid18509040",
                "pmid37598923",
                "pmid37274074",
                "pmid38886959",
                "pmid12453679",
                "pmid21704645",
                "pmid39117070",
                "pmid27926996"
            ]
        },
        "clinical_29": {
            "question": "In a mouse model of sepsis, BML-111 treatment has been shown to reduce cognitive impairment and neuroinflammation through activation of SIRT1 and inhibition of the NF-κB signaling pathway. Considering the pathophysiology of delirium associated with sepsis, which of the following statements is most accurate?",
            "answer": "The answer is:\n\nD. SIRT1 activation reduces glial activation and inflammation via NF-κB suppression, which may protect against sepsis-induced delirium.\n\n**Explanation:**\n\nIn the study, BML-111 activates SIRT1, which inhibits the NF-κB pathway, leading to reduced neuroinflammation and cognitive impairment in mice with sepsis. This mechanism supports option D as it correctly describes how SIRT1 activation suppresses NF-κB to protect against delirium.\n\nNew Answer: The most accurate statement is:\n\nD. SIRT1 activation reduces glial activation and inflammation via NF-κB suppression, which may protect against sepsis-induced delirium.\n\n**Step-by-Step Explanation:**\n\n1. **Understanding BML-111's Mechanism**: From the context, BML-111 activates SIRT1 and inhibits NF-κB signaling, reducing neuroinflammation in a mouse model of sepsis.\n\n2. **Analyzing Options**:\n   - **A**: Incorrect because BML-111 inhibits, not enhances, NF-κB.\n   - **B**: Incorrect as inhibiting SIRT1 (with EX527) negates the benefits of BML-111.\n   - **C**: Incorrect since delirium is linked to inflammation and glial activation.\n   - **D**: Correct as it accurately reflects how SIRT1 activation suppresses NF-κB, reducing inflammation and protecting against delirium.\n\n3. **Conclusion**: Option D aligns with the study's findings about BML-111's effects on SIRT1 and NF-κB pathways in mitigating delirium-associated neuroinflammation.",
            "pmid": [
                "pmid30186119",
                "pmid20471138",
                "pmid20309566",
                "pmid25567339",
                "pmid28236057",
                "pmid29875474",
                "pmid22553034",
                "pmid24557038",
                "pmid37313848",
                "pmid24048854"
            ]
        },
        "clinical_30": {
            "question": "Does overexpression of CX3CL1 improve cognitive function in Alzheimer's disease?",
            "answer": "The analysis of relevant studies consistently shows that overexpression of CX3CL1 enhances neurogenesis, reduces amyloid-beta levels, and mitigates cognitive deficits in Alzheimer's disease models. \n\nAnswer: A. Yes",
            "pmid": [
                "pmid31822518",
                "pmid31849963",
                "pmid31209068",
                "pmid21771791",
                "pmid30031059",
                "pmid24278306",
                "pmid26401931",
                "pmid32662924",
                "pmid20555131",
                "pmid25443284"
            ]
        },
        "clinical_31": {
            "question": "Does the anti-inflammatory effect of Erinacine C, as described, suggest potential benefits for Alzheimer's disease, given its role in neuroinflammation?",
            "answer": "A: A. Yes",
            "pmid": [
                "pmid12453679",
                "pmid31547327",
                "pmid23585364",
                "pmid20555131",
                "pmid21932048",
                "pmid27539598",
                "pmid29501766",
                "pmid36820018",
                "pmid37209001",
                "pmid12930788"
            ]
        },
        "clinical_32": {
            "question": "Does the NOX1/4 inhibitor GKT136901 have potential applications in the treatment of Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid23848532",
                "pmid11487523",
                "pmid31463415",
                "pmid33540879",
                "pmid8997426",
                "pmid10637367",
                "pmid24228074",
                "pmid17939763",
                "pmid18577377",
                "pmid18509646"
            ]
        },
        "clinical_33": {
            "question": "Does the modulation of 5'-nucleotidases (5'NTs) have therapeutic implications for Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid23992313",
                "pmid20401186",
                "pmid18625454",
                "pmid12203047",
                "pmid25443284",
                "pmid32614980",
                "pmid8740986",
                "pmid16246051",
                "pmid32257549",
                "pmid34294612"
            ]
        },
        "clinical_34": {
            "question": "Does the combination of Ocimum sanctum extract and Levetiracetam improve memory impairment in Alzheimer's disease?",
            "answer": "The study referenced by pmid34973350 specifically examines the combination of Ocimum sanctum extract and Levetiracetam in a rat model of Alzheimer's disease. It demonstrates that both individually and together, these treatments ameliorate cognitive dysfunction and improve hippocampal architecture. Therefore, based on this evidence, the combination does improve memory impairment.\n\nAnswer: B. Yes",
            "pmid": [
                "pmid34973350",
                "pmid35900690",
                "pmid32365983",
                "pmid32395598",
                "pmid28643520",
                "pmid35922734",
                "pmid27563424",
                "pmid36777330",
                "pmid35599481",
                "pmid20624417"
            ]
        },
        "clinical_35": {
            "question": "Does activating AhR improve cognitive deficits in an Alzheimer's disease model?",
            "answer": "The study found that activating AhR in Alzheimer's disease models improved cognitive deficits by enhancing Neprilysin (NEP) expression, which breaks down amyloid-beta. The results from object recognition tests and Morris water maze confirmed the cognitive benefits.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid34522212",
                "pmid19805638",
                "pmid25443284",
                "pmid30354809",
                "pmid35782939",
                "pmid8687030",
                "pmid39325017",
                "pmid34294612",
                "pmid34655202",
                "pmid27567825"
            ]
        },
        "clinical_36": {
            "question": "Does T-817MA show potential as a therapeutic agent for Alzheimer's disease?",
            "answer": "The study on T-817MA demonstrates its effectiveness in mitigating motor and cognitive impairments in mice with tau pathology, indicating potential therapeutic benefits for AD. \n\nA: Yes",
            "pmid": [
                "pmid21439944",
                "pmid25443284",
                "pmid39552492",
                "pmid28157092",
                "pmid30344671",
                "pmid31697472",
                "pmid10637367",
                "pmid9205832",
                "pmid17939763",
                "pmid38577889"
            ]
        },
        "clinical_37": {
            "question": "Does narciclasine from Lycoris radiata have a potential therapeutic role in Alzheimer's disease?",
            "answer": "B. No",
            "pmid": [
                "pmid30738987",
                "pmid31945778",
                "pmid38355004",
                "pmid37542650",
                "pmid26023568",
                "pmid33807157",
                "pmid36982332",
                "pmid29389553",
                "pmid39603393",
                "pmid37762479"
            ]
        },
        "clinical_38": {
            "question": "Is Derrubone a potential therapeutic agent for Alzheimer's disease based on its binding to Hsp90alpha CTD?",
            "answer": "The provided research papers do not mention Derrubone or its interaction with Hsp90alpha CTD in the context of Alzheimer's disease. Therefore, based on the given information, there is no evidence supporting Derrubone as a potential therapeutic agent for AD.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid30344671",
                "pmid12203047",
                "pmid26696494",
                "pmid35350668",
                "pmid34064687",
                "pmid32765947",
                "pmid22102154",
                "pmid12212794",
                "pmid31403949",
                "pmid23559013"
            ]
        },
        "clinical_39": {
            "question": "Does beetroot supplementation improve cognitive function in a model simulating Alzheimer's disease?",
            "answer": "The most appropriate answer is A. Yes. The first study directly supports that beetroot supplementation improves cognitive function in a model simulating Alzheimer's disease.\n\n**Answer: A. Yes**\n\nNew Answer:\n\nA: Yes",
            "pmid": [
                "pmid33054666",
                "pmid22995388",
                "pmid24442916",
                "pmid26638900",
                "pmid23566055",
                "pmid39305407",
                "pmid32488469",
                "pmid26023568",
                "pmid21982274",
                "pmid26068423"
            ]
        },
        "clinical_40": {
            "question": "Does SAP removal by CPHPC treatment address Alzheimer's disease?",
            "answer": "The answer is A: Yes. \n\nStep-by-step explanation:\n1. **Identify Relevant Studies**: The studies pmid26842068 and pmid12015594 discuss the role of SAP in amyloidosis and its removal using CPHPC, which is relevant to Alzheimer's disease.\n2. **Analyze Findings**: Both studies indicate that removing SAP can help clear amyloid deposits, a key feature of AD.\n3. **Conclusion**: Based on these findings, SAP removal by CPHPC does address AD.\n\n**Answer:** A: Yes\n\nNew Answer:",
            "pmid": [
                "pmid26842068",
                "pmid19372378",
                "pmid7753801",
                "pmid25066791",
                "pmid27567825",
                "pmid37047347",
                "pmid26758278",
                "pmid24333930",
                "pmid28669331",
                "pmid12015594"
            ]
        },
        "clinical_41": {
            "question": "Does the use of subcutaneous oxycodone in opioid rotation for cancer patients improve delirium?",
            "answer": "The studies indicate that substituting morphine with subcutaneous oxycodone during opioid rotation can lead to a reduction in delirium. Specifically, the first study shows significant improvements in mental state and delirium when switching from morphine to oxycodone.\n\n**Answer: A. Yes**\n\nA. Yes",
            "pmid": [
                "pmid8803381",
                "pmid10423053",
                "pmid16043013",
                "pmid29670416",
                "pmid38409802",
                "pmid32162816",
                "pmid33835902",
                "pmid21861200",
                "pmid29659913",
                "pmid18628169"
            ]
        },
        "clinical_42": {
            "question": "Does cotinine (COT) and 6-hydroxy-L-nicotine (6HLN) improve memory and reduce anxiety in the scopolamine-induced zebrafish model of Alzheimer's disease?",
            "answer": "The available evidence suggests that cotinine (COT) and 6-hydroxy-L-nicotine (6HLN) do improve memory and reduce anxiety in the scopolamine-induced zebrafish model of Alzheimer's disease.\n\n**Answer: A. Yes**\n\nNew Answer:",
            "pmid": [
                "pmid33535660",
                "pmid32824768",
                "pmid23842742",
                "pmid16354790",
                "pmid20888863",
                "pmid16762377",
                "pmid1491741",
                "pmid12649296",
                "pmid11278378",
                "pmid9065319"
            ]
        },
        "clinical_43": {
            "question": "Does the sulfated polysaccharide from pearl oyster nacre improve memory impairment, which could be relevant to Alzheimer's disease?",
            "answer": "The study on pmid33804892 demonstrates that a sulfated polysaccharide from pearl oyster nacre improves memory impairment through mechanisms relevant to Alzheimer's disease. Other studies support the use of various polysaccharides for neuroprotection, reinforcing the conclusion.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid33804892",
                "pmid37781122",
                "pmid24326116",
                "pmid28406733",
                "pmid26638900",
                "pmid33913927",
                "pmid39744139",
                "pmid36402384",
                "pmid30844489",
                "pmid39807036"
            ]
        },
        "clinical_44": {
            "question": "Does ononin treatment improve cognitive impairment in Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid34354404",
                "pmid8997426",
                "pmid26638900",
                "pmid33787038",
                "pmid27767993",
                "pmid11110737",
                "pmid24326116",
                "pmid25108596",
                "pmid17008108",
                "pmid35910833"
            ]
        },
        "clinical_45": {
            "question": "Does muscone improve memory impairment in Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid32538849",
                "pmid24326116",
                "pmid26638900",
                "pmid27567825",
                "pmid11110737",
                "pmid33787038",
                "pmid27767993",
                "pmid32488469",
                "pmid35782939",
                "pmid38468315"
            ]
        },
        "clinical_46": {
            "question": "Does guanabenz treatment protect against Alzheimer's disease-related behavioral and pathological indicators?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid35195784",
                "pmid11110737",
                "pmid18845693",
                "pmid26577751",
                "pmid26638900",
                "pmid36557245",
                "pmid29112116",
                "pmid35815283",
                "pmid33787038",
                "pmid33540879"
            ]
        },
        "clinical_47": {
            "question": "Does chronic exposure to galantamine decrease cellular responses to nicotinic receptor activation in neuroblastoma cells, which is relevant to Alzheimer's disease treatment?",
            "answer": "**Answer: B. No**\n\nThe studies indicate that galantamine enhances or supports nicotinic acetylcholine receptor activity rather than decreasing cellular responses to their activation under chronic exposure conditions relevant to Alzheimer's disease treatment.",
            "pmid": [
                "pmid12649296",
                "pmid28554861",
                "pmid15728839",
                "pmid16354790",
                "pmid16762377",
                "pmid14769831",
                "pmid31823156",
                "pmid20655346",
                "pmid29292543",
                "pmid11110737"
            ]
        },
        "clinical_48": {
            "question": "Can levofloxacin therapy lead to delirium with psychotic features?",
            "answer": "A: A",
            "pmid": [
                "pmid23914753",
                "pmid23909707",
                "pmid18585545",
                "pmid31178301",
                "pmid22390219",
                "pmid20204907",
                "pmid19079356",
                "pmid37133446",
                "pmid23859663",
                "pmid17381385"
            ]
        },
        "clinical_49": {
            "question": "Does Houttuynia cordata improve cognitive deficits in Alzheimer's disease-like models?",
            "answer": "The studies directly examining Houttuynia cordata (HCW) consistently show that it improves cognitive deficits in Alzheimer's disease-like models by protecting against neurotoxicity and reducing amyloid-beta deposits.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid25009697",
                "pmid36814130",
                "pmid29080453",
                "pmid28643520",
                "pmid28279707",
                "pmid32140977",
                "pmid22262263",
                "pmid31661844",
                "pmid35782939",
                "pmid33432644"
            ]
        },
        "clinical_50": {
            "question": "Does Linderae Radix improve cognitive dysfunction in Alzheimer's disease models by inhibiting neuroinflammation and synaptic damage?",
            "answer": "The research indicates that Linderae Radix (LR) effectively improves cognitive dysfunction in Alzheimer's disease models through its anti-inflammatory properties and protection of synaptic structures. The study shows LR reduces pro-inflammatory mediators, decreases microglial activation, and preserves synaptic proteins in the hippocampus, leading to improved cognitive outcomes.\n\nAnswer: A",
            "pmid": [
                "pmid37542650",
                "pmid38081625",
                "pmid32089787",
                "pmid36232612",
                "pmid35586062",
                "pmid29080453",
                "pmid28643520",
                "pmid38954263",
                "pmid35672874",
                "pmid36820018"
            ]
        },
        "clinical_51": {
            "question": "Is NK-4 currently approved for the treatment of Alzheimer's disease or delirium in Japan?",
            "answer": "The contextual information provided does not indicate that NK-4 is currently approved for the treatment of Alzheimer's disease or delirium in Japan.\n\n**Answer: B. No**",
            "pmid": [
                "pmid22238689",
                "pmid36901839",
                "pmid24228074",
                "pmid18845693",
                "pmid28798805",
                "pmid34331670",
                "pmid16762377",
                "pmid12203047",
                "pmid32012948",
                "pmid21683531"
            ]
        },
        "clinical_52": {
            "question": "Does prone positioning reduce the risk of delirium in patients undergoing mechanical ventilation?",
            "answer": "The most relevant study indicates that prone positioning reduces neuronal injury and inflammation markers linked to delirium. Therefore:\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid36405620",
                "pmid24852225",
                "pmid27736515",
                "pmid24259659",
                "pmid36078999",
                "pmid37133446",
                "pmid18514826",
                "pmid28335673",
                "pmid17949984",
                "pmid29430447"
            ]
        },
        "clinical_53": {
            "question": "Does N-stearoylethanolamine have a therapeutic potential for the prevention of cognitive dysfunction caused by neuroinflammation or autoimmune reaction, as it relates to Alzheimer's disease?",
            "answer": "The primary evidence supporting the therapeutic potential of N-stearoylethanolamine (NSE) comes from pmid28963942, where it improved memory and reduced neuroinflammation in mice. Additional studies on anti-inflammatory therapies and cognitive models reinforce this potential.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid28963942",
                "pmid12453679",
                "pmid1776749",
                "pmid8997426",
                "pmid12203047",
                "pmid38577889",
                "pmid32056532",
                "pmid29491219",
                "pmid9205832",
                "pmid38612861"
            ]
        },
        "clinical_54": {
            "question": "Does alpha-chymotrypsin improve neuroinflammation in Alzheimer's disease?",
            "answer": "The contextual information indicates that alpha-chymotrypsin improves neuroinflammation in Alzheimer's disease. Specifically, a study (pmid22464639) showed that treatment with alpha-chymotrypsin reduced pro-inflammatory markers and improved histopathological outcomes in an AD model.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid22464639",
                "pmid12453679",
                "pmid12203047",
                "pmid19800391",
                "pmid2067717",
                "pmid23585364",
                "pmid20555131",
                "pmid14975597",
                "pmid8242380",
                "pmid36820018"
            ]
        },
        "clinical_55": {
            "question": "Does Akebia saponin D (ASD) improve cognitive impairment in Alzheimer's disease by reducing corticosterone levels?",
            "answer": "A: A",
            "pmid": [
                "pmid30092401",
                "pmid36820018",
                "pmid37598923",
                "pmid24810883",
                "pmid28250796",
                "pmid26696494",
                "pmid27567825",
                "pmid27435287",
                "pmid25408503",
                "pmid21471376"
            ]
        },
        "clinical_56": {
            "question": "Does the use of DMARDs reduce the likelihood of Alzheimer's disease and/or dementia in patients with autoimmune disorders?",
            "answer": "A: A",
            "pmid": [
                "pmid38288824",
                "pmid30044040",
                "pmid27096216",
                "pmid39773090",
                "pmid12203047",
                "pmid21932048",
                "pmid39584306",
                "pmid8996832",
                "pmid27647283",
                "pmid34975464"
            ]
        },
        "clinical_57": {
            "question": "Does galantamine treatment improve cognitive function in patients with Alzheimer's disease or mixed dementia?",
            "answer": "The contextual information consistently shows that galantamine treatment leads to significant improvements in cognitive function for patients with Alzheimer's disease or mixed dementia, at least in the short term.\n\n**Answer: A. Yes**\n\nNew Answer:  \nGalantamine improves cognitive function in these patient populations based on studies showing sustained benefits and significant improvements in cognitive assessments over time.\n\nThe answer is:\nA. Yes\n\nANSWER: A",
            "pmid": [
                "pmid12962529",
                "pmid11110737",
                "pmid17664404",
                "pmid18845693",
                "pmid23862185",
                "pmid14560062",
                "pmid24461047",
                "pmid15598477",
                "pmid12860497",
                "pmid28554861"
            ]
        },
        "clinical_58": {
            "question": "Can primidone, which inhibits RIPK1 kinase, potentially be repurposed for the treatment of delirium?",
            "answer": "A: B",
            "pmid": [
                "pmid39541802",
                "pmid38911008",
                "pmid37993790",
                "pmid23859663",
                "pmid38086800",
                "pmid39210294",
                "pmid39415561",
                "pmid24815757",
                "pmid34978",
                "pmid26674479"
            ]
        },
        "clinical_59": {
            "question": "Does 5,19-cyclo-9beta,10xi-androstane-3,17-dione (CAD) have potential therapeutic effects for Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid38203753",
                "pmid17980863",
                "pmid35815283",
                "pmid38612861",
                "pmid38355004",
                "pmid28157092",
                "pmid30354809",
                "pmid8997426",
                "pmid33540879",
                "pmid21606627"
            ]
        },
        "clinical_60": {
            "question": "Does Souvenaid improve cognitive function in individuals with Alzheimer's disease?",
            "answer": "**Answer: B. No**\n\nThe studies analyzed indicate that Souvenaid does not show significant improvement in overall cognitive function for individuals with Alzheimer's disease. While there are hints of potential benefits in specific cognitive domains, such as memory in early stages, these do not lead to a clear conclusion that Souvenaid improves cognitive function broadly.",
            "pmid": [
                "pmid33787038",
                "pmid26638900",
                "pmid33320335",
                "pmid27767993",
                "pmid24326116",
                "pmid33613260",
                "pmid11110737",
                "pmid23742728",
                "pmid26727124",
                "pmid36586644"
            ]
        },
        "clinical_61": {
            "question": "Does temsirolimus have potential therapeutic benefits for Alzheimer's disease?",
            "answer": "Based on the provided context, there is no information about temsirolimus. Therefore, it cannot be concluded that temsirolimus has potential therapeutic benefits for Alzheimer's disease.\n\n**Answer:** B. No",
            "pmid": [
                "pmid24602800",
                "pmid24880087",
                "pmid26638900",
                "pmid24326116",
                "pmid27767993",
                "pmid36820018",
                "pmid11110737",
                "pmid9205832",
                "pmid26068423",
                "pmid34973350"
            ]
        },
        "clinical_62": {
            "question": "Does intermittent theta burst stimulation (iTBS) improve cognitive deficits in an Alzheimer's-like disease model caused by trimethyltin (TMT)?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid35656538",
                "pmid35780960",
                "pmid37586425",
                "pmid37273654",
                "pmid30949496",
                "pmid36263579",
                "pmid37755583",
                "pmid21116051",
                "pmid8128843",
                "pmid29947531"
            ]
        },
        "clinical_63": {
            "question": "Does (R)-ketamine have a potential role as a prophylactic drug for delirium?",
            "answer": "The evidence from pmid34313805 demonstrates that (R)-ketamine can reduce neuroinflammation and cognitive impairment in an LPS-induced delirium model, suggesting its potential as a prophylactic. While another study indicates ketamine may induce delirium-like symptoms, it doesn't specify the enantiomer used. Thus, considering the specific findings about (R)-ketamine, the answer is:\n\nA: Yes",
            "pmid": [
                "pmid38911008",
                "pmid34313805",
                "pmid24815757",
                "pmid35880774",
                "pmid39541802",
                "pmid37993790",
                "pmid37133446",
                "pmid22949902",
                "pmid18577171",
                "pmid19343193"
            ]
        },
        "clinical_64": {
            "question": "Does N2L, a novel lipoic acid-niacin dimer, show potential as a therapeutic agent for Alzheimer's disease by attenuating ferroptosis and lipid peroxidation in HT22 cells?",
            "answer": "A: Yes",
            "pmid": [
                "pmid34171402",
                "pmid31478183",
                "pmid36770835",
                "pmid12203047",
                "pmid34316383",
                "pmid36012451",
                "pmid38729530",
                "pmid37409350",
                "pmid17886039",
                "pmid21276834"
            ]
        },
        "clinical_65": {
            "question": "Does the inhibition of JNK activation improve cognitive deficits in Alzheimer's disease models?",
            "answer": "A: A. Yes",
            "pmid": [
                "pmid22033930",
                "pmid20451607",
                "pmid25611954",
                "pmid24457963",
                "pmid33420799",
                "pmid25443284",
                "pmid20555131",
                "pmid34042039",
                "pmid30026693",
                "pmid28939187"
            ]
        },
        "clinical_66": {
            "question": "Does the use of memantine as an initial antidementia medication increase in individuals with Alzheimer's disease who also have asthma or COPD?",
            "answer": "**Answer:**\n\nA: Yes  \n\nThe use of memantine as an initial antidementia medication increases in individuals with Alzheimer's disease who also have asthma or COPD. This is supported by the study (pmid31929157) which found a higher odds ratio for choosing memantine over AChEIs in this group, likely due to concerns about anticholinergic effects of AChEIs in patients with respiratory conditions.",
            "pmid": [
                "pmid31929157",
                "pmid27786552",
                "pmid24227863",
                "pmid19948208",
                "pmid28917837",
                "pmid15192085",
                "pmid28167259",
                "pmid27911327",
                "pmid19642202",
                "pmid18615702"
            ]
        },
        "clinical_67": {
            "question": "Does cinnarizine improve haloperidol-induced memory impairment, which could be relevant to Alzheimer's disease?",
            "answer": "The study pmid27540345 directly demonstrates that cinnarizine improves haloperidol-induced memory impairment by mitigating oxidative stress, suggesting it could be relevant to conditions like Alzheimer's disease where memory deficits are prominent. Other studies support the neuroprotective effects of related compounds, further indicating potential relevance.\n\nAnswer: A",
            "pmid": [
                "pmid27540345",
                "pmid38203753",
                "pmid37701892",
                "pmid20624417",
                "pmid31910792",
                "pmid8997426",
                "pmid38468315",
                "pmid12203047",
                "pmid12567159",
                "pmid10856449"
            ]
        },
        "clinical_68": {
            "question": "Is propofol recommended for patients with refractory delirium tremens?",
            "answer": "A. Yes",
            "pmid": [
                "pmid9398785",
                "pmid24814732",
                "pmid26893017",
                "pmid39415533",
                "pmid38482541",
                "pmid24259659",
                "pmid34978",
                "pmid18577171",
                "pmid17381385",
                "pmid23859663"
            ]
        },
        "clinical_69": {
            "question": "Does melatonin treatment improve the chemotaxis index in C. elegans exposed to isoflurane, which could be relevant to delirium?",
            "answer": "A: Yes",
            "pmid": [
                "pmid35388108",
                "pmid38911008",
                "pmid24815757",
                "pmid39127141",
                "pmid39541802",
                "pmid33779822",
                "pmid17234821",
                "pmid23256744",
                "pmid39415561",
                "pmid38895540"
            ]
        },
        "clinical_70": {
            "question": "Does COP-22 have potential anti-aging activity that could be used in the therapy of Alzheimer's disease?",
            "answer": "A: A. Yes",
            "pmid": [
                "pmid38347285",
                "pmid15582745",
                "pmid19141069",
                "pmid24333930",
                "pmid26710244",
                "pmid37701892",
                "pmid31697472",
                "pmid22921742",
                "pmid28157092",
                "pmid35815283"
            ]
        },
        "clinical_71": {
            "question": "Does the Huangqi-Gegen drug pair have a potential role in treating Alzheimer's disease?",
            "answer": "The context information does not provide any evidence regarding the Huangqi-Gegen drug pair's role in treating Alzheimer's disease.\n\nAnswer: B. No",
            "pmid": [
                "pmid35656471",
                "pmid34046075",
                "pmid35535155",
                "pmid32140977",
                "pmid32173426",
                "pmid39772836",
                "pmid35069753",
                "pmid31354916",
                "pmid35873623",
                "pmid31563815"
            ]
        },
        "clinical_72": {
            "question": "Does zinc supplementation reduce the risk or slow cognitive decline in individuals with Alzheimer's disease or mild cognitive impairment?",
            "answer": "A: A",
            "pmid": [
                "pmid33597269",
                "pmid21368864",
                "pmid38648940",
                "pmid26883958",
                "pmid17949919",
                "pmid37261605",
                "pmid18625454",
                "pmid36263579",
                "pmid29423819",
                "pmid25066791"
            ]
        },
        "clinical_73": {
            "question": "Does Aquilaria crassna Leaf Extract (ACH) improve lifespan in Caenorhabditis elegans exposed to high glucose, potentially relevant to Alzheimer's disease?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid36079924",
                "pmid26845710",
                "pmid37838776",
                "pmid37375545",
                "pmid38003724",
                "pmid38601465",
                "pmid26236426",
                "pmid36076399",
                "pmid22995388",
                "pmid28279707"
            ]
        },
        "clinical_74": {
            "question": "Is delirium associated with increased odds of non-emergency control intervention use in older psychiatric inpatients?",
            "answer": "The provided contextual information does not address whether delirium is associated with increased odds of non-emergency control intervention use in older psychiatric inpatients.\n\n**Answer: UNRELATED**\n\nNew Answer:  Based on the context provided, it is unrelated. None of the studies discuss non-emergency control intervention use or its association with delirium in psychiatric settings.\n\nAnswer: UNRELATED\n\nNew Answer: The provided information does not address whether delirium is associated with increased odds of non-emergency control intervention use in older psychiatric inpatients.\n\n**Final Answer:** UNRELATED",
            "pmid": [
                "pmid21721434",
                "pmid26397939",
                "pmid17183425",
                "pmid21488579",
                "pmid29966197",
                "pmid21206582",
                "pmid37566435",
                "pmid29723848",
                "pmid37133446",
                "pmid23448799"
            ]
        },
        "clinical_75": {
            "question": "Does Marsilea quadrifolia Linn exhibit potential neuroprotective effects that could be relevant to Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid37781695",
                "pmid28643520",
                "pmid28279707",
                "pmid29080453",
                "pmid39229544",
                "pmid32488469",
                "pmid37114959",
                "pmid32316271",
                "pmid35950787",
                "pmid23833520"
            ]
        },
        "clinical_76": {
            "question": "Does the chloroform extract of Vanda roxburghii exhibit potential in the treatment of Alzheimer's disease?",
            "answer": "The chloroform extract from Vanda roxburghii exhibits potential in treating Alzheimer's disease due to its acetylcholinesterase inhibitory and antioxidant properties. These activities address key aspects of the disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid33855299",
                "pmid28643520",
                "pmid36408377",
                "pmid38441013",
                "pmid37329974",
                "pmid29100755",
                "pmid38355004",
                "pmid26845710",
                "pmid35237756",
                "pmid36982332"
            ]
        },
        "clinical_77": {
            "question": "Does Angelica purpurascens essential oil improve memory impairments through mechanisms relevant to Alzheimer's disease, such as cholinergic modulation and antioxidant effects?",
            "answer": "**Answer: A. Yes**\n\nAngelica purpurascens essential oil (APO) has been shown to improve memory impairments relevant to Alzheimer's disease through cholinergic modulation and antioxidant effects. In a study using a zebrafish model, APO prevented memory deficits caused by scopolamine, increased antioxidant enzyme levels, reduced oxidative stress markers, and decreased acetylcholinesterase (AChE) activity in the brain, indicating its potential therapeutic benefits for Alzheimer's disease.",
            "pmid": [
                "pmid32785956",
                "pmid35448824",
                "pmid37508010",
                "pmid39305407",
                "pmid38339193",
                "pmid23566055",
                "pmid29080453",
                "pmid22995388",
                "pmid21899553",
                "pmid39229544"
            ]
        },
        "clinical_78": {
            "question": "Does tocilizumab treatment reduce cognitive deficits in an Alzheimer's disease model?",
            "answer": "A. Yes",
            "pmid": [
                "pmid39044493",
                "pmid27443846",
                "pmid23742728",
                "pmid27767993",
                "pmid38253184",
                "pmid31076196",
                "pmid23783773",
                "pmid20555131",
                "pmid29434777",
                "pmid25443284"
            ]
        },
        "clinical_79": {
            "question": "Does the cyclic (aza)peptide tracer effectively cross the blood-brain barrier (BBB) to target Abeta oligomers in Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid36442093",
                "pmid16246051",
                "pmid24997450",
                "pmid11181824",
                "pmid27258855",
                "pmid36763536",
                "pmid34494298",
                "pmid22992731",
                "pmid12105192",
                "pmid36994913"
            ]
        },
        "clinical_80": {
            "question": "Does the ethanolic extract of Aster glehni (AG-D) improve cognitive function in a model of Alzheimer's disease?",
            "answer": "The ethanolic extract of Aster glehni (AG-D) improves cognitive function in a scopolamine-induced Alzheimer's disease model by inhibiting acetylcholinesterase activity and enhancing neuroprotective signaling pathways.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid31225769",
                "pmid28643520",
                "pmid27435287",
                "pmid26068423",
                "pmid28279707",
                "pmid16821116",
                "pmid32365983",
                "pmid29080453",
                "pmid35599481",
                "pmid36820018"
            ]
        },
        "clinical_81": {
            "question": "Does MLKL deficiency improve motor symptoms and reduce neuroinflammation in a Parkinson's disease model, which is analogous to changes seen in Alzheimer's disease?",
            "answer": "The analysis shows that MLKL deficiency improves motor symptoms and reduces neuroinflammation in a Parkinson's disease model based on pmid38041169. However, the provided context does not discuss MLKL in Alzheimer's disease, so we cannot confirm if similar effects occur in AD.\n\n**Answer: A. Yes**\n\nThe answer is \"A. Yes\" because MLKL deficiency improves motor symptoms and reduces neuroinflammation in the Parkinson's model as shown, but there's no information about its effect on Alzheimer's.",
            "pmid": [
                "pmid38041169",
                "pmid37488757",
                "pmid22329649",
                "pmid34817756",
                "pmid20555131",
                "pmid28337659",
                "pmid37349821",
                "pmid34042039",
                "pmid12203047",
                "pmid36387285"
            ]
        },
        "clinical_82": {
            "question": "Does music therapy significantly reduce anxiety in patients with Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid24337333",
                "pmid19250995",
                "pmid19628939",
                "pmid36278769",
                "pmid29235615",
                "pmid25711456",
                "pmid32273835",
                "pmid11087767",
                "pmid27790242",
                "pmid22195685"
            ]
        },
        "clinical_83": {
            "question": "Does thiopurine exposure reduce the risk of Alzheimer's disease in patients with inflammatory bowel disease?",
            "answer": "A:",
            "pmid": [
                "pmid31788536",
                "pmid35908596",
                "pmid35470286",
                "pmid37521457",
                "pmid38779559",
                "pmid36820018",
                "pmid38561809",
                "pmid20555131",
                "pmid25652526",
                "pmid12453679"
            ]
        },
        "clinical_84": {
            "question": "Does add-on therapy with a low-dose carbamylating inhibitor enhance the clinical efficacy of donepezil in Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid24217282",
                "pmid11830754",
                "pmid17939763",
                "pmid9853200",
                "pmid12187372",
                "pmid29434777",
                "pmid39539179",
                "pmid9428950",
                "pmid30680019",
                "pmid9876215"
            ]
        },
        "clinical_85": {
            "question": "Does taraxerol have potential therapeutic value in alleviating memory impairments observed in Alzheimer's disease?",
            "answer": "The study by pmid29355563 demonstrates that taraxerol inhibits acetylcholinesterase activity and improves memory impairments in animal models, indicating its potential therapeutic value for Alzheimer's-related cognitive issues.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid29355563",
                "pmid33540879",
                "pmid8997426",
                "pmid11110737",
                "pmid9205832",
                "pmid17897735",
                "pmid19805638",
                "pmid8128843",
                "pmid34655202",
                "pmid26638900"
            ]
        },
        "clinical_86": {
            "question": "Is donepezil approved for the treatment of Alzheimer's disease?",
            "answer": "A: Yes\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Information:** The context provides multiple PMIDs discussing donepezil's use and approval for Alzheimer's disease (AD).\n2. **Extract Approval Details:**\n   - pmid11830754 states donepezil is approved for mild to moderate AD.\n   - pmid17939763 confirms it's licensed for treating AD.\n   - Other PMIDs support its FDA approval and effectiveness in clinical trials.\n3. **Conclusion:** All references indicate that donepezil is indeed approved for treating Alzheimer's disease.\n\n**Answer: A: Yes**\n\nStep-by-Step Answer:\n\nYes, donepezil is approved for the treatment of symptoms associated with mild to moderate Alzheimer's disease as indicated across multiple studies.\n\nNew Answer:\nA: Yes",
            "pmid": [
                "pmid11830754",
                "pmid17939763",
                "pmid9853200",
                "pmid9428950",
                "pmid12187372",
                "pmid23742728",
                "pmid15989517",
                "pmid10637367",
                "pmid9876215",
                "pmid39539179"
            ]
        },
        "clinical_87": {
            "question": "Does donepezil, which is used in Alzheimer's disease, show protective effects against alcohol-induced toxicity in cell culture by inhibiting caspase-3?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid29804239",
                "pmid11830754",
                "pmid19077054",
                "pmid39539179",
                "pmid37298443",
                "pmid15893738",
                "pmid9853200",
                "pmid17939763",
                "pmid9428950",
                "pmid25744714"
            ]
        },
        "clinical_88": {
            "question": "Does the combination of lycopene and human amniotic epithelial cells improve cognitive deficits in Alzheimer's disease?",
            "answer": "The only study addressing the combination of lycopene (LYCO) and human amniotic epithelial cells (HAECs) is pmid33249184, which found that their combination significantly improved cognitive deficits in an Alzheimer's disease rat model. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid33249184",
                "pmid32253029",
                "pmid29454265",
                "pmid29195132",
                "pmid22044877",
                "pmid31606373",
                "pmid31661844",
                "pmid30290256",
                "pmid37823115",
                "pmid21606627"
            ]
        },
        "clinical_89": {
            "question": "Did the patient develop Alzheimer's disease or delirium during the course of her treatment with trimethoprim-sulfamethoxazole?",
            "answer": "The correct answer is **B. No**. The patient did not develop Alzheimer's disease or delirium during her treatment with trimethoprim-sulfamethoxazole.\n\nNew Answer: \n\nThe correct answer is **B. No**.",
            "pmid": [
                "pmid17427765",
                "pmid17317453",
                "pmid19836623",
                "pmid23293526",
                "pmid37566435",
                "pmid18585545",
                "pmid27662296",
                "pmid12187372",
                "pmid36607874",
                "pmid23962100"
            ]
        },
        "clinical_90": {
            "question": "Does stigmasterol treatment alleviate cognitive deficits in a model of Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid35772378",
                "pmid33787038",
                "pmid27767993",
                "pmid1776749",
                "pmid8997426",
                "pmid22921881",
                "pmid9205832",
                "pmid26638900",
                "pmid18354253",
                "pmid11110737"
            ]
        },
        "clinical_91": {
            "question": "Does betulinic acid improve microvascular responsivity and reduce cytokine levels in Alzheimer's disease?",
            "answer": "B: B",
            "pmid": [
                "pmid30178892",
                "pmid28986104",
                "pmid37980676",
                "pmid36770835",
                "pmid21276834",
                "pmid36817510",
                "pmid23645098",
                "pmid34116571",
                "pmid37098656",
                "pmid21606627"
            ]
        },
        "clinical_92": {
            "question": "Does switching from ziprasidone to duloxetine improve neuropsychiatric behavior in a patient with Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid19752843",
                "pmid23293526",
                "pmid15157345",
                "pmid31920655",
                "pmid18354253",
                "pmid26778658",
                "pmid32695312",
                "pmid21492498",
                "pmid12567159",
                "pmid11890487"
            ]
        },
        "clinical_93": {
            "question": "Are pyramidal cell volumes in the dorsolateral prefrontal cortex reduced in Alzheimer's disease compared to post-stroke patients with no dementia?",
            "answer": "The study (pmid24974383) indicates that pyramidal cell volumes in the dorsolateral prefrontal cortex are indeed reduced in Alzheimer's disease compared to post-stroke patients without dementia.\n\n**Answer: A. Yes**\n\nNew Answer:\n\nA. Yes",
            "pmid": [
                "pmid24607963",
                "pmid24974383",
                "pmid22153202",
                "pmid29080407",
                "pmid19220710",
                "pmid19940172",
                "pmid14507668",
                "pmid22651939",
                "pmid9710003",
                "pmid25820930"
            ]
        },
        "clinical_94": {
            "question": "Does amentoflavone improve memory deficits in a model of Alzheimer's disease by influencing autophagy and mTOR signaling?",
            "answer": "The study in pmid33492604 directly demonstrates that amentoflavone improves memory deficits in an Alzheimer's disease model by enhancing autophagy through mTOR signaling. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid33492604",
                "pmid29411261",
                "pmid35682567",
                "pmid31722188",
                "pmid38441013",
                "pmid34188608",
                "pmid30922179",
                "pmid38996935",
                "pmid31060682",
                "pmid30362531"
            ]
        },
        "clinical_95": {
            "question": "Are flavonoids from Millettia brandisiana studied for their effects against Alzheimer's disease pathogenesis?",
            "answer": "A: Yes  \n**Answer:** A",
            "pmid": [
                "pmid38106662",
                "pmid24328060",
                "pmid34569961",
                "pmid36071869",
                "pmid32168835",
                "pmid25229015",
                "pmid39229544",
                "pmid32316271",
                "pmid29100755",
                "pmid22995388"
            ]
        },
        "clinical_96": {
            "question": "Does the compound PADK exhibit a positive effect on CatB that correlates with improved memory in Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid29805718",
                "pmid29944861",
                "pmid30354809",
                "pmid23404502",
                "pmid29491219",
                "pmid8128843",
                "pmid39556267",
                "pmid33029123",
                "pmid2391515",
                "pmid34042039"
            ]
        },
        "clinical_97": {
            "question": "Does menadione sodium bisulfite (MSB) show potential as a therapeutic agent for Alzheimer's disease?",
            "answer": "A: Yes  \nNew Answer:\n\n**Answer:** A. Yes  \n\nMenadione sodium bisulfite (MSB) demonstrates potential as a therapeutic agent for Alzheimer's disease, as shown by its ability to inhibit amyloid-beta aggregation and reduce related toxicity in experimental models.",
            "pmid": [
                "pmid30036601",
                "pmid34294612",
                "pmid29805718",
                "pmid23703159",
                "pmid26638900",
                "pmid34116571",
                "pmid18625454",
                "pmid34812899",
                "pmid32397683",
                "pmid27725131"
            ]
        },
        "clinical_98": {
            "question": "Does pre-infusion of hypertonic saline reduce the incidence of delirium in geriatric patients after shoulder arthroscopy?",
            "answer": "**Answer: A. Yes**\n\nThe study by pmid38082215 directly addresses the question and shows that pre-infusion of hypertonic saline significantly reduces the incidence of delirium in geriatric patients undergoing shoulder arthroscopy.\n\nNew Answer:",
            "pmid": [
                "pmid38082215",
                "pmid36304175",
                "pmid16696749",
                "pmid7762856",
                "pmid39259060",
                "pmid39638735",
                "pmid34901277",
                "pmid37773821",
                "pmid30048325",
                "pmid15467965"
            ]
        },
        "clinical_99": {
            "question": "Does methylpenicinoline from Penicillium sp. (SF-5995) have potential therapeutic effects for Alzheimer's disease or delirium based on its anti-inflammatory properties?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid25379644",
                "pmid39583559",
                "pmid29081887",
                "pmid23612372",
                "pmid38954263",
                "pmid33463937",
                "pmid37623247",
                "pmid29990697",
                "pmid35599481",
                "pmid17406652"
            ]
        },
        "clinical_100": {
            "question": "Does the compound LM-021 exhibit antiaggregative, antioxidative, and neuroprotective effects in models of Alzheimer's disease?",
            "answer": "A: UNRELATED",
            "pmid": [
                "pmid38203753",
                "pmid33582452",
                "pmid38577889",
                "pmid31945778",
                "pmid31520071",
                "pmid11487523",
                "pmid36770835",
                "pmid26797524",
                "pmid28930532",
                "pmid31244664"
            ]
        },
        "clinical_101": {
            "question": "Does the triazole grandisin analogue (TGA) exhibit neuroprotective effects against amyloid-beta oligomer-induced cognitive impairment in Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid32739157",
                "pmid27258855",
                "pmid26696494",
                "pmid26432105",
                "pmid37598923",
                "pmid25390692",
                "pmid16772755",
                "pmid36586644",
                "pmid39552492",
                "pmid22860159"
            ]
        },
        "clinical_102": {
            "question": "Does TKM01 reduce acetylcholinesterase (AChE) activity in an Alzheimer's disease model?",
            "answer": "A: Yes",
            "pmid": [
                "pmid39552492",
                "pmid10637367",
                "pmid17555845",
                "pmid12203047",
                "pmid18587286",
                "pmid19199870",
                "pmid1776749",
                "pmid31520071",
                "pmid31840000",
                "pmid17023131"
            ]
        },
        "clinical_103": {
            "question": "Is Aniracetam used in the treatment of Alzheimer's disease?",
            "answer": "The information provided indicates that Aniracetam is indeed used in the treatment of Alzheimer's disease, as it is mentioned to be effective for behavioral and psychological symptoms of dementia in Alzheimer's patients.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid12070527",
                "pmid25099639",
                "pmid38552113",
                "pmid29946420",
                "pmid17690727",
                "pmid23293526",
                "pmid33540879",
                "pmid17939763",
                "pmid11830754",
                "pmid8997426"
            ]
        },
        "clinical_104": {
            "question": "Does 5-heptadecylresorcinol (AR-C17) have a protective effect against cognitive impairments in a model of Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid32385942",
                "pmid29667108",
                "pmid17600377",
                "pmid21606627",
                "pmid16772755",
                "pmid28157092",
                "pmid8997426",
                "pmid25443284",
                "pmid38355004",
                "pmid12065621"
            ]
        },
        "clinical_105": {
            "question": "Does intermittent fasting improve cognitive function in a model of sepsis, suggesting potential benefits for delirium?",
            "answer": "**Step-by-Step Explanation:**\n\n1. **Review of Contexts**: None of the studies explicitly examine intermittent fasting (IF) in a sepsis model or its effect on delirium.\n2. **Inflammation and Delirium**: While IF reduces inflammation, which is linked to delirium, this connection isn't studied in the context of sepsis within the provided information.\n3. **Conclusion**: Without direct evidence from a sepsis model, we cannot confirm that IF improves cognitive function or benefits delirium in such scenarios.\n\n**Answer: B. No**\n\nNew Answer:\n\nB. No",
            "pmid": [
                "pmid39798403",
                "pmid28970945",
                "pmid37043764",
                "pmid24886300",
                "pmid20471115",
                "pmid37133446",
                "pmid39840463",
                "pmid21766035",
                "pmid39419070",
                "pmid21294938"
            ]
        },
        "clinical_106": {
            "question": "Does donepezil reduce proinflammatory cytokines in Alzheimer's disease patients?",
            "answer": "**Answer: A. Yes**\n\nDonepezil has been shown in studies such as pmid25662507 and pmid34638977 to reduce proinflammatory cytokines like TNF-alpha and IL-1beta in Alzheimer's disease models, indicating its role in lowering these inflammatory markers.\n\n**Final Answer: A. Yes**\n\n---\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid16445950",
                "pmid25662507",
                "pmid29420357",
                "pmid20153342",
                "pmid15118486",
                "pmid23585364",
                "pmid34638977",
                "pmid23742728",
                "pmid29434777",
                "pmid39539179"
            ]
        },
        "clinical_107": {
            "question": "Does octadecaneuropeptide (ODN) have potential therapeutic implications for Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid33250858",
                "pmid31514417",
                "pmid23229789",
                "pmid38216963",
                "pmid12203047",
                "pmid20980077",
                "pmid35104624",
                "pmid18037281",
                "pmid39773090",
                "pmid22527793"
            ]
        },
        "clinical_108": {
            "question": "Does the use of low-dose atypical antipsychotic risperidone improve the 5-year outcome in Alzheimer's disease patients with sleep disturbances?",
            "answer": "The use of low-dose atypical antipsychotic risperidone improves the 5-year outcome in Alzheimer's disease patients with sleep disturbances.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid26279176",
                "pmid16505133",
                "pmid15157345",
                "pmid16315159",
                "pmid17471598",
                "pmid21492498",
                "pmid31920655",
                "pmid10496251",
                "pmid16821257",
                "pmid10084637"
            ]
        },
        "clinical_109": {
            "question": "Are fullerene derivatives with amino acids or peptides being investigated for the treatment of Alzheimer's disease?",
            "answer": "The provided context from pmid35051749 indicates that fullerene derivatives with amino acids or peptides are indeed being investigated for the treatment of Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid35051749",
                "pmid35628525",
                "pmid24222914",
                "pmid26829126",
                "pmid19141069",
                "pmid38470808",
                "pmid22860159",
                "pmid22921742",
                "pmid26362358",
                "pmid12212794"
            ]
        },
        "clinical_110": {
            "question": "Is lithium more cost-effective than aducanumab for treating cognitive decline in patients with mild cognitive impairment or Alzheimer's disease?",
            "answer": "The analysis indicates that lithium is both more effective and significantly cheaper than aducanumab for treating cognitive decline. Multiple studies support its efficacy and lower cost.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35961514",
                "pmid38253184",
                "pmid26402004",
                "pmid28880358",
                "pmid38657568",
                "pmid25018109",
                "pmid10664610",
                "pmid36275418",
                "pmid37897809",
                "pmid30513908"
            ]
        },
        "clinical_111": {
            "question": "Does nabilone show anti-inflammatory effects in agitated patients with Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe study in pmid31547752 indicates that nabilone reduces TNF-alpha levels, a pro-inflammatory cytokine, and correlates this reduction with decreased agitation severity, suggesting anti-inflammatory effects.\n\nNew Answer:\n\nThe answer is based on the provided context where studies suggest that nabilone may have anti-inflammatory effects. However, none of the new contexts directly discuss nabilone's effects on agitated Alzheimer's patients. Since the query specifically asks about nabilone and the provided contexts do not address this, it's better to repeat the original answer.\n\n**Final Answer: A. Yes**\n\nThe studies suggest that nabilone has anti-inflammatory properties in the context of Alzheimer's disease, which may contribute to its effects on agitation.\n\nNew Answer:\n\nThe new context does not provide information about nabilone specifically. Therefore, I will repeat the original answer.\n\n**Answer: A. Yes**\n\nThe study suggests that nabilone has potential anti-inflammatory effects in agitated patients with Alzheimer's disease.\n</think>\n\nThe provided context discusses catalpol as an effective compound for treating Alzheimer's disease by reducing amyloid beta plaques and neuroinflammation, but it does not mention anything about nabilone or its effects on agitated Alzheimer's patients. Therefore, the information is unrelated to the query.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid31547752",
                "pmid31338476",
                "pmid31322567",
                "pmid12453679",
                "pmid23585364",
                "pmid36820018",
                "pmid12930788",
                "pmid21932048",
                "pmid37336148",
                "pmid35815283"
            ]
        },
        "clinical_112": {
            "question": "Does Captopril show greater effectiveness than Perindopril in preventing Alzheimer's disease-like pathology induced by aluminium chloride?",
            "answer": "The study comparing Captopril and Perindopril indicates that Captopril showed greater effectiveness in preventing Alzheimer's disease-like pathology induced by aluminum chloride.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid35243060",
                "pmid20627092",
                "pmid21593435",
                "pmid21981801",
                "pmid25290208",
                "pmid30354809",
                "pmid33540879",
                "pmid21451506",
                "pmid19805638",
                "pmid38448794"
            ]
        },
        "clinical_113": {
            "question": "Does apicidin improve learning and memory impairments in a model of Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid36708130",
                "pmid23966081",
                "pmid25108596",
                "pmid31087219",
                "pmid38468315",
                "pmid23783773",
                "pmid27435287",
                "pmid37209001",
                "pmid34116571",
                "pmid24333930"
            ]
        },
        "clinical_114": {
            "question": "Does the inhibition of tau aggregation by the three Aspergillus nidulans secondary metabolites have potential therapeutic implications for Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid24414310",
                "pmid34009955",
                "pmid39583559",
                "pmid25822288",
                "pmid37038034",
                "pmid21605038",
                "pmid33320518",
                "pmid20678070",
                "pmid21782947",
                "pmid34116571"
            ]
        },
        "clinical_115": {
            "question": "Does donepezil improve cognitive deficits in a patient with neurosyphilis, similar to its use in Alzheimer's disease?",
            "answer": "The context provided includes a specific case where donepezil was used effectively to improve cognitive deficits in a patient with neurosyphilis. This supports the use of donepezil for such conditions similar to its application in Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid26166240",
                "pmid23742728",
                "pmid26778658",
                "pmid12567159",
                "pmid27131829",
                "pmid29434777",
                "pmid11830754",
                "pmid12187372",
                "pmid24401551",
                "pmid15254918"
            ]
        },
        "clinical_116": {
            "question": "Does donepezil, a medication used for Alzheimer's disease, increase collagen 1 expression in mesenchymal stroma cells in an ovine osteoporosis model?",
            "answer": "A: Yes",
            "pmid": [
                "pmid30179213",
                "pmid25450366",
                "pmid35850693",
                "pmid32937955",
                "pmid25662507",
                "pmid34582845",
                "pmid31913348",
                "pmid20153342",
                "pmid25744714",
                "pmid18587286"
            ]
        },
        "clinical_117": {
            "question": "Do Spiroisoxazoline (SIO) alkaloids represent a potential new structural manifold for lead-discovery of new therapeutics for treatment of Alzheimer's disease?",
            "answer": "The context information indicates that Spiroisoxazoline (SIO) alkaloids have been identified as inhibitors of acetylcholinesterase and are considered a potential new structural manifold for developing therapeutics against Alzheimer's disease. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid36095307",
                "pmid34153839",
                "pmid31087219",
                "pmid33991608",
                "pmid23703159",
                "pmid33807157",
                "pmid28852940",
                "pmid33867926",
                "pmid34896111",
                "pmid18577377"
            ]
        },
        "clinical_118": {
            "question": "Does xanthoceraside have potential therapeutic effects for Alzheimer's disease based on its protective effects in SH-SY5Y cells?",
            "answer": "A: Yes",
            "pmid": [
                "pmid23909924",
                "pmid24810883",
                "pmid23966052",
                "pmid20183271",
                "pmid21735075",
                "pmid28744803",
                "pmid23562514",
                "pmid32141445",
                "pmid22102154",
                "pmid34896111"
            ]
        },
        "clinical_119": {
            "question": "Does (m)RVD-hemopressin have a potential therapeutic application in Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe provided context indicates that (m)RVD-hemopressin has potential therapeutic applications in Alzheimer's disease. Studies show it can mitigate Abeta-induced issues and protect against oxidative stress, supporting its use as a therapeutic agent.",
            "pmid": [
                "pmid32241604",
                "pmid37971633",
                "pmid33171279",
                "pmid31730791",
                "pmid35455468",
                "pmid30344671",
                "pmid27567825",
                "pmid30354809",
                "pmid28274813",
                "pmid19805638"
            ]
        },
        "clinical_120": {
            "question": "Does L-serine improve cognitive dysfunction in an ALS/PDC model that presents symptoms analogous to Alzheimer's-like dementia?",
            "answer": "**Answer:** A. Yes  \nL-serine was shown to effectively alleviate cognitive changes and improve cognition in an ALS/PDC rodent model when used alone or in combination with other treatments. The study highlighted that it performed better than other interventions for these specific outcomes.",
            "pmid": [
                "pmid30476904",
                "pmid36142514",
                "pmid1776749",
                "pmid20555131",
                "pmid23783773",
                "pmid31520071",
                "pmid25443284",
                "pmid22869752",
                "pmid29491219",
                "pmid30824685"
            ]
        },
        "clinical_121": {
            "question": "Does cytokine signaling in CAR-T cell therapy have a known relationship with delirium?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid37649721",
                "pmid35791660",
                "pmid24557038",
                "pmid17467406",
                "pmid20309566",
                "pmid28360657",
                "pmid28769556",
                "pmid19269948",
                "pmid37851904",
                "pmid20471115"
            ]
        },
        "clinical_122": {
            "question": "Does the UCNPs-LMB/VQIVYK nanosystem inhibit Tau aggregation to reduce neurotoxicity in Alzheimer's disease?",
            "answer": "**Answer:** A. Yes\n\nThe UCNPs-LMB/VQIVYK nanosystem is explicitly described in pmid37103297 as effective in detecting Tau protein and inhibiting its aggregation, thereby reducing Tau-induced neurotoxicity.",
            "pmid": [
                "pmid37103297",
                "pmid37269953",
                "pmid36562884",
                "pmid21228179",
                "pmid20678070",
                "pmid33320518",
                "pmid34095439",
                "pmid36918909",
                "pmid21605038",
                "pmid19141069"
            ]
        },
        "clinical_123": {
            "question": "Does the aqueous extract of Ziziphus jujuba exhibit antiamnesic effects comparable to donepezil, a standard drug for Alzheimer's disease?",
            "answer": "A: Yes; B: No  \nAnswer: A",
            "pmid": [
                "pmid34194520",
                "pmid35922734",
                "pmid34422074",
                "pmid24244815",
                "pmid24886882",
                "pmid34973350",
                "pmid32316271",
                "pmid28643520",
                "pmid36777330",
                "pmid35900690"
            ]
        },
        "clinical_124": {
            "question": "Does memantine, a drug used for Alzheimer's disease, have a protective effect against cartilage destruction in osteoarthritis?",
            "answer": "A: Yes",
            "pmid": [
                "pmid28545202",
                "pmid28917837",
                "pmid28167259",
                "pmid19948208",
                "pmid19642202",
                "pmid20042680",
                "pmid34120588",
                "pmid18615702",
                "pmid24227863",
                "pmid15192085"
            ]
        },
        "clinical_125": {
            "question": "Does the extract POEE from Marapuama reduce cognitive impairment in an Alzheimer's disease model?",
            "answer": "A: Yes\n\nThe extract POEE from Marapuama reduces cognitive impairment in an Alzheimer's disease model according to the provided context. The study showed that POEE effectively prevented cognitive impairment in mice with Alzheimer's-like symptoms.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid20739160",
                "pmid26068423",
                "pmid36982332",
                "pmid28279707",
                "pmid36777330",
                "pmid31661844",
                "pmid32316271",
                "pmid28643520",
                "pmid34182090",
                "pmid33913927"
            ]
        },
        "clinical_126": {
            "question": "Does xanthoceraside improve cognitive impairment in Alzheimer's disease by promoting neurogenesis?",
            "answer": "A: A",
            "pmid": [
                "pmid28744803",
                "pmid24810883",
                "pmid23909924",
                "pmid21735075",
                "pmid23562514",
                "pmid20183271",
                "pmid23966052",
                "pmid32141445",
                "pmid21606627",
                "pmid38355004"
            ]
        },
        "clinical_127": {
            "question": "Does remifentanil reduce the occurrence of delirium in mechanically ventilated patients?",
            "answer": "The study (pmid28910303) found that remifentanil significantly reduced delirium in mechanically ventilated patients compared to midazolam alone. \n\nA: Yes",
            "pmid": [
                "pmid28910303",
                "pmid18577171",
                "pmid24259659",
                "pmid38911008",
                "pmid17381385",
                "pmid37133446",
                "pmid16678002",
                "pmid38409802",
                "pmid23859663",
                "pmid38482541"
            ]
        },
        "clinical_128": {
            "question": "Does Deacetyl Ganoderic Acid F (DeGA F) have potential therapeutic effects for conditions associated with neural inflammation, such as Alzheimer's disease?",
            "answer": "The provided information indicates that Deacetyl Ganoderic Acid F (DeGA F) exhibits anti-inflammatory properties by targeting pathways such as NF-kappaB, which are relevant to neuroinflammation. It has shown effectiveness in reducing inflammation both in vitro and in vivo models. Therefore, it holds potential therapeutic effects for conditions like Alzheimer's disease associated with neural inflammation.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid31892211",
                "pmid26965310",
                "pmid39625499",
                "pmid34798773",
                "pmid33821438",
                "pmid23645098",
                "pmid21606627",
                "pmid12453679",
                "pmid32480240",
                "pmid18037281"
            ]
        },
        "clinical_129": {
            "question": "Does nervonic acid have the potential to be developed as an antioxidant drug for the prevention and early therapy of Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid37823115",
                "pmid39603393",
                "pmid33431776",
                "pmid25847999",
                "pmid36639003",
                "pmid31945778",
                "pmid11487523",
                "pmid38203753",
                "pmid28630497",
                "pmid36770835"
            ]
        },
        "clinical_130": {
            "question": "Does Lonicera japonica polysaccharide (LJP) improve learning and memory impairments associated with Alzheimer's disease?",
            "answer": "A: Yes\nNew Answer:  A",
            "pmid": [
                "pmid32954750",
                "pmid31661844",
                "pmid30844489",
                "pmid36193798",
                "pmid33913927",
                "pmid27534446",
                "pmid30290256",
                "pmid35586051",
                "pmid34968779",
                "pmid37781122"
            ]
        },
        "clinical_131": {
            "question": "Does the behavioral variant of Alzheimer's disease show reduced attention to salient facial features compared to typical Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid37672106",
                "pmid36268579",
                "pmid30088784",
                "pmid26017202",
                "pmid27056068",
                "pmid7580194",
                "pmid9605726",
                "pmid30405709",
                "pmid2893306",
                "pmid25212911"
            ]
        },
        "clinical_132": {
            "question": "Does cabergoline's neuroprotective effect against oxidative stress suggest a potential role in treating Alzheimer's disease?",
            "answer": "Yes, cabergoline's ability to protect against oxidative stress suggests it could be effective in treating Alzheimer's disease by mitigating oxidative damage associated with the condition.\n\n**Answer: A. Yes**\n\nNew Answer: The neuroprotective effects of cabergoline against oxidative stress suggest a potential role in treating Alzheimer's disease.",
            "pmid": [
                "pmid24914776",
                "pmid31945778",
                "pmid35815283",
                "pmid29112116",
                "pmid15948179",
                "pmid24975829",
                "pmid35195784",
                "pmid14648600",
                "pmid11487523",
                "pmid18554300"
            ]
        },
        "clinical_133": {
            "question": "Does the use of amlodipine in Alzheimer's dementia patients reduce the risk of ischaemic stroke compared to other calcium channel blockers?",
            "answer": "A. Yes",
            "pmid": [
                "pmid32854138",
                "pmid15582745",
                "pmid27512890",
                "pmid25068540",
                "pmid33327915",
                "pmid26727124",
                "pmid37897809",
                "pmid19805638",
                "pmid17664404",
                "pmid39584306"
            ]
        },
        "clinical_134": {
            "question": "Does the core sequence of PIF compete for insulin/amyloid beta in insulin degrading enzyme, potentially offering a treatment for Alzheimer's disease?",
            "answer": "The core sequence of PIF competes with insulin/amyloid beta for binding to IDE, which could lead to a treatment for Alzheimer's disease. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid30338033",
                "pmid15590928",
                "pmid26444774",
                "pmid12161276",
                "pmid12185156",
                "pmid29132916",
                "pmid39481143",
                "pmid27320287",
                "pmid30422705",
                "pmid7753801"
            ]
        },
        "clinical_135": {
            "question": "Does trametinib, a MEK1/2 inhibitor, reduce amyloid beta (Abeta) deposition in a model of Alzheimer's Disease?",
            "answer": "The context information from pmid35948663 explicitly indicates that trametinib, a MEK1/2 inhibitor, reduces amyloid beta (Abeta) deposition in an Alzheimer's Disease model by inducing autophagic lysosomal activation. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35948663",
                "pmid20119496",
                "pmid25303711",
                "pmid26696494",
                "pmid36586644",
                "pmid29327084",
                "pmid28587858",
                "pmid28917837",
                "pmid27567806",
                "pmid32739157"
            ]
        },
        "clinical_136": {
            "question": "Does the ethanolic extract of D. moldavica leaves (EEDM) show potential for treating Alzheimer's disease based on its effects in scopolamine-induced cognitive impairment studies?",
            "answer": "The context discusses the potential of various herbal extracts in mitigating cognitive impairment and Alzheimer's disease (AD). Specifically, the study referenced by pmid32035879 examines the ethanolic extract of D. moldavica leaves (EEDM) and its effects on scopolamine-induced cognitive impairment. The results indicate that EEDM improves cognitive function in this model by ameliorating memory deficits and modulating signaling pathways involved in learning and memory.\n\nGiven this information, the answer is:\n\n**A. Yes**\n\nAnswer: A",
            "pmid": [
                "pmid32035879",
                "pmid29100755",
                "pmid28643520",
                "pmid26068423",
                "pmid32316271",
                "pmid32488469",
                "pmid29389553",
                "pmid38954263",
                "pmid28279707",
                "pmid36777330"
            ]
        },
        "clinical_137": {
            "question": "Does prazosin improve behavioral symptoms in patients with Alzheimer disease experiencing agitation and aggression?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid19700947",
                "pmid35864999",
                "pmid25711456",
                "pmid11087767",
                "pmid16856516",
                "pmid32695312",
                "pmid39648108",
                "pmid17897735",
                "pmid11890487",
                "pmid23293526"
            ]
        },
        "clinical_138": {
            "question": "Does the pro-drug peptide (PDp) exhibit neuroprotective effects against Alzheimer's disease in vitro?",
            "answer": "The pro-drug peptide (PDp) exhibits neuroprotective effects against Alzheimer's disease in vitro as demonstrated by its ability to reduce Abeta-induced cytotoxicity and apoptosis in SH-SY5Y cells. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid30958369",
                "pmid28714389",
                "pmid21346312",
                "pmid27995757",
                "pmid17459354",
                "pmid12105192",
                "pmid36994913",
                "pmid17261088",
                "pmid39773090",
                "pmid18403590"
            ]
        },
        "clinical_139": {
            "question": "Does donepezil treatment affect cholesterol levels in Alzheimer's disease patients?",
            "answer": "A: A\nNew Answer:\n\nYes, donepezil treatment affects cholesterol levels in Alzheimer's disease patients by increasing them.",
            "pmid": [
                "pmid28861608",
                "pmid14599705",
                "pmid30680019",
                "pmid11830754",
                "pmid29434777",
                "pmid30878503",
                "pmid17939763",
                "pmid39539179",
                "pmid9853200",
                "pmid23742728"
            ]
        },
        "clinical_140": {
            "question": "Does the compound ZLWH-23 show potential as a drug lead for Alzheimer's disease treatment?",
            "answer": "The compound ZLWH-23 is not mentioned in any of the provided contexts. \n\nAnswer: UNRELATED",
            "pmid": [
                "pmid18577377",
                "pmid10637367",
                "pmid37261605",
                "pmid30344671",
                "pmid31697472",
                "pmid38203753",
                "pmid26797524",
                "pmid33540879",
                "pmid31244664",
                "pmid1776749"
            ]
        },
        "clinical_141": {
            "question": "Does the presence of cerebral amyloid angiopathy (CAA) correlate with reduced NEP activity in Alzheimer's disease patients?",
            "answer": "The studies consistently indicate a correlation between reduced neprilysin (NEP) activity and the presence of cerebral amyloid angiopathy (CAA) in Alzheimer's disease patients.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid17021406",
                "pmid22482447",
                "pmid17591969",
                "pmid12387451",
                "pmid21382117",
                "pmid38405347",
                "pmid19319544",
                "pmid11395394",
                "pmid35851991",
                "pmid28824801"
            ]
        },
        "clinical_142": {
            "question": "Does the combined treatment of MC5523 and LiCl improve neuroprotection and reduce side effects in the treatment of Alzheimer's disease?",
            "answer": "The combined treatment of MC5523 and LiCl was studied in a preclinical model of Alzheimer's disease, demonstrating enhanced neuroprotection, reduced hepatotoxicity, improved memory function, increased synaptic proteins (Synaptophysin and PSD-95), decreased GSK3beta activity, and prevented Abeta-induced neurotoxicity. \n\n**Answer: A. Yes**\n\nNew Answer:\n\nThe combined treatment of MC5523 and LiCl improves neuroprotection and reduces side effects in the treatment of Alzheimer's disease.\n\n**Answer:**  \nA. Yes",
            "pmid": [
                "pmid30513908",
                "pmid37762479",
                "pmid36275418",
                "pmid34497504",
                "pmid17406652",
                "pmid33540879",
                "pmid36411758",
                "pmid25018109",
                "pmid34856907",
                "pmid24217282"
            ]
        },
        "clinical_143": {
            "question": "Does TRPC3 suppression improve memory deficits in Alzheimer's disease?",
            "answer": "The provided context from pmid39345364 clearly indicates that suppressing TRPC3 improves memory deficits in Alzheimer's disease by rescuing neurotoxicity and enhancing synaptic function.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid39345364",
                "pmid29660945",
                "pmid34302466",
                "pmid39209323",
                "pmid33998138",
                "pmid32061032",
                "pmid25443284",
                "pmid33420799",
                "pmid37755583",
                "pmid2391515"
            ]
        },
        "clinical_144": {
            "question": "Does the use of angiotensin II-inhibiting antihypertensive medications increase the risk of Alzheimer's disease in patients with colorectal cancer compared to angiotensin II-stimulating medications?",
            "answer": "Based on the contextual information provided, the most appropriate answer is:\n\n**Answer: A**\n\nNew Answer:",
            "pmid": [
                "pmid37215552",
                "pmid19805638",
                "pmid30354809",
                "pmid21451506",
                "pmid39584306",
                "pmid15582745",
                "pmid20627092",
                "pmid38685540",
                "pmid10490699",
                "pmid38225990"
            ]
        },
        "clinical_145": {
            "question": "Is QS-21 used in therapeutic vaccines for Alzheimer's disease?",
            "answer": "The context provides evidence that QS-21 has been used in therapeutic vaccines for Alzheimer's disease, specifically as part of adjuvant systems in clinical trials targeting Abeta peptides. \n\nAnswer: A. Yes",
            "pmid": [
                "pmid24950335",
                "pmid31182297",
                "pmid37947289",
                "pmid12110243",
                "pmid31697472",
                "pmid12534311",
                "pmid31839610",
                "pmid24632960",
                "pmid39552492",
                "pmid25405415"
            ]
        },
        "clinical_146": {
            "question": "Is donepezil, an acetylcholinesterase inhibitor, also found to inhibit BACE-1 and thus potentially beneficial for Alzheimer's disease?",
            "answer": "No, the provided context does not indicate that donepezil inhibits BACE-1.\n\n**Answer: B. No**\n\nNew Answer:\n\nBased on the provided information, donepezil is an acetylcholinesterase inhibitor used in treating Alzheimer's disease by enhancing cholinergic neurotransmission. However, there is no mention of it inhibiting BACE-1. Therefore, based on the given contexts, donepezil is not known to inhibit BACE-1.\n\n**Answer: B. No**",
            "pmid": [
                "pmid17541560",
                "pmid10637367",
                "pmid11830754",
                "pmid17939763",
                "pmid9853200",
                "pmid9428950",
                "pmid15989517",
                "pmid18577377",
                "pmid24217282",
                "pmid9876215"
            ]
        },
        "clinical_147": {
            "question": "Does the hydroxylated form of docosahexaenoic acid (DHA-H) improve survival and motor function in a model of Alzheimer's disease?",
            "answer": "The research indicates that DHA-H enhances survival and motor function in Alzheimer's disease models.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid28284721",
                "pmid18037281",
                "pmid21606627",
                "pmid24374316",
                "pmid35782939",
                "pmid31677009",
                "pmid26965310",
                "pmid23645098",
                "pmid12065621",
                "pmid15788759"
            ]
        },
        "clinical_148": {
            "question": "Does Piper wallichii's petroleum ether fraction (PPF) exhibit anti-Alzheimer's disease effects in Caenorhabditis elegans?",
            "answer": "**Answer: A. Yes**\n\nThe contextual information from pmid37327643 clearly supports that Piper wallichii's petroleum ether fraction (PPF) exhibits anti-Alzheimer's disease effects in Caenorhabditis elegans by improving various AD-related outcomes such as reducing paralysis, alleviating amyloid-beta and Tau pathology, and extending lifespan.",
            "pmid": [
                "pmid37327643",
                "pmid32413539",
                "pmid38373507",
                "pmid38003724",
                "pmid30905309",
                "pmid27474225",
                "pmid29709515",
                "pmid37838776",
                "pmid39682936",
                "pmid28119052"
            ]
        },
        "clinical_149": {
            "question": "Does Triticum aestivum L. (TAL) have neuroprotective effects against beta-amyloid-induced cell death and memory impairments in Alzheimer's disease?",
            "answer": "The information indicates that Triticum aestivum L. (TAL) exhibits neuroprotective effects against beta-amyloid-induced cell death and memory impairments in Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid19441012",
                "pmid23833520",
                "pmid38455162",
                "pmid37114959",
                "pmid38363611",
                "pmid25229015",
                "pmid26068423",
                "pmid29100755",
                "pmid28643520",
                "pmid36232612"
            ]
        },
        "clinical_150": {
            "question": "Does early initiation of donepezil treatment improve outcomes for patients with geriatric depression and Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid30037778",
                "pmid19528519",
                "pmid25919986",
                "pmid27790242",
                "pmid23742728",
                "pmid11830754",
                "pmid12187372",
                "pmid9853200",
                "pmid17939763",
                "pmid18354253"
            ]
        },
        "clinical_151": {
            "question": "Does Callicarpa kwangtungensis Chun (CK) improve cognitive function in Alzheimer's disease (AD) models?",
            "answer": "The study in pmid39586557 demonstrates that Callicarpa kwangtungensis Chun (CK) improves cognitive function in Alzheimer's disease models through its anti-neuroinflammatory effects and reduction of amyloid-beta plaques.\n\n**Answer: A. Yes**\n\nNew Answer: Based on the context provided, Callicarpa kwangtungensis Chun (CK) does improve cognitive function in Alzheimer's disease models as shown by significant improvements in cognitive performance, reductions in amyloid-beta plaques, and inhibition of neuroinflammation in AD model studies.\n\nAnswer: A. Yes",
            "pmid": [
                "pmid39586557",
                "pmid29080453",
                "pmid28279707",
                "pmid30844489",
                "pmid32140977",
                "pmid25009697",
                "pmid28643520",
                "pmid31661844",
                "pmid36349022",
                "pmid33432644"
            ]
        },
        "clinical_152": {
            "question": "Does flufenamic acid inhibit the activation of the NLRP3 inflammasome in microglia, thereby offering a potential treatment for Alzheimer's disease?",
            "answer": "Based on the context provided, flufenamic acid does inhibit the activation of the NLRP3 inflammasome in microglia and offers a potential treatment for Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid35474599",
                "pmid24161403",
                "pmid12453679",
                "pmid18295322",
                "pmid28003153",
                "pmid25621771",
                "pmid34478813",
                "pmid34968779",
                "pmid32929691",
                "pmid29743866"
            ]
        },
        "clinical_153": {
            "question": "Can the disruption of gut microbiota caused by treatments like Acyclovir contribute to delirium?",
            "answer": "Yes, the disruption of gut microbiota caused by treatments like Acyclovir can contribute to delirium. The changes in gut bacteria lead to increased inflammation, which is linked to neuroinflammatory processes that underlie delirium.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid20309566",
                "pmid37313848",
                "pmid24557038",
                "pmid39419070",
                "pmid20471115",
                "pmid37133446",
                "pmid32760124",
                "pmid37851904",
                "pmid28585290",
                "pmid19422109"
            ]
        },
        "clinical_154": {
            "question": "Is hypophosphatemia associated with neurotoxicity symptoms resembling delirium in CD19-targeted CAR T-cell therapy?",
            "answer": "The correct answer is A. Yes.\n\n**Answer:**\nA. Yes",
            "pmid": [
                "pmid36259217",
                "pmid35042236",
                "pmid36006611",
                "pmid38566855",
                "pmid36078999",
                "pmid33763368",
                "pmid38937571",
                "pmid32018069",
                "pmid25274115",
                "pmid28049548"
            ]
        },
        "clinical_155": {
            "question": "Does imatinib methanesulfonate reduce hippocampal amyloid-beta and restore cognitive function in a model of Alzheimer's disease following repeated endotoxin exposure?",
            "answer": "A: A",
            "pmid": [
                "pmid23665252",
                "pmid27320209",
                "pmid20555131",
                "pmid19798641",
                "pmid27567806",
                "pmid36586644",
                "pmid23783773",
                "pmid35350668",
                "pmid21116051",
                "pmid25443284"
            ]
        },
        "clinical_156": {
            "question": "Does Armillaria mellea polysaccharides (AMPS) improve cognitive function in Alzheimer's disease?",
            "answer": "The provided context clearly shows that Armillaria mellea polysaccharides (AMPS) improve cognitive function in Alzheimer's disease models. Studies demonstrate enhanced memory, reduced pathological markers, and neuroprotective effects.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid29081887",
                "pmid35924065",
                "pmid38866276",
                "pmid33432644",
                "pmid30290256",
                "pmid37781122",
                "pmid33913927",
                "pmid29080453",
                "pmid28643520",
                "pmid30844489"
            ]
        },
        "clinical_157": {
            "question": "Does donepezil treatment protect against doxorubicin-induced chemobrain by reducing Alzheimer's disease-associated lesions?",
            "answer": "The answer is A. Yes.\n\nStep-by-step explanation:\n\n1. **Understanding the Problem**: The question asks whether donepezil can protect against doxorubicin-induced chemobrain by reducing Alzheimer's-associated lesions.\n\n2. **Reviewing Contexts**:\n   - Donepezil was effective in improving cognitive function and reducing pathological conditions like inflammation and oxidative stress caused by doxorubicin.\n   - It reduced beta-amyloid levels, which are linked to Alzheimer's disease.\n   - Studies show donepezil can mitigate cognitive decline and reduce Alzheimer's-related pathologies.\n\n3. **Conclusion**: Based on the provided contexts, donepezil appears to protect against chemobrain by reducing Alzheimer's-associated lesions.\n\nAnswer: A. Yes",
            "pmid": [
                "pmid34312765",
                "pmid23742728",
                "pmid11830754",
                "pmid17939763",
                "pmid9853200",
                "pmid16772755",
                "pmid24401551",
                "pmid12187372",
                "pmid29434777",
                "pmid27131829"
            ]
        },
        "clinical_158": {
            "question": "Does the compound 4v inhibit Abeta42-induced cytotoxicity and show potential for Alzheimer's disease treatment?",
            "answer": "The compound 4v is not mentioned in any of the provided context information. \n\n**Answer: UNRELATED**",
            "pmid": [
                "pmid19141069",
                "pmid22238689",
                "pmid28131834",
                "pmid16246051",
                "pmid27258855",
                "pmid16805796",
                "pmid22992731",
                "pmid9464644",
                "pmid26696494",
                "pmid12137934"
            ]
        },
        "clinical_159": {
            "question": "What was the outcome of the patient's treatment regarding delirium and Behcet's disease symptoms?",
            "answer": "C. Delirium and Behcets symptoms both resolve",
            "pmid": [
                "pmid27579169",
                "pmid26953013",
                "pmid7211435",
                "pmid669496",
                "pmid37133446",
                "pmid20471115",
                "pmid26397939",
                "pmid16840933",
                "pmid37566435",
                "pmid25417135"
            ]
        },
        "clinical_160": {
            "question": "What was the primary outcome measure in the AMARANTH and DAYBREAK-ALZ trials for assessing lanabecestat's efficacy in Alzheimer's disease?",
            "answer": "The primary outcome measure in the AMARANTH and DAYBREAK-ALZ trials was the 13-item Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-Cog).\n\n**Answer: B. Alzheimer Disease Assessment Scale-cognitive subscale**\n\nNew Answer:",
            "pmid": [
                "pmid31764959",
                "pmid27767993",
                "pmid11110737",
                "pmid18845693",
                "pmid20202480",
                "pmid17664404",
                "pmid33787038",
                "pmid27790242",
                "pmid29093468",
                "pmid24326116"
            ]
        },
        "clinical_161": {
            "question": "What is the relationship between cholinergic drugs used for treating neuroleptic-induced tardive dyskinesia and Alzheimer's disease?",
            "answer": "The correct answer is:\n\n**B. Cholinergic drugs have been primarily developed for Alzheimer's disease.**\n\nThis conclusion is supported by the context which details the development of acetylcholinesterase inhibitors (AChEIs) like donepezil specifically for treating Alzheimer's disease, whereas anticholinergics used in tardive dyskinesia serve a different purpose and are not recommended for TD as per the provided information.",
            "pmid": [
                "pmid38502289",
                "pmid8997426",
                "pmid24217282",
                "pmid18577377",
                "pmid33540879",
                "pmid23293526",
                "pmid37701892",
                "pmid10637367",
                "pmid2694529",
                "pmid1776749"
            ]
        },
        "clinical_162": {
            "question": "What is the effect of ethyl pyruvate on the neurotoxicity induced by aluminum chloride in an in vitro model of Alzheimer's disease?",
            "answer": "The context provides information about pyruvate's protective effects against neurotoxicity in different models, suggesting a potential for ethyl pyruvate to have a similar effect. However, since there's no direct mention of ethyl pyruvate in an AlCl3 in vitro model, the answer should be:\n\nUNRELATED",
            "pmid": [
                "pmid25434488",
                "pmid12917750",
                "pmid33582452",
                "pmid28930532",
                "pmid23219964",
                "pmid38448794",
                "pmid34706318",
                "pmid38228217",
                "pmid34354404",
                "pmid37409350"
            ]
        },
        "clinical_163": {
            "question": "How does the BQCA-SA-P80-NP conjugate improve therapeutic outcomes in Alzheimer's disease?",
            "answer": "The BQCA-SA-P80-NP conjugate enhances therapeutic outcomes in Alzheimer's disease by improving the delivery and retention of BQCA in the brain, thus increasing its effectiveness while minimizing peripheral side effects.\n\nAnswer: B. By enhancing the brain bioavailability of BQCA",
            "pmid": [
                "pmid35423107",
                "pmid25443284",
                "pmid25390692",
                "pmid23017601",
                "pmid32331524",
                "pmid38006681",
                "pmid31697472",
                "pmid21272191",
                "pmid31839610",
                "pmid38577889"
            ]
        },
        "clinical_164": {
            "question": "How does the use of QU-SA-5HTM-PA-PLGA nanoparticles contribute to the management of Alzheimer's disease?",
            "answer": "The QU-SA-5HTM-PA-PLGA nanoparticles contribute to managing Alzheimer's disease by suppressing caspase-3 expression and reducing neuronal apoptosis, which helps protect against neurodegeneration. \n\n**Answer: B**\n\nB. By suppressing caspase-3 expression and reducing neuronal apoptosis",
            "pmid": [
                "pmid33405649",
                "pmid29113362",
                "pmid27591943",
                "pmid35307993",
                "pmid28630497",
                "pmid37206236",
                "pmid33042734",
                "pmid39805185",
                "pmid34874326",
                "pmid38747495"
            ]
        },
        "clinical_165": {
            "question": "What was the effect of nicergoline on the ADAS-Cog score in Alzheimer's disease patients?",
            "answer": "UNRELATED\nNew Answer: The contextual information does not provide any specific details about the effect of nicergoline on the ADAS-Cog score in Alzheimer's disease patients.\n\n**Final Answer**\nB. No significant benefit",
            "pmid": [
                "pmid11687175",
                "pmid9205832",
                "pmid30906380",
                "pmid29568940",
                "pmid15882840",
                "pmid25243157",
                "pmid27767993",
                "pmid39325017",
                "pmid11110737",
                "pmid19199870"
            ]
        },
        "clinical_166": {
            "question": "How does the combined formulation of Ramipril and Black Seed Oil (BSO) address the therapeutic management of Alzheimer's disease?",
            "answer": "A. By enhancing the solubility and bioavailability of Ramipril and THQ, potentially improving cognitive outcomes.",
            "pmid": [
                "pmid39305407",
                "pmid34064687",
                "pmid38612861",
                "pmid36232612",
                "pmid31697472",
                "pmid37598923",
                "pmid36145341",
                "pmid36500385",
                "pmid36820018",
                "pmid26529297"
            ]
        },
        "clinical_167": {
            "question": "What is the potential benefit of combining low doses of lupeol and metformin in the management of dementia, particularly in Alzheimer's disease (AD) type?",
            "answer": "**Answer:**\n\nThe potential benefit of combining low doses of lupeol and metformin in the management of dementia, particularly Alzheimer's disease (AD) type, is that they produce a more pronounced effect than high doses of either agent alone. \n\n**Final Answer:** C",
            "pmid": [
                "pmid38842663",
                "pmid32580040",
                "pmid30958364",
                "pmid39441380",
                "pmid37483818",
                "pmid34283253",
                "pmid37597424",
                "pmid24217282",
                "pmid38203753",
                "pmid33540879"
            ]
        },
        "clinical_168": {
            "question": "What effect does pranlukast have on cognitive deficits associated with Alzheimer's disease?",
            "answer": "The effect of pranlukast on cognitive deficits associated with Alzheimer's disease is that it reverses memory deficits.\n\n**Answer: B. It reverses memory deficits**",
            "pmid": [
                "pmid24229499",
                "pmid19805638",
                "pmid8997426",
                "pmid30354809",
                "pmid20627092",
                "pmid29491219",
                "pmid22982445",
                "pmid35672874",
                "pmid28643520",
                "pmid27702591"
            ]
        },
        "clinical_169": {
            "question": "How might the inclusion of evodiamine in hydroxypropyl-beta-cyclodextrin (HP-beta-CD) affect Alzheimer's disease treatment?",
            "answer": "**Answer:** The inclusion of evodiamine in hydroxypropyl-beta-cyclodextrin (HP-beta-CD) enhances its solubility and bioavailability. This improvement allows more evodiamine to be absorbed and reach the target site, potentially increasing its effectiveness in treating Alzheimer's disease.\n\nA. By enhancing the solubility and bioavailability of evodiamine, potentially improving its efficacy.",
            "pmid": [
                "pmid29883380",
                "pmid21278785",
                "pmid38203753",
                "pmid30563837",
                "pmid39305407",
                "pmid38612861",
                "pmid32166661",
                "pmid37329974",
                "pmid39519271",
                "pmid37823115"
            ]
        },
        "clinical_170": {
            "question": "How does breviscapine combined with BMSCs treatment affect Abeta deposition in Alzheimer's disease?",
            "answer": "The combined treatment with breviscapine and BMSCs reduces Abeta deposition in Alzheimer's disease by promoting the degradation of APP and BAEC1 through increased expression of ciRS-7. This leads to lower levels of Abeta peptides, effectively addressing a key pathological feature of the disease.\n\n**Answer: B. It decreases Abeta deposition by promoting the degradation of APP and BAEC1.**",
            "pmid": [
                "pmid35048805",
                "pmid32144518",
                "pmid24219385",
                "pmid36907286",
                "pmid34116571",
                "pmid25303711",
                "pmid26696494",
                "pmid21276834",
                "pmid17261088",
                "pmid12105192"
            ]
        },
        "clinical_171": {
            "question": "What effect did donepezil treatment have on the gray matter volume in the hippocampus of Alzheimer's disease patients?",
            "answer": "**Answer:** B. Significant increase",
            "pmid": [
                "pmid27131829",
                "pmid18070217",
                "pmid29434777",
                "pmid23783773",
                "pmid31913348",
                "pmid24401551",
                "pmid25266713",
                "pmid15601392",
                "pmid22651939",
                "pmid27790242"
            ]
        },
        "clinical_172": {
            "question": "What is the effect of ETA receptor antagonists on cognitive impairment caused by amyloid-beta in a model of Alzheimer's disease?",
            "answer": "The provided context does not contain any information regarding ETA receptor antagonists and their effect on cognitive impairment caused by amyloid-beta in an Alzheimer's disease model. Therefore, based on the given data, the most appropriate response is:\n\nUNRELATED",
            "pmid": [
                "pmid21116051",
                "pmid12930788",
                "pmid28157092",
                "pmid20555131",
                "pmid29434777",
                "pmid21932048",
                "pmid25390692",
                "pmid23783773",
                "pmid25443284",
                "pmid8997426"
            ]
        },
        "clinical_173": {
            "question": "What effect does vanillin have on memory deficits in a scopolamine-induced model of Alzheimer's disease?",
            "answer": "The most appropriate answer is B. It reverses memory deficits.\n\nAnswer: B. It reverses memory deficits.",
            "pmid": [
                "pmid36408377",
                "pmid38941895",
                "pmid37329974",
                "pmid33171279",
                "pmid1776749",
                "pmid38468315",
                "pmid32056532",
                "pmid29491219",
                "pmid28643520",
                "pmid20627092"
            ]
        },
        "clinical_174": {
            "question": "What was the primary symptom observed in the patient following pembrolizumab therapy that was associated with delirium?",
            "answer": "The primary symptom observed following pembrolizumab therapy that was associated with delirium was **B. Fever**.\n\nAnswer: B",
            "pmid": [
                "pmid36626467",
                "pmid20204907",
                "pmid39958332",
                "pmid22949902",
                "pmid19079356",
                "pmid20471115",
                "pmid7211435",
                "pmid25417135",
                "pmid37133446",
                "pmid39419070"
            ]
        },
        "clinical_175": {
            "question": "What effect does vinpocetine have on memory and learning impairment in an Alzheimer's disease model induced by Abeta peptide?",
            "answer": "The answer is based on multiple studies showing that vinpocetine improves cognitive performance and reduces oxidative stress in AD models. Therefore, it ameliorates memory deficits.\n\n**Answer: B. Ameliorates memory deficits**\n\nNew Answer:\nB. Ameliorates memory deficits",
            "pmid": [
                "pmid31991177",
                "pmid36927298",
                "pmid11200083",
                "pmid31175888",
                "pmid39521153",
                "pmid17008108",
                "pmid26980711",
                "pmid34706318",
                "pmid22869752",
                "pmid32241604"
            ]
        },
        "clinical_176": {
            "question": "What effect does IRL-1620, an endothelin receptor type B agonist, have on Alzheimer's disease (AD) in experimental models?",
            "answer": "The studies indicate that IRL-1620, an endothelin receptor type B agonist, has a beneficial effect on Alzheimer's disease models by improving cognitive function and reducing oxidative stress. \n\nAnswer: B. It improves cognitive function by reducing oxidative stress.",
            "pmid": [
                "pmid24561065",
                "pmid21116051",
                "pmid29947531",
                "pmid28274813",
                "pmid21193044",
                "pmid12383957",
                "pmid25443284",
                "pmid28939187",
                "pmid38682858",
                "pmid36280008"
            ]
        },
        "clinical_177": {
            "question": "What effect does SS31 have on Alzheimer's disease progression in early-stage AD?",
            "answer": "B. It delays the progression of behavioral deficits.\n\n**Answer:**  \nThe correct answer is **B**. SS31 delays the progression of behavioral deficits in early-stage Alzheimer's disease, as indicated by studies showing its protective effects on mitochondrial and synaptic function, reduction of beta-amyloid plaques, and improvement in cognitive impairments.",
            "pmid": [
                "pmid37018887",
                "pmid33991608",
                "pmid33344892",
                "pmid36396271",
                "pmid27767993",
                "pmid28157092",
                "pmid17055782",
                "pmid28186562",
                "pmid28939187",
                "pmid20634578"
            ]
        },
        "clinical_178": {
            "question": "What is a potential benefit of using B6-RES-OPC-HA nanoparticles in the treatment of Alzheimer's disease?",
            "answer": "B. They can scavenge ROS, reduce brain inflammation, and improve learning and memory ability.\n\nStep-by-step explanation:\n\n1. **Identify Relevant Study**: The study pmid37206236 discusses B6-RES-OPC-HA nanoparticles used to treat Alzheimer's disease (AD).\n\n2. **Key Findings**:\n   - These nanoparticles scavenge reactive oxygen species (ROS).\n   - They reduce brain inflammation.\n   - They improve learning and memory abilities in AD mouse models.\n\n3. **Matching with Options**:\n   - Option B directly corresponds to the findings: scavenging ROS, reducing inflammation, and enhancing cognitive functions.\n\n4. **Conclusion**: The correct answer is B based on the study's results regarding B6-RES-OPC-HA nanoparticles.\n\nAnswer: B",
            "pmid": [
                "pmid37206236",
                "pmid28630497",
                "pmid38747495",
                "pmid36949020",
                "pmid39805185",
                "pmid39281976",
                "pmid32464160",
                "pmid24802026",
                "pmid29113362",
                "pmid35095273"
            ]
        },
        "clinical_179": {
            "question": "How does mindfulness-based stress reduction (MBSR) therapy impact outcomes in cirrhosis patients and their caregivers, particularly in relation to Alzheimer's disease or delirium?",
            "answer": "The context provides two studies related to mindfulness-based interventions. Both indicate positive impacts: improved mood, sleep, and HRQOL for patients, along with reduced caregiver burden without adverse effects like increased anxiety.\n\n**Answer:** A. MBSR improves mood, sleep, and HRQOL in patients and reduces caregiver burden.",
            "pmid": [
                "pmid28749453",
                "pmid35010874",
                "pmid25154985",
                "pmid20471115",
                "pmid37133446",
                "pmid37566435",
                "pmid26279176",
                "pmid35017578",
                "pmid18845693",
                "pmid38911008"
            ]
        },
        "clinical_180": {
            "question": "What therapeutic approach does MRZ-99030 represent for Alzheimer's disease?",
            "answer": "The therapeutic approach of MRZ-99030 involves promoting large, non-toxic aggregates of Abeta, which reduces the formation of harmful oligomers. \n\n**Answer: C. Promoting large, non-toxic Abeta aggregates**",
            "pmid": [
                "pmid25634238",
                "pmid19625748",
                "pmid19141069",
                "pmid16246051",
                "pmid32233096",
                "pmid22992731",
                "pmid35759686",
                "pmid36442093",
                "pmid25390692",
                "pmid25368578"
            ]
        },
        "clinical_181": {
            "question": "What is the primary outcome measure used to assess the effectiveness of premedication in preventing emergence delirium in children undergoing strabismus surgery?",
            "answer": "The primary outcome measure used to assess the effectiveness of premedication in preventing emergence delirium in children undergoing strabismus surgery is **A. Paediatric Anaesthesia Emergence Delirium scale**.\n\n**Answer: A. Paediatric Anaesthesia Emergence Delirium scale**",
            "pmid": [
                "pmid32976205",
                "pmid37128675",
                "pmid27635747",
                "pmid36203819",
                "pmid38755693",
                "pmid33045022",
                "pmid37133446",
                "pmid36304175",
                "pmid36224337",
                "pmid27119013"
            ]
        },
        "clinical_182": {
            "question": "What is a key factor that makes ANAVEX 2-73 (blarcamesine) an intriguing candidate for Rett syndrome treatment, based on its profile in Alzheimer's disease?",
            "answer": "The key factor making ANAVEX 2-73 an intriguing candidate for Rett syndrome treatment based on its profile in Alzheimer's disease is its strong safety record and preliminary efficacy.\n\nAnswer: D",
            "pmid": [
                "pmid31704481",
                "pmid23379615",
                "pmid20950278",
                "pmid28587858",
                "pmid31966420",
                "pmid35671352",
                "pmid34502373",
                "pmid26881107",
                "pmid35048805",
                "pmid37598923"
            ]
        },
        "clinical_183": {
            "question": "What effect does reducing the levels of KIF5B have on memory impairment in Alzheimer's disease models?",
            "answer": "**Answer: B. Reduces memory impairment**\n\nReducing the levels of KIF5B improves memory function in Alzheimer's disease models by decreasing tau protein hyperphosphorylation and aggregation, as demonstrated in relevant studies.\n\nNew Answer:\n\nThe effect of reducing KIF5B levels on memory impairment in AD models is to reduce it.",
            "pmid": [
                "pmid29491219",
                "pmid28939187",
                "pmid25443284",
                "pmid27567825",
                "pmid36533331",
                "pmid20555131",
                "pmid27767993",
                "pmid36387285",
                "pmid29132092",
                "pmid37264981"
            ]
        },
        "clinical_184": {
            "question": "What is the effect of donepezil on homocysteine (Hcy) levels and dyssomnia in Alzheimer's disease patients?",
            "answer": "**Answer:**  \nB. Donepezil decreases Hcy levels and improves dyssomnia.\n\n**Explanation:**  \nDonepezil, an acetylcholinesterase inhibitor used to treat Alzheimer's disease, has been shown to lower homocysteine (Hcy) levels more effectively than other treatments such as folic acid and vitamin B12. Additionally, studies indicate that donepezil improves sleep quality by enhancing REM sleep, increasing sleep efficiency, and reducing latency, which helps alleviate dyssomnia in patients with Alzheimer's disease. Therefore, the correct answer is B: Donepezil decreases Hcy levels and improves dyssomnia.",
            "pmid": [
                "pmid30680019",
                "pmid11830754",
                "pmid39539179",
                "pmid28861608",
                "pmid25744714",
                "pmid9428950",
                "pmid35850693",
                "pmid15601392",
                "pmid29804239",
                "pmid19077054"
            ]
        },
        "clinical_185": {
            "question": "What effect did methylene blue have on neurotoxicity in a zebrafish model for tauopathies, specifically in relation to Alzheimer's disease?",
            "answer": "The most appropriate answer based on the provided context is:\n\n**C. It was ineffective in rescuing neurotoxicity.**\n\nExplanation: The study found that methylene blue did not reduce abnormal phosphorylation of Tau, prevent neuronal cell loss, or improve swimming behavior in the zebrafish model for tauopathies related to Alzheimer's disease. Therefore, it was ineffective in rescuing neurotoxicity.",
            "pmid": [
                "pmid20381619",
                "pmid24462887",
                "pmid38228217",
                "pmid33687726",
                "pmid19363289",
                "pmid26852117",
                "pmid38827230",
                "pmid27258855",
                "pmid39039682",
                "pmid21040568"
            ]
        },
        "clinical_186": {
            "question": "What is the protective effect of Housefly (Musca domestica) Larvae powder (HL) against Alzheimer's disease?",
            "answer": "The protective effect of Housefly (Musca domestica) Larvae powder (HL) against Alzheimer's disease is that it enhances memory ability and prevents oxidative stress injury. This conclusion is supported by studies showing HL improves cognitive function and reduces oxidative damage in mice models.\n\n**Answer: B. It enhances memory ability and prevents oxidative stress injury.**\n\nNew Answer:\n\nB",
            "pmid": [
                "pmid30540319",
                "pmid35530205",
                "pmid29745345",
                "pmid16821116",
                "pmid28284721",
                "pmid32321934",
                "pmid36814130",
                "pmid34896111",
                "pmid39833898",
                "pmid24694662"
            ]
        },
        "clinical_187": {
            "question": "In Alzheimer's disease, where was aluminum consistently detected?",
            "answer": "The most appropriate answer is:\n\n**C. Within the tangle-bearing neurons in the hippocampus of Alzheimer's disease cases.**\n\nThis conclusion is based on the context from pmid17004365, which explicitly states that aluminum was consistently detected within the neurofibrillary tangles of tangle-bearing neurons in the hippocampus of Alzheimer's disease patients.",
            "pmid": [
                "pmid17004365",
                "pmid2725861",
                "pmid11276052",
                "pmid7916770",
                "pmid16023263",
                "pmid22269167",
                "pmid10623648",
                "pmid22269161",
                "pmid28890316",
                "pmid2900051"
            ]
        },
        "clinical_188": {
            "question": "What category size affects verbal fluency in Alzheimer's patients?",
            "answer": "The correct answer is C. Large semantic categories.\n\n**Answer: C. Large semantic categories**",
            "pmid": [
                "pmid15010242",
                "pmid37672106",
                "pmid27767993",
                "pmid26017202",
                "pmid29080407",
                "pmid17851237",
                "pmid16286547",
                "pmid34665329",
                "pmid24607963",
                "pmid23558480"
            ]
        },
        "clinical_189": {
            "question": "What brain changes are described as examples of aging and Alzheimer's disease?",
            "answer": "B. Choline acetyltransferase, somatostatin-containing neurons, and dendrites.\n\n**Answer: B.**",
            "pmid": [
                "pmid2893306",
                "pmid11124422",
                "pmid9850923",
                "pmid38102439",
                "pmid21035308",
                "pmid17055782",
                "pmid36396271",
                "pmid35569719",
                "pmid29080407",
                "pmid11276052"
            ]
        },
        "clinical_190": {
            "question": "What changes occur in cortical mean diffusivity (MD) in early Alzheimer's disease?",
            "answer": "C. Cortical MD decreases compared to healthy controls.",
            "pmid": [
                "pmid29080407",
                "pmid22651939",
                "pmid2893306",
                "pmid25267349",
                "pmid31706220",
                "pmid31139072",
                "pmid20202480",
                "pmid24607963",
                "pmid7916770",
                "pmid34665329"
            ]
        },
        "clinical_191": {
            "question": "Which brain region correlates with ideomotor and dressing apraxia in Alzheimer's disease?",
            "answer": "The study in pmid9605726 directly links ideomotor and dressing apraxia to neurofibrillary tangle densities in the anterior cingulate cortex. \n\n**Answer: C. Anterior cingulate cortex**",
            "pmid": [
                "pmid9605726",
                "pmid7916770",
                "pmid38958450",
                "pmid11276052",
                "pmid27195475",
                "pmid10965795",
                "pmid11124422",
                "pmid14507668",
                "pmid18334759",
                "pmid24607963"
            ]
        },
        "clinical_192": {
            "question": "Which animals are proposed as natural, non-transgenic models for Alzheimer's disease research?",
            "answer": "C. The chick embryo and the dog",
            "pmid": [
                "pmid19355852",
                "pmid38228217",
                "pmid33687726",
                "pmid38827230",
                "pmid25443284",
                "pmid30392874",
                "pmid25529196",
                "pmid38735056",
                "pmid20881126",
                "pmid31089063"
            ]
        },
        "clinical_193": {
            "question": "What differences in outcome were observed between men and women with Alzheimer's disease?",
            "answer": "C. Men with Alzheimer's disease had greater comorbid conditions and higher mortality, while women recorded more disability and longer survival.\n\n**Answer: C**",
            "pmid": [
                "pmid20733307",
                "pmid37330146",
                "pmid35708851",
                "pmid33301871",
                "pmid39497354",
                "pmid22367434",
                "pmid29471055",
                "pmid19478482",
                "pmid15010242",
                "pmid30044040"
            ]
        },
        "clinical_194": {
            "question": "How does chronic kidney disease affect cognitive impairment in Alzheimer's disease mice?",
            "answer": "C. Chronic kidney disease accelerates cognitive impairment in 5XFAD mice, potentially through angiotensin II.",
            "pmid": [
                "pmid27916702",
                "pmid12881482",
                "pmid25443284",
                "pmid33597269",
                "pmid39840463",
                "pmid30026693",
                "pmid26003667",
                "pmid34168550",
                "pmid38241837",
                "pmid22033930"
            ]
        },
        "clinical_195": {
            "question": "How does dual tasking affect postural sway in preclinical Alzheimer's disease?",
            "answer": "The correct answer is:\n\nC. Participants with preclinical Alzheimer's disease demonstrated significantly greater dual task cost in postural sway compared to those without preclinical AD.\n\n**Step-by-Step Explanation:**\n\n1. **Understanding Dual Tasking and Postural Sway:** Dual tasking involves performing two tasks simultaneously, which can affect balance (postural sway). In the context of preclinical Alzheimer's disease, this study examined how early-stage individuals fare under such conditions.\n\n2. **Relevant Abstract Analysis:** The abstract with pmid38554257 details a study comparing postural sway in older adults with and without preclinical AD. Using dual task conditions, they found that those with preclinical AD had significantly higher dual task costs (DTC) in postural sway.\n\n3. **Interpreting Results:** Higher DTC means more difficulty maintaining balance while performing another task. This indicates impaired ability to manage multiple tasks concurrently in preclinical stages.\n\n4. **Evaluating Answer Choices:**\n   - A and B are incorrect because they suggest less or no impact, which contradicts the study's findings.\n   - C is correct as it accurately reflects the increased DTC observed in individuals with preclinical AD.\n   - D is incorrect because the study shows effects at the preclinical stage, not just advanced stages.\n\nThus, option C correctly answers how dual tasking affects postural sway in preclinical Alzheimer's disease.",
            "pmid": [
                "pmid38554257",
                "pmid9605726",
                "pmid36396271",
                "pmid17851237",
                "pmid25267349",
                "pmid2893306",
                "pmid29080407",
                "pmid20202480",
                "pmid25820930",
                "pmid19940172"
            ]
        },
        "clinical_196": {
            "question": "What two main factors affect support for Iranian older spousal caregivers of people with Alzheimer's disease?",
            "answer": "C. Caregiver's support-seeking and capacities of support resources.",
            "pmid": [
                "pmid39097934",
                "pmid21488579",
                "pmid38554257",
                "pmid20733307",
                "pmid30044040",
                "pmid39781717",
                "pmid28269768",
                "pmid27122004",
                "pmid30820047",
                "pmid30483306"
            ]
        },
        "clinical_197": {
            "question": "What condition can share cognitive decline and a positive Amyloid-PET scan with Alzheimer's disease?",
            "answer": "The condition that shares cognitive decline and a positive Amyloid-PET scan with Alzheimer's disease is:\n\n**C. Cerebral amyloid angiopathy**\n\nAnswer: C",
            "pmid": [
                "pmid38405347",
                "pmid25820930",
                "pmid37123373",
                "pmid18418593",
                "pmid16286547",
                "pmid38102439",
                "pmid25212911",
                "pmid19940172",
                "pmid24748672",
                "pmid20202480"
            ]
        },
        "clinical_198": {
            "question": "Which brain area shows decreased diffusivity potentially indicating early Alzheimer's disease?",
            "answer": "The most appropriate answer is based on the context from pmid22651939, which highlights decreased diffusivity in the posterior cingulate/precuneus as a potential early indicator of Alzheimer's disease.\n\n**Answer: C. Posterior cingulate/precuneus**",
            "pmid": [
                "pmid22651939",
                "pmid29080407",
                "pmid24607963",
                "pmid11351135",
                "pmid14507668",
                "pmid38958450",
                "pmid11124422",
                "pmid19220710",
                "pmid11276052",
                "pmid25212911"
            ]
        },
        "clinical_199": {
            "question": "Which delirium subtypes are associated with shorter survival periods in terminally ill patients?",
            "answer": "C. Hypoactive and mixed subtypes",
            "pmid": [
                "pmid26397939",
                "pmid37133446",
                "pmid37566435",
                "pmid20471115",
                "pmid36078999",
                "pmid17183425",
                "pmid37610551",
                "pmid31301637",
                "pmid37851904",
                "pmid19269948"
            ]
        },
        "clinical_200": {
            "question": "Which cognitive tests correlate with functional decline in both Parkinson's and Alzheimer's disease?",
            "answer": "B. Rey Auditory Verbal Learning Test (AVLT), Controlled Oral Word Association (COWA), and Animal Fluency;",
            "pmid": [
                "pmid17851237",
                "pmid24748672",
                "pmid25820930",
                "pmid26724962",
                "pmid37672106",
                "pmid20202480",
                "pmid23558480",
                "pmid37123373",
                "pmid22126938",
                "pmid32728647"
            ]
        },
        "clinical_201": {
            "question": "What pathology is linked to iatrogenic Alzheimer's disease in growth hormone recipients?",
            "answer": "The pathology linked to iatrogenic Alzheimer's disease in cadaveric pituitary-derived growth hormone recipients, as described in the context, is characterized by Abeta deposition in brain parenchyma and blood vessels (cerebral amyloid angiopathy) along with neurofibrillary tangles of hyperphosphorylated tau.\n\n**Answer: C. Abeta deposition in brain parenchyma and blood vessels (cerebral amyloid angiopathy) and neurofibrillary tangles of hyperphosphorylated tau.**",
            "pmid": [
                "pmid38287166",
                "pmid10623648",
                "pmid22269167",
                "pmid12960778",
                "pmid32444869",
                "pmid11145195",
                "pmid16023263",
                "pmid19091971",
                "pmid12410385",
                "pmid16943563"
            ]
        },
        "clinical_202": {
            "question": "What functional domains were identified as highly relevant for assessment in early Alzheimer's disease?",
            "answer": "The correct answer is B: Difficulties at work, spatial navigation and memory, and planning skills and memory required for task completion.\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Information:** The first PM (pmid33250792) explicitly lists the highly relevant functional domains as \"difficulties at work,\" \"spatial navigation and memory,\" and \"planning skills and memory required for task completion.\"\n\n2. **Check Other References:** Other PMs discuss various aspects of AD but do not mention these specific domains as highly relevant.\n\n3. **Match with Options:** Option B exactly matches the domains listed in the first PM, making it the correct choice.\n\n**Answer:** B",
            "pmid": [
                "pmid33250792",
                "pmid17851237",
                "pmid37672106",
                "pmid15010242",
                "pmid26017202",
                "pmid36396271",
                "pmid9605726",
                "pmid23558480",
                "pmid34665329",
                "pmid27056068"
            ]
        },
        "clinical_203": {
            "question": "What role do home healthcare nurses play in delirium?",
            "answer": "The most appropriate answer based on the provided information is:\n\n**Answer: C. They play a key role in the assessment, early identification, and management of delirium, and in the support and education of patients and their family caregivers.**\n\nThis aligns with the information from pmid19114784 which explicitly states the roles of home healthcare nurses in delirium.",
            "pmid": [
                "pmid19114784",
                "pmid37133446",
                "pmid28673598",
                "pmid30142098",
                "pmid21488579",
                "pmid22132368",
                "pmid17183425",
                "pmid17352663",
                "pmid23448799",
                "pmid37566435"
            ]
        },
        "clinical_204": {
            "question": "What data types were used to identify conversion from normal cognition to Alzheimer's disease?",
            "answer": "The study utilized magnetic resonance imaging (MRI) and positron emission tomography (PET) data to identify conversions from normal cognition to MCI or Alzheimer's disease. \n\n**Answer:** C. Magnetic resonance imaging and positron emission tomography data.",
            "pmid": [
                "pmid26401783",
                "pmid25212911",
                "pmid20202480",
                "pmid16286547",
                "pmid11276052",
                "pmid8327146",
                "pmid23558480",
                "pmid18418593",
                "pmid7906947",
                "pmid36396271"
            ]
        },
        "clinical_205": {
            "question": "Which brain volumes at baseline predict cognitive outcomes in early-onset Alzheimer's disease?",
            "answer": "The correct answer is:\n\n**C. Hemispheric cortical thickness, ventricular volume, and amygdalar volume.**\n\nThis conclusion is supported by the study (pmid34665329) which specifically found these volumes to predict cognitive outcomes in early-onset Alzheimer's disease.",
            "pmid": [
                "pmid34665329",
                "pmid24607963",
                "pmid29080407",
                "pmid9710003",
                "pmid22651939",
                "pmid20202480",
                "pmid19940172",
                "pmid19683583",
                "pmid19220710",
                "pmid25212911"
            ]
        },
        "clinical_206": {
            "question": "Which factors significantly increase the risk of delirium in trauma ICU patients?",
            "answer": "The most appropriate answer is C. Physical restraints and active infection or sepsis significantly increase the risk of delirium in trauma ICU patients as identified by pmid28335673.\n\n**Answer: C. Physical restraints and active infection or sepsis.**",
            "pmid": [
                "pmid28335673",
                "pmid29657370",
                "pmid17949984",
                "pmid33835902",
                "pmid37133446",
                "pmid38482541",
                "pmid35815182",
                "pmid17352663",
                "pmid20030432",
                "pmid21721434"
            ]
        },
        "clinical_207": {
            "question": "Does combining MAOI with tricyclic antidepressants increase the risk of delirium?",
            "answer": "A: Yes",
            "pmid": [
                "pmid6376486",
                "pmid38409802",
                "pmid38911008",
                "pmid23385102",
                "pmid20204907",
                "pmid26674479",
                "pmid38135802",
                "pmid37133446",
                "pmid34807273",
                "pmid37550780"
            ]
        },
        "clinical_208": {
            "question": "What mechanisms are associated with levofloxacin-induced delirium?",
            "answer": "A",
            "pmid": [
                "pmid31178301",
                "pmid18585545",
                "pmid23914753",
                "pmid23909707",
                "pmid22390219",
                "pmid37313848",
                "pmid19422109",
                "pmid39419070",
                "pmid20309566",
                "pmid7916159"
            ]
        },
        "clinical_209": {
            "question": "Are there cases of delirium related to intrathecal baclofen?",
            "answer": "A: A",
            "pmid": [
                "pmid19079356",
                "pmid34123673",
                "pmid2524220",
                "pmid27058253",
                "pmid31178301",
                "pmid1949310",
                "pmid28585290",
                "pmid33814433",
                "pmid19422109",
                "pmid549538"
            ]
        },
        "clinical_210": {
            "question": "What are the perceived benefits of early out-of-bed mobilisation in reducing delirium risk among patients with severe acquired brain injury?",
            "answer": "The perceived benefits of early out-of-bed mobilization are considered beneficial for reducing delirium risk. \n\nAnswer: C\nNew Answer: C",
            "pmid": [
                "pmid39788872",
                "pmid37133446",
                "pmid28335673",
                "pmid24259659",
                "pmid36973363",
                "pmid28243098",
                "pmid20471115",
                "pmid37566435",
                "pmid36939716",
                "pmid24852225"
            ]
        },
        "clinical_211": {
            "question": "Does concomitant use of hydroxyzine with haloperidol worsen delirium in patients with cancer?",
            "answer": "B. No",
            "pmid": [
                "pmid38409802",
                "pmid32162816",
                "pmid17443602",
                "pmid17381385",
                "pmid22949902",
                "pmid23859663",
                "pmid17317453",
                "pmid23503785",
                "pmid26122223",
                "pmid8803381"
            ]
        },
        "clinical_212": {
            "question": "Does perioperative delirium increase the risk of Alzheimer’s disease?",
            "answer": "B. No",
            "pmid": [
                "pmid35525395",
                "pmid35034675",
                "pmid27662296",
                "pmid36224337",
                "pmid26238230",
                "pmid29723848",
                "pmid37550780",
                "pmid36939716",
                "pmid38161287",
                "pmid37364279"
            ]
        },
        "clinical_213": {
            "question": "What non-motor symptoms of Parkinson’s disease are associated with postoperative delirium in elderly patients undergoing spinal surgery?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid29630637",
                "pmid30051417",
                "pmid10473947",
                "pmid30488836",
                "pmid7762856",
                "pmid23365056",
                "pmid36224337",
                "pmid30692764",
                "pmid36304175",
                "pmid37364279"
            ]
        },
        "clinical_214": {
            "question": "What is the effect of dexmedetomidine infusion on postoperative delirium in elderly patients undergoing oral and maxillofacial surgery?",
            "answer": "The most appropriate answer based on the provided context is:\n\nC. It had no significant effect on postoperative delirium.\n\nAnswer: C",
            "pmid": [
                "pmid35846796",
                "pmid29958125",
                "pmid32477139",
                "pmid19237264",
                "pmid7762856",
                "pmid10473947",
                "pmid36304175",
                "pmid37773821",
                "pmid16670110",
                "pmid36224337"
            ]
        },
        "clinical_215": {
            "question": "What is the effect of the Haga Brain Care Strategy on postoperative delirium rates?",
            "answer": "The Haga Brain Care Strategy leads to a reduction in the incidence of postoperative delirium. \n\n**Answer: C. It leads to a reduction in the incidence of postoperative delirium.**",
            "pmid": [
                "pmid22778141",
                "pmid27119013",
                "pmid19237264",
                "pmid36224337",
                "pmid37773821",
                "pmid10473947",
                "pmid37364279",
                "pmid16670110",
                "pmid30051417",
                "pmid38755693"
            ]
        },
        "clinical_216": {
            "question": "What factors are associated with an increased risk of delirium episodes in elderly patients with asthma during hospitalization?",
            "answer": "The correct answer based on the provided context is:\n\n**D. Advanced age, dementia, smoking, and uncontrolled or partially controlled asthma.**\n\nThis conclusion is supported by the study (pmid34250429) which identifies these factors as associated with an increased risk of delirium in elderly patients with asthma during hospitalization.",
            "pmid": [
                "pmid34250429",
                "pmid21721434",
                "pmid21206582",
                "pmid17183425",
                "pmid37812498",
                "pmid21488579",
                "pmid29966197",
                "pmid22195685",
                "pmid20471115",
                "pmid29723848"
            ]
        },
        "clinical_217": {
            "question": "Do esketamine and dexmedetomidine help in preventing postoperative delirium in elderly patients undergoing thoracic surgery?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid37917895",
                "pmid7762856",
                "pmid29958125",
                "pmid35846796",
                "pmid10473947",
                "pmid16670110",
                "pmid30488836",
                "pmid36304175",
                "pmid38979845",
                "pmid37773821"
            ]
        },
        "clinical_218": {
            "question": "Do melatonin receptor agonists reduce the risk of postoperative delirium compared to zolpidem and temazepam in older adults?",
            "answer": "B. No",
            "pmid": [
                "pmid38979845",
                "pmid38911008",
                "pmid16670110",
                "pmid7762856",
                "pmid30488836",
                "pmid30481216",
                "pmid36224337",
                "pmid37773821",
                "pmid19237264",
                "pmid39541802"
            ]
        },
        "clinical_219": {
            "question": "Does delirium occur after alcohol withdrawal seizures in patients treated with oxazepam?",
            "answer": "The provided context primarily discusses the use of benzodiazepines like oxazepam for managing alcohol withdrawal symptoms, including preventing seizures. It highlights their effectiveness compared to other medications but doesn't specifically address whether delirium occurs after seizures when using oxazepam. Therefore, based on the information given, it's not possible to confirm that delirium does occur in such cases.\n\n**Answer: B. No**\n\nNew Answer:  Based on the contextual information provided above, the most appropriate answer is B. No.\n</think>\n\nBased on the analysis of the context provided, there is no specific evidence indicating that delirium occurs after alcohol withdrawal seizures in patients treated with oxazepam. The primary references discuss the use of benzodiazepines like oxazepam for managing withdrawal symptoms and preventing severe complications but do not specifically address post-seizure delirium.\n\n**Answer: B. No**\n\nThe most appropriate answer is:\n\n**Final Answer: B. No**",
            "pmid": [
                "pmid7573789",
                "pmid9214531",
                "pmid23385102",
                "pmid31568239",
                "pmid26861990",
                "pmid38024021",
                "pmid6139883",
                "pmid35224452",
                "pmid17323538",
                "pmid34978"
            ]
        },
        "clinical_220": {
            "question": "What types of delirium are associated with increased one-year mortality in critically ill patients with cancer?",
            "answer": "C",
            "pmid": [
                "pmid26397939",
                "pmid37610551",
                "pmid37133446",
                "pmid37566435",
                "pmid29657370",
                "pmid20471115",
                "pmid17183425",
                "pmid17352663",
                "pmid36078999",
                "pmid25417135"
            ]
        },
        "clinical_221": {
            "question": "What are the complications associated with delirium in men with spinal cord injury following lower extremity fractures?",
            "answer": "The provided context discusses biomarkers and CSF analysis related to delirium but does not specifically address complications associated with delirium in men with spinal cord injury following lower extremity fractures. Therefore, based on the given information:\n\n**Answer: UNRELATED**",
            "pmid": [
                "pmid23392311",
                "pmid27058253",
                "pmid25943983",
                "pmid28335673",
                "pmid33814433",
                "pmid24093540",
                "pmid39316273",
                "pmid31058343",
                "pmid26675981",
                "pmid34736422"
            ]
        },
        "clinical_222": {
            "question": "Does delirium in neurocritically ill patients predict relevant clinical outcomes such as functional independence and cognition?",
            "answer": "A. Yes",
            "pmid": [
                "pmid30142098",
                "pmid38171949",
                "pmid37133446",
                "pmid36939716",
                "pmid28519903",
                "pmid32881052",
                "pmid11563209",
                "pmid34098376",
                "pmid26397939",
                "pmid28673598"
            ]
        },
        "clinical_223": {
            "question": "Does the presence of Confusion Assessment Method (CAM) core symptoms at baseline predict incident delirium in older long-term care residents?",
            "answer": "The presence of Confusion Assessment Method (CAM) core symptoms at baseline does predict incident delirium in older long-term care residents.\n\n**Answer: A. Yes**\n\nNew Answer:\nA. Yes",
            "pmid": [
                "pmid23448799",
                "pmid37566435",
                "pmid17183425",
                "pmid29966197",
                "pmid34098376",
                "pmid11563209",
                "pmid37133446",
                "pmid21488579",
                "pmid37812498",
                "pmid37251808"
            ]
        },
        "clinical_224": {
            "question": "Does hypercapnia in patients with chronic obstructive pulmonary disease (COPD) lead to delirium?",
            "answer": "The answer is A: Yes. Hypercapnia in patients with chronic obstructive pulmonary disease (COPD) can lead to delirium, as indicated by the provided context.\n\nAnswer: A",
            "pmid": [
                "pmid27736515",
                "pmid17352663",
                "pmid37133446",
                "pmid17949984",
                "pmid36078999",
                "pmid34250429",
                "pmid33835902",
                "pmid37566435",
                "pmid26397939",
                "pmid38135802"
            ]
        },
        "clinical_225": {
            "question": "Does Five-Element music therapy reduce the incidence of delirium in ICU patients with difficult weaning?",
            "answer": "B. No",
            "pmid": [
                "pmid39586722",
                "pmid37133446",
                "pmid24259659",
                "pmid36078999",
                "pmid18577171",
                "pmid20375300",
                "pmid38911008",
                "pmid28335673",
                "pmid17949984",
                "pmid29657370"
            ]
        },
        "clinical_226": {
            "question": "What is the effect of perioperative dexmedetomidine administration on delirium incidence in patients after cardiac surgery?",
            "answer": "C. Perioperative dexmedetomidine administration significantly decreases the incidence of postoperative delirium.\n\n**Step-by-Step Explanation:**\n\n1. **Review Relevant Studies:** \n   - pmid29958125 directly addresses the impact of dexmedetomidine on delirium after cardiac surgery, showing a significant decrease.\n   - Other studies either focus on different patient populations or don't discuss dexmedetomidine's effect on delirium.\n\n2. **Key Findings:**\n   - The meta-analysis (pmid29958125) concludes that dexmedetomidine reduces delirium incidence with statistical significance.\n   - Supporting evidence from other studies, though not specific to cardiac surgery, indicates dexmedetomidine's efficacy in reducing delirium.\n\n3. **Conclusion:**\n   - The most consistent and direct evidence points to a significant decrease in delirium incidence when using perioperative dexmedetomidine in cardiac surgery patients.\n\n**Answer:** C. Perioperative dexmedetomidine administration significantly decreases the incidence of postoperative delirium.",
            "pmid": [
                "pmid29958125",
                "pmid27119013",
                "pmid35846796",
                "pmid10473947",
                "pmid19237264",
                "pmid32987655",
                "pmid37128675",
                "pmid17088170",
                "pmid36224337",
                "pmid34807273"
            ]
        },
        "clinical_227": {
            "question": "Does initiating pharmacologic delirium treatment within 24 hours reduce physical restraint use in ICU patients?",
            "answer": "A. Yes",
            "pmid": [
                "pmid24259659",
                "pmid18577171",
                "pmid20375300",
                "pmid37133446",
                "pmid36078999",
                "pmid33835902",
                "pmid16678002",
                "pmid38482541",
                "pmid28910303",
                "pmid39541802"
            ]
        },
        "clinical_228": {
            "question": "What is the presentation of delirium caused by chloromethcathinone and cannabis ingestion?",
            "answer": "The presentation of delirium caused by chloromethcathinone and cannabis ingestion is best described as:\n\n**C. Prolonged excited delirium syndrome with severe agitation lasting over 24 hours.**\n\nThis conclusion is supported by the case studies in pmid33093258, which detail two instances where patients experienced prolonged agitated delirium following ingestion of these substances.",
            "pmid": [
                "pmid33093258",
                "pmid26956672",
                "pmid34978",
                "pmid36059364",
                "pmid19422109",
                "pmid37133446",
                "pmid34908693",
                "pmid31301637",
                "pmid7211434",
                "pmid25417135"
            ]
        },
        "clinical_229": {
            "question": "Does normal pressure hydrocephalus (NTH) have an association with delirium?",
            "answer": "The answer is A: Yes.\n\nStep-by-step explanation:\n- The first article directly links NTH to delirium in a case study, indicating an association.\n- Other articles discuss various aspects of delirium but do not mention NTH.\n- Therefore, based on the provided context, NTH can be associated with delirium. \n\nAnswer: A",
            "pmid": [
                "pmid1949310",
                "pmid17949984",
                "pmid36078999",
                "pmid28519903",
                "pmid7916159",
                "pmid37550780",
                "pmid37566435",
                "pmid30142098",
                "pmid34978",
                "pmid27058253"
            ]
        },
        "clinical_230": {
            "question": "What is the effect of remimazolam administration at the end of tonsillectomy and adenoidectomy under sevoflurane anesthesia on the incidence of emergence delirium in children?",
            "answer": "C",
            "pmid": [
                "pmid36203819",
                "pmid37128675",
                "pmid39464168",
                "pmid27635747",
                "pmid38895540",
                "pmid28910303",
                "pmid32976205",
                "pmid36979321",
                "pmid32641746",
                "pmid35682930"
            ]
        },
        "clinical_231": {
            "question": "What factors predict ICU admission among Parkinson's disease patients with delirium?",
            "answer": "B",
            "pmid": [
                "pmid30692764",
                "pmid29966197",
                "pmid37812498",
                "pmid21721434",
                "pmid29630637",
                "pmid17183425",
                "pmid37133446",
                "pmid17352663",
                "pmid21488579",
                "pmid17949984"
            ]
        },
        "clinical_232": {
            "question": "An elderly patient is scheduled for primary total joint arthroplasty. Which of the following combinations of factors is most strongly associated with an increased risk of developing postoperative delirium?",
            "answer": "B",
            "pmid": [
                "pmid39259060",
                "pmid28622817",
                "pmid34901277",
                "pmid16696749",
                "pmid39638735",
                "pmid34772392",
                "pmid31880243",
                "pmid15467965",
                "pmid32611398",
                "pmid25774049"
            ]
        },
        "clinical_233": {
            "question": "Which of the following best describes the relationship between BDNF levels and delirium tremens (DT) in alcohol withdrawal?",
            "answer": "The correct answer is D. Lower baseline BDNF levels are associated with an increased risk of delirium tremens (DT) and improve after detoxification.\n\n**Answer:** D.",
            "pmid": [
                "pmid21039634",
                "pmid34060728",
                "pmid32001926",
                "pmid38928583",
                "pmid34978",
                "pmid17250608",
                "pmid7211434",
                "pmid36078999",
                "pmid17434673",
                "pmid20002020"
            ]
        }
    },
    "cell": {
        "cell_0": {
            "question": "Does Platycodin D inhibit beta-amyloid-induced inflammation and oxidative stress in BV-2 cells, relevant to Alzheimer's disease?",
            "answer": "The answer is **A. Yes** because the study (PMID33394221) specifically shows that Platycodin D inhibits beta-amyloid-induced inflammation and oxidative stress in BV-2 cells, which are relevant to Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid33394221",
                "pmid31487775",
                "pmid33811504",
                "pmid38968796",
                "pmid30404965",
                "pmid34329731",
                "pmid24333930",
                "pmid31606373",
                "pmid29454265",
                "pmid21276834"
            ]
        },
        "cell_1": {
            "question": "Do activated astrocytes contribute to Abeta production, implicated in Alzheimer's disease pathogenesis?",
            "answer": "A. Yes",
            "pmid": [
                "pmid22047170",
                "pmid11114266",
                "pmid11755001",
                "pmid25233405",
                "pmid29033790",
                "pmid37248300",
                "pmid22101005",
                "pmid25814669",
                "pmid35872221",
                "pmid33731156"
            ]
        },
        "cell_2": {
            "question": "Does beta-patchoulene alleviate delirium by inhibiting microglia activation through the Sirt1/Nrf2 pathway?",
            "answer": "The provided context does not mention beta-patchoulene or its interaction with the Sirt1/Nrf2 pathway in relation to delirium. Therefore, based on the information available:\n\n**Answer: UNRELATED**",
            "pmid": [
                "pmid22683080",
                "pmid37313848",
                "pmid38911008",
                "pmid31244434",
                "pmid36216079",
                "pmid36077505",
                "pmid34234505",
                "pmid20309566",
                "pmid38566855",
                "pmid39541802"
            ]
        },
        "cell_3": {
            "question": "Do atypical antipsychotic drugs (APDs) reduce beta-amyloid peptide(25-35)-induced PC12 cell death, relevant to Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid14648600",
                "pmid15948179",
                "pmid24424093",
                "pmid8922409",
                "pmid12212794",
                "pmid9410912",
                "pmid28714389",
                "pmid20307525",
                "pmid29120942",
                "pmid26696494"
            ]
        },
        "cell_4": {
            "question": "Does TUDCA reduce p53-induced apoptosis in Alzheimer's disease mutant neuroblastoma cells?",
            "answer": "**Answer: A. Yes**\n\nThe contextual information provided in pmid16923170 directly indicates that TUDCA modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells by reducing nuclear fragmentation and caspase activities, as well as modulating Bcl-2 family expression. Additionally, it shows that TUDCA reduces apoptosis induced by p53 overexpression. Therefore, the answer is yes.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid16923170",
                "pmid25443293",
                "pmid10377452",
                "pmid15208744",
                "pmid9464644",
                "pmid26967221",
                "pmid25457551",
                "pmid25371750",
                "pmid25774173",
                "pmid15548589"
            ]
        },
        "cell_5": {
            "question": "Does oligomeric amyloid-beta (Abeta) stimulate NFAT activation in astrocyte cultures, potentially contributing to Alzheimer's disease progression?",
            "answer": "The provided context does not mention NFAT activation in response to Abeta oligomers. Therefore, we cannot confirm that Abeta stimulates NFAT activation in astrocytes.\n\n**Answer: B. No**\n\nNew Answer: The new context discusses the role of NF-kappaB in COX-2 and PGE2 synthesis induced by Abeta1-42 in astrocytic cells, as well as the toxic effects of Abeta-treated supernatants on neuroblastoma cells that were blocked by PDTC. However, there is no mention of NFAT activation or its role in this process. The additional abstract (pmid35264247) focuses on necroptosis mediated by microglia activation and does not address NFAT or astrocytes directly.\n\nAnswer: B",
            "pmid": [
                "pmid29033790",
                "pmid11114266",
                "pmid20401186",
                "pmid37248300",
                "pmid19828810",
                "pmid25169677",
                "pmid25814669",
                "pmid11137881",
                "pmid20847443",
                "pmid35264247"
            ]
        },
        "cell_6": {
            "question": "Does dihydroactinidiolide (DHAc) protect SH-SY5Y cells from oxidative stress-induced neuronal apoptosis in an Alzheimer's disease model?",
            "answer": "**Answer: A. Yes**\n\nThe study indicates that dihydroactinidiolide (DHAc) protects SH-SY5Y cells from oxidative stress-induced neuronal apoptosis in an Alzheimer's disease model by regulating Nrf2/HO-1 expression and inhibiting the caspase-3/Bax pathway.\n\nNew Answer:\nA. Yes\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid33617922",
                "pmid18037281",
                "pmid38729530",
                "pmid37409350",
                "pmid23645098",
                "pmid31900522",
                "pmid17886039",
                "pmid29873184",
                "pmid24374316",
                "pmid31677009"
            ]
        },
        "cell_7": {
            "question": "Do viral infections contribute to Alzheimer's disease by reducing neprilysin levels in astrocytes?",
            "answer": "The evidence indicates that viral infections can indeed reduce neprilysin (NEP) levels in astrocytes, contributing to Alzheimer's disease. Studies show that viral agonists like poly(I:C) decrease NEP activity, impairing Abeta clearance and increasing neurotoxicity. Additionally, reduced NEP is associated with AD pathologies such as amyloid plaques and cerebral angiopathy. Therefore:\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid38561809",
                "pmid12387451",
                "pmid28765170",
                "pmid24502805",
                "pmid25157230",
                "pmid37009449",
                "pmid23052602",
                "pmid36321194",
                "pmid17591969",
                "pmid17021406"
            ]
        },
        "cell_8": {
            "question": "Does disruption of the Sigma-2 receptor complex-TMEM97, PGRMC1, and LDLR affect Abeta42 uptake in primary neurons, potentially relevant to Alzheimer's disease progression?",
            "answer": "The disruption of the Sigma-2 receptor complex, including TMEM97, PGRMC1, and LDLR, significantly impacts the cellular uptake of Abeta42 in primary neurons. Studies demonstrate that this complex is crucial for internalizing Abeta42 monomers and oligomers, with its disruption leading to reduced uptake. Therefore, this disruption is relevant to Alzheimer's disease progression.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid32572762",
                "pmid25390692",
                "pmid27926996",
                "pmid8740986",
                "pmid18509040",
                "pmid9878757",
                "pmid19710315",
                "pmid18400893",
                "pmid34663480",
                "pmid8687030"
            ]
        },
        "cell_9": {
            "question": "Does AT2R activation contribute to neuroprotection in Alzheimer's disease by inhibiting microglia pro-inflammatory activation?",
            "answer": "**Answer: A. Yes**\n\nAT2R activation contributes to neuroprotection in Alzheimer's disease by inhibiting microglial pro-inflammatory activation.",
            "pmid": [
                "pmid17911636",
                "pmid30076526",
                "pmid21088470",
                "pmid25169677",
                "pmid12453679",
                "pmid18509040",
                "pmid39695808",
                "pmid18835047",
                "pmid25485684",
                "pmid31031598"
            ]
        },
        "cell_10": {
            "question": "Does TRPV4-induced oxidative stress contribute to neurotoxicity in Alzheimer's disease?",
            "answer": "The analysis shows that TRPV4 activation leads to increased production of reactive oxygen species and nitric oxide, contributing to neuronal damage through oxidative stress. Multiple studies confirm the involvement of oxidative stress pathways in Alzheimer's disease neurotoxicity. Therefore, TRPV4-induced oxidative stress does contribute.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid27799895",
                "pmid33774476",
                "pmid36990137",
                "pmid8725383",
                "pmid34922273",
                "pmid21351586",
                "pmid16873963",
                "pmid30288371",
                "pmid33998138",
                "pmid8052661"
            ]
        },
        "cell_11": {
            "question": "Does GPR120 signaling in astrocytes negatively regulate amyloid-beta degradation in Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe study indicates that GPR120 signaling negatively regulates amyloid-beta degradation in astrocytes by controlling the activity of matrix metalloproteinases (MMPs). Inhibiting GPR120 increases MMP activity and reduces TIMP levels, enhancing Abeta degradation. Therefore, GPR120 signaling plays a role in negatively regulating this process.",
            "pmid": [
                "pmid34099509",
                "pmid36161942",
                "pmid25637481",
                "pmid38447415",
                "pmid34981861",
                "pmid28455519",
                "pmid18395194",
                "pmid26200696",
                "pmid11447833",
                "pmid25814669"
            ]
        },
        "cell_12": {
            "question": "Does PQQ protect primary cortical neurons against microglia-mediated neurotoxicity, potentially relevant in Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid22655214",
                "pmid8892352",
                "pmid15172747",
                "pmid22186599",
                "pmid29120942",
                "pmid11592111",
                "pmid25314304",
                "pmid8871946",
                "pmid24934545",
                "pmid24164736"
            ]
        },
        "cell_13": {
            "question": "Does SIRT2 play a significant role in astrocytic GABA production in Alzheimer's disease?",
            "answer": "The provided context specifically addresses SIRT2 and its role in astrocytic GABA production. Studies indicate that inhibiting SIRT2 reduces GABA levels but not H₂O₂, and restoring SIRT2 expression improves memory function. This demonstrates a significant role of SIRT2.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid39815261",
                "pmid24860504",
                "pmid16183991",
                "pmid30362958",
                "pmid33710537",
                "pmid35872221",
                "pmid26045440",
                "pmid31808750",
                "pmid26200696",
                "pmid33021962"
            ]
        },
        "cell_14": {
            "question": "Could an MMP-8 inhibitor be therapeutic for Alzheimer's disease by reducing astrocyte reactivity?",
            "answer": "Based on the information provided, the study in pmid30470240 indicates that an MMP-8 inhibitor can reduce astrocyte reactivity by decreasing inflammatory markers and enhancing antioxidant responses. Therefore, it suggests that an MMP-8 inhibitor could be therapeutic for Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid30470240",
                "pmid9890433",
                "pmid38006681",
                "pmid31264132",
                "pmid20555131",
                "pmid32331524",
                "pmid35883683",
                "pmid30076715",
                "pmid21376707",
                "pmid39563011"
            ]
        },
        "cell_15": {
            "question": "Does hBD3 inhibit Pg LPS-induced oxidative and inflammatory responses in microglia, relevant to Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid28266714",
                "pmid38561809",
                "pmid39002124",
                "pmid36499428",
                "pmid26675131",
                "pmid31677009",
                "pmid34329731",
                "pmid22655214",
                "pmid31382012",
                "pmid24803746"
            ]
        },
        "cell_16": {
            "question": "Does Phillyrin prevent BBB damage by inhibiting microglial neuroinflammation through the PPARgamma/NF-kappaB pathway, potentially relevant to Alzheimer's disease?",
            "answer": "The answer is UNRELATED as the provided contexts do not discuss Phillyrin, its effect on BBB damage, or its interaction with the PPARgamma/NF-kappaB pathway.\n\nUNRELATED",
            "pmid": [
                "pmid32028243",
                "pmid23279783",
                "pmid29132092",
                "pmid29501766",
                "pmid39566407",
                "pmid18789000",
                "pmid12453679",
                "pmid34329731",
                "pmid34834150",
                "pmid12930788"
            ]
        },
        "cell_17": {
            "question": "Could inhibiting pro-inflammatory DAM (Disease-Associated Microglia) be beneficial in Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe analysis of the provided studies indicates that inhibiting pro-inflammatory Disease-Associated Microglia (DAM), particularly those with an M1 phenotype, is likely beneficial in Alzheimer's disease. While microglia initially play a protective role by clearing amyloid beta, chronic activation leads to neurotoxicity through pro-inflammatory cytokines and reactive oxygen species. Targeting this pro-inflammatory response could reduce inflammation and slow disease progression.",
            "pmid": [
                "pmid12453679",
                "pmid11578773",
                "pmid28969867",
                "pmid8996832",
                "pmid31264132",
                "pmid15172747",
                "pmid22655214",
                "pmid29501766",
                "pmid12534311",
                "pmid18835047"
            ]
        },
        "cell_18": {
            "question": "Does hepcidin-mediated neuronal iron deposition and oxidative stress contribute to Alzheimer's-like cognitive impairment in mice exposed to chronic intermittent hypoxia?",
            "answer": "A: Yes",
            "pmid": [
                "pmid34394834",
                "pmid32707154",
                "pmid38195497",
                "pmid33298837",
                "pmid39476996",
                "pmid24863668",
                "pmid35852609",
                "pmid21971404",
                "pmid29867325",
                "pmid34844651"
            ]
        },
        "cell_19": {
            "question": "Does withanolide A reduce 7-ketocholesterol's effects on pro-inflammatory genes in brain endothelial cells, relevant to Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid35159267",
                "pmid38886959",
                "pmid15532546",
                "pmid16866910",
                "pmid23645098",
                "pmid35464321",
                "pmid34671194",
                "pmid30878503",
                "pmid28963942",
                "pmid12453679"
            ]
        },
        "cell_20": {
            "question": "Does dexamethasone inhibit Nox-dependent ROS production in activated microglia, relevant to Alzheimer's disease?",
            "answer": "The study demonstrates that dexamethasone inhibits Nox-dependent ROS production in activated microglia through specific pathways relevant to Alzheimer's disease. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid21615929",
                "pmid11070493",
                "pmid22581365",
                "pmid10922518",
                "pmid11331412",
                "pmid12203047",
                "pmid32823544",
                "pmid11487523",
                "pmid31463415",
                "pmid31677009"
            ]
        },
        "cell_21": {
            "question": "Does DHEA exacerbate nigericin-induced pyroptosis in LPS-primed macrophages, potentially relevant to delirium mechanisms?",
            "answer": "Based on the contextual information provided, DHEA exacerbates nigericin-induced pyroptosis in LPS-primed macrophages. This finding is potentially relevant to delirium mechanisms as delirium is associated with neuroinflammation and systemic inflammation. Therefore, the answer is:\n\n**A. Yes**",
            "pmid": [
                "pmid35440074",
                "pmid31779639",
                "pmid35977927",
                "pmid22683080",
                "pmid11070493",
                "pmid11331412",
                "pmid33901789",
                "pmid36077505",
                "pmid34313805",
                "pmid31892211"
            ]
        },
        "cell_23": {
            "question": "Does arundic acid affect astrocytic EAAT1 expression, implicated in Alzheimer's disease pathogenesis?",
            "answer": "**Answer: A. Yes**\n\nThe study referenced by PMId28812276 demonstrates that arundic acid enhances EAAT1 expression in astrocytes via ERK, Akt, and NF-kappaB pathways, directly implicating it in Alzheimer's disease pathogenesis.\n\nNew Answer:\nBased on the provided context, the answer is **A. Yes**. Arundic acid increases astrocytic EAAT1 expression through specific signaling pathways involved in Alzheimer's disease pathogenesis.",
            "pmid": [
                "pmid28812276",
                "pmid11755001",
                "pmid35738259",
                "pmid22101005",
                "pmid18201952",
                "pmid26875818",
                "pmid35427648",
                "pmid28455519",
                "pmid39603277",
                "pmid29033790"
            ]
        },
        "cell_24": {
            "question": "Does thonningianin A enhance microglial cell autophagy to alleviate Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid30695399",
                "pmid39911633",
                "pmid39736370",
                "pmid24602800",
                "pmid21368103",
                "pmid31900522",
                "pmid31607908",
                "pmid37598923",
                "pmid25421002",
                "pmid30362531"
            ]
        },
        "cell_25": {
            "question": "Does Ferulago angulata extract protect against beta-amyloid-induced toxicity in PC12 cells, relevant to Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid38050568",
                "pmid29389553",
                "pmid27774420",
                "pmid24448790",
                "pmid26845710",
                "pmid26304685",
                "pmid32316271",
                "pmid29081887",
                "pmid20099523",
                "pmid26068423"
            ]
        },
        "cell_26": {
            "question": "Does Sirt1 regulation of microglial activation via the Shh/Gli-1 pathway have implications for Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid16183991",
                "pmid36725745",
                "pmid24860504",
                "pmid26045440",
                "pmid30362958",
                "pmid33021962",
                "pmid39815261",
                "pmid31808750",
                "pmid19893026",
                "pmid9878757"
            ]
        },
        "cell_27": {
            "question": "Does overexpression of presenilin2 and its Alzheimer's-disease-linked variants influence TRPC6-mediated calcium entry in HEK293 cells?",
            "answer": "The contextual information from pmid15601622 directly shows that overexpression of presenilin2 and its Alzheimer's-disease-linked variants inhibits TRPC6-mediated calcium entry in HEK293 cells. This is supported by additional studies indicating presenilins' broader role in calcium signaling.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid15601622",
                "pmid17568632",
                "pmid19382908",
                "pmid11055438",
                "pmid10748169",
                "pmid17437536",
                "pmid18367332",
                "pmid10393846",
                "pmid19337829",
                "pmid10662826"
            ]
        },
        "cell_28": {
            "question": "Does Miltefosine improve Alzheimer's-like pathology by alleviating tauopathy via microglia/neuron crosstalk in mice?",
            "answer": "Yes, based on the provided context, gossypetin shows promise as a therapeutic candidate for Alzheimer's disease by enhancing microglial Abeta clearance and reducing harmful inflammation. The study demonstrates improved cognitive function and reduced Abeta deposition in mice treated with gossypetin, along with enhanced phagocytic activity of microglia and increased MHC II+ population.\n\n**Answer:** A",
            "pmid": [
                "pmid36388134",
                "pmid39767773",
                "pmid39563011",
                "pmid31100304",
                "pmid31982468",
                "pmid20555131",
                "pmid25443284",
                "pmid27072684",
                "pmid30413160",
                "pmid36271414"
            ]
        },
        "cell_29": {
            "question": "Does IRAK-M influence microglial NLRP3 inflammasome activation and GSDMD-mediated pyroptosis, potentially relevant to Alzheimer's disease?",
            "answer": "The provided studies indicate that IRAK-M plays a role in regulating microglial NLRP3 inflammasome activation and GSDMD-mediated pyroptosis. In EAE models, IRAK-M suppresses these processes by inhibiting IRAK1 phosphorylation, suggesting a protective role against excessive inflammation. Given the involvement of NLRP3 and pyroptosis in Alzheimer's disease (AD), it is plausible that IRAK-M could have a similar regulatory effect in AD, potentially influencing the disease pathology.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid36765034",
                "pmid35474599",
                "pmid28003153",
                "pmid23686772",
                "pmid38520135",
                "pmid38565393",
                "pmid32929691",
                "pmid33181351",
                "pmid23100432",
                "pmid36185484"
            ]
        },
        "cell_30": {
            "question": "Does Ponesimod increase microglial Abeta42 phagocytosis relevant to Alzheimer's disease?",
            "answer": "The study (pmid37480622) indicates that Ponesimod enhances microglial Abeta42 phagocytosis by reducing inflammation and activating anti-inflammatory pathways.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid37480622",
                "pmid31982468",
                "pmid20798889",
                "pmid36271414",
                "pmid20878768",
                "pmid12927763",
                "pmid36613460",
                "pmid12032144",
                "pmid37650384",
                "pmid25169677"
            ]
        },
        "cell_31": {
            "question": "Do simvastatin and atorvastatin increase neprilysin secretion from astrocytes, facilitating amyloid beta-protein degradation relevant to Alzheimer's disease?",
            "answer": "The answer is A: Yes.\n\n**Step-by-Step Explanation:**\n\n1. **Study Analysis:** The study (pmid26875818) shows that simvastatin and atorvastatin treatment decreases NEP expression in astrocytes but increases its secretion into the extracellular space.\n2. **Mechanism Identified:** This increase in secretion is due to ERK activation, not reduced cholesterol levels.\n3. **Outcome:** The secreted NEP facilitates the degradation of amyloid beta-protein, which is relevant to Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid26875818",
                "pmid19461118",
                "pmid15532546",
                "pmid26096465",
                "pmid12387451",
                "pmid26520569",
                "pmid32512031",
                "pmid12105192",
                "pmid21744242",
                "pmid24508800"
            ]
        },
        "cell_33": {
            "question": "Does inhibiting microglial activation by 2-Cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride offer potential therapeutic benefits for Alzheimer's disease?",
            "answer": "Based on the context provided, inhibiting microglial activation with 2-Cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride appears to have potential therapeutic benefits for Alzheimer's disease. The compound suppresses inflammatory pathways and reduces neurotoxicity, which are significant factors in the progression of the disease.\n\n**Answer:** A. Yes\n\nStep-by-step explanation:\n\n1. **Understanding the Compound's Effect**: The compound KGH26377 inhibits microglial activation by suppressing NF-kappa B and MAPK signaling pathways. This is crucial because activated microglia contribute to neuroinflammation, a key factor in Alzheimer's disease.\n\n2. **Impact on Inflammatory Markers**: Studies show that the compound reduces levels of various inflammatory markers such as PGE2, TNF-alpha, IL-1beta, ROS, and NO. These reductions indicate a decrease in inflammation, which is beneficial in neurodegenerative conditions like Alzheimer's.\n\n3. **Additional Support from Other Studies**: Other compounds like donepezil and AD16 also target microglial activation and have shown benefits in reducing inflammation and plaque deposition, further supporting the therapeutic potential of inhibiting microglial activation.\n\n4. **Therapeutic Implications**: By modulating microglial function through pathways such as NF-kappa B, the compound can help mitigate neurodegenerative processes, offering a promising approach for treating Alzheimer's disease.\n\n**Conclusion:** Yes, inhibiting microglial activation with 2-Cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride offers potential therapeutic benefits for Alzheimer's disease.",
            "pmid": [
                "pmid24752390",
                "pmid17406652",
                "pmid31264132",
                "pmid38006681",
                "pmid1776749",
                "pmid12137934",
                "pmid37598923",
                "pmid26696494",
                "pmid20153342",
                "pmid33344892"
            ]
        },
        "cell_34": {
            "question": "Does cancer history affect long-term lymphocyte cell death susceptibility in individuals who later develop Alzheimer's disease?",
            "answer": "The studies indicate that individuals with a history of cancer show increased resistance to oxidative stress-induced cell death in their lymphocytes, including those who later develop Alzheimer's disease.\n\n**Answer: A. Yes**\n\nA. Yes",
            "pmid": [
                "pmid29472838",
                "pmid22367434",
                "pmid25274115",
                "pmid11016535",
                "pmid7768042",
                "pmid20541838",
                "pmid16814429",
                "pmid35117294",
                "pmid22428008",
                "pmid37737298"
            ]
        },
        "cell_35": {
            "question": "Can Berberine-treated BMSCs rescue neurons from oxidative stress damage relevant to Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid32108297",
                "pmid34064687",
                "pmid28668383",
                "pmid29132092",
                "pmid33983710",
                "pmid30542442",
                "pmid39566407",
                "pmid29962345",
                "pmid30272344",
                "pmid22459600"
            ]
        },
        "cell_36": {
            "question": "Does beta-amyloid exacerbate inflammation in FAAH-lacking astrocytes through PPAR-alpha, PPAR-gamma, and TRPV1, relevant to Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid22321194",
                "pmid11114266",
                "pmid18780966",
                "pmid11755001",
                "pmid26509334",
                "pmid12453679",
                "pmid17255335",
                "pmid10713108",
                "pmid37248300",
                "pmid10817926"
            ]
        },
        "cell_37": {
            "question": "Does the DSPE-PEG-TPP/MoS2 QD blend reduce oxidative stress and inflammation in Abeta-activated microglial cells in Alzheimer's disease?",
            "answer": "The provided context supports that the DSPE-PEG-TPP/MoS2 QD blend effectively reduces oxidative stress and inflammation in Abeta-activated microglial cells.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid37606394",
                "pmid31923845",
                "pmid27797173",
                "pmid26827641",
                "pmid34874326",
                "pmid15500684",
                "pmid35759686",
                "pmid39521153",
                "pmid28630497",
                "pmid33344892"
            ]
        },
        "cell_38": {
            "question": "Does Erjingpill exhibit anti-neuroinflammatory effects by influencing microglial cell glycolysis relevant to Alzheimer's disease?",
            "answer": "**Answer:**\n\nA. Yes\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Studies:** The key study is pmid38824976, which directly examines Erjing Pill's effect on microglial glycolysis and inflammation.\n\n2. **Analyze Findings:** This study shows that Erjing Pill inhibits glycolysis in BV2 cells, reducing inflammatory responses, indicating anti-neuroinflammatory effects through glycolysis modulation.\n\n3. **Conclusion:** Based on the evidence from pmid38824976, Erjing Pill exhibits anti-neuroinflammatory effects by influencing microglial cell glycolysis in Alzheimer's disease.\n\n**Final Answer: A. Yes**",
            "pmid": [
                "pmid38824976",
                "pmid39183433",
                "pmid12453679",
                "pmid28798805",
                "pmid30208700",
                "pmid26643169",
                "pmid23279783",
                "pmid18780966",
                "pmid37598923",
                "pmid15465624"
            ]
        },
        "cell_39": {
            "question": "Can metformin, rapamycin, or nicotinamide mononucleotide inhibit microglial phagocytosis in a manner relevant to Alzheimer's disease?",
            "answer": "The provided context indicates that metformin, rapamycin, and nicotinamide mononucleotide (NMN) can inhibit microglial phagocytosis in a manner relevant to Alzheimer's disease. Specifically, one study showed that these compounds reduced microglial activation and phagocytosis in a model of cognitive impairment.\n\n**Answer: A. Yes**\n\nFinal Answer:\nA. Yes",
            "pmid": [
                "pmid35769369",
                "pmid31982468",
                "pmid12453679",
                "pmid32580040",
                "pmid37483818",
                "pmid20153342",
                "pmid37598923",
                "pmid29351469",
                "pmid38842663",
                "pmid36271414"
            ]
        },
        "cell_40": {
            "question": "Does BG45 reduce inflammation in the entorhinal cortex of young APP/PS1 mice, relevant to Alzheimer's disease?",
            "answer": "The answer is A: Yes.\n\nNew Answer:\nA: Yes",
            "pmid": [
                "pmid30413160",
                "pmid28003153",
                "pmid20555131",
                "pmid11027218",
                "pmid23780663",
                "pmid12119423",
                "pmid36902234",
                "pmid28969867",
                "pmid25443284",
                "pmid38705540"
            ]
        },
        "cell_41": {
            "question": "Which of the following statements best describes the role of DHA in THP-1 monocytes exposed to Aβ25-35 in the context of Alzheimer's disease (AD)?",
            "answer": "D",
            "pmid": [
                "pmid32199223",
                "pmid21241676",
                "pmid27994540",
                "pmid33737172",
                "pmid35264247",
                "pmid35106914",
                "pmid36602874",
                "pmid26965310",
                "pmid32950573",
                "pmid23645098"
            ]
        },
        "cell_42": {
            "question": "Does chlorogenic acid alleviate inflammatory stress in BV2 cells, relevant to Alzheimer's disease?",
            "answer": "The context information indicates that chlorogenic acid does alleviate inflammatory stress in BV2 cells, which are relevant to Alzheimer's disease due to their role in neuroinflammation.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid35633920",
                "pmid33747165",
                "pmid39334733",
                "pmid36770835",
                "pmid28930532",
                "pmid12453679",
                "pmid38561809",
                "pmid33582452",
                "pmid14975597",
                "pmid20555131"
            ]
        },
        "cell_43": {
            "question": "Does inhibiting RXRalpha nuclear export reduce neuronal apoptosis relevant to Alzheimer's disease?",
            "answer": "Yes, inhibiting RXRalpha nuclear export reduces neuronal apoptosis relevant to Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid31966420",
                "pmid20950278",
                "pmid9410912",
                "pmid32739157",
                "pmid26696494",
                "pmid8922409",
                "pmid22592316",
                "pmid17055782",
                "pmid12212794",
                "pmid28627642"
            ]
        },
        "cell_44": {
            "question": "Is the Sur1-Trpm4 channel implicated in regulating NOS2 expression in microglia, potentially relevant to Alzheimer's disease?",
            "answer": "Yes, the Sur1-Trpm4 channel is implicated in regulating NOS2 expression in microglia, as shown by pmid27246103. This regulation can influence processes related to Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid27246103",
                "pmid36683512",
                "pmid29660945",
                "pmid36564824",
                "pmid34302466",
                "pmid36798226",
                "pmid9878757",
                "pmid34663480",
                "pmid12203047",
                "pmid30911003"
            ]
        },
        "cell_45": {
            "question": "Does glimepiride protect neurons against amyloid-beta-induced synapse damage in Alzheimer's disease?",
            "answer": "The context provided from pmid26432105 and pmid24184877 both explicitly state that glimepiride has protective effects against amyloid-beta-induced synapse damage in neurons. Therefore, the most appropriate answer is:\n\nAnswer: A",
            "pmid": [
                "pmid26432105",
                "pmid24184877",
                "pmid24952384",
                "pmid16772755",
                "pmid20634578",
                "pmid26389963",
                "pmid30186862",
                "pmid25390692",
                "pmid38095632",
                "pmid17459354"
            ]
        },
        "cell_46": {
            "question": "Does CD45RB cross-linking inhibit Abeta-induced microglial activation in Alzheimer's disease?",
            "answer": "A: Yes  \nAnswer: A",
            "pmid": [
                "pmid11027218",
                "pmid18478117",
                "pmid21273420",
                "pmid18434187",
                "pmid8892352",
                "pmid12402041",
                "pmid33029126",
                "pmid22133278",
                "pmid25169677",
                "pmid12927763"
            ]
        },
        "cell_47": {
            "question": "Does donepezil, commonly used for Alzheimer's disease, inhibit MPP+-induced M1 polarization in microglia?",
            "answer": "The provided context does not discuss donepezil's effects on MPP+-induced M1 polarization in microglia. Therefore, based on the given information, we cannot confirm or deny such an effect.\n\n**Answer: B. No**",
            "pmid": [
                "pmid26114860",
                "pmid20153342",
                "pmid24189446",
                "pmid25662507",
                "pmid31264132",
                "pmid29273047",
                "pmid35850693",
                "pmid25744714",
                "pmid19077054",
                "pmid11830754"
            ]
        },
        "cell_48": {
            "question": "Does Spns2 promote pro-inflammatory activation of microglia in Alzheimer's disease?",
            "answer": "The study by pmid30484906 directly demonstrates that Spns2 promotes pro-inflammatory activation of microglia in response to amyloid-beta peptide. Other studies do not contradict this finding.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid30484906",
                "pmid25485684",
                "pmid25169677",
                "pmid29662056",
                "pmid31982468",
                "pmid17911636",
                "pmid11578773",
                "pmid15172747",
                "pmid36620941",
                "pmid39791204"
            ]
        },
        "cell_49": {
            "question": "Does neoechinulin A inhibit amyloid-beta-induced microglia activation, a process relevant to Alzheimer's disease?",
            "answer": "**Answer:** A. Yes\n\nNeoechinulin A inhibits amyloid-beta-induced microglia activation, as shown by its suppression of pro-inflammatory cytokines and protection against inflammation-mediated toxicity in relevant cellular models.\n\nNew Answer:",
            "pmid": [
                "pmid23261590",
                "pmid31982468",
                "pmid12105192",
                "pmid12453679",
                "pmid25169677",
                "pmid38886959",
                "pmid12203047",
                "pmid32028243",
                "pmid20634578",
                "pmid26643169"
            ]
        },
        "cell_50": {
            "question": "Can antioxidants like thymoquinone or EGCG reduce amyloid beta oxidation in neuroblastoma cells, relevant to Alzheimer's disease?",
            "answer": "The provided studies indicate that antioxidants like thymoquinone (TQ) and epigallocatechin-3-gallate (EGCG) can reduce amyloid beta oxidation and associated oxidative stress in neuroblastoma cells, which is relevant to Alzheimer's disease. Therefore, the answer is affirmative.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid25405415",
                "pmid22752387",
                "pmid28630497",
                "pmid24975829",
                "pmid34570578",
                "pmid30623116",
                "pmid30288371",
                "pmid20463406",
                "pmid11487523",
                "pmid20164580"
            ]
        },
        "cell_51": {
            "question": "Does the small molecule MFM 4 inhibit Abeta-induced neuronal toxicity in Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid31140779",
                "pmid22238689",
                "pmid27258855",
                "pmid16246051",
                "pmid20119496",
                "pmid19141069",
                "pmid23523945",
                "pmid32739157",
                "pmid35759686",
                "pmid17261088"
            ]
        },
        "cell_52": {
            "question": "Does quetiapine inhibit microglial activation, potentially relevant to Alzheimer's disease?",
            "answer": "The answer based on the provided context is:\n\n**A. Yes**\n\nQuetiapine inhibits microglial activation, as evidenced by its effects in reducing CD11b-positive cells and attenuating glial activation via the NF-kB pathway in Alzheimer's models.\n\nNew Answer: A. Yes",
            "pmid": [
                "pmid24911389",
                "pmid25618401",
                "pmid26732345",
                "pmid29120942",
                "pmid18554300",
                "pmid22831460",
                "pmid15948179",
                "pmid20153342",
                "pmid14648600",
                "pmid35594435"
            ]
        },
        "cell_53": {
            "question": "Does 2-methoxyestradiol (2ME) protect against neuronal cell death and tau hyperphosphorylation relevant to Alzheimer's Disease?",
            "answer": "A: Yes\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid36208660",
                "pmid9106616",
                "pmid12671307",
                "pmid7488136",
                "pmid16024764",
                "pmid35153729",
                "pmid18037281",
                "pmid17886039",
                "pmid38729530",
                "pmid22798221"
            ]
        },
        "cell_54": {
            "question": "Does Schisandrin treatment restore cell viability in the SH-SY5Y cell model of Alzheimer's disease?",
            "answer": "The contextual information indicates that Schisandrin treatment restores cell viability in the SH-SY5Y cell model of Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid22666518",
                "pmid33542629",
                "pmid31739764",
                "pmid31900522",
                "pmid26696494",
                "pmid17886039",
                "pmid34214019",
                "pmid33815510",
                "pmid10550330",
                "pmid30844489"
            ]
        },
        "cell_55": {
            "question": "Does strontium treatment in high-fat diet-induced NAFLD mice reduce neuroinflammation and improve synaptic plasticity, processes also implicated in Alzheimer's disease?",
            "answer": "The studies indicate that strontium treatment reduces neuroinflammation and improves synaptic health in NAFLD mice, which are processes relevant to Alzheimer's disease. Therefore, the answer is:\n\nA: Yes",
            "pmid": [
                "pmid37373395",
                "pmid33785315",
                "pmid34168550",
                "pmid23099816",
                "pmid37783748",
                "pmid27474225",
                "pmid28328738",
                "pmid34812899",
                "pmid30134549",
                "pmid28963942"
            ]
        },
        "cell_56": {
            "question": "Can mesenchymal stem cells prevent pyroptosis in macrophages exposed to ITO nanoparticles, potentially relevant to Alzheimer's disease?",
            "answer": "Yes, mesenchymal stem cells (MSCs) can prevent pyroptosis in macrophages exposed to ITO nanoparticles. This is supported by a study showing that co-culturing MSCs with macrophages exposed to ITO-NPs reduced inflammation and cell death, indicating their protective role against pyroptosis.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid27194621",
                "pmid33815510",
                "pmid30259257",
                "pmid28630497",
                "pmid37206236",
                "pmid31330912",
                "pmid36388872",
                "pmid39805185",
                "pmid34073900",
                "pmid31089063"
            ]
        },
        "cell_57": {
            "question": "Does Amanita muscaria extract affect proinflammatory cytokines in a manner relevant to Alzheimer's disease or delirium?",
            "answer": "B. No",
            "pmid": [
                "pmid30819080",
                "pmid30290256",
                "pmid26068423",
                "pmid32488469",
                "pmid31635294",
                "pmid27534446",
                "pmid31426492",
                "pmid29389553",
                "pmid33463937",
                "pmid36193798"
            ]
        },
        "cell_58": {
            "question": "Does 9-Methylfascaplysin (9-MF) reduce neuroinflammation and synaptic damage in an Alzheimer's disease model?",
            "answer": "A: Yes",
            "pmid": [
                "pmid39563011",
                "pmid30781608",
                "pmid20555131",
                "pmid30404965",
                "pmid12453679",
                "pmid39767773",
                "pmid38886959",
                "pmid16880827",
                "pmid38006681",
                "pmid27567825"
            ]
        },
        "cell_59": {
            "question": "Can esculetin and fucoidan help prevent Alzheimer's disease by modulating reactive astrocytes and proinflammatory cytokines?",
            "answer": "A: Yes  \nNew Answer:",
            "pmid": [
                "pmid35448455",
                "pmid15926913",
                "pmid28266714",
                "pmid11872267",
                "pmid37209001",
                "pmid39744139",
                "pmid36382256",
                "pmid26006224",
                "pmid29112116",
                "pmid37598923"
            ]
        },
        "cell_60": {
            "question": "Does guanosine show neuroprotective effects in an Alzheimer's disease model by reducing neuronal death and reactive oxygen species?",
            "answer": "The provided studies consistently demonstrate that guanosine exhibits neuroprotective effects by reducing both neuronal death and reactive oxygen species (ROS) in Alzheimer's disease models.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid20846477",
                "pmid36557245",
                "pmid15073525",
                "pmid32789760",
                "pmid27002712",
                "pmid35195784",
                "pmid24975829",
                "pmid31232699",
                "pmid20416364",
                "pmid22381145"
            ]
        },
        "cell_61": {
            "question": "Does microglial activation by silica-coated magnetic nanoparticles contribute to Alzheimer's disease pathogenesis through D-serine secretion?",
            "answer": "The most appropriate answer is:\n\n**A: Yes**\n\n**Explanation:**\nThe study referenced (pmid34384435) provides direct evidence that silica-coated magnetic nanoparticles activate microglia and induce the secretion of D-serine. This neurotoxic effect contributes to neuronal damage, which aligns with mechanisms involved in Alzheimer's disease pathogenesis.",
            "pmid": [
                "pmid34384435",
                "pmid36388872",
                "pmid15172747",
                "pmid29970116",
                "pmid16476660",
                "pmid28251989",
                "pmid24336048",
                "pmid25169677",
                "pmid21971404",
                "pmid8871946"
            ]
        },
        "cell_62": {
            "question": "Does MAC1 receptor activation in microglia contribute to beta-amyloid peptide-induced neurotoxicity associated with Alzheimer's disease?",
            "answer": "Based on the analysis of the provided context, there is no explicit mention of the MAC1 receptor's role in beta-amyloid peptide-induced neurotoxicity. Therefore:\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid25169677",
                "pmid37603311",
                "pmid18835047",
                "pmid22133278",
                "pmid20878768",
                "pmid18780966",
                "pmid15172747",
                "pmid25637481",
                "pmid12927763",
                "pmid21771791"
            ]
        },
        "cell_63": {
            "question": "Does CD45 deficiency contribute to increased neurotoxic Abeta oligomer levels in Alzheimer's disease mice?",
            "answer": "The provided context indicates that CD45 deficiency contributes to increased neurotoxic Abeta oligomer levels in Alzheimer's disease mice. Specifically, studies show that CD45(-/-) mice exhibit higher levels of Abeta oligomers and deposits.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid21273420",
                "pmid16504112",
                "pmid11027218",
                "pmid25893674",
                "pmid12402041",
                "pmid25887956",
                "pmid21070634",
                "pmid12119423",
                "pmid25443284",
                "pmid12881482"
            ]
        },
        "cell_64": {
            "question": "Does astroglial connexin43 deletion in APP/PS1 mice improve cognitive dysfunction in Alzheimer's disease?",
            "answer": "The studies provided indicate that deleting connexin43 in astroglial cells within APP/PS1 mice leads to improved cognitive outcomes. Specifically, pmid30031059 and pmid27391799 both show beneficial effects of Cx43 deletion on cognitive function.\n\n**Answer: A. Yes**\n\nNew Answer:",
            "pmid": [
                "pmid30031059",
                "pmid27391799",
                "pmid20813165",
                "pmid28982320",
                "pmid33117125",
                "pmid31849963",
                "pmid34981861",
                "pmid37609338",
                "pmid12881482",
                "pmid21771791"
            ]
        },
        "cell_65": {
            "question": "Does aging enhance exosomal cytokine mRNA release by Abeta1-42-stimulated macrophages relevant to Alzheimer's disease?",
            "answer": "<think>\nOkay, so I'm trying to figure out whether aging enhances the release of exosomal cytokine mRNA from Abeta1-42-stimulated macrophages in relation to Alzheimer's disease. Let me go through the information step by step.\n\nFirst, looking at the provided context, there are several studies mentioned. The first study (pmid25169677) discusses how human microglia can stimulate neuroblastoma cells to produce more beta-amyloid protein and tau, which is relevant to Alzheimer's disease pathogenesis. It mentions that activated microglia release pro-inflammatory cytokines like IL-6 and IL-1beta, which in turn increase the production of Abeta and tau in neurons. This suggests a positive feedback loop between inflammation and amyloid plaques.\n\nThe second study (pmid27723233) talks about how aging affects microglial activation in Alzheimer's disease models. It shows that aged mice have more activated microglia and reactive astrocytes compared to younger ones. This implies that aging might play a role in enhancing the inflammatory response in the brain, which could contribute to neurodegeneration.\n\nThe third study (pmid25869407) looks at how human T cells respond differently when exposed to exosomes from macrophages treated with Abeta1-42. It finds that these exosomes activate T cells and promote an M1-like phenotype, which is pro-inflammatory. This suggests that exosomal signals can influence immune responses in a way that could exacerbate neuroinflammation.\n\nThe fourth study (pmid25789360) discusses how dendritic cells take up Abeta plaques and present them to T cells via exosomes, leading to an immune response against the brain. This further supports the idea that exosomal communication plays a role in driving inflammation in Alzheimer's disease.\n\nPutting this all together, while none of these studies explicitly state whether aging enhances the release of cytokine mRNA by Abeta1-42-stimulated macrophages, they do suggest that aging is associated with increased neuroinflammation and that exosomes from macrophages can influence immune responses in a way that could contribute to Alzheimer's disease. The context implies that aging might enhance these processes, but without direct evidence from the provided studies, it's not certain.\n\nGiven the lack of explicit data on cytokine mRNA release specifically by macrophages in relation to aging and Abeta1-42 stimulation, I have to conclude based on the information given. Since none of the studies directly address this question, the most appropriate answer is that the context doesn't provide enough information to determine the effect of aging on exosomal cytokine mRNA release in this specific scenario.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid24014820",
                "pmid27723233",
                "pmid9542587",
                "pmid28969867",
                "pmid26257642",
                "pmid12897209",
                "pmid22428008",
                "pmid30115117",
                "pmid30259257",
                "pmid25169677"
            ]
        },
        "cell_66": {
            "question": "Does inhibiting tissue transglutaminase (tTG) promote beta-amyloid (Abeta)-induced apoptosis in SH-SY5Y cells, relevant to Alzheimer's disease?",
            "answer": "The question asks whether inhibiting tissue transglutaminase (tTG) promotes beta-amyloid (Abeta)-induced apoptosis in SH-SY5Y cells relevant to Alzheimer's disease. \n\nFrom the analysis of the provided studies, the most relevant information comes from pmid27665848. This study demonstrates that using an irreversible tTG inhibitor, NTU283, co-treated with Abeta leads to increased apoptosis in SH-SY5Y cells compared to Abeta treatment alone. The findings indicate that inhibiting tTG enhances Abeta-induced apoptosis.\n\nAnswer: A. Yes",
            "pmid": [
                "pmid27665848",
                "pmid18397883",
                "pmid20437185",
                "pmid28391388",
                "pmid24685636",
                "pmid22156619",
                "pmid9464644",
                "pmid18417122",
                "pmid15073525",
                "pmid24424093"
            ]
        },
        "cell_67": {
            "question": "Does Gamma-interferon-inducible lysosomal thiol reductase (GILT) expression in microglia correlate with Alzheimer's disease?",
            "answer": "The evidence from pmid30560017 shows that GILT expression is elevated in microglia of AD patients, correlating with the presence of amyloid-beta deposits. Other studies support the role of microglial activation in AD but don't directly address GILT. Therefore, based on the provided information:\n\n**Answer: A. Yes**\n\nA",
            "pmid": [
                "pmid30560017",
                "pmid20798889",
                "pmid30661261",
                "pmid8996832",
                "pmid33446646",
                "pmid11578773",
                "pmid36798226",
                "pmid33402227",
                "pmid25169677",
                "pmid2935594"
            ]
        },
        "cell_68": {
            "question": "Does Abeta-induced TRPC6 up-regulation in BV-2 microglia contribute to Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid28458019",
                "pmid33029126",
                "pmid33998138",
                "pmid25169677",
                "pmid34663480",
                "pmid29660945",
                "pmid28434692",
                "pmid22133278",
                "pmid35264247",
                "pmid36564824"
            ]
        },
        "cell_69": {
            "question": "Does biliverdin regulate macrophage C5aR expression via the mTOR pathway, potentially relevant to delirium?",
            "answer": "The analysis of the provided context indicates that biliverdin regulates macrophage C5aR expression via the mTOR pathway, as demonstrated in pmid24814708. Additionally, delirium is associated with systemic inflammation and cytokines, suggesting a potential connection between biliverdin's anti-inflammatory effects and delirium. Therefore:\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid24814708",
                "pmid22438844",
                "pmid25191325",
                "pmid39839987",
                "pmid24557038",
                "pmid33901789",
                "pmid39419070",
                "pmid7211434",
                "pmid28360657",
                "pmid20309566"
            ]
        },
        "cell_70": {
            "question": "Does Cu(II) disrupt autophagy-mediated lysosomal degradation of oligomeric Abeta in microglia, contributing to Alzheimer's disease?",
            "answer": "Yes, Cu(II) disrupts autophagy-mediated lysosomal degradation of oligomeric Abeta in microglia, contributing to Alzheimer's disease. The study (PMID 32512069) demonstrates that Cu(II) inhibits this process via the mTOR-TFEB pathway, leading to impaired clearance of Abeta and promoting AD progression.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid32512069",
                "pmid23959870",
                "pmid22844264",
                "pmid19122148",
                "pmid20626553",
                "pmid38787367",
                "pmid32599538",
                "pmid18625454",
                "pmid30362531",
                "pmid25066791"
            ]
        },
        "cell_71": {
            "question": "Does Physalin B reduce cell apoptosis in HEK293/Tau cells, an Alzheimer's disease model?",
            "answer": "The study (pmid37489791) demonstrates that Physalin B reduces cell apoptosis in HEK293/Tau cells, an Alzheimer's disease model, through FoxO1 activation. Therefore:\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid37489791",
                "pmid15073525",
                "pmid24424093",
                "pmid26696494",
                "pmid25774173",
                "pmid15208744",
                "pmid9410912",
                "pmid9464644",
                "pmid28455519",
                "pmid21276834"
            ]
        },
        "cell_72": {
            "question": "Does blocking TGF-beta-Smad2/3 signaling in peripheral macrophages improve Alzheimer's-like pathology in mice?",
            "answer": "The studies pmid18516051 and pmid33737172 demonstrate that blocking TGF-beta-Smad2/3 signaling in macrophages reduces beta-amyloid deposits and improves cognitive functions in mouse models of Alzheimer's disease. Therefore, the answer is:\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid18516051",
                "pmid33737172",
                "pmid28969867",
                "pmid17080199",
                "pmid27422717",
                "pmid18509040",
                "pmid12119423",
                "pmid12032144",
                "pmid39243388",
                "pmid27723233"
            ]
        },
        "cell_73": {
            "question": "Does All-trans retinoic acid (ATRA) increase Transglutaminase 2 (TG2) expression in BV-2 cells and astrocytes involved in Alzheimer's disease?",
            "answer": "The answer is A: Yes.\n\nStep-by-Step Explanation:\n\n1. **Identify Relevant Studies:** The primary study (pmid37916634) directly addresses whether ATRA increases TG2 in BV-2 cells and astrocytes, concluding it does.\n\n2. **Review Supporting Evidence:** Other studies provide context about the role of TG2 in AD but do not contradict the first study's findings. They either confirm TG2's involvement or discuss related mechanisms without opposing the increase caused by ATRA.\n\n3. **Conclusion:** The direct evidence from pmid37916634 supports that ATRA increases TG2 expression, with no conflicting information present.\n\n**Answer:** A: Yes",
            "pmid": [
                "pmid37916634",
                "pmid28391388",
                "pmid20437185",
                "pmid32256561",
                "pmid26881107",
                "pmid27448243",
                "pmid20950278",
                "pmid20817067",
                "pmid23379615",
                "pmid22156619"
            ]
        },
        "cell_74": {
            "question": "Does curcumin inhibit appoptosin-induced apoptosis in SH-SY5Y cells, relevant to Alzheimer's disease?",
            "answer": "Based on the information provided, curcumin inhibits appoptosin-induced apoptosis in SH-SY5Y cells relevant to Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid25891083",
                "pmid22886017",
                "pmid24755072",
                "pmid26971524",
                "pmid27521081",
                "pmid30746607",
                "pmid25774181",
                "pmid28854504",
                "pmid22476982",
                "pmid27594837"
            ]
        },
        "cell_75": {
            "question": "Are glial hypo- and hyperactivation observed in predementia Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid38093257",
                "pmid12960778",
                "pmid14694028",
                "pmid15172747",
                "pmid10095092",
                "pmid30791945",
                "pmid11276052",
                "pmid19940172",
                "pmid25267349",
                "pmid37248300"
            ]
        },
        "cell_76": {
            "question": "Does a diabetic phenotype reduce microglial numbers around beta-amyloid plaques in Alzheimer's disease (mice and humans)?",
            "answer": "A: A",
            "pmid": [
                "pmid33168021",
                "pmid15172747",
                "pmid27425031",
                "pmid38565291",
                "pmid37333071",
                "pmid16476660",
                "pmid18835047",
                "pmid15194867",
                "pmid27723233",
                "pmid8996832"
            ]
        },
        "cell_77": {
            "question": "Does USP19 knockdown reduce ferroptosis in SH-SY5Y cells, alleviating mitochondrial damage in Alzheimer's disease?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid38943386",
                "pmid36068400",
                "pmid38761423",
                "pmid22746342",
                "pmid30042655",
                "pmid35204177",
                "pmid38397840",
                "pmid30791980",
                "pmid35453377",
                "pmid22367970"
            ]
        },
        "cell_78": {
            "question": "Does Bazi Bushen capsule improve cognitive deficits by inhibiting microglia activation and cellular senescence, similarly to Alzheimer's disease treatments?",
            "answer": "The analysis of the provided context shows that Bazi Bushen capsule (BZBS) indeed improves cognitive deficits by targeting mechanisms relevant to Alzheimer's disease treatments, specifically through inhibiting microglial activation and cellular senescence.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid36263579",
                "pmid33029123",
                "pmid28521305",
                "pmid34064687",
                "pmid36232612",
                "pmid39566407",
                "pmid18789000",
                "pmid28279707",
                "pmid25108596",
                "pmid29132092"
            ]
        },
        "cell_79": {
            "question": "Do activated microglia promote GDNF production by BMSCs to protect neurons against oxygen-glucose deprivation, potentially relevant to Alzheimer's disease?",
            "answer": "The most appropriate answer based on the provided context is:\n\nA: Yes",
            "pmid": [
                "pmid28018176",
                "pmid38565291",
                "pmid26257642",
                "pmid25169677",
                "pmid31100304",
                "pmid31257151",
                "pmid18395194",
                "pmid8996832",
                "pmid22655214",
                "pmid11556547"
            ]
        },
        "cell_80": {
            "question": "Does GRP78 play a role in disrupting neuron-microglia communication, similar to its involvement in Alzheimer's disease?",
            "answer": "A: B",
            "pmid": [
                "pmid25637481",
                "pmid37365565",
                "pmid9878757",
                "pmid1647485",
                "pmid15172747",
                "pmid23559013",
                "pmid11813244",
                "pmid10095092",
                "pmid12960778",
                "pmid38791092"
            ]
        },
        "cell_81": {
            "question": "Does increased HO-1 activity in astrocytes contribute to iron-mediated cytotoxicity in Alzheimer's-affected neural tissues?",
            "answer": "The analysis of multiple studies indicates that increased HO-1 activity in astrocytes contributes to iron-mediated cytotoxicity in Alzheimer's disease by promoting iron sequestration, mitochondrial damage, and oxidative stress.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid19250338",
                "pmid12835114",
                "pmid22881289",
                "pmid11053673",
                "pmid21971404",
                "pmid25761244",
                "pmid32707154",
                "pmid24863668",
                "pmid28890316",
                "pmid32708329"
            ]
        },
        "cell_82": {
            "question": "Which of the following best reflects the proposed cellular mechanism contributing to the development of delirium according to the gliocentric perspective?",
            "answer": "The most appropriate answer is:\n\nD. Astrocyte dysfunction impairing the cholinergic anti-inflammatory response, leading to neuroinflammation.\n\n**Answer: D**",
            "pmid": [
                "pmid26029046",
                "pmid39463449",
                "pmid7916159",
                "pmid37313848",
                "pmid28673598",
                "pmid33172595",
                "pmid20309566",
                "pmid37851904",
                "pmid39419070",
                "pmid24557038"
            ]
        },
        "cell_83": {
            "question": "Does CIRP overexpression in astrocytes contribute to Alzheimer's disease development by inhibiting uPA expression?",
            "answer": "The provided context indicates that CIRP overexpression in astrocytes contributes to Alzheimer's disease development by inhibiting uPA expression.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid39741909",
                "pmid30594047",
                "pmid18201952",
                "pmid33783711",
                "pmid11755001",
                "pmid32184914",
                "pmid28455519",
                "pmid19394434",
                "pmid34963475",
                "pmid21771791"
            ]
        },
        "cell_84": {
            "question": "Do CD11c-positive microglia have a suppressive influence on the inflammatory response in Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid11578773",
                "pmid30588668",
                "pmid27425031",
                "pmid15172747",
                "pmid8996832",
                "pmid28969867",
                "pmid16476660",
                "pmid15194867",
                "pmid28434692",
                "pmid8871946"
            ]
        },
        "cell_85": {
            "question": "Does amyloid-beta induce Smac release via AP-1/Bim activation in cerebral endothelial cells relevant to Alzheimer's disease?",
            "answer": "B: No",
            "pmid": [
                "pmid12427831",
                "pmid24997450",
                "pmid24333930",
                "pmid25169677",
                "pmid35851991",
                "pmid24918635",
                "pmid26200696",
                "pmid11755001",
                "pmid22269161",
                "pmid38132159"
            ]
        },
        "cell_86": {
            "question": "Does luteolin induce apoptosis and autophagy in macrophages, potentially relevant to Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid30246034",
                "pmid33335556",
                "pmid28498401",
                "pmid37597424",
                "pmid21368720",
                "pmid26087007",
                "pmid22528780",
                "pmid16765377",
                "pmid30695399",
                "pmid16626961"
            ]
        },
        "cell_87": {
            "question": "Does acute hypoxia affect M1/M2 microglial activation in Alzheimer's disease mice and wild-type littermates?",
            "answer": "The answer is A. Yes.\n\n**Answer:**  \nA. Yes",
            "pmid": [
                "pmid28890695",
                "pmid29867325",
                "pmid37117599",
                "pmid35852609",
                "pmid34844651",
                "pmid39476996",
                "pmid21799251",
                "pmid29141186",
                "pmid38241837",
                "pmid23603149"
            ]
        },
        "cell_88": {
            "question": "Does MKP-1 regulate microglia phenotype and inflammatory factor release in Alzheimer's disease?",
            "answer": "The evidence from two key studies (pmid37602891 and pmid31840000) indicates that MKP-1 plays a role in regulating microglia activity and inflammation in Alzheimer's disease. The first study directly shows MKP-1 affects microglial phenotype and inflammatory factors, while the second demonstrates its impact on Abeta production through MAPK pathways, influencing inflammation.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid37602891",
                "pmid31840000",
                "pmid19800391",
                "pmid15172747",
                "pmid11578773",
                "pmid36396603",
                "pmid18835047",
                "pmid25169677",
                "pmid33998138",
                "pmid31100304"
            ]
        },
        "cell_89": {
            "question": "Does galantamine inhibit beta-amyloid-induced cytostatic autophagy in PC12 cells by decreasing ROS production, relevant to Alzheimer's disease?",
            "answer": "The query asks whether galantamine inhibits beta-amyloid-induced cytostatic autophagy in PC12 cells by decreasing ROS production. The most relevant reference is pmid29292543, which specifically shows that galantamine suppresses Abeta-induced autophagy and reduces ROS via NOX4 downregulation in PC12 cells.\n\n**Answer:** A. Yes\n\nNew Answer:  The answer is \"Yes,\" based on the findings from pmid29292543, which demonstrates that galantamine inhibits beta-amyloid-induced autophagy and reduces ROS levels in PC12 cells.\n\nUNRELATED",
            "pmid": [
                "pmid29292543",
                "pmid28554861",
                "pmid20655346",
                "pmid27793617",
                "pmid31823156",
                "pmid12649296",
                "pmid11110737",
                "pmid30695399",
                "pmid25160744",
                "pmid21368103"
            ]
        },
        "cell_90": {
            "question": "Does adoptive transfer of ex vivo expanded human regulatory T cells reduce amyloid burden in an Alzheimer's disease preclinical model?",
            "answer": "The adoptive transfer of ex vivo expanded human regulatory T cells reduces amyloid burden in an Alzheimer's disease preclinical model.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid36180898",
                "pmid27713140",
                "pmid32954348",
                "pmid38111016",
                "pmid28969867",
                "pmid37737298",
                "pmid33815510",
                "pmid16476660",
                "pmid37943150",
                "pmid10550330"
            ]
        },
        "cell_91": {
            "question": "Which of the following best explains how systemic inflammation contributes to delirium through neuroinflammatory processes at the cellular level?",
            "answer": "The most appropriate answer based on the contextual information provided is:\n\n**C. Microglia exhibit an exaggerated inflammatory response due to age-related priming, amplifying central cytokine signaling.**\n\nThis explanation aligns with the studies indicating increased microglial activity and age-related factors contributing to neuroinflammation in delirium.",
            "pmid": [
                "pmid20309566",
                "pmid24557038",
                "pmid20471138",
                "pmid24048854",
                "pmid29875474",
                "pmid22553034",
                "pmid32592865",
                "pmid21978081",
                "pmid37313848",
                "pmid26029046"
            ]
        },
        "cell_92": {
            "question": "Does passion fruit seed extract protect against beta-amyloid-induced neuronal cell death in an Alzheimer's disease model?",
            "answer": "The first study (pmid35592293) directly addresses passion fruit seed extract and its protective effects against beta-amyloid-induced neuronal cell death in an Alzheimer's disease model. The second study (pmid24328060) discusses flavonoids' general neuroprotective properties but does not specifically mention passion fruit seed extract.\n\n**Answer:** A",
            "pmid": [
                "pmid35592293",
                "pmid32316271",
                "pmid22995388",
                "pmid23833520",
                "pmid32488469",
                "pmid25229015",
                "pmid29389553",
                "pmid25580148",
                "pmid39682936",
                "pmid24328060"
            ]
        },
        "cell_93": {
            "question": "Does FUT8-catalyzed core fucosylation play a role in microglial activation during Alzheimer's disease pathogenesis?",
            "answer": "**Answer: A. Yes**\n\nThe provided context from pmid36692036 indicates that FUT8-catalyzed core fucosylation contributes to microglial activation in Alzheimer's disease pathogenesis.",
            "pmid": [
                "pmid36692036",
                "pmid25169677",
                "pmid39474846",
                "pmid34111442",
                "pmid11677259",
                "pmid30076715",
                "pmid16192374",
                "pmid34315531",
                "pmid15172747",
                "pmid19828810"
            ]
        },
        "cell_94": {
            "question": "Does TGF-beta1 protect against Alzheimer's disease by inhibiting microglial FPR2 expression?",
            "answer": "**Answer:**\n\nBased on the provided context and studies, there is insufficient evidence to conclude that TGF-beta1 protects against Alzheimer's disease (AD) by inhibiting FPR2 on microglia. While some studies suggest that TGF-beta1 signaling may influence immune responses and Abeta clearance, they do not specifically address the role of FPR2 in this process. Therefore, it remains unclear whether TGF-beta1's inhibition of FPR2 contributes to protection against AD.\n\n\\boxed{B}",
            "pmid": [
                "pmid21879289",
                "pmid18516051",
                "pmid17080199",
                "pmid15240683",
                "pmid30539409",
                "pmid36319781",
                "pmid18063474",
                "pmid27713140",
                "pmid32331524",
                "pmid35153729"
            ]
        },
        "cell_95": {
            "question": "Does alpha-boswellic acid affect astrocytic Reelin expression, related to Alzheimer's disease?",
            "answer": "A: A\nNew Answer:\n\nAlpha-boswellic acid does affect astrocytic Reelin expression in the context of Alzheimer's disease. Specifically, it has been shown to up-regulate Reelin expression in human astrocytes treated with streptozotocin, a model for the disease.\n\nAnswer: A",
            "pmid": [
                "pmid27567921",
                "pmid34116571",
                "pmid34607104",
                "pmid36998129",
                "pmid17360894",
                "pmid32109514",
                "pmid20025970",
                "pmid27531658",
                "pmid11755001",
                "pmid26965310"
            ]
        },
        "cell_96": {
            "question": "Does Sig1R downregulation contribute to neuroinflammation-induced microglial dysfunction in Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe study (pmid32653342) demonstrates that downregulation of Sig1R contributes to neuroinflammation-induced microglial dysfunction, indicating that reducing Sig1R expression exacerbates the effects of inflammation on microglia in Alzheimer's disease.",
            "pmid": [
                "pmid32653342",
                "pmid36089405",
                "pmid8996832",
                "pmid15172747",
                "pmid25637481",
                "pmid33402227",
                "pmid18835047",
                "pmid21771791",
                "pmid11578773",
                "pmid37603311"
            ]
        },
        "cell_97": {
            "question": "Does Ca2+-binding protein upregulation in VTA dopamine neurons contribute to their survival in early-stage Alzheimer's disease in Tg2576 mice?",
            "answer": "The most appropriate answer is:\n\nA. Yes\n\n**Step-by-Step Explanation:**\n\n1. **Primary Evidence:** The study by pmid36434727 directly addresses the question, showing that upregulation of Ca²+ binding proteins (Calbindin-D28K and Calretinin) in VTA dopamine neurons contributes to their survival during early AD stages in Tg2576 mice.\n\n2. **Supporting Evidence:** Other studies confirm the role of calcium dysregulation in AD pathogenesis, though they don't specifically address VTA DA neurons or CBP upregulation as a protective mechanism.\n\n3. **Conclusion:** The direct evidence from pmid36434727 supports that Ca²+ binding protein upregulation helps protect VTA dopamine neurons in early-stage AD in Tg2576 mice, leading to the answer \"Yes.\"",
            "pmid": [
                "pmid36434727",
                "pmid12881482",
                "pmid29782955",
                "pmid19337829",
                "pmid9503262",
                "pmid22475800",
                "pmid10662826",
                "pmid22269161",
                "pmid12909083",
                "pmid18596919"
            ]
        },
        "cell_98": {
            "question": "Does demyelination-derived lysophosphatidylserine (LysoPS) contribute to microglial dysfunction and neuropathology in Alzheimer's disease?",
            "answer": "The most relevant study is pmid39741193, which clearly states that LysoPS derived from demyelination contributes to microglial dysfunction and neuropathology in AD.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid39741193",
                "pmid30530526",
                "pmid29353063",
                "pmid38561809",
                "pmid10095092",
                "pmid17349923",
                "pmid25169677",
                "pmid14522241",
                "pmid28928740",
                "pmid33277246"
            ]
        },
        "cell_99": {
            "question": "Does VAP regulate apoptosis in an Alzheimer's disease cell model?",
            "answer": "B",
            "pmid": [
                "pmid34782612",
                "pmid36185484",
                "pmid31047972",
                "pmid9410912",
                "pmid16465389",
                "pmid8922409",
                "pmid17522316",
                "pmid15073525",
                "pmid24424093",
                "pmid10377452"
            ]
        },
        "cell_100": {
            "question": "Does microglial QUIN elevation in the basolateral amygdala contribute to cognitive dysfunction in delirium?",
            "answer": "B. No",
            "pmid": [
                "pmid7916159",
                "pmid26029046",
                "pmid28673598",
                "pmid20309566",
                "pmid39463449",
                "pmid24557038",
                "pmid21978081",
                "pmid32592865",
                "pmid38566855",
                "pmid37566435"
            ]
        },
        "cell_101": {
            "question": "Does 3,5,4'-Trihydroxy-6,7,3'-trimethoxyflavone (TTF) protect astrocytes against oxidative stress involved in Alzheimer's disease?",
            "answer": "The contextual information shows that 3,5,4'-Trihydroxy-6,7,3'-trimethoxyflavone (TTF) protects astrocytes against oxidative stress relevant to Alzheimer's disease.\n\n**Answer: A. Yes**\n\nA: A",
            "pmid": [
                "pmid11182299",
                "pmid24922524",
                "pmid25217804",
                "pmid18037281",
                "pmid38308793",
                "pmid39684454",
                "pmid37191855",
                "pmid31677009",
                "pmid18706502",
                "pmid22102154"
            ]
        },
        "cell_102": {
            "question": "Does microglial CD2AP deficiency protect against amyloidosis in an Alzheimer's disease model?",
            "answer": "A: Yes\n\nThe most relevant study indicates that microglial CD2AP deficiency protects against amyloidosis in an Alzheimer's model. \n\n**Answer:** A. Yes",
            "pmid": [
                "pmid39695808",
                "pmid25887956",
                "pmid39696695",
                "pmid31440393",
                "pmid34958910",
                "pmid21273420",
                "pmid15194867",
                "pmid37609338",
                "pmid27425031",
                "pmid31690660"
            ]
        },
        "cell_103": {
            "question": "Does Aster tataricus have potential anti-neuroinflammatory effects relevant to Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nAster tataricus has demonstrated potential anti-neuroinflammatory effects relevant to Alzheimer's disease by reducing inflammatory markers and inhibiting pathways such as NF-kappaB, which are significant in neuroinflammation associated with AD.",
            "pmid": [
                "pmid28344491",
                "pmid36820018",
                "pmid31225769",
                "pmid35627075",
                "pmid33463937",
                "pmid11510486",
                "pmid36193798",
                "pmid12453679",
                "pmid30622433",
                "pmid26068423"
            ]
        },
        "cell_104": {
            "question": "Does DHCR24 overexpression modulate microglia polarization and inflammatory response in Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid32950573",
                "pmid29115990",
                "pmid37344916",
                "pmid35804281",
                "pmid35296367",
                "pmid15172747",
                "pmid11290384",
                "pmid36450444",
                "pmid25637481",
                "pmid37011864"
            ]
        },
        "cell_105": {
            "question": "Does compound 4c2 exhibit anti-inflammatory effects by reducing pro-inflammatory cytokines like NO, IL-6, and TNF-alpha relevant to Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid12453679",
                "pmid20555131",
                "pmid16237106",
                "pmid36820018",
                "pmid32028243",
                "pmid35987018",
                "pmid35714925",
                "pmid16445950",
                "pmid14975597",
                "pmid12119423"
            ]
        },
        "cell_106": {
            "question": "Does inhibiting microglial activation by PS/PC liposomes suggest a potential Alzheimer's disease treatment?",
            "answer": "**Answer: A. Yes**\n\nThe use of PS/PC liposomes to inhibit microglial activation shows promise as a potential Alzheimer's disease treatment by reducing neuroinflammation and protecting neurons from damage.",
            "pmid": [
                "pmid17349923",
                "pmid33344892",
                "pmid25461285",
                "pmid37373543",
                "pmid31264132",
                "pmid35677758",
                "pmid37333071",
                "pmid34834468",
                "pmid18835047",
                "pmid38006681"
            ]
        },
        "cell_107": {
            "question": "Do T1AM and SG-2 induce autophagy in human glioblastoma cell lines, potentially offering therapeutic benefits for Alzheimer's disease?",
            "answer": "The answer is A. Yes.\n\nT1AM and SG-2 induce autophagy in human glioblastoma cell lines, as shown by increased LC3II/LC3I ratios and decreased p62 levels. Enhancing autophagy has been beneficial in clearing amyloid-beta and improving cognitive function in Alzheimer's models, suggesting therapeutic potential for these compounds.\n\nAnswer: A. Yes",
            "pmid": [
                "pmid29311919",
                "pmid21368103",
                "pmid32110992",
                "pmid30362531",
                "pmid38007654",
                "pmid24602800",
                "pmid25421002",
                "pmid38787367",
                "pmid29631635",
                "pmid30695399"
            ]
        },
        "cell_108": {
            "question": "Does BACE-1 inhibition prevent gamma-secretase inhibitor-evoked Abeta rise in human neuroblastoma SH-SY5Y cells, a model relevant to Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid22018341",
                "pmid19519664",
                "pmid32223911",
                "pmid29327084",
                "pmid15642747",
                "pmid31416794",
                "pmid30626751",
                "pmid18005427",
                "pmid22895721",
                "pmid23202730"
            ]
        },
        "cell_109": {
            "question": "Does Ganoderic Acid D protect human amniotic mesenchymal stem cells against oxidative stress-induced senescence, potentially relevant to Alzheimer's disease?",
            "answer": "A. Yes\n\n**Step-by-Step Explanation:**\n\n1. **Understanding the Query:** The question asks if Ganoderic Acid D (GA-D) protects hAMSCs from oxidative stress-induced senescence and its relevance to Alzheimer's Disease (AD).\n\n2. **Reviewing Relevant Studies:**\n   - GA-D activates PERK/NRF2 pathways in hAMSCs, reducing ROS and proteins like p21/p16, thereby protecting against senescence.\n   - Other studies show that antioxidants and stem cells can mitigate AD by reducing oxidative stress.\n\n3. **Connecting the Dots:** Since GA-D enhances cellular protection mechanisms and AD involves oxidative stress, GA-D's protective effects on hAMSCs are relevant to AD treatment potential.\n\n**Answer: A. Yes**\n\nNew Answer:\nA. Yes\n\nThe provided context shows that Ganoderic Acid D (GA-D) protects human amniotic mesenchymal stem cells against oxidative stress-induced senescence through the PERK/NRF2 pathway, which is relevant to Alzheimer's disease as it involves mechanisms that can mitigate oxidative damage associated with the condition.\n\n**Final Answer: A. Yes**\n\nA. Yes",
            "pmid": [
                "pmid32774686",
                "pmid39625499",
                "pmid34798773",
                "pmid32089787",
                "pmid28554861",
                "pmid34025387",
                "pmid30290256",
                "pmid37507874",
                "pmid33815510",
                "pmid21606627"
            ]
        },
        "cell_110": {
            "question": "Does stearidonic acid (SDA) have a neuroprotective effect against Amyloid-beta-induced neurotoxicity relevant to Alzheimer's disease?",
            "answer": "The study in pmid36552565 clearly demonstrates that stearidonic acid (SDA) has a neuroprotective effect against Amyloid-beta-induced neurotoxicity by protecting cells from apoptosis, oxidative stress, and inflammation. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid36552565",
                "pmid18037281",
                "pmid21606627",
                "pmid23645098",
                "pmid19423322",
                "pmid31677009",
                "pmid26965310",
                "pmid36770835",
                "pmid12105192",
                "pmid12065621"
            ]
        },
        "cell_111": {
            "question": "Does GMFG regulate Abeta42 phagocytosis in macrophages, implicated in Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nGMFG regulates Abeta42 phagocytosis in macrophages implicated in Alzheimer's disease.\n\n**Answer:**  \nThe findings from pmid39243388 indicate that Glia maturation factor-gamma (GMFG) does regulate the phagocytosis of amyloid-beta42 in macrophages, which is relevant to Alzheimer's disease. Therefore, the answer is yes.\n\n**Final Answer: A. Yes**",
            "pmid": [
                "pmid39243388",
                "pmid18434187",
                "pmid12032144",
                "pmid12927763",
                "pmid33737172",
                "pmid27994540",
                "pmid27723233",
                "pmid20798889",
                "pmid31982468",
                "pmid15172747"
            ]
        },
        "cell_112": {
            "question": "Does amyloid beta protein's inhibition of MTT reduction in astrocytes relate to its role in Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid11137881",
                "pmid11755001",
                "pmid11145195",
                "pmid37248300",
                "pmid29033790",
                "pmid28455519",
                "pmid20634578",
                "pmid21376707",
                "pmid26200696",
                "pmid12105192"
            ]
        },
        "cell_113": {
            "question": "Do astrocytes produce amyloid beta when stimulated with certain cytokine combinations relevant to Alzheimer's disease?",
            "answer": "The answer is A. Yes.\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Studies:** Among the provided context, pmid11114266 directly investigates whether astrocytes produce amyloid beta (Abeta) when stimulated with specific cytokines relevant to Alzheimer's disease.\n\n2. **Study Findings:** This study demonstrates that when astrocytes are exposed to interferon-gamma (IFNγ) in combination with either tumor necrosis factor-alpha (TNFα) or interleukin-1beta (IL-1β), they produce significant amounts of Abeta1-40 and Abeta1-42. This occurs in both primary human astrocytes and the U373 cell line.\n\n3. **Conclusion:** The evidence from pmid11114266 clearly shows that certain cytokine combinations can induce Abeta production by astrocytes, which is directly relevant to Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid11114266",
                "pmid1749826",
                "pmid11755001",
                "pmid10817926",
                "pmid29033790",
                "pmid25814669",
                "pmid25169677",
                "pmid37248300",
                "pmid34981861",
                "pmid18780966"
            ]
        },
        "cell_114": {
            "question": "Does nimodipine inhibit microglial IL-1beta release in response to amyloid beta, implicated in Alzheimer's disease?",
            "answer": "The evidence from multiple studies indicates that nimodipine does inhibit microglial IL-1beta release in response to amyloid beta.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid22831460",
                "pmid16399208",
                "pmid31019207",
                "pmid12930788",
                "pmid12453679",
                "pmid15817521",
                "pmid11741404",
                "pmid35883683",
                "pmid26114860",
                "pmid22659089"
            ]
        },
        "cell_115": {
            "question": "Does astrocytic alpha7 nAChR activation inhibit beta-amyloid aggregation in Alzheimer's disease?",
            "answer": "The contextual information provided includes a study (pmid30345917) that specifically shows astrocytic alpha7 nAChR activation inhibits beta-amyloid aggregation by upregulating alphaB-crystallin. Another study (pmid39116785) supports this by showing beneficial effects of alpha7 activation in reducing Abeta levels and improving outcomes before amyloid deposition.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid30345917",
                "pmid28455519",
                "pmid25816313",
                "pmid11755001",
                "pmid37248300",
                "pmid20950278",
                "pmid39116785",
                "pmid26200696",
                "pmid23379615",
                "pmid12105192"
            ]
        },
        "cell_116": {
            "question": "Does S-equol's attenuation of astrocytic NO production have potential implications for mitigating neuroinflammation in Alzheimer's disease?",
            "answer": "The evidence from multiple studies indicates that S-equol reduces nitric oxide production in astrocytes through the GPR30 pathway and that neuroinflammation, including NO-mediated processes, plays a significant role in Alzheimer's disease. Therefore, S-equol's effect on reducing NO could help mitigate neuroinflammation in AD.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid29692883",
                "pmid12453679",
                "pmid11556547",
                "pmid37914355",
                "pmid12203047",
                "pmid10964481",
                "pmid11958858",
                "pmid23428542",
                "pmid35872221",
                "pmid31722531"
            ]
        },
        "cell_117": {
            "question": "Does peroxisome deficiency in neural cells contribute to Alzheimer's disease development by activating the innate immune system and causing CNS axonal loss?",
            "answer": "The analysis of the provided context indicates that peroxisome deficiency in neural cells contributes to Alzheimer's disease development. Specifically, peroxisomal dysfunction leads to increased oxidative stress and inflammation, which activate the innate immune system, and cause axonal loss, as evidenced by studies linking such deficiencies to neurodegenerative processes.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid24060512",
                "pmid12203047",
                "pmid24336108",
                "pmid17055782",
                "pmid10964481",
                "pmid35969330",
                "pmid9138425",
                "pmid9514829",
                "pmid14748735",
                "pmid33417205"
            ]
        },
        "cell_118": {
            "question": "Does biatractylolide protect against glutamate-induced cell damage relevant to Alzheimer's disease?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid36500385",
                "pmid29075302",
                "pmid15003996",
                "pmid16772755",
                "pmid16762377",
                "pmid12391586",
                "pmid30178892",
                "pmid26696494",
                "pmid12203047",
                "pmid32256561"
            ]
        },
        "cell_119": {
            "question": "Does erythrosine B (ER) reduce Abeta-associated impaired neuronal cell function in Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid21998691",
                "pmid26696494",
                "pmid38791223",
                "pmid20950278",
                "pmid26881107",
                "pmid19666073",
                "pmid12917750",
                "pmid17055782",
                "pmid23645098",
                "pmid17008108"
            ]
        },
        "cell_120": {
            "question": "Can Liensinine, Isoliensinine, and Neferine reduce apoptosis in PC12 cells injured by amyloid-beta, potentially offering therapeutic potential for Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid35762411",
                "pmid15073525",
                "pmid9464644",
                "pmid37891552",
                "pmid9410912",
                "pmid30404965",
                "pmid25774173",
                "pmid26696494",
                "pmid33335556",
                "pmid11487523"
            ]
        },
        "cell_121": {
            "question": "Does 25-hydroxyvitamin D3 inhibit nitric oxide production in activated microglia, potentially relevant to Alzheimer's disease?",
            "answer": "The study by pmid25352759 demonstrates that 25-hydroxyvitamin D3 inhibits nitric oxide production in activated microglia, which has potential relevance to Alzheimer's disease. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid25352759",
                "pmid24934545",
                "pmid12203047",
                "pmid37569267",
                "pmid37274074",
                "pmid11070493",
                "pmid18037281",
                "pmid28816551",
                "pmid11592111",
                "pmid21351586"
            ]
        },
        "cell_122": {
            "question": "Does NPS 2143 suppress excess endogenous Abeta42 secretion in human cortical astrocytes and neurons relevant to Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe provided context indicates that NPS 2143 suppresses excess endogenous Abeta42 secretion in human cortical astrocytes and neurons relevant to Alzheimer's disease. This is supported by pmid28455519, which states that NPS 2143 blocks the over-release of toxic Abeta42 fragments, normalizing their levels.\n\n**Final Answer: A. Yes**",
            "pmid": [
                "pmid28455519",
                "pmid23628734",
                "pmid10623648",
                "pmid25342943",
                "pmid11556547",
                "pmid22998035",
                "pmid18400893",
                "pmid23559013",
                "pmid29033790",
                "pmid10964481"
            ]
        },
        "cell_123": {
            "question": "Do Dendrobium polysaccharides improve cognitive impairment in Alzheimer's disease by modulating microglial activation?",
            "answer": "**Answer:** A. Yes  \n\nThe contextual information indicates that Dendrobium officinale polysaccharides (DOP) improve cognitive impairment in Alzheimer's disease by modulating microglial activation. Specifically, pmid30253123 demonstrates that DOP inhibits pro-inflammatory responses and enhances anti-inflammatory activity in microglia, which contributes to improved cognitive function.",
            "pmid": [
                "pmid30253123",
                "pmid39536176",
                "pmid27994964",
                "pmid30844489",
                "pmid33913927",
                "pmid21606627",
                "pmid37781122",
                "pmid28546539",
                "pmid35586062",
                "pmid36402384"
            ]
        },
        "cell_124": {
            "question": "Do murine Abeta oligomers disrupt endothelial barrier integrity through astrocyte-derived factors relevant to Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nAccording to the provided context, murine Abeta oligomers do disrupt endothelial barrier integrity through astrocyte-derived factors relevant to Alzheimer's disease. Specifically, the study demonstrates that while Abeta oligomers alone have minimal effect on endothelial cells, they cause significant disruption when co-cultured with astrocytes, leading to changes in VEGFR signaling and barrier disruption via astrocyte-derived factors. \n\nANSWER: A",
            "pmid": [
                "pmid35163801",
                "pmid24997450",
                "pmid32450297",
                "pmid34494298",
                "pmid35851991",
                "pmid16821113",
                "pmid16246051",
                "pmid24918635",
                "pmid33737172",
                "pmid25233405"
            ]
        },
        "cell_125": {
            "question": "Does inhibiting endothelial cell YAP improve BBB integrity and reduce brain damage in ischemia-reperfusion injury, potentially relevant to Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid34899341",
                "pmid26362823",
                "pmid31047972",
                "pmid23645098",
                "pmid17430246",
                "pmid38132159",
                "pmid24997450",
                "pmid29351469",
                "pmid30178892",
                "pmid21193044"
            ]
        },
        "cell_126": {
            "question": "Is microglia-induced neuroinflammation predominant in the white matter of aging mice and humans, as well as in early-onset Alzheimer's disease (EOAD) brains?",
            "answer": "A. Yes",
            "pmid": [
                "pmid28713239",
                "pmid15172747",
                "pmid8996832",
                "pmid31139072",
                "pmid11578773",
                "pmid9542587",
                "pmid26257642",
                "pmid28434692",
                "pmid8871946",
                "pmid35093614"
            ]
        },
        "cell_127": {
            "question": "Does SRCL presence in astrocytes and microglia suggest a role in amyloid-beta clearance in Alzheimer's disease?",
            "answer": "The presence of SRCL in astrocytes and microglia suggests a potential role in amyloid-beta (Abeta) clearance based on previous studies showing its involvement in binding and clearing Abeta. The new context provided does not discuss SRCL, so it doesn't affect the conclusion.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid16868960",
                "pmid15987691",
                "pmid10550330",
                "pmid11238031",
                "pmid15172747",
                "pmid21076037",
                "pmid11137881",
                "pmid25814669",
                "pmid37248300",
                "pmid34699252"
            ]
        },
        "cell_128": {
            "question": "Does S-Adenosylhomocysteine (SAH) increase microglial cell DNA damage, potentially contributing to Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid22064374",
                "pmid19635394",
                "pmid17851177",
                "pmid23579332",
                "pmid32597804",
                "pmid25169677",
                "pmid26095650",
                "pmid26200696",
                "pmid9878757",
                "pmid25499850"
            ]
        },
        "cell_129": {
            "question": "Does microglial DNase II deficiency contribute to Alzheimer's disease pathology?",
            "answer": "A: A",
            "pmid": [
                "pmid39833906",
                "pmid8730800",
                "pmid28412672",
                "pmid16677790",
                "pmid2935594",
                "pmid33402227",
                "pmid39695808",
                "pmid11029529",
                "pmid26095650",
                "pmid27060961"
            ]
        },
        "cell_130": {
            "question": "Does leptin decrease neprilysin expression in primary cultured astrocytes, potentially contributing to Alzheimer's disease?",
            "answer": "The most appropriate answer is A. Yes.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid24508800",
                "pmid25039425",
                "pmid12387451",
                "pmid23274884",
                "pmid32512031",
                "pmid22921154",
                "pmid19166821",
                "pmid21382117",
                "pmid17591969",
                "pmid17021406"
            ]
        },
        "cell_131": {
            "question": "Does chlorogenic acid enhance autophagy to protect SH-SY5Y cells against H2O2-induced injury, relevant to Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid33747165",
                "pmid30362531",
                "pmid21368103",
                "pmid30695399",
                "pmid38787367",
                "pmid31900522",
                "pmid39736370",
                "pmid24278483",
                "pmid16297550",
                "pmid28806762"
            ]
        },
        "cell_132": {
            "question": "Does curcumin's Nrf2 activation via PKCdelta-mediated p62 phosphorylation at S351 have a protective role in neurons relevant to Alzheimer's disease?",
            "answer": "Based on the provided context and analysis, curcumin activates Nrf2 through PKCdelta-mediated p62 phosphorylation at S351, which plays a protective role in neurons relevant to Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid33875681",
                "pmid26358194",
                "pmid27594837",
                "pmid24755072",
                "pmid25774181",
                "pmid22476982",
                "pmid27060945",
                "pmid28854504",
                "pmid27521081",
                "pmid30746607"
            ]
        },
        "cell_133": {
            "question": "Does PAR2 activation in glial cells contribute to neuroinflammation and neuronal death in Alzheimer's disease?",
            "answer": "The study (pmid17911636) shows that PAR2 activation in glial cells increases proinflammatory responses and contributes to neuronal death in Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid17911636",
                "pmid23076628",
                "pmid14682360",
                "pmid30594047",
                "pmid11556547",
                "pmid10964481",
                "pmid10095092",
                "pmid25169677",
                "pmid17055782",
                "pmid16476770"
            ]
        },
        "cell_134": {
            "question": "Is PKC alpha immunoreactivity enhanced in reactive astrocytes associated with senile plaques in Alzheimer's disease brains?",
            "answer": "A. Yes",
            "pmid": [
                "pmid2376771",
                "pmid1990207",
                "pmid7936052",
                "pmid8327146",
                "pmid3165303",
                "pmid2391515",
                "pmid32512031",
                "pmid11290384",
                "pmid11755001",
                "pmid37248300"
            ]
        },
        "cell_135": {
            "question": "Do women with Alzheimer's disease exhibit weaker cytokine production in response to viral infection compared to men with Alzheimer's disease?",
            "answer": "The provided context indicates that women with Alzheimer's disease exhibit a weaker cytokine production in response to viral infection compared to men with Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35708851",
                "pmid33301871",
                "pmid37330146",
                "pmid17085001",
                "pmid39497354",
                "pmid29039020",
                "pmid7768042",
                "pmid33715827",
                "pmid16814429",
                "pmid10319892"
            ]
        },
        "cell_136": {
            "question": "Does microglial heme oxygenase-1 (HO-1) deletion reduce tauopathy-induced neuroinflammation in the retina of old mice, an Alzheimer's-relevant model?",
            "answer": "A: Yes",
            "pmid": [
                "pmid36358522",
                "pmid32708329",
                "pmid30040734",
                "pmid11053673",
                "pmid19250338",
                "pmid30413160",
                "pmid10936206",
                "pmid25761244",
                "pmid18841019",
                "pmid26257642"
            ]
        },
        "cell_137": {
            "question": "Is defective TNFalpha-dependent control of astrocyte glutamate release associated with Alzheimer's disease?",
            "answer": "The provided context specifically addresses the role of reactive microglia in the progression of Alzheimer's disease (AD) by influencing amyloid-beta (Abeta) and tau production. It highlights how inflammatory cytokines like IL-6 and IL-1beta, as well as Abeta oligomers, can increase tau expression, and how anti-inflammatory treatments might mitigate these effects.\n\nHowever, the query asks about \"defective TNF-alpha-dependent control of astrocyte glutamate release\" in relation to AD. While the context mentions cytokines like IL-6 and IL-1beta, it does not provide information on TNF-alpha or its role in regulating glutamate release by astrocytes. Therefore, based solely on the given context, there is no direct evidence linking defective TNF-alpha-dependent control of astrocyte glutamate release to AD.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid16253995",
                "pmid23579326",
                "pmid20401186",
                "pmid35872221",
                "pmid35569719",
                "pmid19828810",
                "pmid35427648",
                "pmid10964481",
                "pmid10713108",
                "pmid25169677"
            ]
        },
        "cell_138": {
            "question": "Does Abeta binding to phosphatidylserine on neuronal cells contribute to neurotoxicity in Alzheimer's disease?",
            "answer": "The provided context indicates that Abeta binds to phosphatidylserine (PS) on neuronal cells and this interaction is crucial for its neurotoxic effects. Specifically, pmid19324459 demonstrates that Annexin V, which targets PS, inhibits Abeta binding and rescues neurotoxicity, confirming the role of PS in Abeta's toxicity.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid19324459",
                "pmid16210396",
                "pmid25233405",
                "pmid15837797",
                "pmid34494298",
                "pmid28642958",
                "pmid11181824",
                "pmid16626961",
                "pmid11145195",
                "pmid35264247"
            ]
        },
        "cell_139": {
            "question": "Can ultrasound-mediated exosome release from astrocytes alleviate amyloid-beta-induced neurotoxicity in Alzheimer's disease?",
            "answer": "Based on the analysis of the provided studies, the most relevant evidence comes from pmid33754065, which shows that ultrasound increases exosome release from astrocytes and reduces Abeta-induced neurotoxicity. Therefore, the answer is:\n\n**A: Yes**\n\nNew Answer: A",
            "pmid": [
                "pmid33754065",
                "pmid27392863",
                "pmid31410223",
                "pmid18003341",
                "pmid30259257",
                "pmid39588954",
                "pmid33132889",
                "pmid34073900",
                "pmid11137881",
                "pmid37569786"
            ]
        },
        "cell_140": {
            "question": "How does PTPA knockdown affect cell viability and apoptosis relevant to Alzheimer's disease?",
            "answer": "The question asks how PTPA knockdown affects cell viability and apoptosis in Alzheimer's disease. From the provided information, knocking down PTPA induces apoptosis through the mitochondrial pathway by decreasing mitochondrial membrane potential, leading to Bax translocation, cytochrome c release, caspase activation, and PARP cleavage. This results in a decrease in anti-apoptotic proteins like Bcl-xl and Bcl-2.\n\n**Answer:** B. It induces apoptosis through the mitochondrial pathway.",
            "pmid": [
                "pmid24424093",
                "pmid15208744",
                "pmid28413194",
                "pmid16923170",
                "pmid20157251",
                "pmid23017601",
                "pmid12059037",
                "pmid9410912",
                "pmid24821282",
                "pmid32851560"
            ]
        },
        "cell_141": {
            "question": "How does SRPK2 expression affect microglia activation in Alzheimer's disease?",
            "answer": "The most appropriate answer is C: SRPK2 promotes the proinflammatory activation of microglia.\n\nAnswer: C",
            "pmid": [
                "pmid29180839",
                "pmid11290384",
                "pmid35153686",
                "pmid11578773",
                "pmid30758770",
                "pmid18835047",
                "pmid35694923",
                "pmid19800391",
                "pmid25169677",
                "pmid15608143"
            ]
        },
        "cell_142": {
            "question": "Which compound inhibits Abeta aggregation and promotes neurite outgrowth in Alzheimer's disease cell models?",
            "answer": "B. VB-037",
            "pmid": [
                "pmid30707915",
                "pmid19141069",
                "pmid22992731",
                "pmid16805796",
                "pmid32233096",
                "pmid16246051",
                "pmid26362358",
                "pmid30781608",
                "pmid27258855",
                "pmid19625748"
            ]
        },
        "cell_143": {
            "question": "Which of the following best describes the cellular effect of Pon1 deficiency in relation to Alzheimer's disease pathology?",
            "answer": "D. It promotes Trem2-mediated microglial phagocytosis and reduces pro-inflammatory cytokine release.\n\n**Step-by-Step Explanation:**\n\n1. **Understanding the Question:** The question asks about the cellular effects of Pon1 deficiency in relation to Alzheimer's disease (AD) pathology, focusing on how it impacts processes like inflammation, phagocytosis, or neuronal health.\n\n2. **Reviewing the Context:**\n   - **PON Gene Cluster Study (pmid20878768):** This study links paraoxonase activity and PON gene variants to AD risk but doesn't directly address Pon1 deficiency's cellular effects.\n   - **Microglia Function in Prion Disease (pmid35589918):** Discusses how microglia function is affected by Pon1 deficiency, noting increased Trem2 expression, enhanced phagocytosis, and reduced pro-inflammatory cytokines.\n\n3. **Analyzing Options:**\n   - **Option A:** Incorrect because the study shows decreased pro-inflammatory cytokines, not an increase.\n   - **Option B:** Incorrect as it states suppression of Trem2, whereas the study found increased expression.\n   - **Option C:** Unrelated since the context doesn't mention neuronal apoptosis or oxidative stress from Pon1 deficiency.\n   - **Option D:** Correct because it accurately reflects the findings of enhanced phagocytosis and reduced inflammation.\n\n4. **Conclusion:** Based on the evidence, Option D best describes the cellular effects of Pon1 deficiency in AD pathology.\n\n**Answer:**\nD. It promotes Trem2-mediated microglial phagocytosis and reduces pro-inflammatory cytokine release.",
            "pmid": [
                "pmid35589918",
                "pmid36899882",
                "pmid33668379",
                "pmid36683512",
                "pmid29180839",
                "pmid24334724",
                "pmid9151738",
                "pmid25038992",
                "pmid20980077",
                "pmid20878768"
            ]
        },
        "cell_144": {
            "question": "What effect does dipeptidyl vinyl sulfone (VS) have on Abeta-mediated microglial inflammation relevant to Alzheimer's disease?",
            "answer": "The most appropriate answer based on the contextual information provided is:\n\n**B. It reduces HMGB1 and NLRP3-inflammasome expression.**\n\nThis conclusion is supported by the study in pmid27797173, which demonstrates that dipeptidyl vinyl sulfone (VS) inhibits both HMGB1 and NLRP3-inflammasome expression in response to Abeta-mediated microglial inflammation.\n\n**Final Answer: B. It reduces HMGB1 and NLRP3-inflammasome expression.**",
            "pmid": [
                "pmid27797173",
                "pmid31982468",
                "pmid34329731",
                "pmid23279783",
                "pmid35772378",
                "pmid36724966",
                "pmid29743866",
                "pmid20798889",
                "pmid22133278",
                "pmid31722531"
            ]
        },
        "cell_145": {
            "question": "What effect does water-soluble chitosan (WSC) have on pro-inflammatory cytokine production in human astrocytoma cells activated by amyloid beta peptide and interleukin-1beta, relevant to Alzheimer's disease?",
            "answer": "The study in pmid11872267 demonstrates that water-soluble chitosan (WSC) significantly inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-6 in human astrocytoma cells activated by amyloid beta peptide and interleukin-1beta. This indicates a decrease in cytokine production, which aligns with option B.\n\n**Answer: B. WSC decreases pro-inflammatory cytokine production.**",
            "pmid": [
                "pmid11872267",
                "pmid19844776",
                "pmid26006224",
                "pmid23999027",
                "pmid29112116",
                "pmid1749826",
                "pmid34111442",
                "pmid11114266",
                "pmid30844489",
                "pmid31677009"
            ]
        },
        "cell_146": {
            "question": "Which olive biophenol extract showed the highest neuroprotection against H2O2-induced oxidative stress and Cu-induced toxicity in SH-SY5Y cells, suggesting potential Alzheimer's disease benefits?",
            "answer": "The answer is C. Hydroxytyrosol Extreme (HTE).\n\n**Answer: C. Hydroxytyrosol Extreme (HTE)**",
            "pmid": [
                "pmid29109370",
                "pmid39061831",
                "pmid38339193",
                "pmid37508010",
                "pmid29068387",
                "pmid39200504",
                "pmid35592293",
                "pmid35620405",
                "pmid32785956",
                "pmid29417471"
            ]
        },
        "cell_147": {
            "question": "Which of the following best explains how hypoxia contributes to microglial dysfunction in the context of Alzheimer’s disease pathology?",
            "answer": "**Answer:**\n\nThe most appropriate answer is:\n\n**B. Hypoxia overactivates HIF1, which suppresses mitochondrial respiration and proliferation in microglia, reducing their clustering around amyloid plaques.**\n\nThis explanation is supported by the context that describes how hypoxia activates HIF1 signaling in Abeta-associated microglia, leading to quiescence, reduced mitochondrial activity, and decreased ability to cluster around amyloid plaques, which contributes to AD neuropathology.\n\n**Answer:** B",
            "pmid": [
                "pmid37117599",
                "pmid28890695",
                "pmid35852609",
                "pmid29867325",
                "pmid39476996",
                "pmid23603149",
                "pmid34844651",
                "pmid21799251",
                "pmid36724966",
                "pmid32823544"
            ]
        },
        "cell_148": {
            "question": "Epiisopiloturine (EPI), a Pilocarpus microphyllus alkaloid, reduces microglial inflammation. How might this compound potentially influence Alzheimer's disease progression?",
            "answer": "**Answer: B. By inhibiting the TLR4/NF-κB-MAPK signaling pathway in microglia**\n\nEpiisopiloturine (EPI) reduces microglial inflammation by inhibiting the TLR4/NF-κB-MAPK signaling pathway, which is associated with neuroinflammation and could potentially slow Alzheimer's disease progression.",
            "pmid": [
                "pmid37151606",
                "pmid37598923",
                "pmid32166661",
                "pmid36820018",
                "pmid39094545",
                "pmid37190597",
                "pmid30208700",
                "pmid35772378",
                "pmid37336148",
                "pmid31487775"
            ]
        },
        "cell_149": {
            "question": "How does PKC activation affect gliosis in NPC1 patient-derived iPSC glial cells, and what is its implication for Alzheimer's disease?",
            "answer": "B. PKC activation reduces gliosis and restores cholesterol levels; suggesting a potential therapeutic avenue for Alzheimer's disease.",
            "pmid": [
                "pmid28841900",
                "pmid2376771",
                "pmid7936052",
                "pmid2391515",
                "pmid39814010",
                "pmid32512031",
                "pmid3165303",
                "pmid24334724",
                "pmid1990207",
                "pmid23404502"
            ]
        },
        "cell_150": {
            "question": "Which of these is enriched in extracellular vesicles from NEP-enhanced hUC-MSCs and contributed to therapeutic effects in an Alzheimer's disease model?",
            "answer": "The correct answer is **C. NEP**.",
            "pmid": [
                "pmid34552470",
                "pmid32931898",
                "pmid15642747",
                "pmid38293018",
                "pmid16354928",
                "pmid32223911",
                "pmid34899919",
                "pmid33403386",
                "pmid32257549",
                "pmid22926141"
            ]
        },
        "cell_151": {
            "question": "Which cytokine is inhibited by TREM2 in response to Abeta42 in HMC3 cells relevant to Alzheimer's disease?",
            "answer": "The correct answer is:\n\nC. FGF-2",
            "pmid": [
                "pmid33461764",
                "pmid31134514",
                "pmid31727362",
                "pmid32959884",
                "pmid34663480",
                "pmid29362997",
                "pmid36637116",
                "pmid36683512",
                "pmid35082148",
                "pmid33101276"
            ]
        },
        "cell_152": {
            "question": "Which molecule protects human microglial cells (HMC3) against apoptosis and DNA damage induced by LPS and Abeta1-42 aggregates in vitro, offering potential Alzheimer's disease therapeutic benefits?",
            "answer": "The molecule that protects human microglial cells (HMC3) against apoptosis and DNA damage induced by LPS and Abeta1-42 aggregates in vitro is Noradrenaline. \n\nAnswer: C. Noradrenaline",
            "pmid": [
                "pmid39518952",
                "pmid35759686",
                "pmid36770835",
                "pmid34931800",
                "pmid28131834",
                "pmid37373543",
                "pmid17886039",
                "pmid27557632",
                "pmid38006681",
                "pmid23523945"
            ]
        },
        "cell_153": {
            "question": "Which microglial type reduces Abeta plaque deposition in Alzheimer's disease during IL-1beta-dependent neuroinflammation?",
            "answer": "B. Arg1+ microglia",
            "pmid": [
                "pmid15172747",
                "pmid11578773",
                "pmid28434692",
                "pmid20798889",
                "pmid22655214",
                "pmid8996832",
                "pmid28969867",
                "pmid16476660",
                "pmid18835047",
                "pmid27723233"
            ]
        },
        "cell_154": {
            "question": "How does soluble epoxide hydrolase (sEH) affect astrocytic immune responses in an Alzheimer's disease model?",
            "answer": "The correct answer based on the context provided is:\n\n**B. sEH suppresses pro-inflammatory marker expression in activated astrocytes.**\n\nAnswer: **B.**",
            "pmid": [
                "pmid31176371",
                "pmid26200696",
                "pmid32597804",
                "pmid34486652",
                "pmid29688618",
                "pmid24577479",
                "pmid20164580",
                "pmid27465436",
                "pmid36482035",
                "pmid31677009"
            ]
        },
        "cell_155": {
            "question": "What is a potential implication of A20 deficiency for neuroinflammatory diseases like Alzheimer's?",
            "answer": "The potential implication of A20 deficiency for neuroinflammatory diseases like Alzheimer's is that it increases susceptibility to axonal injury. This conclusion is supported by evidence showing reduced neurofilament levels in A20-deficient mice, indicating axonal damage and increased oxidative stress.\n\n**Answer: B. Increased susceptibility to axonal injury**",
            "pmid": [
                "pmid25026958",
                "pmid28337659",
                "pmid29039020",
                "pmid17085001",
                "pmid26124703",
                "pmid19596066",
                "pmid30594047",
                "pmid27335702",
                "pmid31690660",
                "pmid17055782"
            ]
        },
        "cell_156": {
            "question": "Beta-Amyrin reduces microglial inflammation. How might this mechanism be beneficial for Alzheimer's disease?",
            "answer": "Beta-Amyrin reduces microglial inflammation in Alzheimer's disease by modulating the M1/M2 phenotype balance. It decreases pro-inflammatory cytokines and shifts microglia towards an anti-inflammatory state (M2), thereby reducing neuroinflammation which is harmful in Alzheimer's.\n\n**Answer:** D. By modulating M1/M2 microglial phenotype balance to reduce neuroinflammation",
            "pmid": [
                "pmid29501766",
                "pmid28969867",
                "pmid38886959",
                "pmid18835047",
                "pmid25169677",
                "pmid39566407",
                "pmid39094545",
                "pmid23279783",
                "pmid35474599",
                "pmid12453679"
            ]
        },
        "cell_157": {
            "question": "Which of these is associated with increased Kir6.2 expression in reactive astrocytes in Alzheimer's disease?",
            "answer": "C",
            "pmid": [
                "pmid27586053",
                "pmid39603277",
                "pmid34981861",
                "pmid18201952",
                "pmid25814669",
                "pmid18395194",
                "pmid35872221",
                "pmid10095092",
                "pmid33277246",
                "pmid11447833"
            ]
        },
        "cell_158": {
            "question": "Which compound inhibits pro-inflammatory mediator production in microglial cells stimulated with Abeta25-35 and IFN-gamma, suggesting a potential Alzheimer's disease therapeutic approach?",
            "answer": "The correct answer based on the provided context is **B. Tetramethylpyrazine (TMP)**.\n\nAnswer: B",
            "pmid": [
                "pmid24975095",
                "pmid12137934",
                "pmid28157092",
                "pmid27797173",
                "pmid31982468",
                "pmid23279783",
                "pmid32028243",
                "pmid35714925",
                "pmid22133278",
                "pmid34329731"
            ]
        },
        "cell_159": {
            "question": "Which neurosteroid inhibits TLR4 activation in both male and female human macrophages, potentially contributing to anti-inflammatory effects relevant to Alzheimer's disease?",
            "answer": "The correct answer is **A. Allopregnanolone**.\n\nAnswer: A. Allopregnanolone",
            "pmid": [
                "pmid35967446",
                "pmid27359332",
                "pmid27980422",
                "pmid11070493",
                "pmid35772378",
                "pmid28669260",
                "pmid24917787",
                "pmid39183433",
                "pmid12137934",
                "pmid32508567"
            ]
        },
        "cell_160": {
            "question": "How does astrocytic hepcidin overexpression affect Alzheimer's disease symptoms in APP/PS1 mice?",
            "answer": "The studies suggest that astrocytic hepcidin overexpression improves cognitive decline and reduces amyloid-beta plaque formation in APP/PS1 mice.\n\n**Answer: B. Improves cognitive decline**\n\nANSWER: B",
            "pmid": [
                "pmid32707154",
                "pmid28266714",
                "pmid38195497",
                "pmid33298837",
                "pmid30031059",
                "pmid21771791",
                "pmid12881482",
                "pmid30594047",
                "pmid38216963",
                "pmid28191738"
            ]
        },
        "cell_161": {
            "question": "Which molecule, released by astrocytes upon tau oligomer exposure, contributes to cellular senescence and neuropathology in Alzheimer's disease and frontotemporal dementia?",
            "answer": "The molecule released by astrocytes upon exposure to tau oligomers that contributes to cellular senescence and neuropathology in Alzheimer's disease and frontotemporal dementia is HMGB1.\n\n**Answer: A. HMGB1**",
            "pmid": [
                "pmid34289368",
                "pmid33818291",
                "pmid30489222",
                "pmid26490863",
                "pmid37814508",
                "pmid32366836",
                "pmid24718102",
                "pmid30126037",
                "pmid25268947",
                "pmid30108137"
            ]
        },
        "cell_162": {
            "question": "How does glypican 4 (Gpc4) contribute to Alzheimer's disease pathophysiology in neural stem cells?",
            "answer": "The most appropriate answer based on the context is B: By increasing Abeta internalization via LRP1. Gpc4 facilitates Abeta uptake in neural stem cells, contributing to Alzheimer's disease progression.\n\n**Answer:** B",
            "pmid": [
                "pmid34552470",
                "pmid38992568",
                "pmid15084524",
                "pmid33403386",
                "pmid27687691",
                "pmid33556642",
                "pmid36753858",
                "pmid33420799",
                "pmid25637481",
                "pmid26200696"
            ]
        },
        "cell_163": {
            "question": "In Alzheimer's disease, which protein is associated with a stronger neuroinflammatory response compared to Abeta42?",
            "answer": "The correct answer is **A. Hyperphosphorylated tau protein**, as the context indicates it induces a stronger neuroinflammatory response compared to Abeta42.\n\nAnswer: A",
            "pmid": [
                "pmid38105410",
                "pmid7533559",
                "pmid25318543",
                "pmid12960778",
                "pmid11145195",
                "pmid31407125",
                "pmid26509334",
                "pmid25169677",
                "pmid18363842",
                "pmid21228179"
            ]
        },
        "cell_164": {
            "question": "Which Algerian mint extract showed the highest cytoprotective effect on 7-ketocholesterol-treated RAW 264.7 macrophages, potentially relevant to Alzheimer's disease or delirium?",
            "answer": "The study found that Mentha spicata L. (MS) extract demonstrated the highest cytoprotective effect on 7-ketocholesterol-treated RAW 264.7 macrophages among the Algerian mint extracts tested.\n\nAnswer: A. Mentha spicata L. (MS)\n\nNew Answer:\nThe most appropriate answer is A. Mentha spicata L. (MS).",
            "pmid": [
                "pmid32397683",
                "pmid30563252",
                "pmid24448790",
                "pmid32316271",
                "pmid28279707",
                "pmid38138438",
                "pmid26068423",
                "pmid27774420",
                "pmid39229544",
                "pmid39684454"
            ]
        },
        "cell_165": {
            "question": "Which microglial type significantly increased in mice receiving HUMSC-NC transplantation, contributing to amyloid-beta deposition reduction in an Alzheimer's disease model?",
            "answer": "The provided context does not discuss HUMSC-NC transplantation or its effects on microglial types in an Alzheimer's disease model. Therefore, the answer is unrelated to the given options.\n\n**Answer: UNRELATED**",
            "pmid": [
                "pmid33402227",
                "pmid24070198",
                "pmid15194867",
                "pmid16476660",
                "pmid28969867",
                "pmid27425031",
                "pmid38515329",
                "pmid30560017",
                "pmid30661261",
                "pmid38565291"
            ]
        },
        "cell_166": {
            "question": "How does inhibiting microglial choline transport affect M1/M2 polarization, potentially influencing conditions like Alzheimer's disease?",
            "answer": "The inhibition of microglial choline transport affects M1/M2 polarization by suppressing M1 and enhancing M2 polarization, leading to anti-inflammatory responses. \n\n**Final Answer: C**",
            "pmid": [
                "pmid36012189",
                "pmid31264132",
                "pmid38006681",
                "pmid26114860",
                "pmid37274074",
                "pmid34299330",
                "pmid31982468",
                "pmid36365192",
                "pmid28969867",
                "pmid39566407"
            ]
        },
        "cell_167": {
            "question": "Which metal sulfate combination synergistically up-regulates miRNA-125b and miRNA-146a in human astroglial cells, potentially contributing to Alzheimer's disease pathogenesis?",
            "answer": "The combination of iron and aluminum sulfate synergistically up-regulates miRNA-125b and miRNA-146a in human astroglial cells, contributing to Alzheimer's disease pathogenesis.\n\n**Answer: B. Iron and aluminum**",
            "pmid": [
                "pmid22099153",
                "pmid17629564",
                "pmid19540598",
                "pmid28706643",
                "pmid18625454",
                "pmid19679638",
                "pmid26293690",
                "pmid23219964",
                "pmid38648940",
                "pmid24863668"
            ]
        },
        "cell_168": {
            "question": "Which cell type produces significantly less apoE than pericytes and is less involved in Abeta clearance near vasculature in Alzheimer's disease?",
            "answer": "A. Astrocytes",
            "pmid": [
                "pmid37264161",
                "pmid29453790",
                "pmid24336108",
                "pmid39876020",
                "pmid20034483",
                "pmid15172747",
                "pmid38682184",
                "pmid34486652",
                "pmid16476660",
                "pmid26151923"
            ]
        },
        "cell_169": {
            "question": "How does repeated glucose deprivation/reperfusion affect neuronal cells, potentially contributing to Alzheimer's disease?",
            "answer": "B. It decreases cell viability and activates apoptosis pathways.",
            "pmid": [
                "pmid27766247",
                "pmid24124562",
                "pmid17055782",
                "pmid26895791",
                "pmid21035308",
                "pmid11193159",
                "pmid10662826",
                "pmid36206930",
                "pmid19828810",
                "pmid33994936"
            ]
        },
        "cell_170": {
            "question": "How does PIEZO1 channel activation affect microglial function relevant to Alzheimer's disease?",
            "answer": "The activation of the PIEZO1 channel enhances both lysosomal activity and phagocytosis in microglia, which are crucial for clearing amyloid beta plaques associated with Alzheimer's disease.\n\n**Answer: B. Enhances lysosomal activity and phagocytosis;**",
            "pmid": [
                "pmid36368316",
                "pmid38957539",
                "pmid36798430",
                "pmid35706029",
                "pmid37603311",
                "pmid31982468",
                "pmid11290384",
                "pmid15172747",
                "pmid37735240",
                "pmid20878768"
            ]
        },
        "cell_171": {
            "question": "Which intracellular protein binds amyloid-beta in Alzheimer's disease?",
            "answer": "The question asks which intracellular protein binds amyloid-beta peptide in Alzheimer's disease. From the provided context, pmid9338779 explicitly states that ERAB (an intracellular polypeptide) binds amyloid-beta and contributes to neurotoxicity. No other options are supported by the given information.\n\n**Answer: C. ERAB**",
            "pmid": [
                "pmid9338779",
                "pmid11145195",
                "pmid9444352",
                "pmid17384289",
                "pmid11517249",
                "pmid7753801",
                "pmid11351135",
                "pmid1436712",
                "pmid7494461",
                "pmid17100832"
            ]
        },
        "cell_172": {
            "question": "In which Alzheimer's disease stages do initial cytoskeletal changes occur in the basal nucleus of Meynert?",
            "answer": "The initial cytoskeletal changes in the basal nucleus of Meynert occur during **Stages I and II**. \n\nAnswer: C",
            "pmid": [
                "pmid10965795",
                "pmid7916770",
                "pmid10817927",
                "pmid27195475",
                "pmid22269167",
                "pmid7533559",
                "pmid9878757",
                "pmid9850923",
                "pmid11124422",
                "pmid12960778"
            ]
        },
        "cell_173": {
            "question": "How do microglia-derived microvesicles contribute to Alzheimer's disease degeneration?",
            "answer": "The correct answer is C. Microglia-derived microvesicles contribute to Alzheimer's disease degeneration by promoting the formation of soluble amyloid-beta (Abeta) species from insoluble aggregates and trafficking neurotoxic Abeta forms after their internalization into the microvesicles.\n\n**Answer: C**",
            "pmid": [
                "pmid24336048",
                "pmid25169677",
                "pmid15172747",
                "pmid18835047",
                "pmid16476660",
                "pmid22655214",
                "pmid11578773",
                "pmid37333071",
                "pmid31982468",
                "pmid37609338"
            ]
        },
        "cell_174": {
            "question": "What correlates with reduced dendritic arborization in the subiculum of Alzheimer's disease?",
            "answer": "The reduced dendritic arborization in the subiculum of Alzheimer's disease correlates with **C. Neurofibrillary tangle (NFT) densities**.\n\nAnswer: C",
            "pmid": [
                "pmid14507668",
                "pmid7916770",
                "pmid11351135",
                "pmid11276052",
                "pmid2900051",
                "pmid22269167",
                "pmid29080407",
                "pmid8239309",
                "pmid11145195",
                "pmid2725861"
            ]
        },
        "cell_175": {
            "question": "What cells do Alzheimer's disease CSF antibodies selectively recognize?",
            "answer": "The Alzheimer's disease cerebrospinal fluid (CSF) antibodies selectively recognize amoeboid microglial cells and activated microglia/neural macrophages.\n\n**Answer: C. Amoeboid microglial cells and activated microglia/neural macrophages**",
            "pmid": [
                "pmid8871946",
                "pmid8996832",
                "pmid16476660",
                "pmid34975305",
                "pmid12927763",
                "pmid7916770",
                "pmid15172747",
                "pmid38877498",
                "pmid11578773",
                "pmid36703235"
            ]
        },
        "cell_176": {
            "question": "What characteristics define Alzheimer's disease plaques formed by human macrophages?",
            "answer": "The correct answer is:\n\n**B. They consist of aggregated Abeta-peptide, reveal a typical ''Maltese cross'' structure, and are associated with glycosaminoglycanes, apolipoprotein E, cholesterol, and sphingomyelin.**\n\nThis option accurately reflects the characteristics described in the context information about Alzheimer's disease plaques formed by human macrophages.",
            "pmid": [
                "pmid16765377",
                "pmid15172747",
                "pmid27723233",
                "pmid16476660",
                "pmid28969867",
                "pmid28928740",
                "pmid16192374",
                "pmid38105410",
                "pmid28434692",
                "pmid27784770"
            ]
        },
        "cell_177": {
            "question": "What is a key observed link between pro-inflammatory cellular responses and altered brain electrophysiology in the context of inflammation-associated delirium, and what type of signaling is implicated?",
            "answer": "The key observed link between pro-inflammatory cellular responses and altered brain electrophysiology in inflammation-associated delirium involves elevated pro-inflammatory cytokines correlating with increased slow wave activity (SWA). This phenomenon is potentially linked to delirium and influenced by prostaglandin-adenosine signaling.\n\n**Answer: C. Elevated cortical pro-inflammatory cytokines correlate with increased slow wave activity (SWA), a phenomenon potentially linked to delirium and influenced by prostaglandin-adenosine signaling.**",
            "pmid": [
                "pmid20309566",
                "pmid24557038",
                "pmid20471138",
                "pmid32592865",
                "pmid29875474",
                "pmid22553034",
                "pmid24048854",
                "pmid29669581",
                "pmid33648701",
                "pmid37313848"
            ]
        },
        "cell_178": {
            "question": "What pathological features of alpha-synuclein are associated with postoperative delirium in patients undergoing gastrectomy?",
            "answer": "The correct answer is **C**. The studies indicate that both normal and phosphorylated alpha-synuclein are found in the myenteric plexus of the stomach, which aligns with option C.",
            "pmid": [
                "pmid23365056",
                "pmid33409674",
                "pmid29630637",
                "pmid39519398",
                "pmid30051417",
                "pmid36457825",
                "pmid34260706",
                "pmid34093168",
                "pmid37364279",
                "pmid30488836"
            ]
        },
        "cell_179": {
            "question": "What is the role of glia in the pathophysiology of delirium?",
            "answer": "The role of glia in delirium is multifaceted, involving several key mechanisms. Glial cells contribute to delirium through impaired brain energy metabolism and glymphatic dysfunction, which affect waste clearance and nutrient delivery. Additionally, reactive microglia drive neuroinflammation by producing pro-inflammatory cytokines like IL-6, and astrocytes play a role in maintaining the blood-brain barrier, whose disruption can exacerbate delirium symptoms. Furthermore, immune reactivity to glial proteins may contribute to the inflammatory response observed in delirium. These findings are supported across multiple studies that highlight the significant contribution of glia to the pathophysiology of delirium.\n\nAnswer: B",
            "pmid": [
                "pmid39463449",
                "pmid26029046",
                "pmid7916159",
                "pmid37851904",
                "pmid28673598",
                "pmid24557038",
                "pmid20309566",
                "pmid21978081",
                "pmid39419070",
                "pmid19422109"
            ]
        },
        "cell_180": {
            "question": "What cellular mechanisms underlie the effect of electroacupuncture in reducing delirium-like behavior associated with surgical pain?",
            "answer": "The most appropriate answer based on the provided information is:\n\n**B. Electroacupuncture alleviates delirium-like behavior by restoring gut microbiota balance, preventing microglia activation, and reversing dendritic spine elimination.**\n\nThis conclusion aligns with the findings in pmid36003380, which demonstrates that electroacupuncture effectively reduces delirium-like behaviors through these specific mechanisms.",
            "pmid": [
                "pmid36003380",
                "pmid31244434",
                "pmid38895540",
                "pmid30051417",
                "pmid37313848",
                "pmid39419070",
                "pmid37968531",
                "pmid30911820",
                "pmid37851904",
                "pmid20309566"
            ]
        },
        "cell_181": {
            "question": "What cellular mechanisms contribute to delirium as a complication of chimeric antigen receptor T-cell therapy?",
            "answer": "The correct answer is:\n\n**C. Immune effector cell-associated neurotoxicity syndrome (ICANS) causing cytokine release, BBB dysfunction, and neuroinflammation.**\n\nThis aligns with the described mechanisms where ICANS leads to cytokine release, blood-brain barrier dysfunction, and subsequent neuroinflammation, contributing to delirium as a complication of CAR-T therapy.",
            "pmid": [
                "pmid35871757",
                "pmid28049548",
                "pmid24557038",
                "pmid20471138",
                "pmid20309566",
                "pmid37313848",
                "pmid33763368",
                "pmid36259217",
                "pmid39463449",
                "pmid28673598"
            ]
        },
        "cell_182": {
            "question": "What cellular changes in reactive astrocytes are associated with delirium caused by systemic inflammation or acute liver failure?",
            "answer": "The correct answer is **B**. Increased accumulation and redistribution of multivesicular bodies (MVBs), particularly to perivascular endfeet, are associated with delirium caused by systemic inflammation or acute liver failure. \n\nThis conclusion is supported by the study in pmid33172595, which found significant increases in MVBs in astrocytes during conditions like sepsis-associated encephalopathy and acute hepatic encephalopathy, both linked to delirium.\n\n**Answer:** B",
            "pmid": [
                "pmid33172595",
                "pmid39463449",
                "pmid24557038",
                "pmid26029046",
                "pmid3765988",
                "pmid32592865",
                "pmid21978081",
                "pmid39419070",
                "pmid20471138",
                "pmid38566855"
            ]
        },
        "cell_183": {
            "question": "What immune-related mechanisms are implicated in delirium associated with cytomegalovirus colitis in elderly patients?",
            "answer": "The correct answer is D. Age-related immune dysfunction, increased pro-inflammatory cytokines (such as IL-6, IL-8), and impaired cholinergic regulation of microglia contribute to systemic and neuroinflammation.\n\nAnswer: D",
            "pmid": [
                "pmid17467406",
                "pmid24557038",
                "pmid20309566",
                "pmid19269948",
                "pmid20471115",
                "pmid21978081",
                "pmid17203511",
                "pmid32592865",
                "pmid28769556",
                "pmid34034650"
            ]
        },
        "cell_184": {
            "question": "What immune-related factors are associated with delirium in Morvan's syndrome?",
            "answer": "The immune-related factor associated with delirium in Morvan's syndrome is **C: Autoantibodies against voltage-gated potassium channel (VGKC)-complex proteins, particularly anti-CASPR2 antibodies**. \n\nAnswer: C",
            "pmid": [
                "pmid34757245",
                "pmid24557038",
                "pmid30090985",
                "pmid549538",
                "pmid20309566",
                "pmid33901789",
                "pmid28769556",
                "pmid32592865",
                "pmid37649721",
                "pmid33779822"
            ]
        },
        "cell_185": {
            "question": "What effects do antipsychotic medications have on astrocytes in the context of delirium?",
            "answer": "D",
            "pmid": [
                "pmid26029046",
                "pmid39463449",
                "pmid37313848",
                "pmid39355007",
                "pmid14648600",
                "pmid7916159",
                "pmid28286770",
                "pmid33154380",
                "pmid20309566",
                "pmid28673598"
            ]
        },
        "cell_186": {
            "question": "What cellular mechanisms underlie delirium-like behaviors induced by sedation in an inflamed developing brain?",
            "answer": "The cellular mechanisms underlying delirium-like behaviors in this context involve the activation of microglia (Iba1) and astrocytes (GFAP), driven by both inflammation and sedation. This results in glia-mediated neuroinflammatory responses without a significant change in cytokine levels.\n\n**Answer: C**",
            "pmid": [
                "pmid37302746",
                "pmid20309566",
                "pmid24557038",
                "pmid39463449",
                "pmid37313848",
                "pmid32592865",
                "pmid20471138",
                "pmid21978081",
                "pmid39839987",
                "pmid26029046"
            ]
        },
        "cell_187": {
            "question": "What cellular mechanisms underlie delirium induced by lithium therapy?",
            "answer": "C",
            "pmid": [
                "pmid10664610",
                "pmid7916159",
                "pmid37313848",
                "pmid39419070",
                "pmid37851904",
                "pmid3281716",
                "pmid39463449",
                "pmid19422109",
                "pmid28673598",
                "pmid39210294"
            ]
        },
        "cell_188": {
            "question": "What role does complement-dependent synaptic pruning by microglia play in delirium associated with sepsis-associated encephalopathy?",
            "answer": "The correct answer is:\n\n**B. It plays a critical role by leading to synaptic loss, neuronal damage, and cognitive dysfunction.**\n\nThis conclusion is supported by pmid37235660, which directly links complement-dependent synaptic pruning by microglia to neurocognitive deficits in SAE through synapse elimination, resulting in neuronal damage and cognitive impairment.",
            "pmid": [
                "pmid37235660",
                "pmid20471138",
                "pmid32592865",
                "pmid25722876",
                "pmid39559328",
                "pmid35535564",
                "pmid33584734",
                "pmid34234505",
                "pmid37313848",
                "pmid38926390"
            ]
        },
        "cell_189": {
            "question": "What cellular mechanisms are associated with delirium in Wernicke-Korsakoff syndrome?",
            "answer": "The most appropriate answer is:\n\n**D. Reduced alpha-ketoglutarate dehydrogenase activity in astrocytes, leading to impaired energy metabolism and increased microglial activation.**\n\nThis aligns with the studies indicating that WKS involves decreased enzyme activity in astrocytes and associated microglial activation contributing to delirium.",
            "pmid": [
                "pmid23790077",
                "pmid39463449",
                "pmid24557038",
                "pmid7916159",
                "pmid39419070",
                "pmid37851904",
                "pmid37313848",
                "pmid32592865",
                "pmid38566855",
                "pmid20471138"
            ]
        },
        "cell_190": {
            "question": "How does systemic bacterial infection induce microglial activation leading to delirium?",
            "answer": "The answer is based on understanding how systemic bacterial infections trigger an immune response outside the central nervous system (CNS) that communicates with the brain through signaling molecules, leading to microglial activation. This process involves peripheral inflammatory mediators influencing brain cells without direct infection or neuron stimulation.\n\n**Answer:** C. Through immune signaling that activates microglia, resulting in neuroinflammation, which contributes to delirium.",
            "pmid": [
                "pmid20309566",
                "pmid24557038",
                "pmid32592865",
                "pmid20471138",
                "pmid29755322",
                "pmid37313848",
                "pmid22553034",
                "pmid37235660",
                "pmid29875474",
                "pmid24048854"
            ]
        },
        "cell_191": {
            "question": "How does MANF inhibit inflammation and microglia activation in post-operative delirium?",
            "answer": "C. MANF suppresses inflammation and microglial M1 polarization, reducing neuroinflammatory responses.\n\n**Answer: C.**",
            "pmid": [
                "pmid34234505",
                "pmid36077505",
                "pmid35294925",
                "pmid22683080",
                "pmid33250764",
                "pmid35095412",
                "pmid33409674",
                "pmid29743866",
                "pmid20309566",
                "pmid24557038"
            ]
        },
        "cell_192": {
            "question": "Does astrocyte reactivity influence the association between amyloid-beta and tau phosphorylation in preclinical Alzheimer's disease?",
            "answer": "The most appropriate answer is:\n\n**B. Yes, astrocyte reactivity influences this association.**\n\nThis conclusion is supported by the study in pmid37248300, which directly demonstrates that astrocyte reactivity modulates the association between Abeta and tau phosphorylation in preclinical Alzheimer's disease.",
            "pmid": [
                "pmid37248300",
                "pmid11755001",
                "pmid34981861",
                "pmid15172747",
                "pmid25814669",
                "pmid25169677",
                "pmid33818291",
                "pmid11114266",
                "pmid18201952",
                "pmid29033790"
            ]
        },
        "cell_193": {
            "question": "What is the role of syntaxin-4 in the trafficking of ionotropic glutamate receptors in Alzheimer's Disease?",
            "answer": "The correct answer is C. Syntaxin-4 is essential for the trafficking of ionotropic glutamate receptors, which supports basal neurotransmission and synaptic plasticity. Its dysfunction may contribute to synaptic failure in Alzheimer's Disease.\n\nC. It is essential for the trafficking of ionotropic glutamate receptors, supporting basal neurotransmission and synaptic plasticity, and its dysfunction may contribute to synaptic failure.",
            "pmid": [
                "pmid30481567",
                "pmid25964214",
                "pmid26589795",
                "pmid2391515",
                "pmid8740986",
                "pmid25390692",
                "pmid21228179",
                "pmid25394486",
                "pmid17301176",
                "pmid24457963"
            ]
        },
        "cell_194": {
            "question": "What are intranuclear inclusion bodies in the context of Alzheimer's disease?",
            "answer": "C. Filamentous protein aggregates found in neurons and glia, potentially representing a rare neuropathological substrate of dementia, with their reduction suggesting altered nuclear structure or stress-related mechanisms.\n\nAnswer: C",
            "pmid": [
                "pmid7606903",
                "pmid22269167",
                "pmid10623648",
                "pmid16023263",
                "pmid26151923",
                "pmid29895248",
                "pmid32366836",
                "pmid34494298",
                "pmid7916770",
                "pmid36788216"
            ]
        },
        "cell_195": {
            "question": "What role does cathepsin B play in microglial Abeta clearance in Alzheimer's disease?",
            "answer": "Cathepsin B plays a role in enhancing the clearance of amyloid-beta (Abeta) plaques by promoting microglial migration and phagocytosis through PI3K-Akt signaling. This suggests that cathepsin B facilitates the removal of Abeta, contributing positively to the reduction of plaques associated with Alzheimer's disease.\n\n**Answer: B. Cathepsin B promotes microglial migration and phagocytosis of amyloid beta through PI3K-Akt signaling, enhancing Abeta clearance.**\n\nNew Answer: The role of cathepsin B in microglial Abeta clearance involves promoting migration and phagocytosis through PI3K-Akt signaling, which enhances the removal of amyloid-beta. Therefore, the correct answer is:\n\n**B. Cathepsin B promotes microglial migration and phagocytosis of amyloid beta through PI3K-Akt signaling, enhancing Abeta clearance.**\n\nAnswer: **B**",
            "pmid": [
                "pmid39304744",
                "pmid35181976",
                "pmid14522241",
                "pmid39122455",
                "pmid39726227",
                "pmid39453382",
                "pmid17261088",
                "pmid27333034",
                "pmid23816988",
                "pmid20634578"
            ]
        },
        "cell_196": {
            "question": "How does the repeat domain of tau interact with lipid surfaces in the context of Alzheimer's disease?",
            "answer": "The repeat domain of tau binds to lipid micelles and vesicles, folding into an ordered structure upon interaction. This supports the idea that lipid membranes play a role in tau's structural transitions and aggregation processes.\n\n**Answer: C**",
            "pmid": [
                "pmid16908029",
                "pmid30006151",
                "pmid24718102",
                "pmid15721985",
                "pmid27193083",
                "pmid16115884",
                "pmid34369377",
                "pmid7533559",
                "pmid32915536",
                "pmid25268947"
            ]
        },
        "cell_197": {
            "question": "Does the aqueous extract from Toona sinensis leaves inhibit microglia-mediated neuroinflammation in Alzheimer's disease?",
            "answer": "The aqueous extract from Toona sinensis leaves inhibits microglia-mediated neuroinflammation in vitro, as shown by its suppression of pro-inflammatory responses. This suggests potential therapeutic benefits for conditions like Alzheimer's disease.\n\n**Answer: A. Yes**\n\nNew Answer: The provided context does not mention Toona sinensis or its effects on microglia-mediated neuroinflammation in Alzheimer's disease. Therefore, based on the given information, it is unrelated to the query.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid24444536",
                "pmid28279707",
                "pmid36193798",
                "pmid27563424",
                "pmid20079417",
                "pmid35910833",
                "pmid27774420",
                "pmid29238386",
                "pmid33538666",
                "pmid32141445"
            ]
        },
        "cell_198": {
            "question": "Are amplicon vectors suitable for transducing antigen-presenting cells in the context of Alzheimer's disease vaccines?",
            "answer": "A: A",
            "pmid": [
                "pmid16787189",
                "pmid12897209",
                "pmid21975314",
                "pmid23555730",
                "pmid10192224",
                "pmid27186272",
                "pmid22428008",
                "pmid16476660",
                "pmid33029126",
                "pmid10377452"
            ]
        },
        "cell_199": {
            "question": "In the study of Alzheimer's disease pathology, what is a key characteristic of the interaction between cholesterol and amyloid beta (Aβ) that has been noted at the subcellular level?",
            "answer": "The key characteristic noted in the context is a reciprocal regulation between cholesterol and amyloid beta (Aβ) at the subcellular level. This means both influence each other's pathways. \n\n**Answer: C. A pattern of reciprocal regulation between cholesterol and Aβ has been identified, influencing their respective pathways.**",
            "pmid": [
                "pmid22626060",
                "pmid35464321",
                "pmid16866910",
                "pmid37011864",
                "pmid30878503",
                "pmid10440900",
                "pmid12600718",
                "pmid32581851",
                "pmid21448224",
                "pmid37333071"
            ]
        },
        "cell_200": {
            "question": "What is the role of cinnamate derivatives in targeting Alzheimer's disease?",
            "answer": "Cinnamate derivatives exhibit neuroprotective and anti-amyloid effects by inhibiting beta-amyloid aggregation, reducing oxidative stress and inflammation, and targeting multiple pathways such as BuChE, GSK-3β, and PPARα.\n\n**Answer: C**",
            "pmid": [
                "pmid38203753",
                "pmid38355004",
                "pmid38612861",
                "pmid33211296",
                "pmid36232612",
                "pmid31823156",
                "pmid30707915",
                "pmid21272191",
                "pmid34064687",
                "pmid37878046"
            ]
        },
        "cell_201": {
            "question": "Does the infrared spectroscopic analysis of mononuclear leukocytes show differences in protein secondary structure between Alzheimer's disease patients and controls?",
            "answer": "The analysis shows differences in protein secondary structure between AD patients and controls.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid22271100",
                "pmid27239515",
                "pmid33466666",
                "pmid26151923",
                "pmid11351135",
                "pmid8761018",
                "pmid8327146",
                "pmid7768042",
                "pmid18363842",
                "pmid29056898"
            ]
        },
        "cell_202": {
            "question": "What is the role of tubulin acetylation in Alzheimer's disease?",
            "answer": "The role of tubulin acetylation in Alzheimer's disease is best described by option D: Tubulin acetylation is increased and may reflect a compensatory mechanism for impaired microtubule dynamics and Tau dysfunction, but also contributes to disrupted intracellular transport and autophagy. This conclusion is based on the information from pmid36092705, which highlights that tubulin acetylation accumulates in Alzheimer's patients and is linked to reduced microtubule dynamics and potential disruption of cellular processes.\n\nAnswer: D",
            "pmid": [
                "pmid36092705",
                "pmid12522269",
                "pmid32512069",
                "pmid39507380",
                "pmid24387228",
                "pmid38787367",
                "pmid11145195",
                "pmid21228179",
                "pmid12203047",
                "pmid30362958"
            ]
        },
        "cell_203": {
            "question": "Which subcellular organelles are involved in NLRP3 localization and inflammasome assembly in the context of Alzheimer's disease?",
            "answer": "The subcellular organelles involved in NLRP3 localization and inflammasome assembly, particularly in Alzheimer's disease context, are mitochondria, lysosomes, endoplasmic reticulum, Golgi apparatus, endosomes, and the centrosome.\n\n**Answer: B. Mitochondria, lysosomes, endoplasmic reticulum, Golgi apparatus, endosomes, and the centrosome.**\n\nANSWER: B",
            "pmid": [
                "pmid39816134",
                "pmid33181351",
                "pmid36127465",
                "pmid28928740",
                "pmid32929691",
                "pmid23686772",
                "pmid36753858",
                "pmid15465622",
                "pmid38565393",
                "pmid35474599"
            ]
        },
        "cell_204": {
            "question": "What is the role of PrPC in Alzheimer's disease?",
            "answer": "The correct answer is:\n\nC. It has a dual role: promoting neurotoxicity as an amyloid-beta receptor and facilitating amyloid-beta detoxification on exosomes.\n\n**Step-by-Step Explanation:**\n\n1. **Understanding PrPC's Dual Role:** From the provided context, PrPC is involved in two main processes related to Alzheimer's disease. First, it acts as a receptor for Abeta oligomers, which can lead to neurotoxicity. Second, it facilitates the detoxification of Abeta through mechanisms like autophagy.\n\n2. **Analyzing the Options:**\n   - **Option A** only mentions clearing plaques, ignoring the neurotoxic role.\n   - **Option B** is incorrect as there's no mention of exosome formation.\n   - **Option C** correctly identifies both roles, though it specifies exosomes, which weren't explicitly detailed but align with detoxification mechanisms.\n   - **Option D** incorrectly states PrPC degrades tau proteins, which isn't supported.\n\n3. **Conclusion:** Despite the slight discrepancy regarding exosomes, option C best captures the dual role of PrPC in AD as described in the context. \n\nAnswer: C",
            "pmid": [
                "pmid28413194",
                "pmid29660945",
                "pmid24333930",
                "pmid39345364",
                "pmid30362042",
                "pmid32512031",
                "pmid20878768",
                "pmid9410912",
                "pmid34302466",
                "pmid15671026"
            ]
        },
        "cell_205": {
            "question": "How does acute diesel exhaust particle exposure affect P-glycoprotein in the blood-brain barrier related to Alzheimer's disease?",
            "answer": "C. Acute DEP exposure decreases P-gp expression and function, impairing BBB integrity and increasing permeability.",
            "pmid": [
                "pmid37332622",
                "pmid8242380",
                "pmid31382012",
                "pmid24918635",
                "pmid10095092",
                "pmid26855936",
                "pmid38787367",
                "pmid38972885",
                "pmid12203047",
                "pmid31047972"
            ]
        },
        "cell_206": {
            "question": "Does the model simulate microtubule changes in Alzheimer disease?",
            "answer": "The model described in pmid20713128 does simulate microtubule changes in Alzheimer's disease by capturing dynamic instabilities and realistic geometries of degenerating neurons.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid20713128",
                "pmid7916770",
                "pmid36092705",
                "pmid9850923",
                "pmid29080407",
                "pmid19091971",
                "pmid33466666",
                "pmid19355852",
                "pmid22561329",
                "pmid22702220"
            ]
        },
        "cell_207": {
            "question": "What is the role of NRBP1 in the degradation of BRI2 and BRI3 in Alzheimer's disease?",
            "answer": "The correct answer is D. NRBP1 acts as a substrate receptor of a Cullin-RING ubiquitin ligase complex (CRL2/CRL4A) that targets BRI2 and BRI3 for degradation, thereby promoting amyloid-beta production.\n\n**Answer:** D",
            "pmid": [
                "pmid32160551",
                "pmid28980867",
                "pmid26615780",
                "pmid18706502",
                "pmid11083922",
                "pmid10591213",
                "pmid29464060",
                "pmid24086258",
                "pmid35237315",
                "pmid29937728"
            ]
        },
        "cell_208": {
            "question": "What is the antigenic composition of aluminum-induced neurofibrillary degeneration compared to Alzheimer's disease?",
            "answer": "The antigenic composition of aluminum-induced neurofibrillary degeneration differs from Alzheimer's disease. Aluminum-induced cases show strong immunoreactivity for phosphorylated neurofilament proteins but lack staining for tau and MAP2, which are characteristic in Alzheimer's disease.\n\n**Answer: D**",
            "pmid": [
                "pmid2725861",
                "pmid17004365",
                "pmid7916770",
                "pmid7533559",
                "pmid15721985",
                "pmid8052661",
                "pmid10936206",
                "pmid38105410",
                "pmid11276052",
                "pmid28890316"
            ]
        },
        "cell_209": {
            "question": "How does Fli-1 contribute to pericyte loss in Alzheimer's disease?",
            "answer": "The most appropriate answer is:\n\n**C. Fli-1 up-regulation promotes inflammation and Abeta accumulation, contributing to decreased pericyte number.**\n\nThis conclusion is supported by the context indicating that increased Fli-1 levels are associated with higher inflammation and Abeta, leading to fewer pericytes.\n\nAnswer: C",
            "pmid": [
                "pmid35038582",
                "pmid24336108",
                "pmid38682184",
                "pmid29453790",
                "pmid32429102",
                "pmid24918635",
                "pmid10095092",
                "pmid29439343",
                "pmid10393846",
                "pmid28904096"
            ]
        },
        "cell_210": {
            "question": "What role does miR-155 play in Alzheimer's disease?",
            "answer": "The analysis shows that none of the provided studies explicitly discuss miR-155 in the context of Alzheimer's disease. While one study's title mentions miR-155, its abstract focuses on another miRNA, suggesting a possible mislabeling or error. Therefore, based on the given information, there is no relevant data about miR-155.\n\n**Answer: UNRELATED**",
            "pmid": [
                "pmid25983691",
                "pmid34749366",
                "pmid32415525",
                "pmid37300691",
                "pmid29286086",
                "pmid31134481",
                "pmid22926857",
                "pmid35060046",
                "pmid28533191",
                "pmid38111333"
            ]
        },
        "cell_211": {
            "question": "What is the role of human umbilical cord blood derived lineage negative stem cells in treating Alzheimer's disease?",
            "answer": "The correct answer is:\n\nC. They improve cognitive deficits by releasing neuroprotective factors and inhibiting apoptosis, without directly clearing amyloid plaques or differentiating into neurons.\n\nAnswer: C",
            "pmid": [
                "pmid30443207",
                "pmid34566422",
                "pmid33815510",
                "pmid16476660",
                "pmid28643422",
                "pmid31089063",
                "pmid30259257",
                "pmid31606373",
                "pmid34073900",
                "pmid26615780"
            ]
        },
        "cell_212": {
            "question": "What is the role of PIP2 phospholipids in the aggregation of tau filaments in Alzheimer's disease?",
            "answer": "The role of PIP2 phospholipids in the aggregation of tau filaments in Alzheimer's disease is to induce their aggregation, which contributes to harmful effects on neural membranes. \n\nAnswer: C",
            "pmid": [
                "pmid30278104",
                "pmid16908029",
                "pmid15920161",
                "pmid7533559",
                "pmid38946496",
                "pmid34369377",
                "pmid20460118",
                "pmid32915536",
                "pmid17562708",
                "pmid15721985"
            ]
        },
        "cell_213": {
            "question": "What membrane proteins are found to be significantly higher in red blood cells of Alzheimer's disease patients compared to healthy subjects?",
            "answer": "The correct answer is:\n\n**C. The GLUT1 transporter and the insulin receptor (INSR).**\n\nThis conclusion is directly supported by the context provided in pmid27239515, which states that the expression of these proteins is significantly higher in red blood cells of Alzheimer's disease patients compared to healthy subjects.",
            "pmid": [
                "pmid27239515",
                "pmid38791223",
                "pmid22934024",
                "pmid12909083",
                "pmid22926141",
                "pmid2391515",
                "pmid32257549",
                "pmid8242380",
                "pmid11447833",
                "pmid24625803"
            ]
        },
        "cell_214": {
            "question": "What mechanism does EphB2 use to prevent amyloid-beta-induced depletion of glutamate receptors in Alzheimer's disease?",
            "answer": "The mechanism by which EphB2 prevents amyloid-beta-induced depletion of glutamate receptors involves stabilizing AMPA-type receptors such as GluA2 through its PDZ-binding motif, which helps retain NMDA receptors at the neuronal surface. \n\nAnswer: B.",
            "pmid": [
                "pmid26589795",
                "pmid28351972",
                "pmid25390692",
                "pmid21272191",
                "pmid32572762",
                "pmid9338779",
                "pmid17384289",
                "pmid17911636",
                "pmid28346227",
                "pmid21224052"
            ]
        }
    },
    "pathway": {
        "pathway_0": {
            "question": "What is the role of the DJ2/Hsp70 pathway in Alzheimer's disease?",
            "answer": "The DJ2/Hsp70 pathway plays a protective role in Alzheimer's disease by decreasing the aggregation and phosphorylation of tau protein, which helps prevent neurofibrillary tangles and associated pathology. \n\nAnswer: B. It decreases the aggregation and phosphorylation of tau.",
            "pmid": [
                "pmid33972400",
                "pmid18688088",
                "pmid34369377",
                "pmid35760815",
                "pmid12522269",
                "pmid17954934",
                "pmid17304350",
                "pmid22343013",
                "pmid17562708",
                "pmid19491104"
            ]
        },
        "pathway_1": {
            "question": "How does the PPARalpha pathway contribute to the pathogenesis of Alzheimer's Disease?",
            "answer": "The PPARalpha pathway contributes to Alzheimer's Disease by regulating processes that maintain or enhance synaptic plasticity and cognitive function. Activation of PPARalpha has been shown to reduce the negative effects of amyloid-beta peptides, thereby protecting against oxidative stress and inflammation. This suggests a protective role in supporting neural functions related to memory and cognition.\n\n**Answer: B. It regulates synaptic plasticity and cognitive function.**",
            "pmid": [
                "pmid38561809",
                "pmid31100304",
                "pmid11145195",
                "pmid21272191",
                "pmid32121263",
                "pmid26200696",
                "pmid32413539",
                "pmid31677009",
                "pmid25169677",
                "pmid20634578"
            ]
        },
        "pathway_2": {
            "question": "What is the role of the ezrin/radixin/moesin family/phosphatidylinositol-3-kinase/protein kinase B pathway in Alzheimer's disease?",
            "answer": "The ezrin/radixin/moesin family/phosphatidylinositol-3-kinase/protein kinase B pathway plays a protective role by reducing amyloid beta protein-induced apoptosis in PAJU cells. \n\n**Answer: C. It protects PAJU cells from amyloid beta protein-induced apoptosis.**",
            "pmid": [
                "pmid25538739",
                "pmid32744877",
                "pmid32765947",
                "pmid9410912",
                "pmid39117070",
                "pmid26696494",
                "pmid33983710",
                "pmid15208744",
                "pmid18367332",
                "pmid20950278"
            ]
        },
        "pathway_3": {
            "question": "How does the somatostatin pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The somatostatin pathway contributes to Alzheimer's disease primarily by influencing the levels of amyloid-beta (Abeta) peptide through its role in promoting neprilysin activity, which degrades Abeta. The reduction of somatostatin leads to decreased neprilysin activity, resulting in the accumulation of Abeta42 and contributing to the formation of amyloid plaques.\n\n**Answer: C. By increasing the production of amyloid-beta peptide.**\n\nHowever, it's important to clarify that while somatostatin itself does not increase Abeta production, its reduction leads to higher Abeta levels due to impaired degradation.",
            "pmid": [
                "pmid15778722",
                "pmid34445147",
                "pmid28864542",
                "pmid25169677",
                "pmid19559700",
                "pmid2900051",
                "pmid16192374",
                "pmid21228179",
                "pmid20007471",
                "pmid11145195"
            ]
        },
        "pathway_4": {
            "question": "What is the role of the IL-33/ST2 signaling pathway in Alzheimer's disease?",
            "answer": "The IL-33/ST2 signaling pathway plays a role in promoting the recruitment and Abeta phagocytic activity of microglia in Alzheimer's disease, as indicated by the studies examining its effects on cognitive function, amyloid plaques, and immune responses.\n\n**Answer: A. It promotes the recruitment and Abeta phagocytic activity of microglia.**\n\nA",
            "pmid": [
                "pmid27091974",
                "pmid24413615",
                "pmid32505187",
                "pmid18509040",
                "pmid32678011",
                "pmid37117777",
                "pmid28969867",
                "pmid23178247",
                "pmid27422717",
                "pmid25485684"
            ]
        },
        "pathway_5": {
            "question": "How does the beta-secretase pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The beta-secretase pathway contributes to Alzheimer's disease by cleaving the amyloid precursor protein (APP) to generate amyloid-beta (Aβ) peptides. These peptides then aggregate into plaques in the brain, which are a key feature of the disease.\n\n**Answer: A. By cleaving APP to generate A beta peptides; which form plaques.**\n\nANSWER: A",
            "pmid": [
                "pmid21605033",
                "pmid18979630",
                "pmid10656250",
                "pmid10531052",
                "pmid11083922",
                "pmid10591213",
                "pmid30626751",
                "pmid1436712",
                "pmid15992373",
                "pmid20676056"
            ]
        },
        "pathway_6": {
            "question": "What is the role of the ZBTB16-mediated autophagy pathway in Alzheimer's disease?",
            "answer": "The ZBTB16-mediated autophagy pathway in Alzheimer's disease (AD) plays a role in promoting the accumulation of Abeta oligomers and plaques. This occurs because elevated levels of ZBTB16 inhibit ULK1 activity, thereby reducing autophagy and leading to increased Abeta levels.\n\n**Answer: A. It promotes the accumulation of Abeta oligomers and plaques.**",
            "pmid": [
                "pmid30362531",
                "pmid36031168",
                "pmid21368103",
                "pmid28806762",
                "pmid31060682",
                "pmid30594669",
                "pmid29631635",
                "pmid30695399",
                "pmid25421002",
                "pmid22344941"
            ]
        },
        "pathway_7": {
            "question": "How does the adenylyl cyclase pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The adenylyl cyclase (AC) pathway contributes to Alzheimer's disease through specific changes in AC isoforms. The study referenced shows that AC I levels increase in the hippocampus as neurofibrillary staging progresses, which is a key finding supporting this contribution. \n\n**Answer: B. Adenylyl cyclase I levels increase in the hippocampus with neurofibrillary staging.**",
            "pmid": [
                "pmid12960778",
                "pmid8242380",
                "pmid1647485",
                "pmid11447833",
                "pmid8740986",
                "pmid22970285",
                "pmid32614980",
                "pmid29363833",
                "pmid25311278",
                "pmid10095092"
            ]
        },
        "pathway_8": {
            "question": "How does the SP1 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The SP1 pathway contributes to Alzheimer's disease pathogenesis by increasing Abeta production through its role in regulating APP expression and processing.\n\n**Answer: B. By increasing Abeta production**",
            "pmid": [
                "pmid18334759",
                "pmid29662056",
                "pmid38787367",
                "pmid38007654",
                "pmid33420799",
                "pmid30362531",
                "pmid37018887",
                "pmid21368103",
                "pmid36410428",
                "pmid27072684"
            ]
        },
        "pathway_9": {
            "question": "What is the role of the GDE2-RECK-ADAM10 pathway in Alzheimer's disease?",
            "answer": "The GDE2-RECK-ADAM10 pathway plays a protective role in Alzheimer's disease by promoting APP cleavage to generate neuroprotective sAPPalpha. \n\n**Answer: A. It promotes APP cleavage to generate neuroprotective sAPPalpha.**",
            "pmid": [
                "pmid33731436",
                "pmid17301176",
                "pmid21605036",
                "pmid27333034",
                "pmid15146243",
                "pmid24333930",
                "pmid38787367",
                "pmid33420799",
                "pmid39117070",
                "pmid26119306"
            ]
        },
        "pathway_10": {
            "question": "How does the mammalian target of rapamycin (mTOR) pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The mammalian target of rapamycin (mTOR) pathway contributes to Alzheimer's disease by inhibiting autophagy, leading to the accumulation of amyloid-beta (Abeta) plaques. This occurs because active mTOR suppresses autophagy, which is essential for clearing Abeta proteins.\n\n**Answer: B. By inhibiting autophagy; it leads to Abeta accumulation.**",
            "pmid": [
                "pmid31060682",
                "pmid22344941",
                "pmid25914534",
                "pmid31639492",
                "pmid30362531",
                "pmid29729422",
                "pmid25173700",
                "pmid29351469",
                "pmid24411482",
                "pmid23667480"
            ]
        },
        "pathway_11": {
            "question": "What is the role of the enkephalin signaling pathway in Alzheimer's disease?",
            "answer": "The enkephalin signaling pathway contributes to neuronal and behavioral impairments in Alzheimer's disease by elevating enkephalin levels.\n\n**Answer: B**",
            "pmid": [
                "pmid18463254",
                "pmid31722531",
                "pmid30362531",
                "pmid31060682",
                "pmid22527793",
                "pmid31100304",
                "pmid35350668",
                "pmid35672874",
                "pmid17055782",
                "pmid38996935"
            ]
        },
        "pathway_12": {
            "question": "How does the orexin signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The orexin signaling pathway contributes to Alzheimer's disease by influencing the circadian rhythm in the hippocampus. Orexin shortens the period of the hippocampal clock, thereby regulating clock-controlled genes such as Bace1 and Bace2, which are associated with amyloid-beta production.\n\n**Answer: B. By shortening the period of the hippocampal clock and regulating clock-controlled genes.**",
            "pmid": [
                "pmid27796320",
                "pmid37843792",
                "pmid31927055",
                "pmid38682858",
                "pmid33080054",
                "pmid36280008",
                "pmid31442405",
                "pmid19109907",
                "pmid28346227",
                "pmid39117070"
            ]
        },
        "pathway_13": {
            "question": "How does the ABCC1 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "B. ABCC1 increases glutathione release; providing temporary protection from oxidative stress.",
            "pmid": [
                "pmid26200696",
                "pmid24333930",
                "pmid12600718",
                "pmid23579332",
                "pmid10817927",
                "pmid2391515",
                "pmid22970285",
                "pmid24141082",
                "pmid38787367",
                "pmid16873963"
            ]
        },
        "pathway_14": {
            "question": "How does the Grb2 signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The Grb2 signaling pathway contributes to Alzheimer's disease through subtle alterations in its subcellular distribution, which overlap with cytoskeletal abnormalities. This finding is supported by studies showing that these changes occur early in the pathogenesis and are associated with signal transduction issues linked to AD.\n\n**Answer: A.**",
            "pmid": [
                "pmid9878757",
                "pmid17384289",
                "pmid10817927",
                "pmid17080199",
                "pmid10095092",
                "pmid1647485",
                "pmid25637481",
                "pmid11447833",
                "pmid28351972",
                "pmid34705667"
            ]
        },
        "pathway_15": {
            "question": "How does the ErbB2 signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The ErbB2 signaling pathway contributes to Alzheimer's disease by suppressing autophagic flux. Specifically, ErbB2 dissociates Beclin-1 from the Vps34-Vps15 complex, thereby impairing the degradation of APP-C99 and leading to increased amyloid-beta production.\n\n**Answer: B. ErbB2 suppresses autophagic flux by dissociating Beclin-1 from the Vps34-Vps15 complex.**",
            "pmid": [
                "pmid28351972",
                "pmid17384289",
                "pmid29641978",
                "pmid32408680",
                "pmid30626751",
                "pmid9878757",
                "pmid19109907",
                "pmid28980867",
                "pmid9338779",
                "pmid28806762"
            ]
        },
        "pathway_16": {
            "question": "How does the IL-7/IL-7R pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "A",
            "pmid": [
                "pmid39129310",
                "pmid1749826",
                "pmid26509334",
                "pmid11578773",
                "pmid12453679",
                "pmid22096345",
                "pmid31690660",
                "pmid17085001",
                "pmid35986874",
                "pmid29039020"
            ]
        },
        "pathway_17": {
            "question": "How does the Reelin signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The Reelin signaling pathway contributes to Alzheimer's disease pathogenesis in multiple ways when it is impaired. Specifically, its dysfunction leads to increased amyloid-beta peptide production, reduced numbers of Reelin-expressing pyramidal neurons, and promotion of tau protein aggregation. Among these, the most directly mentioned mechanism in the context provided is the increase in amyloid-beta production.\n\n**Answer: A**",
            "pmid": [
                "pmid24599114",
                "pmid27531658",
                "pmid20610758",
                "pmid17360894",
                "pmid20025970",
                "pmid39094979",
                "pmid36919335",
                "pmid26152694",
                "pmid19515914",
                "pmid22495348"
            ]
        },
        "pathway_18": {
            "question": "How does the ZBTB20/GSK-3beta/Tau pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "Based on the provided context, the downregulation of ZBTB20 contributes to Alzheimer's disease by promoting GSK-3β expression and Tau phosphorylation. This pathway is implicated in disease progression as it enhances pathological processes associated with neurodegeneration.\n\n**Answer: B. Downregulation of ZBTB20 promotes GSK-3beta expression and Tau phosphorylation; contributing to disease progression.**",
            "pmid": [
                "pmid36502636",
                "pmid39325351",
                "pmid22927642",
                "pmid14563691",
                "pmid36964897",
                "pmid17562708",
                "pmid14713290",
                "pmid27255602",
                "pmid32851560",
                "pmid21934536"
            ]
        },
        "pathway_19": {
            "question": "Which downstream targets of the AdipoR1/AMPK/TFEB pathway are implicated in Alzheimer's disease development?",
            "answer": "The AdipoR1/AMPK/TFEB pathway activates TFEB, a transcription factor that upregulates genes involved in autophagy and lysosome function. These include lysosomal enzymes and autophagy-related proteins, which are critical for clearing beta-amyloid plaques and neurofibrillary tangles associated with Alzheimer's disease.\n\n**Answer: A. Lysosomal enzymes and autophagy-related proteins.**",
            "pmid": [
                "pmid30362531",
                "pmid38787367",
                "pmid31060682",
                "pmid37013375",
                "pmid29501742",
                "pmid29353063",
                "pmid36031168",
                "pmid22927642",
                "pmid26855936",
                "pmid26159189"
            ]
        },
        "pathway_20": {
            "question": "How does the VDAC1-AKT-GSK3beta signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The VDAC1-AKT-GSK3β signaling pathway contributes to Alzheimer's disease by promoting neuroinflammation and amyloid-beta overproduction.\n\n**Answer:** A",
            "pmid": [
                "pmid22926141",
                "pmid21228179",
                "pmid23202730",
                "pmid22927642",
                "pmid20930307",
                "pmid38992568",
                "pmid28864542",
                "pmid8239309",
                "pmid16183991",
                "pmid25169677"
            ]
        },
        "pathway_21": {
            "question": "What is the impact of zinc on the Raf/MEK/ERK pathway in Alzheimer's disease?",
            "answer": "The impact of zinc on the Raf/MEK/ERK pathway in Alzheimer's disease is that zinc activates this pathway, which leads to tau phosphorylation at serine 214.\n\n**Answer:** B. Zinc activates the pathway; leading to tau phosphorylation at serine 214.",
            "pmid": [
                "pmid21934536",
                "pmid19111579",
                "pmid22892311",
                "pmid15812314",
                "pmid22528780",
                "pmid33597269",
                "pmid38648940",
                "pmid26883958",
                "pmid17949919",
                "pmid21368864"
            ]
        },
        "pathway_22": {
            "question": "How does the Th-9 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The Th-9 pathway contributes to Alzheimer's disease by producing IL-9, which is linked to heightened neuroinflammation.\n\nAnswer: A. By producing IL-9; which is associated with increased neuroinflammation.",
            "pmid": [
                "pmid21167930",
                "pmid11578773",
                "pmid21514692",
                "pmid19800391",
                "pmid25169677",
                "pmid28969867",
                "pmid1749826",
                "pmid22096345",
                "pmid26509334",
                "pmid36703235"
            ]
        },
        "pathway_23": {
            "question": "What is the role of the reelin pathway in Alzheimer's disease?",
            "answer": "The Reelin pathway plays a significant role in neuronal development and function, particularly in promoting neurite outgrowth. In the context of Alzheimer's disease (AD), its functionality is disrupted due to interactions with amyloid-beta (Abeta) plaques and the presence of the APP cytoplasmic domain. Here's a concise breakdown:\n\n- **Option A**: Reelin promotes neurite outgrowth, as shown in studies where it works alongside APP to encourage neuronal growth.\n- **Option B**: While Reelin normally promotes outgrowth, the presence of the APP cytoplasmic domain can disrupt this process by interfering with Reelin signaling, leading to inhibited promotion rather than outright inhibition of outgrowth.\n- **Option C**: There's no clear evidence that Reelin enhances synaptic plasticity through increased APP cleavage; instead, it affects surface levels and endocytosis.\n- **Option D**: Reelin helps reduce Abeta formation. In its absence or dysfunction, as in AD, Abeta plaques increase, indicating a protective role against amyloidogenesis.\n\n**Answer:** A and D are correct based on the studies. However, since the question asks for the best fit, **A: It promotes neurite outgrowth in hippocampal neurons** is the most direct and supported answer regarding Reelin's role.",
            "pmid": [
                "pmid24599114",
                "pmid36919335",
                "pmid17360894",
                "pmid17169463",
                "pmid27531658",
                "pmid39094979",
                "pmid19515914",
                "pmid20610758",
                "pmid26152694",
                "pmid20025970"
            ]
        },
        "pathway_24": {
            "question": "How does the NOD2/p-p38 MAPK/BACE1 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The NOD2/p-p38 MAPK/BACE1 pathway contributes to Alzheimer's disease by increasing the production of Abeta1-42 oligomers through activation of p-p38 MAPK and BACE1. \n\n**Answer: B. By increasing the production of Abeta1-42 oligomers through activation of p-p38 MAPK and BACE1.**",
            "pmid": [
                "pmid30626751",
                "pmid33070520",
                "pmid19109907",
                "pmid22895721",
                "pmid16354928",
                "pmid11677259",
                "pmid18005427",
                "pmid10817927",
                "pmid15642747",
                "pmid35909315"
            ]
        },
        "pathway_25": {
            "question": "What is the role of the MAP2K3 pathway in Alzheimer's disease?",
            "answer": "The context discusses how CD2AP deficiency activates p38 MAPK, contributing to AD through tau phosphorylation and neuronal apoptosis. MAP2K3 (MEK3) activates p38, but the provided options don't address this mechanism or p38's role. Thus, none of the options A-D fit.\n\nNew Answer: UNRELATED",
            "pmid": [
                "pmid24334724",
                "pmid11677259",
                "pmid29662056",
                "pmid21771791",
                "pmid2391515",
                "pmid8239309",
                "pmid14713290",
                "pmid15608143",
                "pmid10817927",
                "pmid39696695"
            ]
        },
        "pathway_26": {
            "question": "How does the cGAS-STING pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The cGAS-STING pathway plays a significant role in the pathogenesis of Alzheimer's disease by inducing chronic neuroinflammation and contributing to neuronal dysfunction. This pathway activates microglia, leading to pro-inflammatory responses that exacerbate amyloid-beta pathology and tau hyperphosphorylation, ultimately worsening AD progression.\n\n**Answer: B. It induces chronic inflammation and contributes to neuronal dysfunction.**",
            "pmid": [
                "pmid37118112",
                "pmid39908354",
                "pmid39218977",
                "pmid37609338",
                "pmid39634577",
                "pmid25169677",
                "pmid38561809",
                "pmid26509334",
                "pmid16192374",
                "pmid33181351"
            ]
        },
        "pathway_27": {
            "question": "How does the AMPK signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The AMPK signaling pathway contributes to Alzheimer's disease (AD) by modulating inflammation and autophagy processes, as evidenced by studies showing its role in reducing neuroinflammation and enhancing amyloid-beta clearance. \n\n**Answer: B. By modulating inflammation and autophagy processes.**",
            "pmid": [
                "pmid32519244",
                "pmid34042039",
                "pmid8239309",
                "pmid32739363",
                "pmid19166821",
                "pmid24334724",
                "pmid2391515",
                "pmid11290384",
                "pmid29662056",
                "pmid38996935"
            ]
        },
        "pathway_28": {
            "question": "How does the farnesylation pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The farnesylation pathway contributes to Alzheimer's disease by increasing the levels of farnesylated proteins like H-Ras, which leads to hyperactivation of downstream effectors such as ERK. This upregulation is associated with increased amyloid-beta production and neurotoxicity, contributing to the progression of AD.\n\n**Answer: B. By increasing the levels of farnesylated proteins like H-Ras; leading to hyperactivation of downstream effectors.**",
            "pmid": [
                "pmid34315531",
                "pmid24136196",
                "pmid33098528",
                "pmid28864542",
                "pmid11145195",
                "pmid25169677",
                "pmid21228179",
                "pmid25499850",
                "pmid17055782",
                "pmid35427648"
            ]
        },
        "pathway_29": {
            "question": "How does the RanBP9-cofilin pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The RanBP9-cofilin pathway contributes to Alzheimer's disease by promoting amyloid beta generation and disrupting focal adhesion. This is supported by multiple studies showing that RanBP9 enhances Abeta production through APP endocytosis and causes mitochondrial dysfunction, leading to neurodegeneration.\n\n**Answer: A. By promoting amyloid beta generation and disrupting focal adhesion.**",
            "pmid": [
                "pmid23982146",
                "pmid25741591",
                "pmid22361682",
                "pmid23348590",
                "pmid22367970",
                "pmid29464060",
                "pmid35969330",
                "pmid16192374",
                "pmid21545753",
                "pmid9878757"
            ]
        },
        "pathway_30": {
            "question": "How does the homeostatic amyloid-reducing pathway contribute to the pathogenesis of Alzheimer's Disease?",
            "answer": "The homeostatic amyloid-reducing pathway contributes to mitigating Alzheimer's Disease (AD) by upregulating genes that reduce amyloid-beta levels. Therefore, when this pathway functions properly, it helps prevent AD progression.\n\n**Answer:** B. By upregulating genes that reduce amyloid levels.",
            "pmid": [
                "pmid32121263",
                "pmid28864542",
                "pmid21228179",
                "pmid11145195",
                "pmid38167174",
                "pmid25169677",
                "pmid32444869",
                "pmid19166821",
                "pmid12582468",
                "pmid16192374"
            ]
        },
        "pathway_31": {
            "question": "What is the role of the Gcn2 pathway in modulating immune response in Alzheimer's disease?",
            "answer": "C",
            "pmid": [
                "pmid38791092",
                "pmid18395194",
                "pmid39002124",
                "pmid39908354",
                "pmid25485684",
                "pmid17911636",
                "pmid8892352",
                "pmid10817927",
                "pmid31100304",
                "pmid24256275"
            ]
        },
        "pathway_32": {
            "question": "What is the role of the visual pathway in [Alzheimer's disease]?",
            "answer": "B. It shows consistent involvement even in preclinical stages.",
            "pmid": [
                "pmid30405709",
                "pmid38972885",
                "pmid20847434",
                "pmid31809334",
                "pmid36396271",
                "pmid17055782",
                "pmid10095092",
                "pmid7916770",
                "pmid25788142",
                "pmid27909396"
            ]
        },
        "pathway_33": {
            "question": "How does the visual information transmission pathway (V-H pathway) contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "B. Dysregulation of hemoglobin expression in the V-H pathway leads to pathway dysfunction.",
            "pmid": [
                "pmid38972885",
                "pmid30405709",
                "pmid19319544",
                "pmid8239309",
                "pmid2391515",
                "pmid8740986",
                "pmid21228179",
                "pmid17055782",
                "pmid1436712",
                "pmid26200696"
            ]
        },
        "pathway_34": {
            "question": "What is the role of the sphingosine kinase/sphingosine-1-phosphate (SphK/S1P) pathway in Alzheimer's disease?",
            "answer": "The SphK/S1P pathway has a dual role in Alzheimer's disease. While it can be protective under certain conditions, the context provided shows that its dysregulation contributes to neuroinflammation and synaptic damage. \n\nANSWER: C",
            "pmid": [
                "pmid36410428",
                "pmid39051215",
                "pmid29662056",
                "pmid38791223",
                "pmid23667698",
                "pmid14748735",
                "pmid38007654",
                "pmid30484906",
                "pmid16626961",
                "pmid26696494"
            ]
        },
        "pathway_35": {
            "question": "Which downstream targets of the circ-AXL pathway are implicated in Alzheimer's Disease development?",
            "answer": "The downstream targets of the circ-AXL pathway implicated in Alzheimer's Disease development include BACE1 (A), Amyloid-beta (B), Neurite outgrowth (C), and Apoptosis rate (D). \n\n**Answer: A, B, C, D**",
            "pmid": [
                "pmid30626751",
                "pmid35167942",
                "pmid15642747",
                "pmid32223911",
                "pmid19109907",
                "pmid16354928",
                "pmid18005427",
                "pmid22998035",
                "pmid10817927",
                "pmid11145195"
            ]
        },
        "pathway_36": {
            "question": "Is kynurenine pathway activation associated with poor prognosis in Alzheimer's disease?",
            "answer": "The analysis indicates that activation of the kynurenine pathway is linked to higher levels of neuroprotective metabolites like KYNA in AD patients, which correlates with slower disease progression. Thus, it is not associated with a poor prognosis.\n\n**Answer: B. No**",
            "pmid": [
                "pmid36754068",
                "pmid24346138",
                "pmid20639188",
                "pmid18201952",
                "pmid32276479",
                "pmid37264981",
                "pmid21683531",
                "pmid32012948",
                "pmid25938971",
                "pmid37111372"
            ]
        },
        "pathway_37": {
            "question": "How does the Th17 cell differentiation pathway contribute to the pathogenesis of Late-Onset Alzheimer's Disease (LOAD)?",
            "answer": "The Th17 cell differentiation pathway contributes to the pathogenesis of Late-Onset Alzheimer's Disease (LOAD) by promoting the activation of microglia and neuroinflammation. This is supported by evidence showing increased Th17 activity in AD patients and their role in producing pro-inflammatory cytokines that activate microglia, leading to neuroinflammation.\n\n**Answer: B. By promoting the activation of microglia and neuroinflammation.**",
            "pmid": [
                "pmid21167930",
                "pmid23365075",
                "pmid28969867",
                "pmid34864659",
                "pmid16476660",
                "pmid37907046",
                "pmid32954348",
                "pmid27713140",
                "pmid11578773",
                "pmid37943150"
            ]
        },
        "pathway_38": {
            "question": "What is the role of the hsa-miR-146a STAT1 MYC pathway in Alzheimer's disease?",
            "answer": "The role of the hsa-miR-146a STAT1 MYC pathway in Alzheimer's disease is identified as a potential key pathway, though further validation is required.\n\n**Answer: A. It is a potential key pathway in AD progression; requiring further validation.**\n\n**New Answer:** The hsa-miR-146a STAT1 MYC pathway has been identified as a potential key pathway in the progression of Alzheimer's disease, but it requires additional research to confirm its role.\n\n**Step-by-Step Explanation:**\n1. **Identify Relevant Information**: Only one abstract (pmid23990414) mentions hsa-miR-146a STAT1 MYC as a potential key pathway in AD progression.\n2. **Contextualize Findings**: The study indicates this pathway is significant but hasn't been fully validated yet.\n3. **Select the Appropriate Answer**: Based on the context, option A fits best.\n\n**Final Answer:** A. It is a potential key pathway in AD progression; requiring further validation.",
            "pmid": [
                "pmid23990414",
                "pmid39117070",
                "pmid34026326",
                "pmid34992508",
                "pmid36214709",
                "pmid31333395",
                "pmid32415525",
                "pmid36798226",
                "pmid35592504",
                "pmid33915734"
            ]
        },
        "pathway_39": {
            "question": "What is the role of the Lfng/Notch1 signaling pathway in Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid36453506",
                "pmid21771791",
                "pmid22934024",
                "pmid30539409",
                "pmid25485684",
                "pmid17080199",
                "pmid28694093",
                "pmid18509040",
                "pmid37603311",
                "pmid16014629"
            ]
        },
        "pathway_40": {
            "question": "How does the IFNgamma pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The IFNgamma pathway contributes to Alzheimer's disease by infiltrating macrophages and natural killer cells that release IFNgamma, leading to glial activation. This process increases the expression of pro-inflammatory cytokines and promotes the overproduction of beta-amyloid and tau proteins, which are central to AD pathogenesis.\n\n**Answer: C**",
            "pmid": [
                "pmid23780663",
                "pmid25169677",
                "pmid39908354",
                "pmid28969867",
                "pmid11578773",
                "pmid11114266",
                "pmid31100304",
                "pmid19808651",
                "pmid12453679",
                "pmid39474846"
            ]
        },
        "pathway_41": {
            "question": "What is the role of the secretory pathway of APP in familial Alzheimer's disease with the Val717 to Ile mutation?",
            "answer": "The secretory pathway of APP with the Val717 to Ile mutation does not lead to altered production of amyloidogenic full-length beta/A4 protein. The study showed that the ratio of specific fragments wasn't decreased, indicating no change in generating this protein via the secretory pathway.\n\n**Answer: B. It does not alter the production of amyloidogenic full-length beta/A4 protein.**",
            "pmid": [
                "pmid1436712",
                "pmid8886002",
                "pmid15992373",
                "pmid8012386",
                "pmid21605033",
                "pmid27060961",
                "pmid21500352",
                "pmid8474686",
                "pmid21812781",
                "pmid17560791"
            ]
        },
        "pathway_42": {
            "question": "How does the p21ras intracellular signal transduction pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The p21ras intracellular signal transduction pathway contributes to Alzheimer's disease by impairing differentiation control and promoting neuronal re-entry into the cell cycle. This is supported by evidence showing that impairment of p21ras leads to loss of differentiation control, causing neurons to attempt re-entering the cell cycle, which ultimately results in neurodegeneration.\n\n**Answer: B. By impairing differentiation control and promoting neuronal re-entry into the cell cycle.**",
            "pmid": [
                "pmid11193159",
                "pmid9878757",
                "pmid15548589",
                "pmid9850923",
                "pmid10817927",
                "pmid8239309",
                "pmid2391515",
                "pmid8740986",
                "pmid33420799",
                "pmid36287323"
            ]
        },
        "pathway_43": {
            "question": "Which downstream targets of the MIAT pathway are implicated in the development of Alzheimer's disease?",
            "answer": "D. Amyloid-beta and tau proteins.",
            "pmid": [
                "pmid24710686",
                "pmid8740986",
                "pmid33998138",
                "pmid16210396",
                "pmid22926141",
                "pmid22998035",
                "pmid21704011",
                "pmid30362958",
                "pmid31060682",
                "pmid33580194"
            ]
        },
        "pathway_44": {
            "question": "What is the role of the YAP/p73/Bax pathway in Alzheimer's disease?",
            "answer": "The YAP/p73/Bax pathway is involved in promoting apoptosis when exposed to Abeta(25-35). Specifically, YAP moves to the nucleus where it interacts with p73, leading to increased Bax expression and activation, which triggers apoptosis.\n\n**Answer: A. It promotes apoptosis in response to Abeta(25-35).**",
            "pmid": [
                "pmid21562856",
                "pmid22592316",
                "pmid12183349",
                "pmid15208744",
                "pmid8922409",
                "pmid24424093",
                "pmid17553417",
                "pmid21945154",
                "pmid15837797",
                "pmid9410912"
            ]
        },
        "pathway_45": {
            "question": "How does the RIPK1 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The RIPK1 pathway contributes to Alzheimer's disease by mediating the induction of a disease-associated microglial (DAM) phenotype, which involves increased inflammation and reduced phagocytic activity. \n\n**Answer: C. By mediating the induction of a disease-associated microglial (DAM) phenotype;**",
            "pmid": [
                "pmid28904096",
                "pmid35106914",
                "pmid37633326",
                "pmid36602874",
                "pmid36766759",
                "pmid34480965",
                "pmid16192374",
                "pmid11290384",
                "pmid31048504",
                "pmid25169677"
            ]
        },
        "pathway_46": {
            "question": "What is the role of signal transduction pathways in Alzheimer's disease?",
            "answer": "The role of signal transduction pathways in Alzheimer's disease is characterized by their contribution to the disease through dysregulation of second messengers. This conclusion is supported by multiple studies indicating disruptions in pathways involving G-proteins, PKC isoforms, and other signaling molecules that exacerbate AD pathology.\n\n**Answer: B. They contribute to the pathogenesis through dysregulation of second messengers.**",
            "pmid": [
                "pmid8740986",
                "pmid2391515",
                "pmid9878757",
                "pmid8239309",
                "pmid9850923",
                "pmid11193159",
                "pmid17055782",
                "pmid11447833",
                "pmid8687030",
                "pmid17080199"
            ]
        },
        "pathway_47": {
            "question": "How does the hexosamine biosynthesis pathway (HBP) contribute to the pathogenesis of Alzheimer disease?",
            "answer": "B",
            "pmid": [
                "pmid23579332",
                "pmid35969330",
                "pmid25148700",
                "pmid31382012",
                "pmid26642316",
                "pmid36204837",
                "pmid30412792",
                "pmid33086751",
                "pmid19596066",
                "pmid35427648"
            ]
        },
        "pathway_48": {
            "question": "How does the BRCA1/BARD1 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The most appropriate answer based on the context is:\n\n**B. It decreases DSB levels by activating a compensatory mechanism in the pathological situation.**\n\nNew Answer: B",
            "pmid": [
                "pmid35237315",
                "pmid26615780",
                "pmid29634233",
                "pmid29439343",
                "pmid25499850",
                "pmid39117070",
                "pmid30873920",
                "pmid36502636",
                "pmid28806762",
                "pmid17344400"
            ]
        },
        "pathway_49": {
            "question": "How does the p53 pathway contribute to the pathogenesis of Alzheimer's disease in Down syndrome?",
            "answer": "The p53 pathway contributes to Alzheimer's disease pathogenesis in Down syndrome by activating downstream targets such as BAX and caspase-3, which promote apoptosis.\n\n**Answer: B. By activating downstream targets like BAX and caspase-3; leading to apoptosis.**",
            "pmid": [
                "pmid26967221",
                "pmid10027687",
                "pmid32962300",
                "pmid10666665",
                "pmid24735980",
                "pmid10666670",
                "pmid23224708",
                "pmid11771742",
                "pmid16442855",
                "pmid28807816"
            ]
        },
        "pathway_50": {
            "question": "How does the Akt pathway contribute to the pathogenesis of prostate cancer and Alzheimer's disease?",
            "answer": "The Akt pathway contributes to the progression of both prostate cancer and Alzheimer's disease. In prostate cancer, it promotes cell survival and proliferation, aiding cancer progression. In Alzheimer's, while Akt typically supports neuronal survival, excessive activation can contribute to neurodegeneration. Thus, the most appropriate answer is:\n\n**A. It contributes to the progression of both diseases by promoting cell survival and proliferation.**\n\nAnswer: A",
            "pmid": [
                "pmid38225990",
                "pmid35985445",
                "pmid16014629",
                "pmid28694093",
                "pmid11062251",
                "pmid17222949",
                "pmid29358916",
                "pmid14563691",
                "pmid31840000",
                "pmid22367434"
            ]
        },
        "pathway_51": {
            "question": "How does the HGF/MET pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The HGF/MET pathway contributes to Alzheimer's disease by promoting synaptic dysfunction and physical loss of synapses.\n\n**Answer:** A. By promoting synaptic dysfunction and physical loss of synapses.",
            "pmid": [
                "pmid35903536",
                "pmid24444253",
                "pmid30539409",
                "pmid17080199",
                "pmid26200696",
                "pmid31100304",
                "pmid18395194",
                "pmid36319781",
                "pmid36287323",
                "pmid35427648"
            ]
        },
        "pathway_52": {
            "question": "What is the role of the betaPP binding pathway in Very Late Onset Dementia of the Alzheimer type?",
            "answer": "The role of the betaPP binding pathway in Very Late Onset Dementia (VLOD-AD) involves attenuating the interaction between FE65 and betaPP. This reduced binding contributes to a protective effect against the disease.\n\n**Answer: C**",
            "pmid": [
                "pmid29353063",
                "pmid11145195",
                "pmid9410912",
                "pmid18400893",
                "pmid28642958",
                "pmid11854179",
                "pmid15778722",
                "pmid20634578",
                "pmid10095092",
                "pmid19710315"
            ]
        },
        "pathway_53": {
            "question": "How does the MLKL-USP7-UBA52 signaling pathway contribute to the pathogenesis of Alzheimer disease (AD)?",
            "answer": "The MLKL-USP7-UBA52 signaling pathway contributes to Alzheimer's disease by maintaining ubiquitin homeostasis, which is critical for autophagy and preventing neurodegeneration.\n\n**Answer: B. It maintains ubiquitin homeostasis; which is critical for autophagy and preventing neurodegeneration.**",
            "pmid": [
                "pmid39193909",
                "pmid29631635",
                "pmid18688088",
                "pmid30362531",
                "pmid38787367",
                "pmid28864542",
                "pmid28806762",
                "pmid23816988",
                "pmid19166821",
                "pmid28351972"
            ]
        },
        "pathway_54": {
            "question": "How does the SNAI2 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The question regarding the SNAI2 pathway's contribution to Alzheimer's disease cannot be answered based on the provided context. The context discusses other pathways (TREM2 and Spns2) but does not mention SNAI2.\n\n**Answer: UNRELATED**",
            "pmid": [
                "pmid38016947",
                "pmid38006681",
                "pmid30626751",
                "pmid38472200",
                "pmid37598923",
                "pmid39117070",
                "pmid28320965",
                "pmid28806762",
                "pmid36683512",
                "pmid30484906"
            ]
        },
        "pathway_55": {
            "question": "How does the ERK/S6 signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The ERK/S6 signaling pathway contributes to Alzheimer's disease by promoting the somatodendritic accumulation of Tau through de novo protein synthesis. This occurs as amyloid-beta activates Fyn kinase, which then triggers the ERK/S6 pathway, leading to increased Tau synthesis and aggregation.\n\n**Answer: A**",
            "pmid": [
                "pmid18688088",
                "pmid28864542",
                "pmid26582459",
                "pmid18367332",
                "pmid29641978",
                "pmid16014629",
                "pmid11677259",
                "pmid19666073",
                "pmid14563691",
                "pmid21241676"
            ]
        },
        "pathway_56": {
            "question": "How does the PUMA pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The PUMA pathway contributes to Alzheimer's disease pathogenesis by inducing neuronal apoptosis through caspase-8 activation. This process involves the activation of caspase-8, which leads to downstream events such as Bax translocation and mitochondrial damage, ultimately causing cell death. \n\n**Answer: B. It induces neuronal apoptosis through caspase-8 activation.**",
            "pmid": [
                "pmid25457551",
                "pmid18032672",
                "pmid34782612",
                "pmid24567336",
                "pmid30362042",
                "pmid25311278",
                "pmid21272191",
                "pmid15208744",
                "pmid25173404",
                "pmid29363833"
            ]
        },
        "pathway_57": {
            "question": "How does the metabotropic glutamate receptor signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The metabotropic glutamate receptor (mGluR) signaling pathway contributes to the pathogenesis of Alzheimer's disease by increasing synaptic C1q production and promoting microglial phagocytosis, leading to synaptic loss and cognitive deficits.\n\n**Answer: B. By increasing synaptic C1q production and promoting microglial phagocytosis.**",
            "pmid": [
                "pmid30652266",
                "pmid32008166",
                "pmid24886239",
                "pmid36515857",
                "pmid8740986",
                "pmid11447833",
                "pmid27103515",
                "pmid16219804",
                "pmid2391515",
                "pmid37603311"
            ]
        },
        "pathway_58": {
            "question": "Does melatonin play a role in protecting against BBB disruption in Alzheimer's disease by inhibiting MMP-9 via the NOTCH3/NF-kappaB pathway?",
            "answer": "A: A\n\nThe correct answer is **A. Yes** because the study in PMID31811815 clearly demonstrates that melatonin protects against BBB disruption by inhibiting MMP-9 via the NOTCH3/NF-kappaB pathway.\n\n**Answer:** A",
            "pmid": [
                "pmid23857055",
                "pmid16364209",
                "pmid31209782",
                "pmid37857668",
                "pmid26123100",
                "pmid18590917",
                "pmid33254429",
                "pmid10231726",
                "pmid35648367",
                "pmid31811815"
            ]
        },
        "pathway_59": {
            "question": "Does dioscin alleviate Alzheimer's disease by regulating the RAGE/NOX4 pathway?",
            "answer": "The study shows that dioscin alleviates Alzheimer's disease by regulating the RAGE/NOX4 pathway through reducing oxidative stress and inflammation. \n\nAnswer: A. Yes",
            "pmid": [
                "pmid35691153",
                "pmid39105973",
                "pmid27725131",
                "pmid36077321",
                "pmid22837815",
                "pmid12203047",
                "pmid33617922",
                "pmid20555131",
                "pmid26696494",
                "pmid36214721"
            ]
        },
        "pathway_60": {
            "question": "Does rhANP treatment mitigate LPS-induced cognitive dysfunction by influencing pathways relevant to Alzheimer's disease?",
            "answer": "The most appropriate answer is B. No.\n\n**Step-by-Step Explanation:**\n\n1. **Understand the Query:** The question asks if rhANP treatment mitigates LPS-induced cognitive dysfunction through pathways relevant to AD.\n2. **Review Context:** The provided context discusses sitagliptin's effects on neuroinflammation and Alzheimer's disease mechanisms, but it doesn't mention rhANP or its specific effects on LPS-induced issues.\n3. **Conclusion:** Since the context lacks information about rhANP's role in these pathways, we cannot confirm if it mitigates such dysfunction based on the given data.\n\n**Answer:** B. No",
            "pmid": [
                "pmid34949194",
                "pmid21932048",
                "pmid23665252",
                "pmid36214721",
                "pmid38561809",
                "pmid30026693",
                "pmid39209323",
                "pmid34302466",
                "pmid20555131",
                "pmid30186862"
            ]
        },
        "pathway_61": {
            "question": "Does the combination of panobinostat and ponatinib synergistically overcome imatinib-resistant CML cells by affecting pathways related to delirium or Alzheimer's disease?",
            "answer": "The combination of panobinostat and ponatinib is primarily studied for overcoming imatinib-resistant CML through kinase inhibition and epigenetic modifications. The provided context does not mention any effects on pathways related to delirium or Alzheimer's disease.\n\n**Answer: B. No**\n\nBased on the given information, there is no evidence that panobinostat and ponatinib affect delirium or Alzheimer's-related pathways in their role against imatinib-resistant CML.",
            "pmid": [
                "pmid23665252",
                "pmid33540879",
                "pmid16762377",
                "pmid24217282",
                "pmid38672280",
                "pmid19447162",
                "pmid27567806",
                "pmid25393881",
                "pmid15532546",
                "pmid29805718"
            ]
        },
        "pathway_62": {
            "question": "Does Yuk-Gunja-Tang (YG) exert neuroprotective effects by activating the ERK/CREB/BDNF signaling pathway in Alzheimer's disease?",
            "answer": "The contextual information indicates that Yuk-Gunja-Tang (YG) activates the ERK/CREB/BDNF signaling pathway and has neuroprotective effects in Alzheimer's disease models. \n\n**Answer: A. Yes**\n\nA.",
            "pmid": [
                "pmid36386241",
                "pmid32739157",
                "pmid28798805",
                "pmid24975829",
                "pmid32255663",
                "pmid20132474",
                "pmid16183991",
                "pmid20451607",
                "pmid31563815",
                "pmid29507588"
            ]
        },
        "pathway_63": {
            "question": "Does Huanglian Jiedu decoction (HLJDD) regulate the microbiota flora homeostasis to treat Alzheimer's disease through multiple targets and pathways?",
            "answer": "The most relevant information comes from pmid37009506, which states that HLJDD treats Alzheimer's disease by regulating microbiota flora homeostasis via multiple targets and pathways.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid37009506",
                "pmid34168550",
                "pmid35069753",
                "pmid31563815",
                "pmid28546539",
                "pmid29234427",
                "pmid39772836",
                "pmid35586051",
                "pmid35656471",
                "pmid36814130"
            ]
        },
        "pathway_64": {
            "question": "Does ursolic acid inhibit the activation of transcription factors NF-kappaB, AP-1, and NF-AT, which are involved in inflammatory pathways, potentially relevant to delirium?",
            "answer": "Based on the evidence provided, ursolic acid does inhibit the activation of NF-kappaB, AP-1, and NF-AT, which are involved in inflammatory pathways relevant to delirium.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid37649721",
                "pmid22363615",
                "pmid38566855",
                "pmid15473667",
                "pmid20309566",
                "pmid20471115",
                "pmid28360657",
                "pmid39839987",
                "pmid39419070",
                "pmid32691721"
            ]
        },
        "pathway_65": {
            "question": "Does ellagic acid inhibit the PI3K/Akt/FOXO3a signaling pathway, which may be relevant to Alzheimer's disease or delirium?",
            "answer": "A: A",
            "pmid": [
                "pmid34373703",
                "pmid31722531",
                "pmid39556267",
                "pmid37823115",
                "pmid36770835",
                "pmid23279783",
                "pmid26696494",
                "pmid28930532",
                "pmid36214721",
                "pmid27725131"
            ]
        },
        "pathway_66": {
            "question": "Does linarin's activation of the PI3K/Akt pathway contribute to neuroprotection against Abeta-induced neurotoxicity, potentially offering therapeutic benefits for Alzheimer's disease?",
            "answer": "The provided context discusses how astragalosides (AST) inhibit beta-amyloid (Abeta)-induced apoptosis in cortical neurons through modulation of the PI3K/AKT and ERK pathways. However, the query specifically asks about linarin, which is not mentioned in the given context. Since there is no information about linarin or its effects on the PI3K/Akt pathway in the provided context, it cannot be used to answer the question.\n\nAnswer: B. No",
            "pmid": [
                "pmid21652214",
                "pmid16762377",
                "pmid34040526",
                "pmid19293145",
                "pmid11278378",
                "pmid20416364",
                "pmid31823156",
                "pmid21391434",
                "pmid15208744",
                "pmid26696494"
            ]
        },
        "pathway_67": {
            "question": "Does danshensu exhibit potential as a therapeutic agent for Alzheimer's disease by improving cognitive impairments through the PKA-CREB signaling pathway?",
            "answer": "**Answer: A. Yes**\n\nDanshensu has demonstrated potential as a therapeutic agent for Alzheimer's disease by improving cognitive impairments through the activation of the PKA-CREB signaling pathway, as shown in mice models where it alleviated both scopolamine and amyloid-beta-induced cognitive deficits.",
            "pmid": [
                "pmid31425745",
                "pmid37315666",
                "pmid31563815",
                "pmid33029123",
                "pmid33898246",
                "pmid31683034",
                "pmid20079417",
                "pmid31354916",
                "pmid29238386",
                "pmid35350668"
            ]
        },
        "pathway_68": {
            "question": "Does engeletin attenuate oxidative stress and neuroinflammation in Alzheimer's disease by modulating the Keap1/Nrf2 pathway?",
            "answer": "A. Yes",
            "pmid": [
                "pmid32445069",
                "pmid36068400",
                "pmid32744877",
                "pmid18706502",
                "pmid22186599",
                "pmid24975829",
                "pmid19844776",
                "pmid31232699",
                "pmid38729530",
                "pmid18602817"
            ]
        },
        "pathway_69": {
            "question": "Does 5-Hydroxymethylfurfural (5-HMF) have a potential therapeutic role in Alzheimer's disease by targeting inflammatory pathways?",
            "answer": "The analysis of the provided studies shows that while 5-Hydroxymethylfurfural (5-HMF) targets key inflammatory pathways like MAPK and NF-kappaB, which are relevant in Alzheimer's disease, there is no direct evidence from the given context showing its therapeutic effect specifically on AD models. Therefore:\n\n**Answer: B. No**\n\nThe reasoning hinges on the lack of specific studies demonstrating 5-HMF's efficacy in treating or mitigating Alzheimer's disease despite its anti-inflammatory properties.",
            "pmid": [
                "pmid30642099",
                "pmid34188608",
                "pmid24161403",
                "pmid12453679",
                "pmid30404965",
                "pmid26965310",
                "pmid20555131",
                "pmid28157092",
                "pmid17886039",
                "pmid23279783"
            ]
        },
        "pathway_70": {
            "question": "Does the CEBPalpha/circAPLP2/miR-671-5p pathway play a role in regulating CNTN1/2 expression in Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid36734072",
                "pmid32035423",
                "pmid34990931",
                "pmid34024830",
                "pmid35060046",
                "pmid34992508",
                "pmid26258756",
                "pmid36453506",
                "pmid31263630",
                "pmid26398571"
            ]
        },
        "pathway_71": {
            "question": "Does gamma-Glutamylcysteine reduce neuroinflammation in Alzheimer's disease by inhibiting the NF-kappaB signaling pathway?",
            "answer": "The answer is A. Yes, based on the study (pmid35714925), gamma-Glutamylcysteine reduces neuroinflammation in Alzheimer's disease by inhibiting the NF-kappaB signaling pathway.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid35714925",
                "pmid23279783",
                "pmid32583667",
                "pmid12453679",
                "pmid15473667",
                "pmid37991969",
                "pmid36820018",
                "pmid20555131",
                "pmid16183991",
                "pmid18395194"
            ]
        },
        "pathway_72": {
            "question": "Does Lancao decoction (LC) activate the PI3K/AKT pathway to enhance ERK activity in the treatment of Alzheimer's disease?",
            "answer": "The provided context does not include any information about Lancao decoction (LC) activating the PI3K/AKT pathway or enhancing ERK activity. Therefore, based on the given context, we cannot confirm whether LC activates this pathway.\n\n**Answer: UNRELATED**\n\nNew Answer:",
            "pmid": [
                "pmid21652214",
                "pmid38061471",
                "pmid35528169",
                "pmid39528121",
                "pmid30802512",
                "pmid18367332",
                "pmid21297267",
                "pmid32140977",
                "pmid39625499",
                "pmid39911633"
            ]
        },
        "pathway_73": {
            "question": "Does the anti-inflammatory effect of taraxasterol involve the LXRalpha-ABCA1 signaling pathway, which is relevant to Alzheimer's disease?",
            "answer": "**Answer:**  \nA. Yes",
            "pmid": [
                "pmid29670526",
                "pmid23585364",
                "pmid15532546",
                "pmid28623716",
                "pmid35772378",
                "pmid36820018",
                "pmid12453679",
                "pmid29355563",
                "pmid20555131",
                "pmid36382256"
            ]
        },
        "pathway_74": {
            "question": "Does Pterostilbene regulate the PDE4A-CREB-BDNF pathway to protect against Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid29737568",
                "pmid31737188",
                "pmid35496289",
                "pmid21982274",
                "pmid17222949",
                "pmid38355004",
                "pmid32739157",
                "pmid29728920",
                "pmid29962345",
                "pmid20007471"
            ]
        },
        "pathway_75": {
            "question": "Does the PD1/PD-L1 pathway play a role in the neuroinflammation of Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid21514692",
                "pmid38248256",
                "pmid38561809",
                "pmid10095092",
                "pmid12453679",
                "pmid27335702",
                "pmid12127594",
                "pmid26509334",
                "pmid22096345",
                "pmid8996832"
            ]
        },
        "pathway_76": {
            "question": "Does dysiarenone's inhibition of the 5-LOX/NF-kappaB/MAPK pathway have potential implications for treating Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid33664584",
                "pmid23279783",
                "pmid28623716",
                "pmid28779511",
                "pmid30092401",
                "pmid32896600",
                "pmid35917097",
                "pmid37209001",
                "pmid11070493",
                "pmid38729530"
            ]
        },
        "pathway_77": {
            "question": "Does dexmedetomidine mitigate propofol-induced neurotoxicity by enhancing the PI3K/Akt pathway, which is relevant to delirium?",
            "answer": "**Answer: A. Yes**\n\nDexmedetomidine does mitigate propofol-induced neurotoxicity by enhancing the PI3K/Akt pathway, which plays a role in reducing neuroinflammation and is therefore relevant to delirium.",
            "pmid": [
                "pmid30143847",
                "pmid30214209",
                "pmid36077505",
                "pmid22683080",
                "pmid34807273",
                "pmid28286770",
                "pmid37313848",
                "pmid39419070",
                "pmid32869521",
                "pmid29743866"
            ]
        },
        "pathway_78": {
            "question": "Are pathways related to Alzheimer's disease upregulated in NK cells of elderly patients with NSCLC compared to younger patients?",
            "answer": "The contextual information does not provide any data related to NK cells, NSCLC, or comparisons between elderly and younger patients regarding Alzheimer's disease pathways. Therefore, the answer is:\n\nUNRELATED",
            "pmid": [
                "pmid10817927",
                "pmid3165303",
                "pmid22367434",
                "pmid2391515",
                "pmid2376771",
                "pmid20541838",
                "pmid12203047",
                "pmid24334724",
                "pmid9514829",
                "pmid7936052"
            ]
        },
        "pathway_79": {
            "question": "Does neuronal cathepsin S increase neuroinflammation and cause cognitive decline in Alzheimer's disease through the CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway?",
            "answer": "The answer is A: Yes.\n\n**Answer:**  \nA",
            "pmid": [
                "pmid39453382",
                "pmid14522241",
                "pmid35181976",
                "pmid39304744",
                "pmid39122455",
                "pmid39726227",
                "pmid30575263",
                "pmid27335702",
                "pmid21771791",
                "pmid17055782"
            ]
        },
        "pathway_80": {
            "question": "Does miR-330 targeting VAV1 through the MAPK signaling pathway reduce amyloid beta-protein production in Alzheimer's disease?",
            "answer": "The provided context discusses several studies related to microRNAs and Alzheimer's disease (AD). However, none of these studies specifically mention miR-330 targeting VAV1 through the MAPK signaling pathway or its role in reducing amyloid beta-protein production. The closest study mentioned is one where miR-338-5p targets BACE1 to reduce Abeta formation, but this does not address the specific question about miR-330 and VAV1.\n\nSince the new context does not provide any information related to miR-330 targeting VAV1 through the MAPK pathway, we cannot answer the query based on the provided context. Therefore, the appropriate response is:\n\n**Answer: UNRELATED**\n\nHowever, if forced to choose between A or B based on the original question alone without additional context, the correct answer would be:\n\n**A. Yes**\n\nBecause miR-330 has been shown in other studies to target VAV1 through the MAPK pathway and reduce Abeta production.\n\nFinal Answer: A. Yes",
            "pmid": [
                "pmid29369410",
                "pmid31385301",
                "pmid28533191",
                "pmid32415525",
                "pmid31134481",
                "pmid32092796",
                "pmid26398571",
                "pmid29378298",
                "pmid30576233",
                "pmid29286086"
            ]
        },
        "pathway_81": {
            "question": "Does the modulation of TLR4/NF-kappaB and Nrf2/HO-1 signaling pathways by naloxone have a known relationship with Alzheimer's disease or delirium?",
            "answer": "B: No",
            "pmid": [
                "pmid22527793",
                "pmid38566855",
                "pmid21932048",
                "pmid37661242",
                "pmid31547752",
                "pmid18463254",
                "pmid34373698",
                "pmid33814433",
                "pmid20309566",
                "pmid12453679"
            ]
        },
        "pathway_82": {
            "question": "Does miR-106b influence the TGF-beta signaling pathway, thereby contributing to the pathogenesis of Alzheimer's disease?",
            "answer": "The provided information confirms that miR-106b influences the TGF-beta signaling pathway by targeting SMAD4, contributing to Alzheimer's disease progression.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid20709030",
                "pmid27520374",
                "pmid24604632",
                "pmid37300691",
                "pmid26847596",
                "pmid22926857",
                "pmid26398571",
                "pmid29286086",
                "pmid24586483",
                "pmid34749366"
            ]
        },
        "pathway_83": {
            "question": "Does meclizine's effect on neuroinflammation through the AKT/NF-kappabeta/ERK/JNK pathway have implications for the treatment of Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid12453679",
                "pmid37733253",
                "pmid37991969",
                "pmid20555131",
                "pmid23279783",
                "pmid15465624",
                "pmid19447162",
                "pmid2391515",
                "pmid39002124",
                "pmid29420357"
            ]
        },
        "pathway_84": {
            "question": "Does silibinin exert neuroprotective effects on sporadic Alzheimer's disease models by inhibiting the GluN2B pathway?",
            "answer": "A: A",
            "pmid": [
                "pmid36610115",
                "pmid28852940",
                "pmid31087219",
                "pmid31669775",
                "pmid28004303",
                "pmid21382422",
                "pmid33991608",
                "pmid38529039",
                "pmid27926996",
                "pmid33867926"
            ]
        },
        "pathway_85": {
            "question": "Do the lipid fractions from sandfish eggs inhibit pathways known to be involved in Alzheimer's disease?",
            "answer": "A: **Yes**\n\nThe lipid fractions from sandfish eggs inhibit pathways such as NF-kB and MAPK, which are involved in inflammation processes linked to Alzheimer's disease.",
            "pmid": [
                "pmid32967264",
                "pmid21448224",
                "pmid32581851",
                "pmid16866910",
                "pmid36552565",
                "pmid12373863",
                "pmid30878503",
                "pmid22626060",
                "pmid35464321",
                "pmid28284721"
            ]
        },
        "pathway_86": {
            "question": "Does the activation of the IRE1alpha-XBP1 and ATF6 pathways differ between Alzheimer's disease and amyotrophic lateral sclerosis (ALS)?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid10319892",
                "pmid34486652",
                "pmid28341998",
                "pmid9878757",
                "pmid8239309",
                "pmid11029529",
                "pmid10095092",
                "pmid38105410",
                "pmid9073026",
                "pmid12740599"
            ]
        },
        "pathway_87": {
            "question": "Does FTO activation contribute to Alzheimer's disease by affecting the TSC1-mTOR-Tau pathway?",
            "answer": "A: A",
            "pmid": [
                "pmid29501742",
                "pmid21098976",
                "pmid16115884",
                "pmid19828810",
                "pmid25914534",
                "pmid33466666",
                "pmid20401186",
                "pmid2391515",
                "pmid8239309",
                "pmid21228179"
            ]
        },
        "pathway_88": {
            "question": "Does the activation of the IRE1alpha/XBP1 pathway attenuate disease severity in models of proteotoxic Charcot-Marie-Tooth type 1B, similar to potential therapeutic avenues in Alzheimer's disease?",
            "answer": "The activation of the IRE1alpha/XBP1 pathway is beneficial in reducing the severity of CMT1B, suggesting it could serve as a therapeutic avenue. However, in Alzheimer's disease, inhibiting this pathway is more beneficial.\n\nAnswer: A. Yes",
            "pmid": [
                "pmid28341998",
                "pmid37016577",
                "pmid36396603",
                "pmid35350668",
                "pmid38352425",
                "pmid21272191",
                "pmid36964897",
                "pmid12740599",
                "pmid25443284",
                "pmid31840000"
            ]
        },
        "pathway_89": {
            "question": "Does KMU-1170 inhibit the activation of NF-kappaB and NLRP3 inflammasome signaling pathways, which are relevant to Alzheimer's disease?",
            "answer": "The provided context does not mention KMU-1170. Therefore, there is no information available to determine whether KMU-1170 inhibits NF-kappaB or NLRP3 inflammasome signaling pathways in the context of Alzheimer's disease.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid37991969",
                "pmid38565393",
                "pmid28003153",
                "pmid32028243",
                "pmid12453679",
                "pmid32929691",
                "pmid15473667",
                "pmid33181351",
                "pmid20555131",
                "pmid37602891"
            ]
        },
        "pathway_90": {
            "question": "Does berberine (Ber) have a role in treating Alzheimer's disease (AD) by influencing the miR-188/NOS1 pathway?",
            "answer": "A. Yes",
            "pmid": [
                "pmid32779043",
                "pmid30542442",
                "pmid29132092",
                "pmid34064687",
                "pmid33361598",
                "pmid33983710",
                "pmid28822725",
                "pmid22459600",
                "pmid39566407",
                "pmid29962345"
            ]
        },
        "pathway_91": {
            "question": "Does MLK3 activation via the AP-1 pathway contribute to inflammatory responses in macrophages, which could be relevant to Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid33737172",
                "pmid36142785",
                "pmid11677259",
                "pmid35474599",
                "pmid11578773",
                "pmid28969867",
                "pmid19800391",
                "pmid21771791",
                "pmid15172747",
                "pmid27723233"
            ]
        },
        "pathway_92": {
            "question": "Does the Bushen-Yizhi formula (BSYZ) target the endoplasmic reticulum (ER) stress pathway to improve cognitive deficits in Alzheimer's disease?",
            "answer": "The Bushen-Yizhi formula (BSYZ) has been shown to target the endoplasmic reticulum (ER) stress pathway in a study using SAMP8 mice. The research demonstrated that BSYZ improved cognitive function by affecting the SIRT1/ER stress pathway, reducing ER stress-associated proteins such as PERK, IRE-1α, eIF-2α, BIP, PDI, and CHOP. This indicates that BSYZ does indeed target the ER stress pathway to improve cognitive deficits in Alzheimer's disease.\n\n**Answer: A. Yes**\n\nThe study referenced (pmid28521305) provides clear evidence that BSYZ affects the ER stress pathway, specifically by reducing ER stress-associated proteins and improving cognitive function in a model of Alzheimer's disease. While other studies discuss related mechanisms or different formulas, they do not contradict this finding.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid28521305",
                "pmid29449587",
                "pmid21272191",
                "pmid33029123",
                "pmid20493918",
                "pmid37586159",
                "pmid31683034",
                "pmid35360200",
                "pmid23618865",
                "pmid35350668"
            ]
        },
        "pathway_93": {
            "question": "Does FLZ enhance the BDNF/TrkB/CREB signaling pathway, which is implicated in Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nFLZ enhances the BDNF/TrkB/CREB signaling pathway as evidenced by studies showing increased BDNF expression and activation of downstream effects, contributing to neuroprotection in Alzheimer's disease models.",
            "pmid": [
                "pmid20154710",
                "pmid24223757",
                "pmid25621771",
                "pmid12203047",
                "pmid17344400",
                "pmid29728920",
                "pmid20401186",
                "pmid33597269",
                "pmid19625748",
                "pmid17080199"
            ]
        },
        "pathway_94": {
            "question": "Does the inhibition of CSF1R via Ki20227 affect the NLRP3 pathway in a manner relevant to Alzheimer's disease?",
            "answer": "The inhibition of CSF1R with Ki20227 does affect the NLRP3 pathway, as shown in an ischemic stroke model where it reduces inflammation and promotes neuroprotection. Since the NLRP3 pathway is implicated in Alzheimer's disease progression through neuroinflammation and amyloid-beta accumulation, this effect is relevant to AD.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid32908485",
                "pmid38565393",
                "pmid32929691",
                "pmid37264981",
                "pmid12203047",
                "pmid37055801",
                "pmid28003153",
                "pmid20555131",
                "pmid33181351",
                "pmid20451607"
            ]
        },
        "pathway_95": {
            "question": "Does hesperetin exert neuroprotective effects by targeting the SIRT6/NLRP3 pathway in a model of Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid30756299",
                "pmid30884890",
                "pmid29136946",
                "pmid30949953",
                "pmid37382831",
                "pmid31027240",
                "pmid24860504",
                "pmid29120942",
                "pmid14648600",
                "pmid28266714"
            ]
        },
        "pathway_96": {
            "question": "Does geranylgeranylacetone (GGA) suppress Alzheimer's disease-related phenotypes via the ERK/p38 MAPK signaling pathway?",
            "answer": "A: Yes",
            "pmid": [
                "pmid29285052",
                "pmid10095092",
                "pmid32744877",
                "pmid11447833",
                "pmid29641978",
                "pmid34297968",
                "pmid23202730",
                "pmid36161942",
                "pmid25637481",
                "pmid35714925"
            ]
        },
        "pathway_97": {
            "question": "Does sevoflurane induce pyroptosis in Alzheimer's disease through the NLRP3/caspase-1/GSDMD pathway?",
            "answer": "The answer is B. No",
            "pmid": [
                "pmid35682930",
                "pmid39490772",
                "pmid36696410",
                "pmid33200801",
                "pmid21244349",
                "pmid26236713",
                "pmid35309893",
                "pmid21519046",
                "pmid36185484",
                "pmid38481801"
            ]
        },
        "pathway_98": {
            "question": "Does Ginsenoside Re inhibit the ROS/ASK-1 dependent mitochondrial apoptosis pathway in Alzheimer's disease?",
            "answer": "The most appropriate answer is:\n\nA: Yes",
            "pmid": [
                "pmid31344860",
                "pmid22381145",
                "pmid26111763",
                "pmid21472290",
                "pmid28756148",
                "pmid29865080",
                "pmid34374655",
                "pmid35054451",
                "pmid23538162",
                "pmid32784451"
            ]
        },
        "pathway_99": {
            "question": "Does saikosaponin-D have potential therapeutic effects for Alzheimer's disease based on its antioxidant properties and Nrf2 pathway activation?",
            "answer": "A: Yes",
            "pmid": [
                "pmid26710244",
                "pmid34994954",
                "pmid28250796",
                "pmid31563815",
                "pmid35691153",
                "pmid38575939",
                "pmid36918872",
                "pmid29411261",
                "pmid32317964",
                "pmid33617922"
            ]
        },
        "pathway_100": {
            "question": "Does TMEM43 play a role in pathways associated with Alzheimer's disease?",
            "answer": "The provided context does not mention TMEM43 or any association between TMEM43 and Alzheimer's disease pathways. Therefore, based on the given information, there is no evidence suggesting that TMEM43 plays a role in these pathways.\n\nAnswer: B. No",
            "pmid": [
                "pmid24684749",
                "pmid36683512",
                "pmid36546684",
                "pmid39084860",
                "pmid34930382",
                "pmid39051708",
                "pmid24899047",
                "pmid31520071",
                "pmid15464268",
                "pmid23692967"
            ]
        },
        "pathway_101": {
            "question": "Does Gypenoside IX alleviate Alzheimer's disease-like neuropathology by restoring the Akt/GSK-3beta pathway?",
            "answer": "**Answer: A. Yes**\n\nGypenoside IX alleviates Alzheimer's disease-like neuropathology by restoring the Akt/GSK-3beta pathway, as supported by the provided context from pmid38095632.\n\nFinal Answer:  The correct answer is **A. Yes**.",
            "pmid": [
                "pmid38095632",
                "pmid36325883",
                "pmid33556642",
                "pmid10095092",
                "pmid26696494",
                "pmid26432105",
                "pmid32721448",
                "pmid24329968",
                "pmid35714925",
                "pmid33420799"
            ]
        },
        "pathway_102": {
            "question": "Does activation of the delta-opioid receptor (DOR) inhibit HMGB1 pathway in Alzheimer's disease?",
            "answer": "Based on the analysis of the provided references, specifically pmid39893485, it is concluded that activation of the delta-opioid receptor (DOR) does inhibit the HMGB1 pathway in Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid39893485",
                "pmid32425755",
                "pmid22527793",
                "pmid37191426",
                "pmid36937877",
                "pmid12203047",
                "pmid28939187",
                "pmid31520071",
                "pmid2694529",
                "pmid11730949"
            ]
        },
        "pathway_103": {
            "question": "Is the iRhom2-TNF-alpha-BAFF signaling pathway associated with Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid22096345",
                "pmid38151421",
                "pmid8239309",
                "pmid35986874",
                "pmid12782345",
                "pmid34486652",
                "pmid18706502",
                "pmid19828810",
                "pmid9878757",
                "pmid12453679"
            ]
        },
        "pathway_104": {
            "question": "Does galectin-3 activation of the Tyro3 receptor tyrosine kinase pathway play a role in Alzheimer's disease?",
            "answer": "B. No",
            "pmid": [
                "pmid11447833",
                "pmid32664510",
                "pmid24809457",
                "pmid34900086",
                "pmid33686023",
                "pmid10095092",
                "pmid14563691",
                "pmid21771791",
                "pmid2391515",
                "pmid8740986"
            ]
        },
        "pathway_105": {
            "question": "Does Dl-3-n-butylphthalide (NBP) improve cognitive impairment in Alzheimer's disease through the regulation of the STEP/ERK/CREB pathway?",
            "answer": "The provided context indicates that Dl-3-n-butylphthalide (NBP) does improve cognitive impairment in Alzheimer's disease through the regulation of the STEP/ERK/CREB pathway. Specifically, a study shows that NBP reduces STEP61 activation and increases phosphorylated ERK1/2 and CREB levels, thereby enhancing cognitive function.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35350668",
                "pmid26827641",
                "pmid29728920",
                "pmid30026693",
                "pmid33642981",
                "pmid33420799",
                "pmid12203047",
                "pmid17008108",
                "pmid23404502",
                "pmid39773090"
            ]
        },
        "pathway_106": {
            "question": "Does nicergoline improve cognitive function in Alzheimer's disease by inhibiting the PI3K/AKT signaling pathway?",
            "answer": "The available context indicates that nicergoline does improve cognitive function in Alzheimer's disease through inhibition of the PI3K/AKT signaling pathway.\n\n**Answer: A. Yes**\n\nNew Answer:  The context provided discusses nicergoline and its effects but doesn't specifically address whether it inhibits the PI3K/AKT signaling pathway to improve cognitive function in Alzheimer's disease. Therefore, based on the given information, the answer remains:\n\nB. No",
            "pmid": [
                "pmid29568940",
                "pmid9205832",
                "pmid11687175",
                "pmid15882840",
                "pmid39325017",
                "pmid30906380",
                "pmid25243157",
                "pmid36214721",
                "pmid34856907",
                "pmid20555131"
            ]
        },
        "pathway_107": {
            "question": "Does moscatilin mitigate glycation-mediated damages relevant to Alzheimer's disease by activating AMPK and suppressing the RAGE/NF-kappaB pathway in SH-SY5Y cells?",
            "answer": "The answer is A. Yes.\n\nStep-by-step explanation:\n1. Moscatilin activates AMPK and suppresses RAGE/NF-kappaB pathway in SH-SY5Y cells.\n2. This mechanism mitigates glycation-mediated damages relevant to Alzheimer's disease.\n\nAnswer:  \nA. Yes",
            "pmid": [
                "pmid33036367",
                "pmid31291099",
                "pmid23279783",
                "pmid34329731",
                "pmid26696494",
                "pmid25102327",
                "pmid21704011",
                "pmid26577515",
                "pmid20555131",
                "pmid28320965"
            ]
        },
        "pathway_108": {
            "question": "Does Artemether activate the AMPK/GSK3beta signaling pathway, which is associated with neuroprotection in Alzheimer's disease?",
            "answer": "The analysis confirms that Artemether activates the AMPK/GSK3beta pathway, contributing to neuroprotection against Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid31871541",
                "pmid34655202",
                "pmid2391515",
                "pmid35598091",
                "pmid8239309",
                "pmid8740986",
                "pmid32519244",
                "pmid9878757",
                "pmid20950278",
                "pmid32765947"
            ]
        },
        "pathway_109": {
            "question": "Does Fuzhisan improve cognitive ability in Alzheimer's disease by affecting autophagy pathways?",
            "answer": "A. Yes",
            "pmid": [
                "pmid39736370",
                "pmid31607908",
                "pmid27518086",
                "pmid39911633",
                "pmid39873362",
                "pmid25050129",
                "pmid38575939",
                "pmid30362531",
                "pmid30695399",
                "pmid30922179"
            ]
        },
        "pathway_110": {
            "question": "Does ranuncoside show potential for managing Alzheimer's disease by modulating Nrf2 and NF-kB signaling pathways?",
            "answer": "The study demonstrates that ranuncoside modulates both Nrf2 and NF-κB signaling pathways, which are beneficial against Alzheimer's disease. \n\nAnswer: A",
            "pmid": [
                "pmid37533493",
                "pmid18440671",
                "pmid20401186",
                "pmid32800555",
                "pmid12203047",
                "pmid34601013",
                "pmid36820018",
                "pmid36555798",
                "pmid38924927",
                "pmid18706502"
            ]
        },
        "pathway_111": {
            "question": "Do heparan sulfate proteoglycan (HSPG)-mediated pathways regulate the internalization of brain-derived tau oligomers (BDTOs) in Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid32366836",
                "pmid15084524",
                "pmid21289173",
                "pmid34095227",
                "pmid33403386",
                "pmid38992568",
                "pmid34552470",
                "pmid25169677",
                "pmid26490863",
                "pmid28864542"
            ]
        },
        "pathway_112": {
            "question": "Does 8-weeks of aerobic exercise improve cognitive function in Alzheimer's disease by upregulating the Xc-/GPx4 pathway in the prefrontal cortex?",
            "answer": "A: A. Yes\nNew Answer:\n\nThe study indicates that 8 weeks of aerobic exercise improves cognitive function in Alzheimer's disease mice models by upregulating the Xc-/GPx4 pathway, thereby mitigating ferroptosis and reducing cognitive deficits.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid32273835",
                "pmid32561386",
                "pmid36124291",
                "pmid33403644",
                "pmid23827013",
                "pmid39315073",
                "pmid32383993",
                "pmid26855936",
                "pmid37013375",
                "pmid33641078"
            ]
        },
        "pathway_113": {
            "question": "Does Ampelopsin improve cognitive impairment in Alzheimer's disease by inhibiting neuroinflammation and oxidative stress pathways?",
            "answer": "A: A\n\nThe correct answer is **Yes**.\n\n**Answer:**  \nA: Yes",
            "pmid": [
                "pmid31797758",
                "pmid24561065",
                "pmid29411261",
                "pmid39521153",
                "pmid36214721",
                "pmid36232612",
                "pmid12203047",
                "pmid21193044",
                "pmid27567825",
                "pmid34042039"
            ]
        },
        "pathway_114": {
            "question": "Does donepezil improve cognitive function in a tree shrew model of Alzheimer's disease by activating the BDNF/TrkB signaling pathway?",
            "answer": "**Answer: A. Yes**\n\nDonepezil improves cognitive function in a tree shrew model of Alzheimer's disease by activating the BDNF/TrkB signaling pathway, as shown in pmid30105614.",
            "pmid": [
                "pmid30105614",
                "pmid31913348",
                "pmid25662507",
                "pmid23783773",
                "pmid35850693",
                "pmid25266713",
                "pmid27002982",
                "pmid24401551",
                "pmid34312765",
                "pmid25744714"
            ]
        },
        "pathway_115": {
            "question": "Does melatonin regulate the interplay of molecular signaling associated with the APP-BP1 pathway to prevent pathogenic mechanisms in Alzheimer's disease?",
            "answer": "The provided contexts discuss melatonin's effects on oxidative stress and DAPK1 regulation but do not mention the APP-BP1 pathway.\n\n**Answer: UNRELATED**",
            "pmid": [
                "pmid31209782",
                "pmid26123100",
                "pmid32579500",
                "pmid23857055",
                "pmid16364209",
                "pmid10231726",
                "pmid33254429",
                "pmid9407389",
                "pmid18590917",
                "pmid32358852"
            ]
        },
        "pathway_116": {
            "question": "Does copper exposure activate the PI3K/Akt pathway, which is implicated in metabolic disorders like Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid11795876",
                "pmid15276868",
                "pmid24748564",
                "pmid32599538",
                "pmid23760784",
                "pmid23959870",
                "pmid25066791",
                "pmid20626553",
                "pmid28669331",
                "pmid19122148"
            ]
        },
        "pathway_117": {
            "question": "Does miR-204 silencing reduce mitochondrial autophagy and ROS production in Alzheimer's disease via the TRPML1-activated STAT3 pathway?",
            "answer": "The provided context does not include any discussion of miR-204, TRPML1, or the STAT3 pathway in relation to mitochondrial autophagy and ROS production in Alzheimer's disease.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid34026326",
                "pmid27397902",
                "pmid27235866",
                "pmid33155636",
                "pmid33575111",
                "pmid32092796",
                "pmid32950103",
                "pmid24604632",
                "pmid34992508",
                "pmid31134481"
            ]
        },
        "pathway_118": {
            "question": "Does tetrahydroalstonine modulate the PI3K/AKT signaling pathway to reduce cell apoptosis in Alzheimer's disease?",
            "answer": "The context information specifically indicates that tetrahydroalstonine (THA) regulates the PI3K/AKT signaling pathway to reduce cell apoptosis in Alzheimer's disease. \n\n**Answer:** A. Yes",
            "pmid": [
                "pmid38061471",
                "pmid26696494",
                "pmid16762377",
                "pmid28131834",
                "pmid11278378",
                "pmid15208744",
                "pmid31900522",
                "pmid2391515",
                "pmid9410912",
                "pmid11062251"
            ]
        },
        "pathway_119": {
            "question": "Does Ecliptae Herba exert its anti-Alzheimer's effect through multi-component, multi-target, and multi-pathway mechanisms?",
            "answer": "The study on Ecliptae Herba (EH) demonstrates that it works through a network of components affecting different targets and pathways, confirming a multi-component, multi-target, and multi-pathway mechanism.\n\n**Answer: A. Yes**\n\nStep-by-Step Explanation:\n1. **Component Analysis**: EH contains 50 identified components, including apigenin and luteolin.\n2. **Target Engagement**: These compounds interact with various targets related to AD, such as the serotonergic synapse and calcium signaling pathways.\n3. **Pathway Involvement**: The mechanism involves multiple biological pathways, supporting a multi-pathway approach.\n\nThus, EH exerts its anti-Alzheimer's effect through a combination of multi-component, multi-target, and multi-pathway mechanisms.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid37454776",
                "pmid29080453",
                "pmid28279707",
                "pmid32140977",
                "pmid36232612",
                "pmid38355004",
                "pmid28643520",
                "pmid39229544",
                "pmid29100755",
                "pmid36814130"
            ]
        },
        "pathway_120": {
            "question": "Does 1,7-diphenyl-4-hepten-3-one (C1) mitigate Alzheimer's disease by inhibiting pyroptosis through the Nrf2 pathway?",
            "answer": "The most appropriate answer is A: Yes.\n\nAnswer: A",
            "pmid": [
                "pmid37878046",
                "pmid12212794",
                "pmid28131834",
                "pmid36185484",
                "pmid19141069",
                "pmid25434488",
                "pmid31722188",
                "pmid28482635",
                "pmid19586540",
                "pmid32892233"
            ]
        },
        "pathway_121": {
            "question": "Does Isoamericanin A improve memory impairment in Alzheimer's disease by suppressing the NADPH oxidase-dependent NF-kappaB signaling pathway?",
            "answer": "**Answer:**\n\nA. Yes",
            "pmid": [
                "pmid37209001",
                "pmid36214721",
                "pmid34834150",
                "pmid34354404",
                "pmid36382256",
                "pmid19766184",
                "pmid31722531",
                "pmid25108596",
                "pmid36820018",
                "pmid29132092"
            ]
        },
        "pathway_122": {
            "question": "Does the ERK5/KLF4 signaling pathway play a role in protecting neurons against oxidative stress, which is implicated in Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid25015774",
                "pmid39648181",
                "pmid18706502",
                "pmid24334724",
                "pmid22186599",
                "pmid33420799",
                "pmid8725383",
                "pmid22746342",
                "pmid20977891",
                "pmid39231208"
            ]
        },
        "pathway_123": {
            "question": "Does black mulberry fruit extract alleviate Alzheimer's disease-like symptoms in C. elegans through the DAF-16 insulin signaling pathway?",
            "answer": "A: A",
            "pmid": [
                "pmid36076399",
                "pmid22995388",
                "pmid32488469",
                "pmid32316271",
                "pmid25580148",
                "pmid39200504",
                "pmid37838776",
                "pmid26068423",
                "pmid29100755",
                "pmid35592293"
            ]
        },
        "pathway_124": {
            "question": "Does sevoflurane exposure affect the AKT/GSK3β signaling pathway, which is implicated in Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid24580743",
                "pmid35682930",
                "pmid39490772",
                "pmid31351473",
                "pmid33200801",
                "pmid26236713",
                "pmid35309893",
                "pmid33980987",
                "pmid36696410",
                "pmid38415263"
            ]
        },
        "pathway_125": {
            "question": "Does tripchlorolide inhibit the NF-kappaB and JNK signaling pathways to protect neuronal cells from beta-amyloid neurotoxicity in Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nTripchlorolide inhibits both the NF-kappaB and JNK signaling pathways, contributing to the protection of neuronal cells from beta-amyloid neurotoxicity in Alzheimer's disease.",
            "pmid": [
                "pmid19170180",
                "pmid34316383",
                "pmid37624431",
                "pmid25661995",
                "pmid26906357",
                "pmid32028243",
                "pmid28669260",
                "pmid28623716",
                "pmid33582452",
                "pmid20451607"
            ]
        },
        "pathway_126": {
            "question": "Does the FGF2/FGFR1 pathway play a role in mitigating astrocyte-mediated neuroinflammation after infrasound exposure, which could be relevant to Alzheimer's disease or delirium?",
            "answer": "The FGF2/FGFR1 pathway plays a role in mitigating astrocyte-mediated neuroinflammation following infrasound exposure, as demonstrated by studies showing its inhibitory effects on pro-inflammatory cytokines and astrocyte activation. This relevance extends to conditions like Alzheimer's disease, where neuroinflammation is implicated.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid30210273",
                "pmid26729092",
                "pmid35620581",
                "pmid10095092",
                "pmid27335702",
                "pmid26095650",
                "pmid33407614",
                "pmid20401186",
                "pmid35569719",
                "pmid31410223"
            ]
        },
        "pathway_127": {
            "question": "Does ginkgetin's antiplatelet effect involve the cyclic AMP or cyclic GMP pathways, which are relevant in Alzheimer's disease?",
            "answer": "The antiplatelet effect of ginkgetin does not involve cyclic AMP or cyclic GMP pathways. \n\n**Answer:** B. No",
            "pmid": [
                "pmid38334198",
                "pmid22372534",
                "pmid22381145",
                "pmid23219964",
                "pmid34478813",
                "pmid34374655",
                "pmid30186862",
                "pmid34968779",
                "pmid23538162",
                "pmid37066913"
            ]
        },
        "pathway_128": {
            "question": "Does Mori Cortex Radicis (MCR) help prevent neuronal damage associated with Alzheimer's disease by activating the IRS/Akt signaling pathway?",
            "answer": "A: Yes",
            "pmid": [
                "pmid32575897",
                "pmid20950278",
                "pmid34566422",
                "pmid23379615",
                "pmid26881107",
                "pmid29351469",
                "pmid31264132",
                "pmid39566407",
                "pmid21704011",
                "pmid25637481"
            ]
        },
        "pathway_129": {
            "question": "Does Notoginsenoside R1 alleviate inflammation caused by amyloid-beta in Alzheimer's disease by inhibiting the SphK1/NF-kappaB pathway?",
            "answer": "A. Yes",
            "pmid": [
                "pmid38063180",
                "pmid24975829",
                "pmid25714973",
                "pmid12453679",
                "pmid35714925",
                "pmid36214721",
                "pmid34968779",
                "pmid28623716",
                "pmid12930788",
                "pmid23279783"
            ]
        },
        "pathway_130": {
            "question": "Does sodium houttuyfonate inhibit the NLRP3/GSDMD pathway to improve memory impairment in Alzheimer's disease?",
            "answer": "The context explicitly states that sodium houttuyfonate inhibits the NLRP3/GSDMD pathway to improve memory impairment in AD. Therefore, the correct answer is:\n\nA: Yes",
            "pmid": [
                "pmid34188608",
                "pmid21593570",
                "pmid12203047",
                "pmid37823115",
                "pmid31945778",
                "pmid31958090",
                "pmid34812899",
                "pmid27567825",
                "pmid1417674",
                "pmid23404502"
            ]
        },
        "pathway_131": {
            "question": "Does 11,12-Diacetyl-carnosol (NO.20) protect SH-SY5Y cells from hydrogen peroxide damage through the Nrf2/HO-1 pathway, which may be relevant to Alzheimer's disease?",
            "answer": "The provided context clearly indicates that 11,12-Diacetyl-carnosol (NO.20) protects SH-SY5Y cells from hydrogen peroxide damage through the Nrf2/HO-1 pathway, which is relevant to Alzheimer's disease due to its role in mitigating oxidative stress.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35620405",
                "pmid17886039",
                "pmid26577515",
                "pmid33617922",
                "pmid34896111",
                "pmid29335845",
                "pmid18706502",
                "pmid30404965",
                "pmid38355004",
                "pmid31606373"
            ]
        },
        "pathway_132": {
            "question": "Does the up-regulation of the P38/HIF-1alpha pathway by intranasal deferoxamine have a role in mitigating Alzheimer's disease-related synapse loss?",
            "answer": "**Answer: A. Yes**\n\nIntranasal deferoxamine (DFO) upregulates the P38/HIF-1alpha pathway, which plays a role in mitigating Alzheimer's disease-related synapse loss by reducing beta-amyloid deposition and inducing neuroprotective proteins like BDNF.",
            "pmid": [
                "pmid26082716",
                "pmid25445365",
                "pmid22547371",
                "pmid22717236",
                "pmid23262393",
                "pmid12203047",
                "pmid31100304",
                "pmid30922179",
                "pmid17055782",
                "pmid34315531"
            ]
        },
        "pathway_133": {
            "question": "Does MGST3 regulate amyloidogenesis, a process associated with Alzheimer's disease, through the RGS4-mediated AKT signaling pathway?",
            "answer": "The query asks whether MGST3 regulates amyloidogenesis through the RGS4-mediated AKT signaling pathway. The provided context specifically addresses this in pmid38971310, where it's shown that MGST3 knockdown reduces BACE1 levels and affects amyloidogenesis via RGS4 and AKT pathways.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid38971310",
                "pmid22927642",
                "pmid23579332",
                "pmid36161942",
                "pmid26293690",
                "pmid16014629",
                "pmid21376707",
                "pmid9878757",
                "pmid35903536",
                "pmid10550330"
            ]
        },
        "pathway_134": {
            "question": "Does Raddeanin A (RDA) improve BRB function in Alzheimer's disease-related retinopathy by inhibiting NLRP3-mediated inflammation and Wnt/beta-catenin pathway-mediated apoptosis?",
            "answer": "The contextual information confirms that Raddeanin A (RDA) does improve BRB function in Alzheimer's disease-related retinopathy by targeting NLRP3-mediated inflammation and Wnt/beta-catenin pathway-mediated apoptosis.\n\nA: Yes",
            "pmid": [
                "pmid38834846",
                "pmid23379615",
                "pmid20950278",
                "pmid31966420",
                "pmid32241604",
                "pmid31712409",
                "pmid26881107",
                "pmid32256561",
                "pmid36214721",
                "pmid26965310"
            ]
        },
        "pathway_135": {
            "question": "Does hyperforin affect Alzheimer's disease by regulating the Akt/GSK-3beta signaling pathway in PC12 cells?",
            "answer": "A: A",
            "pmid": [
                "pmid28961505",
                "pmid30404965",
                "pmid21383880",
                "pmid16880827",
                "pmid8239309",
                "pmid28694093",
                "pmid19828810",
                "pmid20401186",
                "pmid10490699",
                "pmid29501742"
            ]
        },
        "pathway_136": {
            "question": "Does Icariside II mitigate myocardial ischemia and reperfusion injury by activating the PI3K/AKT signaling pathway, which could have implications for Alzheimer's disease?",
            "answer": "B. No",
            "pmid": [
                "pmid25705234",
                "pmid30405422",
                "pmid28210222",
                "pmid31554962",
                "pmid33455039",
                "pmid32784451",
                "pmid26696494",
                "pmid39002124",
                "pmid35857717",
                "pmid27109920"
            ]
        },
        "pathway_137": {
            "question": "Does the \"JAK2-STAT3-BACE1\" pathway play a role in the neuroprotective effects of beta-caryophyllene against Alzheimer's disease?",
            "answer": "The study in pmid35296033 explicitly demonstrates that beta-caryophyllene (BCP) exerts neuroprotective effects through the inhibition of the JAK2-STAT3-BACE1 pathway. Other studies discuss different compounds or pathways, but none contradict this finding.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35296033",
                "pmid28821008",
                "pmid31606373",
                "pmid38355004",
                "pmid30626751",
                "pmid19765580",
                "pmid20307525",
                "pmid30032423",
                "pmid32223911",
                "pmid36232612"
            ]
        },
        "pathway_138": {
            "question": "Does the WNT signaling pathway have a protective association with colorectal cancer in a Saudi population, similar to its role in Alzheimer's disease?",
            "answer": "B. No",
            "pmid": [
                "pmid31485167",
                "pmid32636651",
                "pmid33122978",
                "pmid30833544",
                "pmid29066910",
                "pmid30498395",
                "pmid38225990",
                "pmid39023696",
                "pmid20442453",
                "pmid37005662"
            ]
        },
        "pathway_139": {
            "question": "Does TGF-beta1 restore synaptic plasticity and memory in an Alzheimer's model through the PI3K/Akt/Wnt/beta-catenin pathway?",
            "answer": "The evidence from the abstracts indicates that TGF-beta1 restores synaptic plasticity and memory in an Alzheimer's model via the PI3K/Akt/Wnt/beta-catenin pathway.\n\n**Answer: A. Yes**\n\n**Step-by-Step Explanation:**\n1. **Identify Relevant Abstracts:** The primary source is pmid30539409, which explicitly states that TGF-beta1 restores memory and synaptic plasticity through the PI3K/Akt/Wnt/beta-catenin pathway.\n2. **Supporting Evidence:** Other abstracts confirm TGF-beta1's protective role in AD but do not specifically mention the pathway in question.\n3. **Conclusion:** Based on pmid30539409, the answer is affirmative.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid30539409",
                "pmid17080199",
                "pmid26059637",
                "pmid21879289",
                "pmid18063474",
                "pmid33420799",
                "pmid20881126",
                "pmid31822518",
                "pmid25443284",
                "pmid35903536"
            ]
        },
        "pathway_140": {
            "question": "Does berberine activate the AMPK/mTOR/Ulk1 pathway to attenuate IL-1beta-induced damage in nucleus pulposus cells, which could have implications for Alzheimer's disease?",
            "answer": "B. No",
            "pmid": [
                "pmid35915801",
                "pmid30542442",
                "pmid28822725",
                "pmid29132092",
                "pmid30873920",
                "pmid33361598",
                "pmid22943182",
                "pmid39566407",
                "pmid28668383",
                "pmid22459600"
            ]
        },
        "pathway_141": {
            "question": "Does donepezil suppress intracellular Ca2+ mobilization through the PI3K pathway in rodent microglia, which is relevant to Alzheimer's disease?",
            "answer": "<think>\nOkay, so I'm trying to figure out whether donepezil affects intracellular calcium (Ca²+) levels in rodent microglia through the PI3K pathway. From the context provided, I see that donepezil is known to have anti-inflammatory effects and can influence various signaling pathways involved in neuroinflammation.\n\nLooking at the first study (pmid29273047), it specifically mentions that donepezil suppresses intracellular Ca²+ mobilization via the PI3K pathway in rodent microglia. This seems directly relevant to the question because it clearly states both the effect on Ca²+ and the mechanism involving PI3K.\n\nThe other studies discuss various effects of donepezil, like reducing inflammation, modulating different signaling pathways (like MAPK, NF-kB, STAT3), and improving cognitive outcomes in Alzheimer's models. However, none of these other abstracts mention anything about intracellular Ca²+ or the PI3K pathway specifically.\n\nSince only pmid29273047 directly addresses both the suppression of Ca²+ mobilization and the involvement of the PI3K pathway, it seems that the answer is affirmative. Therefore, donepezil does suppress intracellular Ca²+ mobilization through the PI3K pathway in rodent microglia.\n\nAnswer: A",
            "pmid": [
                "pmid29273047",
                "pmid20153342",
                "pmid35850693",
                "pmid25662507",
                "pmid26114860",
                "pmid31913348",
                "pmid25744714",
                "pmid27002982",
                "pmid34638977",
                "pmid24189446"
            ]
        },
        "pathway_142": {
            "question": "Does baicalin inhibit the Ras-ERK signaling pathway in SH-SY5Y cells exposed to Abeta 1-42 to attenuate apoptosis, which is relevant to Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nBaicalin inhibits the Ras-ERK signaling pathway in SH-SY5Y cells exposed to Abeta 1-42, which is relevant to Alzheimer's disease. This conclusion is supported by the study detailed in pmid35528169, where baicalin was shown to reduce apoptosis by targeting this pathway.",
            "pmid": [
                "pmid35528169",
                "pmid24219385",
                "pmid25596671",
                "pmid21276834",
                "pmid25108596",
                "pmid38006681",
                "pmid26696494",
                "pmid37098656",
                "pmid32739157",
                "pmid36817510"
            ]
        },
        "pathway_143": {
            "question": "Does exercise training reduce cerebrovascular dysfunction in Alzheimer's disease by modulating the P2Y2 receptor and ER stress pathways?",
            "answer": "The study (pmid32383993) explicitly demonstrates that exercise training reduces cerebrovascular dysfunction in Alzheimer's disease by modulating the P2Y2 receptor and ER stress pathways. It shows that exercise converts ATP-induced vasoconstriction to vasodilation, increases P2Y2 receptor expression, enhances eNOS activity, and decreases ER stress markers. Other studies do not address these specific pathways.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid32383993",
                "pmid32561386",
                "pmid33403644",
                "pmid32273835",
                "pmid23827013",
                "pmid36124291",
                "pmid37013375",
                "pmid39751855",
                "pmid33641078",
                "pmid37964627"
            ]
        },
        "pathway_144": {
            "question": "Does vitegnoside mitigate neuronal injury and inflammation in an Alzheimer's disease cell model through the p38 MAPK/JNK pathway?",
            "answer": "A: A",
            "pmid": [
                "pmid31561371",
                "pmid12453679",
                "pmid24975829",
                "pmid18442091",
                "pmid20555131",
                "pmid35772378",
                "pmid34968779",
                "pmid22378890",
                "pmid31100304",
                "pmid35986874"
            ]
        },
        "pathway_145": {
            "question": "Does the acetylcholine-PKC-beta-PIX-Rac1-PAK pathway play a role in aversive learning, which is used to screen Alzheimer's disease drugs?",
            "answer": "The acetylcholine-PKC-beta-PIX-Rac1-PAK pathway is indeed involved in aversive learning, which is used for screening Alzheimer's disease drugs.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35665767",
                "pmid37787112",
                "pmid17555845",
                "pmid37569255",
                "pmid2391515",
                "pmid2694529",
                "pmid10637367",
                "pmid16762377",
                "pmid21820453",
                "pmid1776749"
            ]
        },
        "pathway_146": {
            "question": "Does protease nexin-1 (PN-1) protect against Alzheimer's disease by regulating the sonic hedgehog signaling pathway?",
            "answer": "The analysis of the provided context indicates that protease nexin-1 (PN-1) does protect against Alzheimer's disease by regulating the sonic hedgehog signaling pathway.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid32449865",
                "pmid2813392",
                "pmid18403590",
                "pmid38492808",
                "pmid12105192",
                "pmid21382117",
                "pmid12387451",
                "pmid32744877",
                "pmid17591969",
                "pmid25714973"
            ]
        },
        "pathway_147": {
            "question": "Does methylnissolin-3-O-beta-d-glucopyranoside (MNG) from Astragalus membranaceus show cytoprotective effects relevant to Alzheimer's disease through the Nrf2/HO-1 pathway?",
            "answer": "A. Yes",
            "pmid": [
                "pmid34202670",
                "pmid32800555",
                "pmid32739157",
                "pmid24905226",
                "pmid12203047",
                "pmid39594453",
                "pmid36820018",
                "pmid34896111",
                "pmid26696494",
                "pmid26577515"
            ]
        },
        "pathway_148": {
            "question": "Does the protective effect of PFTalpha on alcohol-induced osteonecrosis of the femoral head involve pathways related to Alzheimer's disease or delirium?",
            "answer": "The protective effect of PFTalpha on alcohol-induced osteonecrosis involves mechanisms like p53 and Wnt/beta-catenin signaling, which are unrelated to the pathways associated with Alzheimer's or delirium. Therefore, the answer is:\n\nAnswer: B. No",
            "pmid": [
                "pmid29246013",
                "pmid33814433",
                "pmid37298443",
                "pmid27662296",
                "pmid29282410",
                "pmid38937571",
                "pmid19032583",
                "pmid29804239",
                "pmid15486488",
                "pmid17434673"
            ]
        },
        "pathway_149": {
            "question": "Does SAR1A influence the progression of delirium through the PI3K/AKT/mTOR pathway?",
            "answer": "B. No",
            "pmid": [
                "pmid37649721",
                "pmid37313848",
                "pmid39419070",
                "pmid28673598",
                "pmid37851904",
                "pmid20309566",
                "pmid33779822",
                "pmid27760517",
                "pmid24557038",
                "pmid7916159"
            ]
        },
        "pathway_150": {
            "question": "Does Amarogentin (AMA) isolated from Gentiana rigescens Franch exhibit potential therapeutic effects for Alzheimer's disease by targeting the insulin receptor and activating downstream signaling pathways?",
            "answer": "The information provided suggests that Amarogentin (AMA) targets the insulin receptor and activates downstream signaling pathways. While there is no direct mention of Alzheimer's disease in the context, the mechanisms involved—such as targeting INSR and activating downstream pathways—are relevant to conditions like AD where these pathways are implicated.\n\nBased on this reasoning, the most appropriate answer is:\n\n**Answer: A. Yes**\n\nNew Answer: The information provided suggests that Amarogentin (AMA) exhibits potential therapeutic effects for Alzheimer's disease by targeting the insulin receptor and activating downstream signaling pathways.",
            "pmid": [
                "pmid34065446",
                "pmid32831994",
                "pmid32316271",
                "pmid25714973",
                "pmid24328060",
                "pmid30563837",
                "pmid38061471",
                "pmid37066913",
                "pmid27615431",
                "pmid32739157"
            ]
        },
        "pathway_151": {
            "question": "Does isoliquiritigenin alleviate Semen Strychni-induced neurotoxicity by restoring the neurotransmitter metabolic pathway, which could be relevant to Alzheimer's disease or delirium?",
            "answer": "The answer is A. Yes.\n\n**Step-by-Step Explanation:**\n\n1. **Mechanism of Isoliquiritigenin**: The study (pmid34867385) demonstrates that isoliquiritigenin alleviates Semen Strychni-induced neurotoxicity by restoring dopamine and 5-HT neurotransmitter pathways, which are crucial for brain function.\n\n2. **Relevance to Alzheimer's Disease**:\n   - NMDA receptors are implicated in AD (pmid31520071), and isoliquiritigenin activates these receptors.\n   - Mitochondrial dysfunction and metabolism issues in AD are addressed by compounds targeting cellular energy, as shown with L-carnitine (pmid34440878).\n\n3. **Relevance to Delirium**:\n   - Scopolamine, a cholinergic antagonist, is used to model delirium (pmid37313848), affecting neurotransmitter systems similar to how isoliquiritigenin restores pathways.\n\nThus, isoliquiritigenin's effect on neurotransmitters is relevant to both conditions. \n\n**Answer:** A. Yes",
            "pmid": [
                "pmid34867385",
                "pmid22666518",
                "pmid36214721",
                "pmid21382422",
                "pmid2067717",
                "pmid11556547",
                "pmid12203047",
                "pmid37313848",
                "pmid31520071",
                "pmid34440878"
            ]
        },
        "pathway_152": {
            "question": "Does metformin activate the ATF2/CREB-PGC-1alpha pathway to protect dopaminergic neurons, which could be relevant for Alzheimer's disease?",
            "answer": "The study (pmid28611284) demonstrates that metformin activates the ATF2/CREB-PGC-1alpha pathway to protect dopaminergic neurons in Parkinson's disease. While other studies show metformin's benefits in Alzheimer's through different mechanisms, this specific pathway could have relevance due to shared neurodegenerative processes.\n\n**Answer: A. Yes**\n\nA. Yes",
            "pmid": [
                "pmid28611284",
                "pmid32580040",
                "pmid34283253",
                "pmid37483818",
                "pmid27467571",
                "pmid30958364",
                "pmid30909226",
                "pmid39441380",
                "pmid38139841",
                "pmid38842663"
            ]
        },
        "pathway_153": {
            "question": "Does Guhan Yangshengjing (GHYSJ) regulate the BACE1 expression pathway to treat Alzheimer's disease?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid38492794",
                "pmid32223911",
                "pmid20455082",
                "pmid18005427",
                "pmid35656471",
                "pmid23202730",
                "pmid19441127",
                "pmid15784960",
                "pmid30626751",
                "pmid26846559"
            ]
        },
        "pathway_154": {
            "question": "Does Armillariella tabescens-derived polysaccharides alleviate neuroinflammation and cognitive injury in Alzheimer's disease through the Keap-1/Nrf2 pathway?",
            "answer": "The provided context does not contain specific information about Armillariella tabescens-derived polysaccharides alleviating neuroinflammation and cognitive injury in Alzheimer's disease through the Keap-1/Nrf2 pathway. Therefore, the most appropriate response is:\n\nB.\n\n**Answer:**\n\nB.",
            "pmid": [
                "pmid38866276",
                "pmid32800555",
                "pmid30290256",
                "pmid29081887",
                "pmid36402384",
                "pmid30844489",
                "pmid33913927",
                "pmid37781122",
                "pmid39305407",
                "pmid30878614"
            ]
        },
        "pathway_155": {
            "question": "Does SKF83959 improve cognitive dysfunction in Alzheimer's disease by modulating the hippocampal BDNF signaling pathway?",
            "answer": "The study (pmid29491219) shows that SKF83959 improves memory impairments and antagonizes scopolamine-induced effects on BDNF signaling in the hippocampus, with its protective effects being TrkB-dependent. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid29491219",
                "pmid28939187",
                "pmid17344400",
                "pmid20401186",
                "pmid30026693",
                "pmid33420799",
                "pmid25443284",
                "pmid12203047",
                "pmid19828810",
                "pmid30539409"
            ]
        },
        "pathway_156": {
            "question": "Does Rhodiola rosea, Withania somnifera, and Eleutherococcus senticosus inhibit the leukotriene signaling pathway, which is beneficial in Alzheimer disease?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid38355004",
                "pmid33807157",
                "pmid30987861",
                "pmid37209001",
                "pmid37542650",
                "pmid29081887",
                "pmid22995388",
                "pmid26304685",
                "pmid24328060",
                "pmid25405415"
            ]
        },
        "pathway_157": {
            "question": "Does the A beta peptide activate complement pathways, contributing to inflammation in Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid10193429",
                "pmid9687521",
                "pmid10192224",
                "pmid8892352",
                "pmid12119423",
                "pmid22428008",
                "pmid11578773",
                "pmid12534311",
                "pmid26509334",
                "pmid33804666"
            ]
        },
        "pathway_158": {
            "question": "Does Chrysophanol exert neuroprotective effects by interfering with endoplasmic reticulum stress apoptotic pathways in Alzheimer's disease?",
            "answer": "The study in pmid34791341 clearly indicates that chrysophanol exerts neuroprotective effects by interfering with endoplasmic reticulum stress apoptotic pathways in Alzheimer's disease.\n\n**Answer: A**\n\nNew Answer:\nA",
            "pmid": [
                "pmid38355004",
                "pmid37780805",
                "pmid34791341",
                "pmid32764873",
                "pmid20655346",
                "pmid17404060",
                "pmid19844776",
                "pmid18602817",
                "pmid31232699",
                "pmid35857717"
            ]
        },
        "pathway_159": {
            "question": "Does the overexpression of BACE1 contribute to memory and cognitive deficits in Alzheimer's disease by regulating the cAMP/PKA/CREB pathway?",
            "answer": "A: Yes",
            "pmid": [
                "pmid22895721",
                "pmid18005427",
                "pmid32223911",
                "pmid20455082",
                "pmid16354928",
                "pmid30626751",
                "pmid19441127",
                "pmid15642747",
                "pmid26846559",
                "pmid31442405"
            ]
        },
        "pathway_160": {
            "question": "Does Anle138b affect pathways related to neuroinflammation in Alzheimer's disease?",
            "answer": "The provided context does not mention Anle138b or its effects on neuroinflammation pathways in Alzheimer's disease. Therefore, based on the given information, we cannot conclude whether Anle138b affects such pathways.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid12453679",
                "pmid34486652",
                "pmid22096345",
                "pmid36918909",
                "pmid12203047",
                "pmid26509334",
                "pmid37854772",
                "pmid32076055",
                "pmid35986874",
                "pmid11276052"
            ]
        },
        "pathway_161": {
            "question": "Does Astragaloside IV improve memory impairment related to Alzheimer's disease by promoting the PPARgamma/BDNF signaling pathway?",
            "answer": "The answer is A. Yes. Astragaloside IV does improve memory impairment related to Alzheimer's disease by promoting the PPARgamma/BDNF signaling pathway, as evidenced by the study in pmid32739157.\n\nA: A",
            "pmid": [
                "pmid32739157",
                "pmid36820018",
                "pmid26696494",
                "pmid37598923",
                "pmid24905226",
                "pmid32800555",
                "pmid12203047",
                "pmid27435287",
                "pmid38577889",
                "pmid10095092"
            ]
        },
        "pathway_162": {
            "question": "** Does minocycline improve cognitive deficits in Alzheimer's-like pathology by inhibiting the Cdk5/p25 signaling pathway?",
            "answer": "The provided context clearly indicates that minocycline improves cognitive deficits in Alzheimer's-like pathology by inhibiting the Cdk5/p25 signaling pathway. The study pmid34856907 directly supports this conclusion, showing that minocycline not only improves learning and memory but also specifically targets the Cdk5/p25 pathway to mitigate AD symptoms.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid34856907",
                "pmid17406652",
                "pmid20555131",
                "pmid19001528",
                "pmid27539598",
                "pmid25443284",
                "pmid2391515",
                "pmid36508924",
                "pmid36907286",
                "pmid23783773"
            ]
        },
        "pathway_163": {
            "question": "Does formononetin target the tumor necrosis factor (TNF) receptor signaling pathway in Alzheimer's disease?",
            "answer": "The answer is \"No\" because the provided context does not mention formononetin targeting the TNF receptor signaling pathway. It only discusses its effects on pro-inflammatory factors like TNF-α.\n\n**Answer: B. No**",
            "pmid": [
                "pmid31175839",
                "pmid12453679",
                "pmid16237106",
                "pmid22096345",
                "pmid37598923",
                "pmid17237425",
                "pmid32331524",
                "pmid9464644",
                "pmid34834150",
                "pmid23017601"
            ]
        },
        "pathway_164": {
            "question": "Does l-theanine inhibit the NMDA receptor pathway to protect against Alzheimer's disease in a cell model?",
            "answer": "Yes, based on the study by pmid20416364, l-theanine protects against Alzheimer's disease in a cell model by inhibiting the NMDA receptor pathway.\n\nAnswer: A. Yes",
            "pmid": [
                "pmid20416364",
                "pmid34336115",
                "pmid29944861",
                "pmid19766184",
                "pmid31952134",
                "pmid12203047",
                "pmid17555845",
                "pmid16762377",
                "pmid20132474",
                "pmid20950278"
            ]
        },
        "pathway_165": {
            "question": "Does S6 kinase phosphorylation via the PI3K-PD1 pathway contribute to tau pathology and actin pathology in Alzheimer's disease?",
            "answer": "The studies provided consistently show that S6 kinase phosphorylation through the PI3K-PD1 pathway is implicated in both tau and actin pathologies in Alzheimer's disease. Specifically, phosphorylated S6K at T229 was found in neurofibrillary tangles and Hirano bodies, which are indicative of tau and actin pathologies respectively. Additionally, Fyn-mediated ERK/S6 signaling promotes tau accumulation. Therefore:\n\n**A. Yes**",
            "pmid": [
                "pmid26582459",
                "pmid18688088",
                "pmid17562708",
                "pmid7533559",
                "pmid11677259",
                "pmid14563691",
                "pmid16014629",
                "pmid28864542",
                "pmid3165303",
                "pmid38946496"
            ]
        },
        "pathway_166": {
            "question": "Does malnutrition exacerbate neuropsychiatric symptoms in Alzheimer's disease by suppressing the cAMP signaling pathway?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid39868480",
                "pmid37246509",
                "pmid31434232",
                "pmid37840496",
                "pmid21035308",
                "pmid22329649",
                "pmid17055782",
                "pmid37391269",
                "pmid38102439",
                "pmid19940172"
            ]
        },
        "pathway_167": {
            "question": "Does pimozide reduce tau aggregates in an Alzheimer's disease model by activating autophagy through the AMPK-ULK1 pathway?",
            "answer": "A: Yes",
            "pmid": [
                "pmid28632947",
                "pmid23667480",
                "pmid25421002",
                "pmid30362531",
                "pmid21368103",
                "pmid31900522",
                "pmid25173700",
                "pmid32591533",
                "pmid22344941",
                "pmid20555131"
            ]
        },
        "pathway_168": {
            "question": "Does Ginsenoside Compound K alleviate Amyloid beta42-induced neuroinflammation in Alzheimer's disease through the LRP1 pathway?",
            "answer": "A: A",
            "pmid": [
                "pmid34968779",
                "pmid29865080",
                "pmid35054451",
                "pmid34374655",
                "pmid28756148",
                "pmid26111763",
                "pmid22381145",
                "pmid34478813",
                "pmid35672874",
                "pmid31344860"
            ]
        },
        "pathway_169": {
            "question": "Does beta-asarone show potential as a therapy for Alzheimer's disease by modulating the P13K/Akt/Nrf2 signaling pathway?",
            "answer": "A: Yes",
            "pmid": [
                "pmid34040526",
                "pmid21391434",
                "pmid25160744",
                "pmid20307525",
                "pmid26271288",
                "pmid35204164",
                "pmid26696494",
                "pmid9205832",
                "pmid39325017",
                "pmid25390692"
            ]
        },
        "pathway_170": {
            "question": "Does Kai-Xin-San improve cognitive dysfunction in Alzheimer's disease by regulating the SIRT3-mediated neuronal cell apoptosis pathway?",
            "answer": "Answer: A. Yes",
            "pmid": [
                "pmid35303280",
                "pmid36918872",
                "pmid31354916",
                "pmid32317964",
                "pmid31563815",
                "pmid25050129",
                "pmid38575939",
                "pmid26710244",
                "pmid35069753",
                "pmid34046075"
            ]
        },
        "pathway_171": {
            "question": "Does the chemokine SDF-1alpha suppress Abeta-induced neurotoxicity in Alzheimer's disease by activating specific signaling pathways?",
            "answer": "A. Yes",
            "pmid": [
                "pmid21704645",
                "pmid25371750",
                "pmid35821178",
                "pmid18400893",
                "pmid35264247",
                "pmid9464644",
                "pmid17055782",
                "pmid15837797",
                "pmid20634578",
                "pmid31722531"
            ]
        },
        "pathway_172": {
            "question": "Do kuwanon T and sanggenon A exert anti-inflammatory effects relevant to Alzheimer's disease by regulating NF-kappaB and HO-1/Nrf2 pathways in BV2 and RAW264.7 cells?",
            "answer": "**Answer: A. Yes**\n\nKuwanon T and Sanggenon A exert anti-inflammatory effects relevant to Alzheimer's disease by regulating NF-kappaB and HO-1/Nrf2 pathways in BV2 and RAW264.7 cells.\n\nNew Answer:\n\nA. Yes",
            "pmid": [
                "pmid37991969",
                "pmid28798805",
                "pmid36820018",
                "pmid12453679",
                "pmid31563815",
                "pmid15473667",
                "pmid37098656",
                "pmid34946724",
                "pmid32317964",
                "pmid35303280"
            ]
        },
        "pathway_173": {
            "question": "Does the Hippo/YAP pathway play a role in the effect of GDNF against Abeta-induced inflammation in microglial cells, which is relevant to Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid32255663",
                "pmid18395194",
                "pmid18780966",
                "pmid20798889",
                "pmid25169677",
                "pmid11114266",
                "pmid34552470",
                "pmid20401186",
                "pmid23279783",
                "pmid12960778"
            ]
        },
        "pathway_174": {
            "question": "Does Sagacious Confucius' Pillow Elixir (SCPE) improve cognitive function by regulating the PI3K/Akt/mTOR signaling pathway in Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe study (pmid37517091) provides evidence that Sagacious Confucius' Pillow Elixir (SCPE) improves cognitive function by interacting with the PI3K/Akt/mTOR signaling pathway, as demonstrated through experiments in a chronic inflammation model. This suggests that SCPE may enhance cognitive outcomes via this pathway in Alzheimer's disease.",
            "pmid": [
                "pmid37517091",
                "pmid36249769",
                "pmid32140977",
                "pmid30844489",
                "pmid28521305",
                "pmid31607908",
                "pmid35069753",
                "pmid23660953",
                "pmid28279707",
                "pmid31661844"
            ]
        },
        "pathway_175": {
            "question": "How might EGCG influence pathways associated with Alzheimer's disease in early aged hypertension?",
            "answer": "The correct answer is:\n\n**B. By activating pro-survival pathways such as Sirt1/PI3K/AKT**\n\n**Explanation:**\nEGCG has been shown to enhance pro-survival pathways like Sirt1/PI3K/AKT, which help in reducing neural cell death and apoptosis. This aligns with the findings from pmid34456710 where EGCG treatment reduced apoptotic markers and increased levels of Bcl-2 family proteins. Additionally, other studies confirm EGCG's protective effects against neurotoxicity by inhibiting stress-mediated pathways, further supporting its role in activating pro-survival mechanisms.",
            "pmid": [
                "pmid34456710",
                "pmid11193159",
                "pmid10817927",
                "pmid38472200",
                "pmid17055782",
                "pmid15960984",
                "pmid27335702",
                "pmid29446867",
                "pmid28694093",
                "pmid10095092"
            ]
        },
        "pathway_176": {
            "question": "Which pathway is associated with the protective effects of bavachin in LPS-induced AKI, potentially relevant to Alzheimer's disease or delirium?",
            "answer": "The protective effects of bavachin in LPS-induced AKI, relevant to Alzheimer's disease or delirium, are most closely associated with the **NF-κB signaling pathway**.\n\n**Answer: C. The NF-kappaB signaling pathway**",
            "pmid": [
                "pmid25052843",
                "pmid31722531",
                "pmid15208744",
                "pmid28623716",
                "pmid35474599",
                "pmid21683531",
                "pmid35672874",
                "pmid33277246",
                "pmid15917189",
                "pmid27535978"
            ]
        },
        "pathway_177": {
            "question": "Which of the following pathways is identified as a significant shared pathway between delirium and Alzheimer's disease?",
            "answer": "The correct answer is:\n\n**B. Neuroinflammation and glutamatergic signaling pathway**\n\nThis conclusion is based on the study (pmid39210294) that explicitly identifies these pathways as significant shared mechanisms between delirium and Alzheimer's disease.",
            "pmid": [
                "pmid39210294",
                "pmid22329649",
                "pmid32592865",
                "pmid28673598",
                "pmid7916159",
                "pmid38566855",
                "pmid37313848",
                "pmid33277246",
                "pmid12127594",
                "pmid20309566"
            ]
        },
        "pathway_178": {
            "question": "What signaling pathway was found to mediate the interaction between Abeta and IL-1beta, contributing to neuronal damage in Alzheimer's disease?",
            "answer": "The interaction between Abeta and IL-1beta contributing to neuronal damage in Alzheimer's disease is mediated by the **PLC-CN-NFAT1 signaling pathway**. This conclusion is supported by the study detailed in pmid38749336, which highlights this pathway as a key mechanism for their synergistic effect on neuronal damage.\n\n**Answer: B. PLC-CN-NFAT1 signaling**",
            "pmid": [
                "pmid38749336",
                "pmid11290384",
                "pmid21241676",
                "pmid2391515",
                "pmid19666073",
                "pmid16183991",
                "pmid35264247",
                "pmid17055782",
                "pmid8239309",
                "pmid23582659"
            ]
        },
        "pathway_179": {
            "question": "Which pathway does bilberry anthocyanins regulate to improve cognitive dysfunction in Alzheimer's disease?",
            "answer": "The most appropriate answer is A. CD33/TREM2/TYROBP signaling pathway.\n\nAnswer: A",
            "pmid": [
                "pmid32003387",
                "pmid22995388",
                "pmid34739938",
                "pmid31232699",
                "pmid26304685",
                "pmid36500385",
                "pmid24328060",
                "pmid38355004",
                "pmid34116571",
                "pmid32109514"
            ]
        },
        "pathway_180": {
            "question": "Which pathway is activated by the MFH formula to prevent cognitive deficits in Alzheimer's disease?",
            "answer": "The AEA-Trpv1-Nrf2 pathway is activated by the MFH formula to prevent cognitive deficits in Alzheimer's disease. \n\nAnswer: A. The AEA-Trpv1-Nrf2 pathway",
            "pmid": [
                "pmid39305407",
                "pmid18706502",
                "pmid35350668",
                "pmid30922179",
                "pmid12203047",
                "pmid12960778",
                "pmid33998138",
                "pmid33420799",
                "pmid16873963",
                "pmid37854772"
            ]
        },
        "pathway_181": {
            "question": "What pathway does PPSR inhibit to reduce microglial inflammation in Alzheimer's disease?",
            "answer": "B. NLRP3/caspase 1 pathway",
            "pmid": [
                "pmid34874326",
                "pmid25485684",
                "pmid38886959",
                "pmid17911636",
                "pmid15608143",
                "pmid28623716",
                "pmid39117070",
                "pmid39741193",
                "pmid16219804",
                "pmid36515857"
            ]
        },
        "pathway_182": {
            "question": "Which signaling pathway is implicated in the protective effects of ITH91/IQM157 against neuronal cell death in an Alzheimer's disease model?",
            "answer": "The question asks about the signaling pathway implicated in the protective effects of ITH91/IQM157 against neuronal cell death in an Alzheimer's model. After reviewing the provided context, none of the articles specifically mention ITH91 or IQM157. Therefore, based on the given information, there is no direct evidence linking these compounds to any of the listed pathways (A-D). \n\nAnswer: UNRELATED",
            "pmid": [
                "pmid27068745",
                "pmid20451607",
                "pmid15608143",
                "pmid15208744",
                "pmid23559013",
                "pmid22033930",
                "pmid25052843",
                "pmid30539409",
                "pmid33420799",
                "pmid39648181"
            ]
        },
        "pathway_183": {
            "question": "In Alzheimer's disease, beta-amyloid-induced apoptosis is associated with up-regulation of which enzyme via the mitogen-activated protein kinase-NF-kappaB pathway?",
            "answer": "The enzyme associated with beta-amyloid-induced apoptosis through the mitogen-activated protein kinase-NF-kappaB pathway in Alzheimer's disease is **Cyclooxygenase-2 (COX-2)**. \n\n**Answer: B. Cyclooxygenase-2 (COX-2)**",
            "pmid": [
                "pmid15917189",
                "pmid31392591",
                "pmid20847443",
                "pmid22430645",
                "pmid28698968",
                "pmid20358486",
                "pmid23076628",
                "pmid16626961",
                "pmid25052843",
                "pmid20122965"
            ]
        },
        "pathway_184": {
            "question": "Which brain networks are dysfunctional in delirium?",
            "answer": "The answer is C: The default-mode network, salience network, frontoparietal control network, and dorsal attention network are dysfunctional in delirium.\n\nAnswer: C",
            "pmid": [
                "pmid28673598",
                "pmid7916159",
                "pmid28519903",
                "pmid37851904",
                "pmid39419070",
                "pmid19422109",
                "pmid26029046",
                "pmid3765988",
                "pmid20309566",
                "pmid24557038"
            ]
        },
        "pathway_185": {
            "question": "How does substrate translocation activity change with Alzheimer's disease progression?",
            "answer": "C",
            "pmid": [
                "pmid38787367",
                "pmid8242380",
                "pmid7936052",
                "pmid8740986",
                "pmid2391515",
                "pmid11447833",
                "pmid26051801",
                "pmid9850923",
                "pmid10095092",
                "pmid9878757"
            ]
        },
        "pathway_186": {
            "question": "Which brain region disconnection is associated with memory impairment in oldest-old Alzheimer's patients?",
            "answer": "The disconnection between the right superior parietal lobule (SPL) and the precuneus is associated with memory impairment in oldest-old Alzheimer's patients. \n\n**Answer: C. Disconnection between the right superior parietal lobule (SPL) and the precuneus.**\n\nNew Answer: C.",
            "pmid": [
                "pmid32728647",
                "pmid24607963",
                "pmid11124422",
                "pmid22651939",
                "pmid25820930",
                "pmid31139072",
                "pmid37597700",
                "pmid19220710",
                "pmid20202480",
                "pmid29080407"
            ]
        },
        "pathway_187": {
            "question": "What happens to I2(PP2A) levels in the neocortex in Alzheimer's disease?",
            "answer": "The correct answer based on the provided context is:\n\nC. They significantly increase.\n\n**Answer:** C",
            "pmid": [
                "pmid15920161",
                "pmid17055782",
                "pmid2893306",
                "pmid10095092",
                "pmid29080407",
                "pmid3165303",
                "pmid30594047",
                "pmid2391515",
                "pmid7936052",
                "pmid31520071"
            ]
        },
        "pathway_188": {
            "question": "What brain region shows the highest proportion of cortical thickness outliers in Alzheimer's Disease?",
            "answer": "C. Parahippocampal gyrus",
            "pmid": [
                "pmid37127353",
                "pmid19220710",
                "pmid24607963",
                "pmid29080407",
                "pmid14507668",
                "pmid10965795",
                "pmid11351135",
                "pmid38958450",
                "pmid7916770",
                "pmid9878757"
            ]
        },
        "pathway_189": {
            "question": "What potential pathways are linked to delirium after cardiac surgery?",
            "answer": "The potential pathways linked to delirium after cardiac surgery include neurotransmitter interference, global cognitive disorder, and neuroinflammation. These are explicitly mentioned in the provided context.\n\n**Answer: B. Neurotransmitter interference, global cognitive disorder, and neuroinflammation.**",
            "pmid": [
                "pmid27119013",
                "pmid17088170",
                "pmid29881262",
                "pmid10473947",
                "pmid33918634",
                "pmid32987655",
                "pmid38223851",
                "pmid30051417",
                "pmid18314455",
                "pmid39774401"
            ]
        },
        "pathway_190": {
            "question": "What molecular pathways are alike between long COVID-19 and Alzheimer's disease?",
            "answer": "The molecular pathways shared between long COVID-19 and Alzheimer's disease include misregulations in folate-mediated one-carbon metabolism, a deficit of CoQ10, and disease-associated microglia. These were specifically mentioned in the context provided.\n\n**Answer: C. Misregulations in folate-mediated one-carbon metabolism, a deficit of CoQ10, and disease-associated microglia.**",
            "pmid": [
                "pmid38393535",
                "pmid33283188",
                "pmid36089575",
                "pmid33052346",
                "pmid35055344",
                "pmid36767513",
                "pmid33567524",
                "pmid38259635",
                "pmid33941272",
                "pmid34833377"
            ]
        },
        "pathway_191": {
            "question": "Which axis does tangeretin activate to prevent cognitive deficit in delirium?",
            "answer": "The correct answer is:\n\n**C. RORalpha/gamma-E4BP4 axis**\n\nThis conclusion is drawn from the study which specifically identifies tangeretin as activating this axis to prevent cognitive deficits in delirium, as described in pmid36216079.",
            "pmid": [
                "pmid36216079",
                "pmid28673598",
                "pmid37313848",
                "pmid7916159",
                "pmid10473937",
                "pmid39297465",
                "pmid24557038",
                "pmid37330271",
                "pmid38911008",
                "pmid38566855"
            ]
        },
        "pathway_192": {
            "question": "What is identified as a unifying mechanism present in all 30 Alzheimer's disease risk factors?",
            "answer": "The correct answer is:\n\n**C. Dysfunction of the neuroimmune-neuroinflammation axis.**\n\nThis conclusion is supported by pmid38248256, which explicitly identifies neuroinflammation as the unifying mechanism across all 30 risk factors for Alzheimer's disease, emphasizing the role of microglia activation and pro-inflammatory cytokines.",
            "pmid": [
                "pmid38248256",
                "pmid39781717",
                "pmid12582468",
                "pmid30820047",
                "pmid11145195",
                "pmid36396271",
                "pmid32121263",
                "pmid17055782",
                "pmid26509334",
                "pmid15649702"
            ]
        },
        "pathway_193": {
            "question": "What is the mechanism by which concurrent lithium and electroconvulsive therapy leads to delirium?",
            "answer": "The mechanism by which concurrent lithium and electroconvulsive therapy leads to delirium is best explained by option C. According to the provided context, repeated ECT seizures may cause toxic delirium in patients taking lithium, suggesting that the combination of these treatments can lead to toxicity, especially in individuals with preexisting brain damage.\n\n**Answer: C**",
            "pmid": [
                "pmid3281716",
                "pmid10664610",
                "pmid34978",
                "pmid20204907",
                "pmid39419070",
                "pmid37313848",
                "pmid37133446",
                "pmid38911008",
                "pmid7916159",
                "pmid19422109"
            ]
        },
        "pathway_194": {
            "question": "Does bacteremia contribute to the pathophysiology of delirium in elderly patients with community-acquired pneumonia?",
            "answer": "C. Yes, bacteremia can contribute to the pathophysiology of delirium.\n\n**Answer: C**",
            "pmid": [
                "pmid27078731",
                "pmid20471115",
                "pmid17467406",
                "pmid28769556",
                "pmid37566435",
                "pmid17203511",
                "pmid20309566",
                "pmid21978081",
                "pmid21488579",
                "pmid34034650"
            ]
        },
        "pathway_195": {
            "question": "How does reduced opioid usage via regional analgesia influence delirium risk in geriatric trauma patients?",
            "answer": "The most appropriate answer based on the provided context is:\n\n**C. Regional analgesia decreases the need for opioid medications, which reduces the risk of delirium.**\n\nThis conclusion is supported by a study that found regional analgesia reduced opioid use and subsequently lowered delirium risk in geriatric trauma patients. Other studies suggest avoiding excessive opioid use can help prevent delirium.\n\n**Answer:** C",
            "pmid": [
                "pmid30048325",
                "pmid33835902",
                "pmid20375300",
                "pmid28910303",
                "pmid36304175",
                "pmid39638735",
                "pmid7762856",
                "pmid16670110",
                "pmid8803381",
                "pmid34901277"
            ]
        },
        "pathway_196": {
            "question": "What neurotransmitter systems are implicated in delirium associated with Charles Bonnet Syndrome?",
            "answer": "The neurotransmitter systems implicated in delirium associated with Charles Bonnet Syndrome include acetylcholine and dopamine.\n\n**Answer: C. Acetylcholine and dopamine are suspected to be involved.**",
            "pmid": [
                "pmid36059364",
                "pmid7916159",
                "pmid28673598",
                "pmid32018069",
                "pmid19422109",
                "pmid37313848",
                "pmid19541436",
                "pmid34978",
                "pmid7211434",
                "pmid17234821"
            ]
        },
        "pathway_197": {
            "question": "What neuroendocrine pathways are implicated in mediating delirium in pregnant women during COVID-19-related stress?",
            "answer": "The neuroendocrine pathways implicated in mediating delirium in pregnant women during COVID-19-related stress are the hypothalamic-pituitary-adrenal (HPA) axis and the hypothalamic-pituitary-thyroid (HPT) axis. These findings are supported by studies that highlight their involvement in response to stress and the associated psychological symptoms, particularly during the pandemic.\n\n**Answer: C. The HPA axis and HPT axis**",
            "pmid": [
                "pmid36141770",
                "pmid10473937",
                "pmid28673598",
                "pmid7916159",
                "pmid33336596",
                "pmid24557038",
                "pmid20131213",
                "pmid39463449",
                "pmid28828226",
                "pmid39419070"
            ]
        },
        "pathway_198": {
            "question": "What signaling pathways are influenced by statins in the context of delirium?",
            "answer": "The correct answer is:\n\n**C. Pathways associated with neuroinflammation, neurotransmitter regulation, cerebral hypoperfusion, and microthrombosis.**\n\n**Step-by-Step Explanation:**\n\n1. **Understanding the Question:** The question asks which signaling pathways are influenced by statins in the context of delirium.\n\n2. **Reviewing Relevant Abstracts:** \n   - The abstract from pmid32691721 explicitly states that statins can alleviate delirium by affecting neuroinflammation, neurotransmitters, cerebral hypoperfusion, and microthrombosis.\n   - Other abstracts discuss various aspects of delirium's pathophysiology but do not mention statins directly.\n\n3. **Connecting Statins to Pathways:** Since pmid32691721 links statins to these specific pathways, it supports option C as the correct answer.\n\n**Answer:** C",
            "pmid": [
                "pmid32691721",
                "pmid28673598",
                "pmid39419070",
                "pmid37851904",
                "pmid7916159",
                "pmid37313848",
                "pmid17234821",
                "pmid20309566",
                "pmid38566855",
                "pmid39463449"
            ]
        },
        "pathway_199": {
            "question": "What is the effect of switching from H2 receptor antagonists to proton pump inhibitors on delirium incidence in cancer patients?",
            "answer": "C. Switching reduces delirium incidence.",
            "pmid": [
                "pmid22949902",
                "pmid38409802",
                "pmid37133446",
                "pmid39541802",
                "pmid38911008",
                "pmid32691721",
                "pmid26674479",
                "pmid31574089",
                "pmid36224337",
                "pmid37313848"
            ]
        },
        "pathway_200": {
            "question": "What signaling pathways are influenced by co-ultraPEALut in relation to delirium?",
            "answer": "C",
            "pmid": [
                "pmid31244434",
                "pmid37313848",
                "pmid38566855",
                "pmid26675131",
                "pmid34234505",
                "pmid37968531",
                "pmid39839987",
                "pmid36077505",
                "pmid37760032",
                "pmid37446267"
            ]
        },
        "pathway_201": {
            "question": "What changes in beta-endorphin signaling are associated with delirium?",
            "answer": "C",
            "pmid": [
                "pmid2524220",
                "pmid28673598",
                "pmid39419070",
                "pmid24557038",
                "pmid20309566",
                "pmid7916159",
                "pmid39839987",
                "pmid37851904",
                "pmid39463449",
                "pmid38566855"
            ]
        },
        "pathway_202": {
            "question": "What role does the circadian rhythm protein Period 2 (PER2) play in the pathophysiology of delirium?",
            "answer": "C. It maintains cognitive function, and its disruption is linked to delirium-like phenotypes.",
            "pmid": [
                "pmid35713240",
                "pmid29489460",
                "pmid23916192",
                "pmid39541802",
                "pmid39419070",
                "pmid34321570",
                "pmid37851904",
                "pmid28673598",
                "pmid7916159",
                "pmid38911008"
            ]
        },
        "pathway_203": {
            "question": "What role do pro-inflammatory cytokines play in the development of delirium in Alzheimer’s disease patients?",
            "answer": "The role of pro-inflammatory cytokines in delirium among Alzheimer's disease patients involves reducing cholinergic system activity, exacerbating cognitive dysfunction and contributing to delirium.\n\n**Answer:** C",
            "pmid": [
                "pmid12127594",
                "pmid32592865",
                "pmid24048854",
                "pmid24557038",
                "pmid20309566",
                "pmid22553034",
                "pmid12453679",
                "pmid27335702",
                "pmid21932048",
                "pmid1749826"
            ]
        },
        "pathway_204": {
            "question": "According to the neuroinflammatory hypothesis of delirium, what is a key sequence of pathway events linking peripheral inflammation to the development of this neuropsychiatric syndrome?",
            "answer": "<think>\nOkay, so I need to determine the most appropriate answer based on the context provided. The question is about the key sequence of pathway events linking peripheral inflammation to delirium according to the neuroinflammatory hypothesis.\n\nLooking at the new context:\n\n- They used three mouse models: anesthesia with surgery (AS), systemic inflammation, and neurotransmission modulation.\n- Bacterial lipopolysaccharide (LPS) and scopolamine (Scop) were used. Both reduced neuronal activities in brain networks related to delirium.\n- Scop caused reversible cognitive impairment and hyperactive behavior without loss of cholinergic neurons but affected hippocampal synaptic functions.\n\nFrom the abstracts:\n\n1. pmid20309566: Peripheral inflammation induces activation of brain cells, leading to pro-inflammatory cytokines in the CNS and neuronal dysfunction.\n2. pmid24557038: Systemic inflammation triggers a neuroinflammatory response with microglia activation, especially in susceptible individuals.\n3. pmid20471138: Peripheral inflammation leads to brain cytokine expression without neuronal loss, causing cognitive symptoms.\n4. pmid37313848: Discusses the use of scopolamine and systemic inflammation affecting brain networks.\n\nPutting this together:\n\n- Peripheral inflammation (like LPS) activates brain cells.\n- This activation leads to pro-inflammatory cytokines in the CNS.\n- These cytokines cause neuronal dysfunction, such as synaptic issues, leading to delirium symptoms.\n\nThe options are A-D. Option A matches this sequence: peripheral inflammation triggers brain cell activation and cytokine expression, causing neuronal dysfunction.\n\n**Answer:** A",
            "pmid": [
                "pmid20309566",
                "pmid24557038",
                "pmid20471138",
                "pmid24048854",
                "pmid22553034",
                "pmid29875474",
                "pmid33648701",
                "pmid32592865",
                "pmid37313848",
                "pmid7916159"
            ]
        },
        "pathway_205": {
            "question": "What is the role of cytokine-acetylcholine interaction in the pathophysiology of delirium during septic encephalopathy?",
            "answer": "The role of cytokine-acetylcholine interaction in septic encephalopathy involves leading to neuronal loss and alterations in cholinergic signaling, which contributes to delirium.\n\n**Answer: B. It leads to neuronal loss and alterations in cholinergic signaling.**",
            "pmid": [
                "pmid25722876",
                "pmid22553034",
                "pmid37313848",
                "pmid39839987",
                "pmid37235660",
                "pmid20309566",
                "pmid24557038",
                "pmid32592865",
                "pmid20471138",
                "pmid28236057"
            ]
        },
        "pathway_206": {
            "question": "What biological mechanisms are associated with opioid-induced delirium in critically ill adults?",
            "answer": "The correct answer is:\n\n**C. Opioid-induced delirium may involve disruptions in neurotransmitter systems and neuroinflammatory pathways.**\n\nThis conclusion aligns with the context provided, which consistently points to the involvement of both neurotransmitter imbalances (such as cholinergic changes) and inflammatory processes in the pathophysiology of delirium.",
            "pmid": [
                "pmid33835902",
                "pmid37313848",
                "pmid28673598",
                "pmid39419070",
                "pmid37133446",
                "pmid20309566",
                "pmid7916159",
                "pmid19422109",
                "pmid37851904",
                "pmid30051417"
            ]
        },
        "pathway_207": {
            "question": "What antibodies are associated with delirium in cases of Hashimoto's encephalopathy?",
            "answer": "The question asks about antibodies associated with delirium in Hashimoto's encephalopathy. From the context provided:\n\n- **PMID31494584** mentions anti-TPO antibodies in a case of Hashimoto's encephalopathy presenting with delirium.\n\nConsidering the options:\n\n- Option C includes anti-TPO, which is directly mentioned, and other thyroid-related antibodies.\n\nTherefore, the best answer based on the context is:\n\nANSWER: C",
            "pmid": [
                "pmid34757245",
                "pmid23962100",
                "pmid24557038",
                "pmid549538",
                "pmid31494584",
                "pmid7211434",
                "pmid32018069",
                "pmid38566855",
                "pmid17234821",
                "pmid32592865"
            ]
        },
        "pathway_208": {
            "question": "What biological effect of olanzapine is linked to delirium development in elderly patients?",
            "answer": "The intrinsic anticholinergic effects of olanzapine are linked to delirium development in elderly patients because they reduce cholinergic activity, which is a known factor contributing to delirium.\n\n**Answer: C. The intrinsic anticholinergic effects of the drug.**",
            "pmid": [
                "pmid16368923",
                "pmid12868070",
                "pmid33154380",
                "pmid17317453",
                "pmid37082516",
                "pmid19422109",
                "pmid15948179",
                "pmid32162816",
                "pmid38911008",
                "pmid26029046"
            ]
        },
        "pathway_209": {
            "question": "What inflammatory markers are associated with delirium in older adults?",
            "answer": "The inflammatory markers associated with delirium in older adults include C-reactive protein (CRP), Tumor necrosis factor alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-8 (IL-8), and Neutrophil-lymphocyte ratio (NLR). These markers were consistently mentioned across multiple studies as being linked to delirium.\n\n**Answer: C. C-reactive protein (CRP), Tumor necrosis factor alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Neutrophil-lymphocyte ratio (NLR)**",
            "pmid": [
                "pmid37251808",
                "pmid34034650",
                "pmid28769556",
                "pmid17467406",
                "pmid31856187",
                "pmid19269948",
                "pmid37649721",
                "pmid34912245",
                "pmid22903241",
                "pmid17234821"
            ]
        },
        "pathway_210": {
            "question": "What signaling pathways are implicated in delirium development through sleep disruption by sedative-hypnotic agents?",
            "answer": "The question asks about the signaling pathways implicated in delirium development through sleep disruption caused by sedative-hypnotic agents. Based on the provided context, these agents likely disrupt circadian rhythms, affecting melatonin secretion and suprachiasmatic nucleus connectivity. They also influence GABA-A receptors, alpha(2) adrenoceptors, and orexin receptors. This corresponds to option C.\n\n**Answer:** C. Disruption of circadian rhythms, altered connectivity from the suprachiasmatic nucleus, deficiencies in melatonin, and effects on GABA-A, alpha(2) adrenoceptors, and orexin receptors.",
            "pmid": [
                "pmid39541802",
                "pmid38911008",
                "pmid37313848",
                "pmid32329703",
                "pmid28673598",
                "pmid39415561",
                "pmid7916159",
                "pmid35713240",
                "pmid29489460",
                "pmid24815757"
            ]
        },
        "pathway_211": {
            "question": "In elderly patients undergoing surgery, pre-operative dysregulation within which of the following biological processes, marked by specific circulating mediators, has been identified as a significant risk factor for the development of post-operative delirium?",
            "answer": "The correct answer is C: The inflammatory response, particularly evidenced by high pre-operative levels of Interleukin-6 (IL-6).\n\n**Answer:** C",
            "pmid": [
                "pmid36224337",
                "pmid25368603",
                "pmid33918634",
                "pmid30051417",
                "pmid18314455",
                "pmid10473947",
                "pmid39259057",
                "pmid39774401",
                "pmid35294925",
                "pmid37364279"
            ]
        },
        "pathway_212": {
            "question": "What signaling cascades are implicated in the development of delirium during sepsis?",
            "answer": "The signaling cascades implicated in delirium during sepsis include neuroinflammation, cytokine activation, blood-brain barrier breakdown, and neurotransmitter imbalances. \n\nAnswer: B. Neuroinflammation, cytokine activation, blood-brain barrier breakdown, and neurotransmitter imbalances.",
            "pmid": [
                "pmid25567339",
                "pmid39419070",
                "pmid25722876",
                "pmid24557038",
                "pmid38647548",
                "pmid35791660",
                "pmid28673598",
                "pmid37133446",
                "pmid33794468",
                "pmid20309566"
            ]
        },
        "pathway_213": {
            "question": "What matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are associated with delirium?",
            "answer": "The correct answer is:\n\n**C. Higher levels of MMP-2, MMP-3, MMP-10, TIMP-1, and TIMP-2, as well as lower levels of TIMP-4.**\n\nThis corresponds to the findings from pmid38937571 before adjusting for other factors like acute trauma or dementia.",
            "pmid": [
                "pmid38937571",
                "pmid7211434",
                "pmid9890433",
                "pmid3765988",
                "pmid38566855",
                "pmid33901789",
                "pmid17234821",
                "pmid39604493",
                "pmid33779822",
                "pmid39839987"
            ]
        },
        "pathway_214": {
            "question": "What are the potential signaling pathways disrupted by synthetic cannabinoid use in this case of delirium?",
            "answer": "The use of synthetic cannabinoids disrupts multiple signaling pathways involved in delirium, including GABAergic, glutamatergic, cholinergic, and dopaminergic systems. \n\n**Answer: B. GABAergic, glutamatergic, cholinergic, and dopaminergic pathways.**",
            "pmid": [
                "pmid28673598",
                "pmid37313848",
                "pmid7916159",
                "pmid19422109",
                "pmid22553034",
                "pmid26956672",
                "pmid39419070",
                "pmid36437738",
                "pmid37851904",
                "pmid37133446"
            ]
        },
        "pathway_215": {
            "question": "What role does beta-arrestin1 play in regulating mitochondrial fission through Drp1 during postoperative delirium?",
            "answer": "The most appropriate answer based on the provided context is:\n\nC. Beta-arrestin1 interacts with Drp1; its deletion promotes Drp1 translocation to the mitochondrial membrane, causing mitochondrial fragmentation and dysfunction, contributing to cognitive dysfunctions in POD.\n\n**Answer:** C",
            "pmid": [
                "pmid37170230",
                "pmid28432138",
                "pmid29464060",
                "pmid22367970",
                "pmid37968531",
                "pmid35078269",
                "pmid33465841",
                "pmid24252614",
                "pmid39604493",
                "pmid18599615"
            ]
        },
        "pathway_216": {
            "question": "What cytokine levels are associated with cognitive dysfunction following delirium in intensive care unit survivors?",
            "answer": "The answer is:\n\n**Answer: UNRELATED**\n\nNew Answer:",
            "pmid": [
                "pmid35791660",
                "pmid17467406",
                "pmid37712803",
                "pmid19269948",
                "pmid20471115",
                "pmid31929159",
                "pmid17203511",
                "pmid24557038",
                "pmid28360657",
                "pmid21978081"
            ]
        },
        "pathway_217": {
            "question": "What signaling pathway is implicated in the use of phenobarbital for managing delirium associated with gamma-hydroxybutyrate withdrawal?",
            "answer": "The signaling pathway implicated in the use of phenobarbital for managing delirium associated with gamma-hydroxybutyrate (GHB) withdrawal is the **GABA-A receptor signaling pathway**.\n\n**Answer: C. GABA-A receptor signaling pathway.**",
            "pmid": [
                "pmid36269081",
                "pmid28673598",
                "pmid37313848",
                "pmid24914776",
                "pmid39541802",
                "pmid27760517",
                "pmid35665767",
                "pmid38106167",
                "pmid32008166",
                "pmid33029123"
            ]
        },
        "pathway_218": {
            "question": "What are the common pharmacological effects of oseltamivir and amantadine that may contribute to delirium?",
            "answer": "The common pharmacological effects of oseltamivir and amantadine that may contribute to delirium are blocking nicotinic acetylcholine receptor channels and activating the dopaminergic system.\n\n**Answer: D. Blocking nicotinic acetylcholine receptor channels and activation of the dopaminergic system.**",
            "pmid": [
                "pmid29925727",
                "pmid39541802",
                "pmid38911008",
                "pmid27760517",
                "pmid29570959",
                "pmid39415561",
                "pmid25038833",
                "pmid12649296",
                "pmid24815757",
                "pmid37313848"
            ]
        },
        "pathway_219": {
            "question": "What receptor oversaturation is associated with delirium/sedation syndrome caused by olanzapine?",
            "answer": "The delirium/sedation syndrome caused by olanzapine is associated with the oversaturation of **H1 and M1 receptors**.\n\n**Answer: C. H1 and M1 receptors**",
            "pmid": [
                "pmid37082516",
                "pmid38895540",
                "pmid33154380",
                "pmid23962100",
                "pmid12868070",
                "pmid28673598",
                "pmid38911008",
                "pmid7916159",
                "pmid11730949",
                "pmid11912074"
            ]
        },
        "pathway_220": {
            "question": "What signaling cascade involving cyclooxygenase-1 (COX-1) contributes to delirium during systemic inflammation?",
            "answer": "The correct answer is:\n\n**D. Systemic inflammation increases IL-1beta, which enhances COX-1 expression in microglia, leading to increased prostaglandin E2 production and subsequent cognitive dysfunction and delirium.**\n\nThis aligns with the context provided, where systemic inflammation leads to increased IL-1beta, promoting COX-1 activity in microglia, resulting in elevated PGE2 levels and contributing to cognitive deficits linked to delirium.\n\nNew Answer: D",
            "pmid": [
                "pmid24048854",
                "pmid29875474",
                "pmid22553034",
                "pmid20471138",
                "pmid20309566",
                "pmid24557038",
                "pmid32592865",
                "pmid34589882",
                "pmid39839987",
                "pmid20122965"
            ]
        },
        "pathway_221": {
            "question": "Investigations into the molecular underpinnings of postoperative delirium (POD) suggest that its development can be mediated by specific intracellular signaling cascades. According to findings implicating inflammatory processes, which pathway profile is consistent with a mediatory role in POD?",
            "answer": "The studies indicate that POD involves upregulation of the TLR4/NF-kappaB/MAGI-2 pathway with increased pro-inflammatory cytokines. This aligns with option C.\n\n**Step-by-Step Explanation:**\n\n1. **Understanding the Question:** The question asks which signaling pathway is involved in POD based on inflammatory processes.\n\n2. **Reviewing the Context:**\n   - Study pmid35294925 identified increased TLR4, NF-kappaB, MAGI-2, IL-1β, and TNF-α in POD patients.\n   - Study pmid39604493 highlighted neuroinflammation and TLR pathways as key factors.\n\n3. **Analyzing Options:**\n   - **A & B:** Not supported by the context which focuses on inflammation and not cholinergic or dopaminergic systems.\n   - **C:** Matches the studies' findings of increased TLR4/NF-kappaB/MAGI-2 activity with pro-inflammatory cytokines.\n   - **D:** Contradicts the findings as NF-kappaB was upregulated, not suppressed.\n\n4. **Conclusion:** Option C is consistent with the provided evidence on POD's molecular underpinnings.\n\n**Answer: C**\n\nNew Answer:\n\nThe studies indicate that POD involves upregulation of the TLR4/NF-kappaB/MAGI-2 pathway with increased pro-inflammatory cytokines. This aligns with option C, which states that the TLR4/NF-kappaB/MAGI-2 pathway is associated with increased pro-inflammatory cytokine activity in POD.\n\n**Answer: C**\n\nNew Answer:\n\nThe findings suggest that the TLR4/NF-kappaB/MAGI-2 pathway is upregulated and linked to increased pro-inflammatory cytokines, supporting option C as the correct answer.\n\n**Answer: C**",
            "pmid": [
                "pmid35294925",
                "pmid37170230",
                "pmid34234505",
                "pmid30051417",
                "pmid33409674",
                "pmid39519398",
                "pmid33250764",
                "pmid39604493",
                "pmid34093168",
                "pmid20309566"
            ]
        },
        "pathway_222": {
            "question": "What neurotransmitter receptor pathways are implicated in delirium caused by baclofen withdrawal?",
            "answer": "The correct answer is:\n\nC. The GABAB receptor signaling pathway.\n\nBaclofen works by activating GABAB receptors, so its abrupt withdrawal leads to a decrease in inhibitory neurotransmitter activity, contributing to delirium symptoms.",
            "pmid": [
                "pmid28673598",
                "pmid37313848",
                "pmid34123673",
                "pmid7916159",
                "pmid8740986",
                "pmid19422109",
                "pmid38566855",
                "pmid14682360",
                "pmid39419070",
                "pmid22934024"
            ]
        },
        "pathway_223": {
            "question": "How does miR-219-5p affect tau phosphorylation via TTBK1 and GSK-3beta in the context of delirium associated with Alzheimer’s disease?",
            "answer": "I'm sorry, an unexpected error occurred while processing your question. Please try again later.",
            "pmid": null
        },
        "pathway_224": {
            "question": "What neuropeptides are involved in the brain's response during delirium caused by distant organ damage?",
            "answer": "C. Beta-endorphin, orexin, and oxytocin levels increase in the brain without associated cytokine elevation.",
            "pmid": [
                "pmid26711566",
                "pmid20309566",
                "pmid7916159",
                "pmid24557038",
                "pmid39839987",
                "pmid28673598",
                "pmid38566855",
                "pmid39419070",
                "pmid32592865",
                "pmid37313848"
            ]
        },
        "pathway_225": {
            "question": "How does abrupt zolpidem withdrawal affect neurotransmitter systems in the development of delirium?",
            "answer": "The correct answer is **C. It disrupts neurotransmitter systems, specifically impairing gamma-aminobutyric acid (GABA) signaling.**\n\n**Explanation:**\nZolpidem works by enhancing GABA activity, which promotes sleep. Abrupt withdrawal leads to a sudden decrease in GABA signaling, causing overactivity in the brain and symptoms like delirium. The case study supports this mechanism, and treatment with a benzodiazepine (lorazepam), which also affects GABA receptors, was effective.",
            "pmid": [
                "pmid37313848",
                "pmid38024021",
                "pmid27760517",
                "pmid32018069",
                "pmid28673598",
                "pmid38895540",
                "pmid39541802",
                "pmid34978",
                "pmid21039634",
                "pmid22553034"
            ]
        },
        "pathway_226": {
            "question": "What cytokine changes are associated with postoperative delirium after esophagectomy?",
            "answer": "The most appropriate answer is:\n\n**C. Elevated levels of interleukin-8 (IL-8) and interleukin-10 (IL-10).**\n\nThis conclusion is based on the study that specifically examined esophagectomy patients, showing increased IL-8 and IL-10 in those with delirium, supported by findings from other studies.\n\n**Answer:** C",
            "pmid": [
                "pmid33774004",
                "pmid36224337",
                "pmid24345656",
                "pmid18314455",
                "pmid34044881",
                "pmid33409674",
                "pmid35180288",
                "pmid35791660",
                "pmid25368603",
                "pmid24093540"
            ]
        },
        "pathway_227": {
            "question": "What are the mechanisms through which valproic acid modulates delirium?",
            "answer": "The mechanisms through which valproic acid modulates delirium are best described in option C. Valproic acid works through neurotransmitter modulation, neuroinflammation, oxidative stress, and transcriptional changes, as detailed in the provided context.\n\n**Answer:**  \nC. Through neurotransmitter modulation, neuroinflammation, oxidative stress, and transcriptional changes.",
            "pmid": [
                "pmid26674479",
                "pmid39210294",
                "pmid28673598",
                "pmid39419070",
                "pmid36677060",
                "pmid19422109",
                "pmid7916159",
                "pmid37313848",
                "pmid34978",
                "pmid37993790"
            ]
        },
        "pathway_228": {
            "question": "Which signaling pathway is regulated by miR-539-5p in Alzheimer's disease?",
            "answer": "The signaling pathway regulated by miR-539-5p in Alzheimer's disease is the **PI3K/AKT/GSK-3β signaling pathway**. This conclusion is based on the information from pmid32415525, which states that miR-539-5p targets GSK-3β and regulates this pathway.\n\nAnswer: C. PI3K/AKT/GSK-3beta signaling pathway\n\nThe answer is:\n\nC. PI3K/AKT/GSK-3beta signaling pathway",
            "pmid": [
                "pmid32415525",
                "pmid34992508",
                "pmid33915734",
                "pmid31134481",
                "pmid32092796",
                "pmid23990414",
                "pmid26398571",
                "pmid27235866",
                "pmid34026326",
                "pmid36214709"
            ]
        },
        "pathway_229": {
            "question": "What is the role of synaptosomal miRNAs in Alzheimer's disease?",
            "answer": "The role of synaptosomal miRNAs in Alzheimer's disease involves their upregulation during disease progression. These miRNAs play a significant role in synapse function, nervous system development, and GABAergic synapse activity.\n\n**Answer: B. They are upregulated during disease progression and are involved in synapse function, nervous system development, and GABAergic synapse activity.**",
            "pmid": [
                "pmid35941185",
                "pmid31997075",
                "pmid29378298",
                "pmid35154541",
                "pmid39868313",
                "pmid22926857",
                "pmid32092796",
                "pmid32035423",
                "pmid29643768",
                "pmid37192007"
            ]
        }
    },
    "metabolism": {
        "metabolism_0": {
            "question": "Does isoforsythiaside (IFY) improve mitochondrial function to protect against Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nIsoforsythiaside (IFY) improves mitochondrial function by inhibiting apoptosis and enhancing cell viability through the PI3K/AKT pathway, thereby protecting against Alzheimer's disease as demonstrated in studies with transgenic models and Abeta-induced cells.\n\nNew Answer:\n\nThe answer is based on pmid32784451, which provides evidence that IFY improves mitochondrial function by inhibiting apoptosis and enhancing cell viability through the PI3K/AKT pathway. Therefore, the correct answer is:\n\n**A. Yes**\n\nAnswer: A",
            "pmid": [
                "pmid32784451",
                "pmid36012451",
                "pmid29873184",
                "pmid23226091",
                "pmid28186562",
                "pmid35857717",
                "pmid26708452",
                "pmid34440878",
                "pmid30171839",
                "pmid26581638"
            ]
        },
        "metabolism_1": {
            "question": "Are alterations in purine metabolism observed in the frontal cortex at early stages of Alzheimer's disease?",
            "answer": "Yes, alterations in purine metabolism are observed in the frontal cortex at early stages of Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid29363833",
                "pmid25311278",
                "pmid19940172",
                "pmid26855936",
                "pmid21035308",
                "pmid3165303",
                "pmid24746363",
                "pmid18241242",
                "pmid25212911",
                "pmid7936052"
            ]
        },
        "metabolism_2": {
            "question": "Does TFR1 knockdown alleviate iron overload and mitochondrial dysfunction in neural cells differentiated from Alzheimer's disease-derived induced pluripotent stem cells?",
            "answer": "The contextual information supports the conclusion that knocking down TFR1 alleviates iron overload and mitochondrial dysfunction. Therefore:\n\nAnswer: A",
            "pmid": [
                "pmid38321571",
                "pmid35453377",
                "pmid22746342",
                "pmid38296900",
                "pmid30042655",
                "pmid39730291",
                "pmid29424844",
                "pmid22717236",
                "pmid23262393",
                "pmid24863668"
            ]
        },
        "metabolism_3": {
            "question": "Does ergothioneine (ET) have a protective effect against mitochondrial damage caused by 7-ketocholesterol in human brain endothelial cells, which could be relevant to Alzheimer's disease?",
            "answer": "The provided context information clearly indicates that ergothioneine (ET) has a protective effect against mitochondrial damage caused by 7-ketocholesterol in human brain endothelial cells. This is demonstrated in pmid36982572, where ET significantly reduced the effects of 7-KC-induced mitochondrial damage. Given the relevance of mitochondrial dysfunction to Alzheimer's disease, this finding suggests a potential protective role for ET in conditions like Alzheimer's.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid36982572",
                "pmid38334622",
                "pmid35370675",
                "pmid28274813",
                "pmid12671307",
                "pmid21116051",
                "pmid38729530",
                "pmid9106616",
                "pmid31927055",
                "pmid30514054"
            ]
        },
        "metabolism_4": {
            "question": "Does impaired vitamin B12 availability contribute to the development of Alzheimer's disease through ER stress pathways?",
            "answer": "Yes, impaired vitamin B12 availability can contribute to Alzheimer's disease (AD) development via ER stress pathways. Vitamin B12 deficiency increases homocysteine levels (hyperhomocysteinemia), a risk factor for AD and vascular cognitive impairment. Additionally, B12 deficiency leads to oxidative stress and triggers ER stress markers like GRP78 and CHOP in cells, which can contribute to neurodegeneration associated with AD.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid36010649",
                "pmid30823595",
                "pmid23224755",
                "pmid23519122",
                "pmid24554143",
                "pmid18525129",
                "pmid20209467",
                "pmid16088136",
                "pmid15207414",
                "pmid30429785"
            ]
        },
        "metabolism_5": {
            "question": "Does Corchorus depressus (Cd) exhibit potential as an antioxidant and inhibitor of enzymes relevant to Alzheimer's disease?",
            "answer": "**Answer:** Yes, Corchorus depressus exhibits potential as an antioxidant and inhibitor of enzymes relevant to Alzheimer's disease.\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Information:** The first reference (pmid29200727) specifically discusses Corchorus depressus (Cd). It mentions that Cd has strong antioxidant activity and inhibits enzymes like AChE and BChE, which are relevant to Alzheimer's disease.\n\n2. **Assess Relevance of Other References:** The other references discuss different compounds or plants but do not mention Cd, so they don't contribute to answering the query about Cd.\n\n3. **Conclusion:** Based on the first reference, Cd shows potential as an antioxidant and enzyme inhibitor in the context of Alzheimer's disease.\n\n**Final Answer: A. Yes**\n\nAnswer:\nA. Yes",
            "pmid": [
                "pmid29200727",
                "pmid32160161",
                "pmid17886039",
                "pmid38355004",
                "pmid28406733",
                "pmid35691153",
                "pmid38347285",
                "pmid25506036",
                "pmid38954263",
                "pmid29112116"
            ]
        },
        "metabolism_6": {
            "question": "Does catalpol improve mitochondrial function in N2a/APP695swe cells, which is relevant to Alzheimer's disease?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid30171839",
                "pmid37336148",
                "pmid36012451",
                "pmid32477145",
                "pmid29873184",
                "pmid22935417",
                "pmid35815283",
                "pmid9169522",
                "pmid35699892",
                "pmid22077634"
            ]
        },
        "metabolism_7": {
            "question": "Does impaired mitochondrial biogenesis contribute to mitochondrial dysfunction in Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid22077634",
                "pmid19667196",
                "pmid21545753",
                "pmid9169522",
                "pmid26221414",
                "pmid16677790",
                "pmid39880979",
                "pmid35969330",
                "pmid32084533",
                "pmid16873963"
            ]
        },
        "metabolism_8": {
            "question": "Is anosognosia independently associated with hypometabolism in specific brain regions in Alzheimer's disease?",
            "answer": "The key study (pmid29022655) directly links anosognosia to hypometabolism in specific brain regions like the posterior cingulate cortex and precuneus, indicating an independent association.\n\n**Answer: A. Yes**\n\nANSWER:\nA. Yes",
            "pmid": [
                "pmid7580194",
                "pmid29022655",
                "pmid31161466",
                "pmid11276052",
                "pmid19940172",
                "pmid25820930",
                "pmid38511196",
                "pmid25267349",
                "pmid21035308",
                "pmid9605726"
            ]
        },
        "metabolism_9": {
            "question": "Does the regulation of cholesterol metabolism by cis- and trans-palmitoleic acid isomers have any known association with delirium?",
            "answer": "The regulation of cholesterol metabolism by cis- and trans-palmitoleic acid isomers does not have a known direct association with delirium based on the provided context. While both involve pathways related to inflammation and HMG-CoA reductase, there's no explicit link established in the information given.\n\nAnswer: B. No",
            "pmid": [
                "pmid33363473",
                "pmid7211434",
                "pmid38223851",
                "pmid33779822",
                "pmid38566855",
                "pmid39519398",
                "pmid3765988",
                "pmid37722373",
                "pmid17234821",
                "pmid32691721"
            ]
        },
        "metabolism_10": {
            "question": "Does Apolipoprotein E4 (ApoE4) suppress mitochondrial function via the PGC-1alpha-Sirt3 pathway, contributing to Alzheimer's disease?",
            "answer": "The question asks whether Apolipoprotein E4 (ApoE4) suppresses mitochondrial function via the PGC-1alpha-Sirt3 pathway, contributing to Alzheimer's disease. \n\nFrom the provided abstracts, pmid31808750 directly addresses this by showing that ApoE4 mice have lower levels of Sirt3 and PGC-1alpha, leading to mitochondrial dysfunction. Additionally, manipulating Sirt3 levels affected ATP production and oxygen consumption in neurons, indicating a role for the PGC-1alpha-Sirt3 pathway. Other studies support mitochondrial issues in ApoE4 but do not specifically mention this pathway.\n\nAnswer: A. Yes",
            "pmid": [
                "pmid36753858",
                "pmid31808750",
                "pmid32457210",
                "pmid30032423",
                "pmid10366621",
                "pmid34486652",
                "pmid21545753",
                "pmid37854772",
                "pmid35969330",
                "pmid38217595"
            ]
        },
        "metabolism_11": {
            "question": "Does the d-enantiomeric decapeptide inhibit Cu2+-mediated amyloid beta-protein aggregation, a process linked to Alzheimer's disease?",
            "answer": "Yes, the d-enantiomeric decapeptide inhibits Cu2+-mediated amyloid beta-protein aggregation. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid30650306",
                "pmid32264585",
                "pmid22422637",
                "pmid29372182",
                "pmid19324459",
                "pmid39361095",
                "pmid22992731",
                "pmid20634578",
                "pmid22844264",
                "pmid24333930"
            ]
        },
        "metabolism_12": {
            "question": "Does di-O-demethylcurcumin protect against neuronal death in Alzheimer's disease by suppressing mitochondrial and ER stress pathways?",
            "answer": "Based on the context provided, di-O-demethylcurcumin has been shown to protect against neuronal death in Alzheimer's disease models. The study in pmid25451798 specifically demonstrates that di-O-demethylcurcumin improves cell viability and decreases apoptosis in SK-N-SH cells treated with Abeta25-35. It suppresses both mitochondrial apoptosis by regulating Bcl-XL/Bax ratio, reducing ROS levels, cytochrome c release, and caspase activity, as well as ER stress pathways by downregulating PERK, IRE1, ATF6, CHOP, and cleaved caspase-12. Therefore, the answer is:\n\n**Answer: A. Yes**\n\nThe studies suggest that di-O-demethylcurcumin effectively protects against neuronal death by suppressing both mitochondrial apoptosis and ER stress pathways in Alzheimer's disease models.",
            "pmid": [
                "pmid25451798",
                "pmid26358194",
                "pmid27521081",
                "pmid22886017",
                "pmid28854504",
                "pmid26264395",
                "pmid22476982",
                "pmid30746607",
                "pmid26971524",
                "pmid35857717"
            ]
        },
        "metabolism_13": {
            "question": "Does the mitochondrial permeability transition pore contribute to mitochondrial dysfunction in fibroblasts of patients with sporadic Alzheimer's disease?",
            "answer": "The study by pmid30199818 directly demonstrates that mPTP activation contributes to mitochondrial dysfunction in sporadic Alzheimer's disease fibroblasts. Blocking mPTP with Cyclosporine A improves calcium dysregulation, supporting this conclusion.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid30199818",
                "pmid27713335",
                "pmid29056898",
                "pmid30171839",
                "pmid9169522",
                "pmid21545753",
                "pmid22077634",
                "pmid18599615",
                "pmid19667196",
                "pmid35969330"
            ]
        },
        "metabolism_14": {
            "question": "Does docosahexaenoic acid (DHA) modulation of the Nrf2/HO-1 pathway have potential implications for nutraceutical therapy in Alzheimer's disease?",
            "answer": "B\n\nAnswer: B",
            "pmid": [
                "pmid26965310",
                "pmid18037281",
                "pmid21606627",
                "pmid31677009",
                "pmid35782939",
                "pmid24374316",
                "pmid15788759",
                "pmid23645098",
                "pmid28284721",
                "pmid32486013"
            ]
        },
        "metabolism_15": {
            "question": "Does the suppression of neuronal cholesterol biosynthesis contribute to the pathogenesis of Alzheimer's disease through impaired IGF-1-Akt signaling?",
            "answer": "The suppression of neuronal cholesterol biosynthesis contributes to Alzheimer's disease pathogenesis by impairing IGF-1-Akt signaling.\n\nAnswer: A. Yes",
            "pmid": [
                "pmid34671194",
                "pmid26370080",
                "pmid27155148",
                "pmid16246039",
                "pmid21448224",
                "pmid26095650",
                "pmid37011864",
                "pmid17080199",
                "pmid22626060",
                "pmid12600718"
            ]
        },
        "metabolism_16": {
            "question": "Does the silencing of LncRNA BDNF-AS reduce oxidative stress in PC12 cells modeling Alzheimer's disease?",
            "answer": "The study by pmid29902125 indicates that silencing LncRNA BDNF-AS reduces oxidative stress in PC12 cells by lowering ROS and MDA levels while increasing SOD and CAT activities.\n\n**Answer: A. Yes**\n\nA. Yes",
            "pmid": [
                "pmid29902125",
                "pmid37286157",
                "pmid34990931",
                "pmid37217807",
                "pmid12203047",
                "pmid18706502",
                "pmid17344400",
                "pmid36092938",
                "pmid33234729",
                "pmid29634233"
            ]
        },
        "metabolism_17": {
            "question": "Does dietary lipophilic iron influence amyloidogenesis in Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid29424844",
                "pmid30791980",
                "pmid28890316",
                "pmid18525129",
                "pmid17628213",
                "pmid32444869",
                "pmid24199959",
                "pmid21971404",
                "pmid35391749",
                "pmid35453377"
            ]
        },
        "metabolism_18": {
            "question": "Is HMGA1 implicated in the regulation of glucose metabolism, which may have implications for Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid30034366",
                "pmid17284348",
                "pmid19446537",
                "pmid36204837",
                "pmid20450896",
                "pmid33912566",
                "pmid26855936",
                "pmid21035308",
                "pmid38565291",
                "pmid36206930"
            ]
        },
        "metabolism_19": {
            "question": "Does Sirtuin3-dependent mitochondrial redox homeostasis have a protective role against AGEs-induced intervertebral disc degeneration, potentially relevant to Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid31808750",
                "pmid24046746",
                "pmid26045440",
                "pmid19667196",
                "pmid9169522",
                "pmid36056557",
                "pmid30216853",
                "pmid32457210",
                "pmid30362958",
                "pmid16873963"
            ]
        },
        "metabolism_20": {
            "question": "Does the methanolic extract of Teucrium stocksianum (METS) demonstrate potential benefits in managing oxidative stress, which is implicated in Alzheimer's disease?",
            "answer": "A: Yes\nNew Answer: A",
            "pmid": [
                "pmid32160161",
                "pmid36295014",
                "pmid26845710",
                "pmid37373177",
                "pmid26068423",
                "pmid24893601",
                "pmid27774420",
                "pmid29081887",
                "pmid28643520",
                "pmid36708701"
            ]
        },
        "metabolism_21": {
            "question": "Does the oxidation of methionine 35 in the amyloid beta-peptide (1-42) reduce toxicity in neuroblastoma cells by enhancing the expression and function of methionine sulfoxide reductase A (MsrA), which has implications for Alzheimer's disease?",
            "answer": "The question asks if oxidizing methionine 35 in amyloid-beta (1-42) reduces toxicity by enhancing MsrA expression and function. The provided context doesn't address this directly but does discuss Abeta's role in neurotoxicity, mitochondrial issues, and oxidative stress. However, without specific info on methionine 35 or MsrA, the original answer stands.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid20060866",
                "pmid15207347",
                "pmid38275641",
                "pmid10535332",
                "pmid15680223",
                "pmid32597804",
                "pmid23579332",
                "pmid11181824",
                "pmid20463406",
                "pmid20164580"
            ]
        },
        "metabolism_22": {
            "question": "Does the fixed combination of citicoline, coenzyme Q10, and vitamin B3 have synergistic protective effects on neuronal cells relevant to Alzheimer's disease?",
            "answer": "The study specifically examining the combination of citicoline, CoQ10, and vitamin B3 found synergistic protective effects against oxidative stress in neuronal cells. This supports their use in protecting against Alzheimer's-related damage.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35889920",
                "pmid22186599",
                "pmid12917750",
                "pmid26881107",
                "pmid11592111",
                "pmid38203753",
                "pmid31606373",
                "pmid23537659",
                "pmid12119423",
                "pmid29120942"
            ]
        },
        "metabolism_23": {
            "question": "Does tacrine treatment improve glucose metabolism in Alzheimer patients as shown by PET scans?",
            "answer": "The provided context does not contain any information about tacrine treatment or its effects on glucose metabolism in Alzheimer's patients. Therefore, based on the given context, it is unrelated to the question asked.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid8128843",
                "pmid1491741",
                "pmid9065319",
                "pmid7906947",
                "pmid7902055",
                "pmid26855936",
                "pmid19940172",
                "pmid33086751",
                "pmid21035308",
                "pmid25212911"
            ]
        },
        "metabolism_24": {
            "question": "Does thymoquinone (TQ) show potential for treating Alzheimer's disease by reducing oxidative stress and mitochondrial dysfunction in PC 12 cells exposed to Abeta(25-35)?",
            "answer": "A: A",
            "pmid": [
                "pmid22752387",
                "pmid23537659",
                "pmid30623116",
                "pmid24101432",
                "pmid34570578",
                "pmid35440326",
                "pmid25405415",
                "pmid36012451",
                "pmid39521153",
                "pmid34046075"
            ]
        },
        "metabolism_25": {
            "question": "Can tyrosine modifications of the insulin-degrading enzyme (IDE) help in controlling the substrate specificity for Alzheimer's disease?",
            "answer": "The study in pmid39481143 demonstrates that modifying tyrosine residues in IDE with Cookson reagent altered its substrate specificity, leading to increased Abeta degradation without affecting insulin. This suggests that such modifications could be a targeted approach for treating Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid39481143",
                "pmid15590928",
                "pmid27320287",
                "pmid12161276",
                "pmid29132916",
                "pmid26444774",
                "pmid17496198",
                "pmid18996360",
                "pmid30422705",
                "pmid26651592"
            ]
        },
        "metabolism_26": {
            "question": "Does mitochondrial dihydrolipoyl succinyltransferase (DLST) deficiency contribute to Alzheimer's disease?",
            "answer": "The provided context indicates that mitochondrial dihydrolipoyl succinyltransferase (DLST) deficiency contributes to Alzheimer's disease by increasing amyloid plaques, Abeta oligomers, and oxidative stress, as well as worsening cognitive deficits in mouse models. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid19596066",
                "pmid11464464",
                "pmid16873963",
                "pmid10873585",
                "pmid16677790",
                "pmid18599615",
                "pmid33580194",
                "pmid35969330",
                "pmid32457210",
                "pmid15126281"
            ]
        },
        "metabolism_27": {
            "question": "Does PFKM play a role in enhancing oxidative phosphorylation and glycolysis, which might be relevant to Alzheimer's disease?",
            "answer": "The role of PFKM in enhancing oxidative phosphorylation (OXPHOS) and glycolysis has been observed in the context of cardiotoxicity. Given that Alzheimer's disease involves mitochondrial dysfunction, including issues with OXPHOS and glycolysis, it is plausible that PFKM could play a relevant role in mitigating these processes in AD as well.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35804014",
                "pmid3165303",
                "pmid26855936",
                "pmid7936052",
                "pmid35969330",
                "pmid31520071",
                "pmid32084533",
                "pmid1990207",
                "pmid10095092",
                "pmid2376771"
            ]
        },
        "metabolism_28": {
            "question": "Does donepezil reduce mitochondrial amyloid-beta accumulation in Alzheimer's disease models?",
            "answer": "A: Yes; B. No  \nBased on the provided context, donepezil reduces mitochondrial amyloid-beta accumulation in Alzheimer's disease models as shown by pmid25744714.\n\n**Answer:** A",
            "pmid": [
                "pmid25744714",
                "pmid27002982",
                "pmid29873184",
                "pmid23783773",
                "pmid29434777",
                "pmid11830754",
                "pmid35850693",
                "pmid25662507",
                "pmid26581638",
                "pmid17939763"
            ]
        },
        "metabolism_29": {
            "question": "Does miR-494-3p play a role in the degeneration of retinal pigment epithelial cells by influencing mitochondrial integrity, which could be relevant to Alzheimer's disease or delirium?",
            "answer": "B) No",
            "pmid": [
                "pmid37163276",
                "pmid34026326",
                "pmid33575111",
                "pmid32950103",
                "pmid34958029",
                "pmid24604632",
                "pmid27235866",
                "pmid29369410",
                "pmid31134481",
                "pmid31181293"
            ]
        },
        "metabolism_30": {
            "question": "Does ATP interaction with amyloid-beta protein have potential significance to Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid24625803",
                "pmid38584155",
                "pmid32915536",
                "pmid31830415",
                "pmid30362042",
                "pmid38791223",
                "pmid20634578",
                "pmid29441941",
                "pmid21464905",
                "pmid8915608"
            ]
        },
        "metabolism_31": {
            "question": "Does Schisandrin B diet alleviate hepatotoxicity by inhibiting oxidative stress and ferroptosis, which could have implications for Alzheimer's disease or delirium?",
            "answer": "A. Yes",
            "pmid": [
                "pmid22666518",
                "pmid36060128",
                "pmid33542629",
                "pmid23224755",
                "pmid35204177",
                "pmid18037281",
                "pmid30475761",
                "pmid37780805",
                "pmid38492808",
                "pmid37018970"
            ]
        },
        "metabolism_32": {
            "question": "Does metformin alleviate lead-induced mitochondrial fragmentation via AMPK/Nrf2 activation in SH-SY5Y cells, which is relevant to Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid32863218",
                "pmid28611284",
                "pmid37483818",
                "pmid34283253",
                "pmid32580040",
                "pmid30958364",
                "pmid39441380",
                "pmid27467571",
                "pmid30909226",
                "pmid38139841"
            ]
        },
        "metabolism_33": {
            "question": "Does the chloroform fraction of Stephania japonica inhibit acetylcholinesterase and oxidative stress, which are relevant to Alzheimer's disease?",
            "answer": "The chloroform fraction of Stephania japonica effectively inhibits acetylcholinesterase and exhibits potent antioxidant activity, both of which are pertinent to Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35237756",
                "pmid28643520",
                "pmid32160161",
                "pmid38355004",
                "pmid32148536",
                "pmid26845710",
                "pmid29080453",
                "pmid28930532",
                "pmid27774420",
                "pmid36535434"
            ]
        },
        "metabolism_34": {
            "question": "Does piracetam improve mitochondrial function in cells exposed to beta-amyloid, which is implicated in Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nPiracetam has been shown to enhance mitochondrial function in cells exposed to beta-amyloid (Abeta), a key factor implicated in Alzheimer's disease. Studies indicate that piracetam increases ATP production, restores mitochondrial membrane potential, and improves cellular morphology under Abeta-induced stress, thereby providing protection against oxidative damage and promoting neurite outgrowth. These findings consistently support the conclusion that piracetam has beneficial effects on mitochondrial function in this context.",
            "pmid": [
                "pmid24059528",
                "pmid20218980",
                "pmid20877425",
                "pmid27747106",
                "pmid29873184",
                "pmid37373177",
                "pmid30922179",
                "pmid32457210",
                "pmid26581638",
                "pmid38729530"
            ]
        },
        "metabolism_35": {
            "question": "Does curcumin enhance mitochondrial fusion activity and reduce fission machinery in Alzheimer's disease-like neurons?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid27521081",
                "pmid22886017",
                "pmid22476982",
                "pmid24755072",
                "pmid27594837",
                "pmid28854504",
                "pmid30746607",
                "pmid21253949",
                "pmid27060945",
                "pmid39507234"
            ]
        },
        "metabolism_36": {
            "question": "Does copper deficiency during inflammation affect the expression of proteins involved in iron metabolism, potentially linking to Alzheimer's disease?",
            "answer": "Yes, copper deficiency during inflammation can affect the expression of proteins involved in iron metabolism, which may have implications for conditions like Alzheimer's disease.\n\n**Answer: A. Yes**\n\nStep-by-Step Explanation:\n\n1. **Copper Deficiency Impact**: Studies show that copper deficiency affects proteins such as ceruloplasmin and ferroportin, crucial for iron metabolism. This disruption can lead to altered iron transport and distribution in the body.\n\n2. **Inflammation's Role**: Inflammatory conditions, marked by increased interleukin-6 (IL-6), exacerbate these effects. Inflammation can lead to further changes in protein expression, compounding the impact on iron metabolism.\n\n3. **Link to Alzheimer's Disease**: Research indicates that copper dysregulation is present in some Alzheimer's disease patients, with elevated non-ceruloplasmin copper levels and associations with gene variants affecting copper homeostasis. Additionally, low copper levels can disrupt amyloid-beta (Abeta) regulation, a key factor in Alzheimer's progression.\n\n4. **Conclusion**: The interplay between copper deficiency, inflammation, and iron metabolism suggests a potential pathway linking these factors to Alzheimer's disease. This highlights the importance of balanced copper levels in maintaining proper brain function and preventing neurodegenerative conditions.\n\n**Final Answer: A. Yes**",
            "pmid": [
                "pmid28118841",
                "pmid27729845",
                "pmid25066791",
                "pmid23760784",
                "pmid24748564",
                "pmid20626553",
                "pmid34209820",
                "pmid28669331",
                "pmid23959870",
                "pmid37047347"
            ]
        },
        "metabolism_37": {
            "question": "Does diazoxide pretreatment prevent oxidative stress in cholinergic neurons related to Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid24771316",
                "pmid26496862",
                "pmid22551949",
                "pmid8725383",
                "pmid21351586",
                "pmid12203047",
                "pmid37343463",
                "pmid11767950",
                "pmid11487523",
                "pmid31463415"
            ]
        },
        "metabolism_38": {
            "question": "Does the tumor stroma of metastasis-prone breast cancer patients show transcriptional similarities to Alzheimer's disease?",
            "answer": "The tumor stroma of metastasis-prone breast cancer patients does show transcriptional similarities to Alzheimer's disease based on the provided abstracts. \n\n**Answer:** A. Yes",
            "pmid": [
                "pmid20442453",
                "pmid28719625",
                "pmid23691268",
                "pmid38225990",
                "pmid22367434",
                "pmid29634233",
                "pmid31608105",
                "pmid38685540",
                "pmid28694093",
                "pmid10817927"
            ]
        },
        "metabolism_39": {
            "question": "Does increased cerebral glucose metabolism correlate with worse verbal memory performance in Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid21035308",
                "pmid38102439",
                "pmid19940172",
                "pmid26855936",
                "pmid37123373",
                "pmid25212911",
                "pmid33994936",
                "pmid16286547",
                "pmid36206930",
                "pmid36204837"
            ]
        },
        "metabolism_40": {
            "question": "Does the dysregulation of iron metabolism in Parkinson's disease (PD) occur in a similar manner in Alzheimer's disease?",
            "answer": "The dysregulation of iron metabolism in Parkinson's disease (PD) involves localized iron overload leading to oxidative stress and alpha-synuclein aggregation. In contrast, Alzheimer's disease (AD) exhibits mixed patterns, including both local iron accumulation near plaques and systemic deficiencies, with mechanisms involving ferroptosis and interactions between iron, amyloid-beta, and tau proteins. Therefore, the manner of dysregulation differs significantly.\n\n**Answer: B. No**",
            "pmid": [
                "pmid31687080",
                "pmid27039308",
                "pmid15665414",
                "pmid33799121",
                "pmid22754573",
                "pmid24199959",
                "pmid28890316",
                "pmid21971404",
                "pmid35391749",
                "pmid35453377"
            ]
        },
        "metabolism_41": {
            "question": "Does Orexin-A exacerbate Alzheimer's disease by inducing mitochondrial impairment?",
            "answer": "A: A\n\nNew Answer: Yes, Orexin-A exacerbates Alzheimer's disease by inducing mitochondrial impairment. Studies have shown that Orexin-A worsens cognitive deficits in AD models, increases amyloid-beta levels, and causes mitochondrial dysfunction such as impaired ATP production and oxidative stress. Additionally, Orexin-A reduces mitochondrial biogenesis and increases mitophagy, further contributing to mitochondrial damage associated with AD progression.",
            "pmid": [
                "pmid31927055",
                "pmid33080054",
                "pmid36280008",
                "pmid38682858",
                "pmid32457210",
                "pmid35969330",
                "pmid30288371",
                "pmid37843792",
                "pmid16873963",
                "pmid38729530"
            ]
        },
        "metabolism_42": {
            "question": "Does the inhibition of the mitochondrial Na+/Ca2+ exchanger (NCLX) contribute to neurodegeneration in Alzheimer's disease?",
            "answer": "The study by pmid31918031 directly demonstrates that tau protein inhibits the mitochondrial Na+/Ca2+ exchanger (NCLX), which results in mitochondrial depolarization and increased vulnerability to calcium-induced cell death. This finding indicates a significant role of NCLX inhibition in neurodegenerative processes associated with Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid12203047",
                "pmid25102327",
                "pmid32967303",
                "pmid29873184",
                "pmid32656500",
                "pmid9169522",
                "pmid22935417",
                "pmid30922179",
                "pmid31918031",
                "pmid30288371"
            ]
        },
        "metabolism_43": {
            "question": "Does IMM-H004 protect neuronal mitochondrial function in Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid23523945",
                "pmid23226091",
                "pmid29873184",
                "pmid32457210",
                "pmid27444386",
                "pmid36753858",
                "pmid26581638",
                "pmid28186562",
                "pmid38729530",
                "pmid39713820"
            ]
        },
        "metabolism_44": {
            "question": "Does Salvianolic acid B protect against mitochondrial dysfunction in Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid29551684",
                "pmid23703159",
                "pmid36012451",
                "pmid29873184",
                "pmid38729530",
                "pmid36770835",
                "pmid18037281",
                "pmid23226091",
                "pmid37373177",
                "pmid21606627"
            ]
        },
        "metabolism_45": {
            "question": "Does UDCA improve mitochondrial function in fibroblasts from patients with Alzheimer's disease?",
            "answer": "Yes.\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Information:** The study in pmid30171839 directly addresses UDCA's effect on mitochondrial function in AD fibroblasts, showing improvements.\n2. **Evaluate Other Studies:** Other studies discuss mitochondrial issues but don't mention UDCA, so they don't affect the answer.\n3. **Conclusion:** Based solely on pmid30171839, UDCA does improve mitochondrial function.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid30171839",
                "pmid9169522",
                "pmid30199818",
                "pmid29056898",
                "pmid36012451",
                "pmid22077634",
                "pmid32457210",
                "pmid30922179",
                "pmid22935417",
                "pmid32084533"
            ]
        },
        "metabolism_46": {
            "question": "Does the pattern of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen?",
            "answer": "The pattern of glucose hypometabolism in Down syndrome does resemble sporadic Alzheimer's disease, with the exception of activity in the putamen.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid33490360",
                "pmid29254096",
                "pmid14694028",
                "pmid29977201",
                "pmid32258359",
                "pmid32962300",
                "pmid10666665",
                "pmid15068237",
                "pmid39307112",
                "pmid36204837"
            ]
        },
        "metabolism_47": {
            "question": "Does Zuo Gui Wan (ZGW) improve cognitive function in Alzheimer's disease (AD) animal models by inhibiting mitochondrial fission and activating AMPK/PGC-1alpha-regulated mitochondrial bioenergetics?",
            "answer": "The answer is A: Yes.\n\n**Step-by-Step Explanation:**\n\n1. **Understanding the Question:** The question asks whether Zuo Gui Wan (ZGW) improves cognitive function in Alzheimer's disease (AD) animal models by inhibiting mitochondrial fission and activating AMPK/PGC-1alpha-regulated mitochondrial bioenergetics.\n\n2. **Reviewing Relevant Context:** From pmid39884486, it is stated that ZGW enhances cognitive performance in APP/PS1 mice. It specifically mentions that ZGW inhibits mitochondrial fission by suppressing phosphorylated Drp1 and activates the AMPK/PGC-1alpha pathway, which improves mitochondrial function.\n\n3. **Conclusion:** The provided context directly supports that ZGW works through these mechanisms to improve cognitive function in AD models.\n\n**Answer: A. Yes**\n\nFinal Answer:\nA\n\nAnswer: \nA",
            "pmid": [
                "pmid39884486",
                "pmid39873362",
                "pmid38575939",
                "pmid30742114",
                "pmid36918872",
                "pmid35360200",
                "pmid29843688",
                "pmid31100304",
                "pmid21368864",
                "pmid30922179"
            ]
        },
        "metabolism_48": {
            "question": "Does sialic acid metabolism play a role in Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid33867926",
                "pmid33991608",
                "pmid28320965",
                "pmid12203047",
                "pmid26855936",
                "pmid29093468",
                "pmid31087219",
                "pmid38529039",
                "pmid29363833",
                "pmid36089405"
            ]
        },
        "metabolism_49": {
            "question": "Does mannose consumption exacerbate Alzheimer's disease pathogenesis?",
            "answer": "A: Yes",
            "pmid": [
                "pmid39807036",
                "pmid37781122",
                "pmid17942401",
                "pmid24326116",
                "pmid24411482",
                "pmid20209467",
                "pmid19088473",
                "pmid33991608",
                "pmid8761018",
                "pmid15788759"
            ]
        },
        "metabolism_50": {
            "question": "Does maternal choline supplementation reduce brain homocysteine levels and improve cognitive deficits in Alzheimer's disease across multiple generations?",
            "answer": "**Answer: A. Yes**\n\nMaternal choline supplementation has been shown to reduce brain homocysteine levels and improve cognitive deficits in Alzheimer's disease across multiple generations, as demonstrated by studies using APP/PS1 mice models.",
            "pmid": [
                "pmid30622336",
                "pmid31560162",
                "pmid37214805",
                "pmid38904658",
                "pmid31298459",
                "pmid23224755",
                "pmid19088473",
                "pmid11455131",
                "pmid16088136",
                "pmid15207414"
            ]
        },
        "metabolism_51": {
            "question": "Does Codonopsis pilosula Polysaccharides alleviate energy dysmetabolism in Alzheimer's disease?",
            "answer": "The most appropriate answer is:\n\nA: Yes",
            "pmid": [
                "pmid34102973",
                "pmid30542264",
                "pmid32652518",
                "pmid36535434",
                "pmid30290256",
                "pmid33432644",
                "pmid37781122",
                "pmid37373177",
                "pmid33913927",
                "pmid25498712"
            ]
        },
        "metabolism_52": {
            "question": "Does mitochondrial dysfunction in the proximal axon initial segment contribute to TAU missorting observed in Alzheimer's disease?",
            "answer": "The answer based on the provided information is:\n\nUNRELATED",
            "pmid": [
                "pmid29623026",
                "pmid21545753",
                "pmid30006151",
                "pmid29895248",
                "pmid32882957",
                "pmid25888814",
                "pmid32851560",
                "pmid39584307",
                "pmid16677790",
                "pmid26221414"
            ]
        },
        "metabolism_53": {
            "question": "Is there a significant difference in homocysteine metabolism between Alzheimer's disease patients and vascular dementia patients as shown by the methionine loading test?",
            "answer": "The methionine loading test did not show a significant difference in homocysteine metabolism between Alzheimer's disease and vascular dementia patients.\n\n**Answer: B. No**",
            "pmid": [
                "pmid20209467",
                "pmid15207414",
                "pmid16088136",
                "pmid19088473",
                "pmid12784029",
                "pmid27380243",
                "pmid19342053",
                "pmid11455131",
                "pmid15537514",
                "pmid23224755"
            ]
        },
        "metabolism_54": {
            "question": "Does amarogentin exhibit potential benefits for Alzheimer's disease by reducing reactive oxygen species (ROS) and improving the survival rate of PC12 cells under oxidative stress?",
            "answer": "A: A. Yes",
            "pmid": [
                "pmid24975829",
                "pmid21276834",
                "pmid32831994",
                "pmid28630497",
                "pmid23966081",
                "pmid28554861",
                "pmid35598091",
                "pmid34294612",
                "pmid24512768",
                "pmid26696494"
            ]
        },
        "metabolism_55": {
            "question": "Does the loss of SLC38A10 lead to lower cholesterol levels, which could have implications in neurodegenerative diseases like Alzheimer's disease?",
            "answer": "The analysis of the provided abstracts reveals that none discuss SLC38A10. All studies focus on other genes related to cholesterol metabolism and their association with Alzheimer's disease, but there is no mention or implication regarding SLC38A10.\n\n**Answer: UNRELATED**",
            "pmid": [
                "pmid12600718",
                "pmid30878503",
                "pmid35296367",
                "pmid16866910",
                "pmid27155148",
                "pmid15649702",
                "pmid15860461",
                "pmid17284348",
                "pmid18073484",
                "pmid21448224"
            ]
        },
        "metabolism_56": {
            "question": "Does the regulation of lipid metabolism involving G-quadruplex structure in ACBP genes have any reported connection to Alzheimer's disease or delirium?",
            "answer": "B. No",
            "pmid": [
                "pmid12373863",
                "pmid32581851",
                "pmid10490699",
                "pmid21448224",
                "pmid32422896",
                "pmid26855936",
                "pmid17284348",
                "pmid22329649",
                "pmid12600718",
                "pmid33057949"
            ]
        },
        "metabolism_57": {
            "question": "Does the lavender aqueous extract treatment affect metabolic pathways related to amino acids in Alzheimer's disease models?",
            "answer": "A: A",
            "pmid": [
                "pmid29849984",
                "pmid24746363",
                "pmid12203047",
                "pmid32785956",
                "pmid22995388",
                "pmid20416364",
                "pmid28554861",
                "pmid26855936",
                "pmid22329649",
                "pmid24448790"
            ]
        },
        "metabolism_58": {
            "question": "How does urolithin A mitigate high glucose-induced amyloidogenesis in Alzheimer's disease?",
            "answer": "The most appropriate answer based on the provided context information is:\n\n**B. By reducing TGM2-dependent ER-mitochondria contacts**\n\nThis conclusion is directly supported by the study in pmid32704090, which demonstrates that urolithin A reduces TGM2 expression and thereby decreases ER-mitochondria contacts, mitigating amyloidogenesis.\n\nNew Answer: B. By reducing TGM2-dependent ER-mitochondria contacts",
            "pmid": [
                "pmid32704090",
                "pmid34905594",
                "pmid32042368",
                "pmid36012451",
                "pmid32098107",
                "pmid30171839",
                "pmid25434488",
                "pmid30742114",
                "pmid19596066",
                "pmid24905226"
            ]
        },
        "metabolism_59": {
            "question": "Which short-chain fatty acid (SCFA) metabolite of Akkermansia muciniphila is implicated in protecting against Alzheimer's disease by maintaining mitochondrial homeostasis?",
            "answer": "The correct answer is B. Propionic acid.\n\nNew Answer: B. Propionic acid",
            "pmid": [
                "pmid39833898",
                "pmid32321934",
                "pmid37671803",
                "pmid28284721",
                "pmid24448790",
                "pmid37373177",
                "pmid32486013",
                "pmid37018970",
                "pmid38866276",
                "pmid30290256"
            ]
        },
        "metabolism_60": {
            "question": "How might hydrogen sulfide (H2S) affect mitochondrial dynamics in neuroblastoma cells, and what implication does this have for Alzheimer's disease?",
            "answer": "**Answer: A. H2S decreases mitochondrial fission via Drp1/ERK1/2 pathway; potentially benefiting Alzheimers disease.**\n\nThe study indicates that hydrogen sulfide (H₂S) inhibits mitochondrial fission in neuroblastoma cells through the Drp1/ERK1/2 signaling pathway, which could be beneficial for Alzheimer's disease by reducing mitochondrial dysfunction associated with excessive fission.",
            "pmid": [
                "pmid28560384",
                "pmid26708452",
                "pmid20674619",
                "pmid27026591",
                "pmid22542418",
                "pmid36482297",
                "pmid36482035",
                "pmid32597804",
                "pmid23579332",
                "pmid17851177"
            ]
        },
        "metabolism_61": {
            "question": "Which metabolic pathway is activated in FH-deficient renal cell carcinoma cells when exposed to asparagine, potentially linking to delirium-related metabolic dysregulation?",
            "answer": "The correct answer is:\n\nA. Hexosamine biosynthetic pathway (HBP)\n\nNew Answer:",
            "pmid": [
                "pmid32774853",
                "pmid31948056",
                "pmid16375719",
                "pmid29439324",
                "pmid34440878",
                "pmid25148700",
                "pmid29533007",
                "pmid35624799",
                "pmid33994936",
                "pmid36206930"
            ]
        },
        "metabolism_62": {
            "question": "In Alzheimer's disease, which metabolic process in astrocytes is implicated in both detoxifying Abeta-derived ammonia and causing memory impairment?",
            "answer": "The urea cycle in astrocytes is involved in detoxifying Abeta-derived ammonia but also contributes to memory impairment in Alzheimer's disease.\n\n**Answer: B. Urea cycle**",
            "pmid": [
                "pmid35738259",
                "pmid35872221",
                "pmid26855936",
                "pmid35427648",
                "pmid35569719",
                "pmid22329649",
                "pmid21035308",
                "pmid35921813",
                "pmid16210396",
                "pmid19940172"
            ]
        },
        "metabolism_63": {
            "question": "Which amino acid combination derived from garlic and buna-shimeji is associated with suppression of CCl4-induced hepatic injury, potentially relevant to neurodegenerative conditions like Alzheimer's disease?",
            "answer": "The study in pmid34199038 highlights that the combination of ACSO from garlic and ornithine derived from buna-shimeji effectively suppresses CCl4-induced hepatic injury. This combination is noted for its potential relevance to neurodegenerative conditions like Alzheimer's disease, given the protective effects observed.\n\n**Answer: A. S-allyl-l-cysteine sulfoxide (ACSO) and ornithine**",
            "pmid": [
                "pmid34199038",
                "pmid31328121",
                "pmid25365295",
                "pmid23219964",
                "pmid20416364",
                "pmid23579332",
                "pmid28930532",
                "pmid38203753",
                "pmid32597804",
                "pmid25393881"
            ]
        },
        "metabolism_64": {
            "question": "Which miRNAs were found to be elevated in Alzheimer's disease brain tissues and might modulate arginine metabolism?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid18234899",
                "pmid26398571",
                "pmid32035423",
                "pmid35941185",
                "pmid35154541",
                "pmid24604632",
                "pmid34224891",
                "pmid34945753",
                "pmid27235866",
                "pmid31333395"
            ]
        },
        "metabolism_65": {
            "question": "Which of the following is associated with LacCer-induced oxidative stress and has been implicated in the pathogenesis of Alzheimer's disease?",
            "answer": "D. Tumor necrosis factor-alpha (TNF-alpha)",
            "pmid": [
                "pmid16873963",
                "pmid19596066",
                "pmid31520071",
                "pmid16677790",
                "pmid21545753",
                "pmid36010649",
                "pmid35969330",
                "pmid8725383",
                "pmid14748735",
                "pmid26221414"
            ]
        },
        "metabolism_66": {
            "question": "How does mycolactone affect mitochondrial distribution in DRG neurons, and what is its relevance to Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid39171353",
                "pmid30412792",
                "pmid24710686",
                "pmid26221414",
                "pmid33580194",
                "pmid30171839",
                "pmid29873184",
                "pmid38729530",
                "pmid30922179",
                "pmid22367970"
            ]
        },
        "metabolism_67": {
            "question": "How does the anti-oxidative effect of ATB-344 relate to delirium?",
            "answer": "The anti-oxidative effect of ATB-344 relates to delirium by reducing inflammation, which is a known contributing factor. \n\n**Answer: C. It reduces inflammation; a known factor in delirium.**",
            "pmid": [
                "pmid39419070",
                "pmid37313848",
                "pmid37851904",
                "pmid39210294",
                "pmid37133446",
                "pmid31244434",
                "pmid24557038",
                "pmid19422109",
                "pmid17234821",
                "pmid20309566"
            ]
        },
        "metabolism_68": {
            "question": "In Alzheimer's disease, the expression of CD38 in senescent microglia is influenced by which of the following factors?",
            "answer": "The factor influencing CD38 expression in senescent microglia in Alzheimer's disease is related to the NAD+/NADH ratio.\n\n**Answer: D. NAD+ / NADH ratio**",
            "pmid": [
                "pmid31293510",
                "pmid25893674",
                "pmid9169522",
                "pmid37373543",
                "pmid19667196",
                "pmid21545753",
                "pmid29056898",
                "pmid26257642",
                "pmid31520071",
                "pmid32084533"
            ]
        },
        "metabolism_69": {
            "question": "How does hydroxy-alpha-sanshool (HAS) affect glycogen synthesis in liver cells, which is relevant to understanding metabolic processes in Alzheimer's disease?",
            "answer": "B. HAS increases glycogen synthesis by activating the PI3K/Akt/GSK-3β/GS pathway.",
            "pmid": [
                "pmid34896111",
                "pmid36582530",
                "pmid25102327",
                "pmid23579332",
                "pmid33086751",
                "pmid26708452",
                "pmid22927642",
                "pmid22798221",
                "pmid26855936",
                "pmid37871878"
            ]
        },
        "metabolism_70": {
            "question": "How might resveratrol's activation of the Keap-1/Nrf2 pathway in obese-asthmatic rats relate to Alzheimer's disease?",
            "answer": "The activation of the Keap-1/Nrf2 pathway by resveratrol in obese-asthmatic rats suggests a potential reduction in oxidative stress. This aligns with resveratrol's known effects on mitigating oxidative damage relevant to Alzheimer's disease.\n\n**Answer: A**\n\nNew Answer: The most appropriate answer is \"A.\"",
            "pmid": [
                "pmid29097221",
                "pmid33571701",
                "pmid21982274",
                "pmid29948950",
                "pmid25024312",
                "pmid26980711",
                "pmid35688816",
                "pmid39105797",
                "pmid31232699",
                "pmid31737188"
            ]
        },
        "metabolism_71": {
            "question": "Which of the following was shown to have antineuroinflammatory effects against Alzheimer's disease by upregulating GPR41 and suppressing the ERK/JNK/NF-kB pathway?",
            "answer": "The correct answer is **A. Acetate (Ace)** because it was shown to upregulate GPR41 and suppress the ERK/JNK/NF-kB pathway, leading to antineuroinflammatory effects in Alzheimer's disease.\n\n**Answer: A. Acetate (Ace)**",
            "pmid": [
                "pmid32583667",
                "pmid12453679",
                "pmid32028243",
                "pmid35714925",
                "pmid23279783",
                "pmid35986874",
                "pmid26509334",
                "pmid14975597",
                "pmid37598923",
                "pmid15465624"
            ]
        },
        "metabolism_72": {
            "question": "Sodium butyrate (NaB) is known to inhibit which enzyme to reduce neuroinflammation in Alzheimer's disease?",
            "answer": "The enzyme inhibited by Sodium butyrate (NaB) to reduce neuroinflammation in Alzheimer's disease is Histone deacetylase (HDAC).\n\n**Answer: B. Histone deacetylase (HDAC)**",
            "pmid": [
                "pmid33785315",
                "pmid34812899",
                "pmid31958090",
                "pmid21593570",
                "pmid29867447",
                "pmid32028243",
                "pmid37823115",
                "pmid23645098",
                "pmid21606627",
                "pmid34607104"
            ]
        },
        "metabolism_73": {
            "question": "Which of the following NAD(+)-dependent enzymes has been shown to strongly affect the pathological changes of Alzheimer's disease (AD)?",
            "answer": "The answer is D. Both B and C.\n\nStep-by-step explanation:\n\n- **Option A (PARP-1):** While PARP-1's role in AD is discussed, particularly in relation to oxidative stress and neuronal death, it's not stated that PARP-1 \"strongly affects the pathological changes\" of AD as much as SIRT1 and SIRT2.\n\n- **Options B and C (SIRT1 and SIRT2):** The abstract pmid22204321 explicitly states that both SIRT1 and SIRT2 are implicated in affecting AD's pathological changes. This makes option D correct.\n\nAnswer: D",
            "pmid": [
                "pmid36959156",
                "pmid22204321",
                "pmid22430645",
                "pmid24386592",
                "pmid31280708",
                "pmid29363833",
                "pmid17027152",
                "pmid23076628",
                "pmid30922179",
                "pmid30362958"
            ]
        },
        "metabolism_74": {
            "question": "How does WGX50 mitigate doxorubicin-induced cardiotoxicity, which shares similarities with the mitochondrial dysfunction observed in Alzheimer's disease?",
            "answer": "The correct answer is:\n\n**C. By reducing mitochondrial ROS and inhibiting ferroptosis**\n\nWGX50 mitigates doxorubicin-induced cardiotoxicity by reducing mitochondrial ROS levels and inhibiting ferroptosis, a mechanism that aligns with strategies to address mitochondrial dysfunction in conditions like Alzheimer's disease, where oxidative stress plays a significant role.",
            "pmid": [
                "pmid37978379",
                "pmid38568919",
                "pmid35804014",
                "pmid37416768",
                "pmid35237161",
                "pmid36012451",
                "pmid25102327",
                "pmid29873184",
                "pmid24905226",
                "pmid23691268"
            ]
        },
        "metabolism_75": {
            "question": "Which polyphenolic compounds isolated from Corallodiscus flabellata B. L. Burtt are reported to ameliorate amyloid beta-protein induced Alzheimer's disease neuronal injury?",
            "answer": "The polyphenolic compounds isolated from Corallodiscus flabellata B. L. Burtt that are reported to ameliorate amyloid beta-protein induced Alzheimer's disease neuronal injury are 3,4-Dihydroxyphenylethanol-8-O-[4-O-trans-caffeoyl-beta-D-apiofuranosyl-(1→3)-beta-D-glucopyranosyl (1→6)][1]-beta-D-glucopyranoside and hydroxytyrosol (HT). These are listed in option D.\n\nANSWER: D",
            "pmid": [
                "pmid36535434",
                "pmid29100755",
                "pmid25229015",
                "pmid32316271",
                "pmid16880827",
                "pmid24328060",
                "pmid26304685",
                "pmid34569961",
                "pmid30036601",
                "pmid22995388"
            ]
        },
        "metabolism_76": {
            "question": "How does the interaction between VDAC1 and Abeta contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The interaction between VDAC1 and Abeta contributes to Alzheimer's disease by promoting mitochondrial dysfunction, which impairs ATP production and energy supply to neurons. \n\n**Answer: C. It promotes mitochondrial dysfunction; leading to impaired energy supply.**",
            "pmid": [
                "pmid22926141",
                "pmid29551631",
                "pmid35955694",
                "pmid22995655",
                "pmid16210396",
                "pmid20930307",
                "pmid25888814",
                "pmid21545753",
                "pmid25233405",
                "pmid15837797"
            ]
        },
        "metabolism_77": {
            "question": "How does OCIAD1 contribute to neurodegeneration in Alzheimer's disease?",
            "answer": "The answer is determined by examining each provided context. The only relevant information about OCIAD1 comes from pmid31931285, which states that OCIAD1 impairs mitochondrial function, leading to neurodegeneration in Alzheimer's disease.\n\n**Answer: B. By impairing mitochondrial function**",
            "pmid": [
                "pmid31931285",
                "pmid38216963",
                "pmid31927055",
                "pmid35738259",
                "pmid26615780",
                "pmid29634233",
                "pmid26095650",
                "pmid16210396",
                "pmid35357374",
                "pmid26200696"
            ]
        },
        "metabolism_78": {
            "question": "Which metabolic cluster in tear fluid is associated with the progression of proliferative diabetic retinopathy (PDR), a condition that shares systemic attributes with Alzheimer's disease?",
            "answer": "The metabolic cluster associated with PDR progression in tear fluid is ceramides.\n\n**Answer: C. Ceramides**\n\nNew Answer: The most appropriate answer is C. Ceramides.",
            "pmid": [
                "pmid36845280",
                "pmid34592130",
                "pmid35296367",
                "pmid36204837",
                "pmid33277246",
                "pmid36206930",
                "pmid32581851",
                "pmid37871878",
                "pmid26444774",
                "pmid33994936"
            ]
        },
        "metabolism_79": {
            "question": "Which molecule is identified as a critical regulator of death-associated protein kinase 1 (DAPK1) in Alzheimer's disease?",
            "answer": "The molecule identified as a critical regulator of death-associated protein kinase 1 (DAPK1) in Alzheimer's disease is Melatonin.\n\n**Answer: B. Melatonin**",
            "pmid": [
                "pmid32358852",
                "pmid22785394",
                "pmid17562708",
                "pmid27557632",
                "pmid12740599",
                "pmid26582459",
                "pmid37633326",
                "pmid31840000",
                "pmid7533559",
                "pmid35106914"
            ]
        },
        "metabolism_80": {
            "question": "Which metabolic pathways were restored by Bushen Tiansui Formula (BSTSF) in the treatment of Alzheimer's disease in rats?",
            "answer": "The metabolic pathways restored by Bushen Tiansui Formula (BSTSF) in treating Alzheimer's disease in rats include sphingolipid metabolism, glycerophospholipid metabolism, linoleic acid metabolism, amino acid metabolism, and glutamine/glutamate metabolism. Therefore, the correct answer is:\n\nD. All of the above\n\n**Answer: D. All of the above**",
            "pmid": [
                "pmid32655770",
                "pmid31683034",
                "pmid36339577",
                "pmid33029123",
                "pmid28379235",
                "pmid38649307",
                "pmid22329649",
                "pmid32461378",
                "pmid35069753",
                "pmid29449587"
            ]
        },
        "metabolism_81": {
            "question": "How does mild hypothermia affect isoflurane-induced cytotoxicity and DNA damage, potentially relevant to neurodegenerative conditions like Alzheimer's disease?",
            "answer": "The most appropriate answer is B: Reduces cytotoxicity and DNA damage.",
            "pmid": [
                "pmid28228717",
                "pmid27194299",
                "pmid24961763",
                "pmid21244349",
                "pmid21519046",
                "pmid24386592",
                "pmid39490772",
                "pmid25274115",
                "pmid22542418",
                "pmid33747165"
            ]
        },
        "metabolism_82": {
            "question": "Which selenium compound was found to preferentially increase the expression and activity of thioredoxin reductase, thereby reducing tau phosphorylation in Alzheimer's disease models?",
            "answer": "C",
            "pmid": [
                "pmid36978950",
                "pmid27465436",
                "pmid24577479",
                "pmid29688618",
                "pmid26311427",
                "pmid32597804",
                "pmid23579332",
                "pmid22528780",
                "pmid21934536",
                "pmid23219964"
            ]
        },
        "metabolism_83": {
            "question": "How does Exendin-4 (Ex-4) influence mitochondrial function in neurons under palmitic acid-induced oxidative stress, which is relevant to Alzheimer's disease pathophysiology?",
            "answer": "The studies indicate that Exendin-4 (Ex-4) enhances mitochondrial function by preventing dysfunction and reducing reactive oxygen species (ROS) production under palmitic acid-induced oxidative stress. This is beneficial in the context of Alzheimer's disease pathophysiology.\n\n**Answer: B. Ex-4 improves mitochondrial function and reduces ROS production.**",
            "pmid": [
                "pmid33435277",
                "pmid36753858",
                "pmid33774476",
                "pmid32457210",
                "pmid21901364",
                "pmid21545753",
                "pmid16210396",
                "pmid11181824",
                "pmid24710686",
                "pmid27444386"
            ]
        },
        "metabolism_84": {
            "question": "Which mitochondrial dysfunction is associated with NF-kappaB signaling and may contribute to Alzheimer's disease?",
            "answer": "The answer is **B. Decreased ATP production**.\n\nExplanation: The context shows that NF-kappaB signaling leads to decreased ATP production by inhibiting COX activity, which is crucial for mitochondrial energy production in Alzheimer's disease.",
            "pmid": [
                "pmid25052843",
                "pmid30199818",
                "pmid9169522",
                "pmid21545753",
                "pmid28317877",
                "pmid22077634",
                "pmid39730291",
                "pmid16677790",
                "pmid19667196",
                "pmid32967303"
            ]
        },
        "metabolism_85": {
            "question": "Which of the following is associated with increased GPR84 expression in macrophages and may contribute to the pathophysiology of Alzheimer's disease?",
            "answer": "The answer is D. All of the above.\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Information:** The study (pmid29973940) states that hyperglycemia, hypercholesterolemia, and oxidized LDL increase GPR84 expression in macrophages.\n\n2. **Link to Alzheimer's Disease Pathophysiology:** Other studies indicate that lipid metabolism and inflammation play significant roles in AD. Increased GPR84 leads to more inflammation, which can worsen AD symptoms.\n\n3. **Conclusion:** All three factors (A, B, C) contribute to increased GPR84 expression and are linked to AD pathophysiology.\n\n**Answer:** D. All of the above",
            "pmid": [
                "pmid29973940",
                "pmid25637481",
                "pmid16765377",
                "pmid19446537",
                "pmid17284348",
                "pmid27723233",
                "pmid32581851",
                "pmid38561809",
                "pmid10440900",
                "pmid35296367"
            ]
        },
        "metabolism_86": {
            "question": "How does avasimibe modulate cholesterol metabolism to enhance the efficacy of the Kras vaccine, potentially offering insights into treatments for Alzheimer's disease?",
            "answer": "The answer is **A**. \n\n**Explanation:**\nAvasimibe enhances the Kras vaccine's efficacy by inhibiting ACAT1, reducing cholesterol in T cells, thereby enhancing their ability to target tumors. This mechanism of modulating cholesterol metabolism in immune cells suggests potential therapeutic applications for Alzheimer's disease, where neuroinflammation and lipid metabolism play significant roles.\n\n**Answer:** A",
            "pmid": [
                "pmid31680003",
                "pmid39117070",
                "pmid21448224",
                "pmid36770835",
                "pmid35672874",
                "pmid28963942",
                "pmid24602800",
                "pmid23665252",
                "pmid30032423",
                "pmid32583667"
            ]
        },
        "metabolism_87": {
            "question": "How might decreased PSA expression in the liver be related to Alzheimer's disease progression?",
            "answer": "The most appropriate answer based on the analysis is:\n\n**A. Increased triglyceride accumulation in the liver**\n\n**Step-by-Step Explanation:**\n1. **Identify Potential Misinterpretation**: \"PSA\" was likely intended to refer to PPARalpha, as it's a key regulator of lipid metabolism mentioned in the context.\n2. **Role of PPARalpha**: PPARalpha promotes fatty acid beta-oxidation. Reduced expression would impair this process.\n3. **Implications for Triglycerides**: Impaired beta-oxidation leads to decreased fat breakdown and potential triglyceride accumulation.\n\n**Answer:** A",
            "pmid": [
                "pmid26642316",
                "pmid32422896",
                "pmid31520071",
                "pmid24278306",
                "pmid16873963",
                "pmid38787367",
                "pmid11276052",
                "pmid10095092",
                "pmid37891827",
                "pmid3165303"
            ]
        },
        "metabolism_88": {
            "question": "Which natural compound found in olive oil has been shown to protect against 7-ketocholesterol-induced mitochondrial and peroxisomal dysfunction in microglial cells, which may be relevant to neurodegenerative diseases like Alzheimer's disease?",
            "answer": "The natural compounds found in olive oil that protect against 7-ketocholesterol-induced mitochondrial and peroxisomal dysfunction are:\n\nA. Alpha-tocopherol  \nB. Gamma-tocopherol  \nC. Oleic acid  \n\nEach of these compounds has been shown to be effective based on the provided context.\n\n**Answer:**\n\nA. Alpha-tocopherol; B. Gamma-tocopherol; C. Oleic acid",
            "pmid": [
                "pmid27897980",
                "pmid39061831",
                "pmid37508010",
                "pmid29068387",
                "pmid35888732",
                "pmid38339193",
                "pmid29435099",
                "pmid29109370",
                "pmid38036892",
                "pmid36770835"
            ]
        },
        "metabolism_89": {
            "question": "Methazolamide (MTZ) prevents mitochondrial dysfunction in Alzheimer's disease by inhibiting the release of which molecule from mitochondria?",
            "answer": "The question asks which molecule Methazolamide (MTZ) prevents from being released by mitochondria in Alzheimer's disease. From the provided context, MTZ is shown to inhibit the release of cytochrome c (CytC), which then prevents caspase activation. Therefore, the answer is:\n\n**B. Cytochrome c (CytC)**",
            "pmid": [
                "pmid26581638",
                "pmid29873184",
                "pmid30922179",
                "pmid39713820",
                "pmid25744714",
                "pmid27444386",
                "pmid33155636",
                "pmid33580194",
                "pmid22381145",
                "pmid23226091"
            ]
        },
        "metabolism_90": {
            "question": "What effect did the extracts of Salvia triloba and Piper nigrum have on oxidative stress in Alzheimer's disease-induced rats?",
            "answer": "The provided context does not mention anything about Salvia triloba or Piper nigrum extracts and their effects on oxidative stress in Alzheimer's disease-induced rats. Since the new context is unrelated to the query, we must rely on the original information.\n\nUNRELATED",
            "pmid": [
                "pmid22957416",
                "pmid23631499",
                "pmid24442916",
                "pmid26023568",
                "pmid34724130",
                "pmid19441012",
                "pmid27563424",
                "pmid35950787",
                "pmid37114959",
                "pmid29551684"
            ]
        },
        "metabolism_91": {
            "question": "Which metabolic pathway regulated by Jingfang Granules is associated with brain protection in Alzheimer's disease?",
            "answer": "C. Lipid metabolism",
            "pmid": [
                "pmid32655770",
                "pmid22329649",
                "pmid26855936",
                "pmid25311278",
                "pmid29363833",
                "pmid12373863",
                "pmid38565291",
                "pmid35872221",
                "pmid25061554",
                "pmid21035308"
            ]
        },
        "metabolism_92": {
            "question": "Which enzyme's inhibition partially mediates Abeta25-35-induced cytotoxicity in Alzheimer's disease?",
            "answer": "The enzyme whose inhibition partially mediates Abeta25-35-induced cytotoxicity in Alzheimer's disease is **Glucosylceramide Synthase (GCS)**.\n\n**Answer: A. Glucosylceramide synthase (GCS)**",
            "pmid": [
                "pmid34602551",
                "pmid12649271",
                "pmid16626961",
                "pmid14709545",
                "pmid17261088",
                "pmid19519664",
                "pmid26051801",
                "pmid16524368",
                "pmid24164736",
                "pmid19324459"
            ]
        },
        "metabolism_93": {
            "question": "How does spermine oxidase overexpression affect the brain in a way that could be relevant to Alzheimer's disease?",
            "answer": "The most appropriate answer based on the contextual information provided is:\n\n**A. It increases oxidative stress; which is implicated in Alzheimer's disease.**\n\n**Step-by-Step Explanation:**\n\n1. **Understanding Spermine Oxidase (SMO):**\n   - SMO is an enzyme involved in the catabolism of polyamines, specifically oxidizing spermine to produce H2O2 and other reactive oxygen species (ROS).\n\n2. **Impact of Overexpression:**\n   - The provided context discusses studies where SMO is overexpressed in mouse models.\n     - pmid35885061: Overexpression leads to increased ROS production, causing oxidative stress, excitotoxicity, neuronal damage, and reactive astrocytosis.\n     - pmid23840306: Higher H2O2 levels were observed, confirming increased oxidative stress. This overexpression also resulted in cognitive deficits and enhanced susceptibility to excitotoxicity.\n\n3. **Relevance to Alzheimer's Disease (AD):**\n   - Oxidative stress is a well-documented factor in AD progression.\n   - Increased ROS from SMO overexpression contributes to neuronal damage and impairs cognitive function, aligning with AD pathogenesis.\n\n4. **Evaluating Options:**\n   - **A:** Correctly identifies that increased oxidative stress is implicated in AD, which matches the context.\n   - **B:** While polyamine levels are affected, the context doesn't support this as a neuroprotective mechanism.\n   - **C and D:** These options contradict the evidence; SMO overexpression does not improve cognitive function or reduce oxidative stress.\n\n**Conclusion:**\nSMO overexpression increases oxidative stress, which is relevant to Alzheimer's disease progression. Therefore, option A is correct.\n\n**Answer:** A",
            "pmid": [
                "pmid11223914",
                "pmid35885061",
                "pmid23840306",
                "pmid32457210",
                "pmid31520071",
                "pmid35969330",
                "pmid29093468",
                "pmid37343463",
                "pmid35430632",
                "pmid38275641"
            ]
        },
        "metabolism_94": {
            "question": "Which enzyme has been suggested to link sulfur amino acids with lipid metabolism and may also play a role in Alzheimer's disease?",
            "answer": "The enzyme stearoyl-CoA desaturase-1 (SCD-1) has been suggested to link sulfur amino acids with lipid metabolism and may play a role in Alzheimer's disease. \n\n**Answer: A. SCD-1**",
            "pmid": [
                "pmid26046927",
                "pmid23579332",
                "pmid12373863",
                "pmid28320965",
                "pmid21448224",
                "pmid17284348",
                "pmid17851177",
                "pmid16626961",
                "pmid16873963",
                "pmid32742127"
            ]
        },
        "metabolism_95": {
            "question": "Which factor is associated with improved muscle strength in older individuals with inadequate protein intake, potentially relevant to conditions like Alzheimer's disease or delirium?",
            "answer": "The factor associated with improved muscle strength in older individuals with inadequate protein intake is **Branched-chain amino acids (BCAAs) and eicosapentaenoic acid (EPA)**. BCAAs support muscle protein synthesis, while EPA has anti-inflammatory properties that may mitigate conditions like Alzheimer's disease or delirium.\n\n**Answer: B. Branched-chain amino acids and eicosapentaenoic acid**",
            "pmid": [
                "pmid29311975",
                "pmid33266508",
                "pmid37754219",
                "pmid26444783",
                "pmid20209467",
                "pmid8761018",
                "pmid15277174",
                "pmid11455131",
                "pmid24411482",
                "pmid29093468"
            ]
        },
        "metabolism_96": {
            "question": "Which of the following pesticides was found to not cause mitochondrial fragmentation or functional damage, nor inhibit the activity of the proteasome, thus potentially reducing the risk of Parkinsonism and possibly Alzheimer's disease?",
            "answer": "C",
            "pmid": [
                "pmid29168786",
                "pmid23544381",
                "pmid24503016",
                "pmid33991619",
                "pmid39485576",
                "pmid17936647",
                "pmid33379372",
                "pmid34122727",
                "pmid25310739",
                "pmid22381145"
            ]
        },
        "metabolism_97": {
            "question": "How does SERCA activation by CDN1163 potentially influence metabolic processes relevant to Alzheimer's disease?",
            "answer": "The activation of SERCA by CDN1163 enhances fatty acid beta-oxidation, which aligns with improving energy metabolism relevant to Alzheimer's disease.\n\n**Answer: B. Enhances fatty acid beta-oxidation**",
            "pmid": [
                "pmid34909682",
                "pmid30362958",
                "pmid31257151",
                "pmid28320965",
                "pmid36204837",
                "pmid38565291",
                "pmid26855936",
                "pmid33086751",
                "pmid29439343",
                "pmid26965310"
            ]
        },
        "metabolism_98": {
            "question": "Which mung bean component is shown to regulate heat stress and may have implications for neurodegenerative diseases like Alzheimer's due to its antioxidant properties?",
            "answer": "The correct answer is C. Mung bean polyphenols.\n\n**Answer:**  \nC. Mung bean polyphenols",
            "pmid": [
                "pmid36890864",
                "pmid34551518",
                "pmid39200504",
                "pmid36738696",
                "pmid32316271",
                "pmid18602817",
                "pmid36535434",
                "pmid22995388",
                "pmid27050422",
                "pmid25229015"
            ]
        },
        "metabolism_99": {
            "question": "In Alzheimer's disease, how does hexokinase 2 (HK2) deficiency in microglial cells affect ATP generation and beta-amyloid clearance?",
            "answer": "B. HK2 deficiency increases ATP generation through lipid metabolism and enhances beta-amyloid clearance.",
            "pmid": [
                "pmid36203054",
                "pmid39002124",
                "pmid36787364",
                "pmid35969330",
                "pmid19596066",
                "pmid24625803",
                "pmid29662056",
                "pmid22329649",
                "pmid11464464",
                "pmid36204837"
            ]
        },
        "metabolism_100": {
            "question": "In rapidly progressive Alzheimer's disease (rpAD), compared to typical Alzheimer's disease (tAD), which of the following is true regarding mitochondrial dynamics?",
            "answer": "The correct answer is:\n\n**B. rpAD shows a more pronounced decline in mitochondrial dynamics regulators.**\n\nThis conclusion is based on the study (pmid39584307) which found that while both rpAD and tAD show significant declines, rpAD exhibits a more severe reduction in mitochondrial dynamics regulators compared to tAD.",
            "pmid": [
                "pmid39584307",
                "pmid21545753",
                "pmid19667196",
                "pmid32084533",
                "pmid39880979",
                "pmid22077634",
                "pmid16677790",
                "pmid33465841",
                "pmid26221414",
                "pmid30171839"
            ]
        },
        "metabolism_101": {
            "question": "Which metabolic pathway affected by the You-Gui Pill (YGP) in treating Kidney-Yang Deficiency Syndrome (KYDS) is also implicated in Alzheimer's disease?",
            "answer": "The correct answer is:\n\nC. TCA cycle\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Pathways in Alzheimer's Disease (AD):**\n   - From the context, AD is linked to mitochondrial dysfunction and glucose hypometabolism. The TCA cycle is central to mitochondrial energy production.\n\n2. **Understand You-Gui Pill (YGP) and KYDS:**\n   - YGP treats Kidney-Yang Deficiency Syndrome, which involves issues with energy metabolism, suggesting involvement of pathways like the TCA cycle.\n\n3. **Connect Both Concepts:**\n   - Both AD and YGP's effects on KYDS implicate mitochondrial function, particularly the TCA cycle, in their respective conditions.\n\n4. **Eliminate Other Options:**\n   - Glycine/serine/threonine and butanoate metabolism are not prominently mentioned in the context of AD.\n   - Dicarboxylate metabolism lacks specific references in the provided information.\n\n**Answer:** C. TCA cycle",
            "pmid": [
                "pmid22329649",
                "pmid32461378",
                "pmid29439324",
                "pmid24746363",
                "pmid36204837",
                "pmid25311278",
                "pmid29363833",
                "pmid30412792",
                "pmid36754068",
                "pmid33086751"
            ]
        },
        "metabolism_102": {
            "question": "Which COX-2 inhibitor was found to potentially affect kynurenic acid (KYNA) production, a biomarker implicated in Alzheimer's disease and delirium?",
            "answer": "The COX-2 inhibitor found to potentially affect kynurenic acid (KYNA) production is:\n\n**Answer:** B. Niflumic acid",
            "pmid": [
                "pmid30178287",
                "pmid32276479",
                "pmid32012948",
                "pmid30800661",
                "pmid20639188",
                "pmid36754068",
                "pmid20847443",
                "pmid37264981",
                "pmid28733707",
                "pmid25938971"
            ]
        },
        "metabolism_103": {
            "question": "Willin/FRMD6 downregulation is associated with which feature of Alzheimer's disease pathogenesis?",
            "answer": "The correct answer is B: Mitochondrial dysfunction and fragmentation.\n\n**Answer:**  \nB. Mitochondrial dysfunction and fragmentation",
            "pmid": [
                "pmid36231104",
                "pmid34831245",
                "pmid22495348",
                "pmid33277246",
                "pmid33580194",
                "pmid39171353",
                "pmid12881482",
                "pmid24710686",
                "pmid16677790",
                "pmid9878757"
            ]
        },
        "metabolism_104": {
            "question": "Which mitochondrial haplogroup cluster is associated with an increased risk of age-related macular degeneration (AMD) and may also influence the bioenergetic processes implicated in Alzheimer's disease?",
            "answer": "The correct answer is A. JTU.\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Information:** The context highlights that the JTU mitochondrial haplogroup cluster is associated with an increased risk of AMD, as mentioned in a study linking specific haplogroups to higher AMD risk.\n\n2. **Link to Alzheimer's Disease:** Several studies indicate that mitochondrial dysfunction and oxidative stress are significant factors in Alzheimer's disease. Since mitochondrial bioenergetics are crucial for both AMD and Alzheimer's, the JTU cluster's association with AMD suggests it might also influence these processes in Alzheimer's.\n\n3. **Conclusion:** Based on the provided context, the JTU haplogroup is identified as being associated with AMD and potentially impacting mitochondrial functions relevant to Alzheimer's disease.\n\n**Answer:** A. JTU",
            "pmid": [
                "pmid23302509",
                "pmid18461138",
                "pmid34152079",
                "pmid10377009",
                "pmid23244519",
                "pmid15464268",
                "pmid26305120",
                "pmid19667196",
                "pmid17537576",
                "pmid16873963"
            ]
        },
        "metabolism_105": {
            "question": "Which metabolic change in Alzheimer's disease obscures the typical phenotype of type 2 diabetes?",
            "answer": "**Answer:**\n\nB. PLS-DA modeling resulted in poor classification accuracy for type 2 diabetes in Alzheimer's disease subjects.\n\n**Explanation:**\n\nThe study analyzed metabolic profiles using PLS-DA modeling across four groups and found that classifying T2D status in AD subjects was challenging, indicating that AD obscures typical T2D phenotypes. This aligns with option B, which highlights the poor classification accuracy of T2D in AD patients.",
            "pmid": [
                "pmid29351484",
                "pmid32739014",
                "pmid25212911",
                "pmid36204837",
                "pmid37891827",
                "pmid29471055",
                "pmid36206930",
                "pmid21035308",
                "pmid34439505",
                "pmid18189240"
            ]
        },
        "metabolism_106": {
            "question": "In Alzheimer disease, what is the relationship between argininosuccinate synthetase (ASS) and inducible nitric oxide synthase (iNOS) expression in neurons and glia?",
            "answer": "A",
            "pmid": [
                "pmid11556547",
                "pmid11958858",
                "pmid29439324",
                "pmid10964481",
                "pmid9138425",
                "pmid26971935",
                "pmid24746363",
                "pmid9514829",
                "pmid12203047",
                "pmid21351586"
            ]
        },
        "metabolism_107": {
            "question": "Which early onset neurodegenerative disorder was found to have lower levels of kynurenine pathway metabolites in specific brain regions compared to Alzheimer's disease?",
            "answer": "The early onset neurodegenerative disorder with lower kynurenine pathway metabolite levels in specific brain regions compared to Alzheimer's disease is **ALS**.\n\nAnswer: A. ALS",
            "pmid": [
                "pmid37111372",
                "pmid32276479",
                "pmid36754068",
                "pmid20639188",
                "pmid37264981",
                "pmid38566855",
                "pmid32012948",
                "pmid31520071",
                "pmid22329649",
                "pmid24346138"
            ]
        },
        "metabolism_108": {
            "question": "Which factor was found to upregulate glutaminyl cyclase (QC) expression in neuronal cells, contributing to Alzheimer's disease pathogenesis?",
            "answer": "The factor identified as upregulating glutaminyl cyclase (QC) expression in neuronal cells, contributing to Alzheimer's disease pathogenesis, is perturbed intracellular Ca²+ homeostasis.\n\n**Answer: C. Perturbed intracellular Ca(2+) homeostasis**",
            "pmid": [
                "pmid22970285",
                "pmid24164736",
                "pmid32614980",
                "pmid11145195",
                "pmid12960778",
                "pmid23902769",
                "pmid19337829",
                "pmid8922409",
                "pmid25318543",
                "pmid36515857"
            ]
        },
        "metabolism_109": {
            "question": "Which metabolite associated with a high-fiber diet was found to have the strongest binding affinity for SPEG, a gene linked to Alzheimer's disease?",
            "answer": "The correct answer is A. Acetamidobenzoic acid.\n\n**Answer:** A. Acetamidobenzoic acid",
            "pmid": [
                "pmid36733447",
                "pmid32793799",
                "pmid39833898",
                "pmid23579332",
                "pmid15788759",
                "pmid39807036",
                "pmid26159189",
                "pmid26855936",
                "pmid24411482",
                "pmid37018970"
            ]
        },
        "metabolism_110": {
            "question": "How might the biphasic effect of Carthamus Tinctorius extract on oxidative stress influence Alzheimer's disease treatment?",
            "answer": "The biphasic effect of Carthamus Tinctorius extract suggests it may have dual roles in modulating oxidative stress, making option B the best choice. \n\n**Answer: B. The extract may have dual roles in modulating oxidative stress in Alzheimer's disease.**",
            "pmid": [
                "pmid38968796",
                "pmid38455162",
                "pmid26068423",
                "pmid26845710",
                "pmid33463937",
                "pmid22995388",
                "pmid29100755",
                "pmid26304685",
                "pmid23566055",
                "pmid34182090"
            ]
        },
        "metabolism_111": {
            "question": "What metabolic process is primarily affected by Shengmai-San (SMS) intervention in Alzheimer's disease?",
            "answer": "The answer is C. Lipid Peroxidation.",
            "pmid": [
                "pmid28379235",
                "pmid26855936",
                "pmid22329649",
                "pmid36204837",
                "pmid30412792",
                "pmid25061554",
                "pmid16873963",
                "pmid33086751",
                "pmid36206930",
                "pmid19596066"
            ]
        },
        "metabolism_112": {
            "question": "In Alzheimer's disease, where is increased HNE-histidine Michael adduct detected in the hippocampus?",
            "answer": "The HNE-histidine Michael adduct is significantly higher in the CA2, CA3, and CA4 sectors of the hippocampus in Alzheimer's disease patients, specifically within the perikarya of pyramidal cells.\n\n**Answer: C. Significantly higher in the CA2, CA3, and CA4 sectors, specifically in the perikarya of pyramidal cells.**",
            "pmid": [
                "pmid19729853",
                "pmid24444253",
                "pmid12960778",
                "pmid1647485",
                "pmid23582659",
                "pmid30040734",
                "pmid10623648",
                "pmid26923404",
                "pmid35569719",
                "pmid38958450"
            ]
        },
        "metabolism_113": {
            "question": "In Alzheimer-type dementia, which brain region shows decreased alpha-glucosidase activity?",
            "answer": "The correct answer based on the provided context is:\n\n**C. Temporal cortex**\n\nThis conclusion is drawn from pmid2935594, which explicitly states that there was a selective decrease in alpha-glucosidase activity in the temporal cortex of patients with Alzheimer-type dementia.",
            "pmid": [
                "pmid2935594",
                "pmid12960778",
                "pmid10095092",
                "pmid29363833",
                "pmid26855936",
                "pmid1647485",
                "pmid8327146",
                "pmid19940172",
                "pmid11276052",
                "pmid11351135"
            ]
        },
        "metabolism_114": {
            "question": "What metabolic changes are associated with postoperative delirium in patients undergoing surgery for oral carcinoma?",
            "answer": "The provided context discusses cytokines and biomarkers like CRP, IL-8, IL-10, S100 protein, and insulin-like growth factor 1 in relation to delirium. There is no mention of metabolic markers such as hemoglobin, sodium, or red blood cell count. Therefore, the answer is unrelated.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid19237264",
                "pmid39519398",
                "pmid36224337",
                "pmid36801548",
                "pmid27119013",
                "pmid37364279",
                "pmid38223851",
                "pmid33918634",
                "pmid18314455",
                "pmid33774004"
            ]
        },
        "metabolism_115": {
            "question": "What metabolic disruptions are linked to delirium in cases of massive amygdalin overdose?",
            "answer": "C",
            "pmid": [
                "pmid31322009",
                "pmid7211434",
                "pmid24987188",
                "pmid39419070",
                "pmid33093258",
                "pmid19541436",
                "pmid19422109",
                "pmid32018069",
                "pmid27790150",
                "pmid3765988"
            ]
        },
        "metabolism_116": {
            "question": "What metabolic disruptions are linked to delirium in liver transplant patients receiving cyclosporine?",
            "answer": "C",
            "pmid": [
                "pmid2003144",
                "pmid7211434",
                "pmid36078999",
                "pmid39519398",
                "pmid7211435",
                "pmid38223851",
                "pmid36937934",
                "pmid39419070",
                "pmid37133446",
                "pmid34908693"
            ]
        },
        "metabolism_117": {
            "question": "What metabolic disruptions are linked to delirium in geriatric general medical patients?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid21206582",
                "pmid37754219",
                "pmid19422109",
                "pmid36078999",
                "pmid39419070",
                "pmid20471115",
                "pmid17183425",
                "pmid21488579",
                "pmid21721434",
                "pmid32018069"
            ]
        },
        "metabolism_118": {
            "question": "What metabolic factors are associated with postoperative delirium in older patients undergoing cholecystectomy?",
            "answer": "The study on POD after cholecystectomy (pmid37336783) identifies lower BMI, hypoalbuminemia, and electrolyte imbalance as associated factors. Thus, the correct answer is:\n\n**D. Lower body mass index (BMI), hypoalbuminemia, and electrolyte imbalance.**\n\nAnswer: D",
            "pmid": [
                "pmid37336783",
                "pmid30488836",
                "pmid39259057",
                "pmid10473947",
                "pmid36224337",
                "pmid37773821",
                "pmid39774401",
                "pmid38755693",
                "pmid27119013",
                "pmid27526790"
            ]
        },
        "metabolism_119": {
            "question": "What metabolic or nutritional factor is most strongly associated with delirium development in CICU patients?",
            "answer": "B. Low serum albumin level",
            "pmid": [
                "pmid36937934",
                "pmid37754219",
                "pmid36078999",
                "pmid17352663",
                "pmid17234821",
                "pmid20471115",
                "pmid28360657",
                "pmid21766035",
                "pmid39419070",
                "pmid17949984"
            ]
        },
        "metabolism_120": {
            "question": "What mitochondrial dysfunctions are associated with delirium in an animal model of contrast-induced nephropathy?",
            "answer": "The correct answer is **B**.\n\n**Answer:**  \nB. Decreased activities of mitochondrial respiratory chain complexes I and IV in the cerebral cortex, inhibited complex I activity in the prefrontal cortex, and reduced creatine kinase activity in the cerebral cortex.",
            "pmid": [
                "pmid21437673",
                "pmid28673598",
                "pmid39419070",
                "pmid37313848",
                "pmid37851904",
                "pmid7916159",
                "pmid3765988",
                "pmid20471138",
                "pmid39463449",
                "pmid19667196"
            ]
        },
        "metabolism_121": {
            "question": "What is the association between antidiabetic medications and delirium development?",
            "answer": "The most appropriate answer is:\n\nB. The use of sulfonylurea and insulin may be associated with an increased risk of delirium development.\n\n**Answer:** B",
            "pmid": [
                "pmid38135802",
                "pmid39210294",
                "pmid37550780",
                "pmid17317453",
                "pmid38911008",
                "pmid21766035",
                "pmid20030432",
                "pmid37133446",
                "pmid32691721",
                "pmid32329703"
            ]
        }
    },
    "genetic": {
        "genetic_0": {
            "question": "How is PCT expression altered in ICU delirium?",
            "answer": "The answer based on the provided context is:\n\nC: PCT levels are significantly increased in delirium patients compared to non-delirium patients.",
            "pmid": [
                "pmid30045794",
                "pmid36078999",
                "pmid34912245",
                "pmid31896448",
                "pmid28769556",
                "pmid17352663",
                "pmid35791660",
                "pmid35815182",
                "pmid22903241",
                "pmid37133446"
            ]
        },
        "genetic_1": {
            "question": "What mechanism is primarily targeted by URMC-099 to prevent hippocampal vascular and synaptic injury in a model of delirium superimposed on dementia?",
            "answer": "The mechanism primarily targeted by URMC-099 is the suppression of inflammatory endothelial activation and microglial-mediated synaptic loss.\n\n**Answer: D. Suppression of inflammatory endothelial activation and microglial-mediated synaptic loss.**",
            "pmid": [
                "pmid35535564",
                "pmid37313848",
                "pmid29351469",
                "pmid26362823",
                "pmid34302466",
                "pmid15608143",
                "pmid20471138",
                "pmid26581638",
                "pmid30040734",
                "pmid33420799"
            ]
        },
        "genetic_2": {
            "question": "How does IL6ST expression vary across disease stages in Delirium?",
            "answer": "**Answer:** D",
            "pmid": [
                "pmid36045041",
                "pmid32590150",
                "pmid34192631",
                "pmid32650186",
                "pmid34887385",
                "pmid36266784",
                "pmid30405391",
                "pmid21851175",
                "pmid37722373",
                "pmid39419070"
            ]
        },
        "genetic_3": {
            "question": "Which of the following is NOT supported by the identification of a significant CpG site near LDLRAD4 in patients with delirium?",
            "answer": "The identification of a significant CpG site near LDLRAD4 supports epigenetic regulation influencing immune response and cholinergic synapse pathways, as well as DNA methylation serving as biomarkers. However, there is no evidence linking LDLRAD4 protein mutations to delirium.\n\n**Answer: D**",
            "pmid": [
                "pmid32590150",
                "pmid34192631",
                "pmid33779822",
                "pmid32650186",
                "pmid34887385",
                "pmid36266784",
                "pmid19309018",
                "pmid37722373",
                "pmid19219710",
                "pmid30405391"
            ]
        },
        "genetic_5": {
            "question": "What is the function of IL-1RA in delirium-related biological processes?",
            "answer": "The context provided from pmid19269948 indicates that low levels of IL-1RA are significantly associated with delirium. Therefore, the correct answer is:\n\n**C: Low levels of IL-1RA are significantly associated with delirium.**\n\nAnswer: C",
            "pmid": [
                "pmid19269948",
                "pmid28360657",
                "pmid24557038",
                "pmid20471115",
                "pmid17203511",
                "pmid39419070",
                "pmid20309566",
                "pmid28769556",
                "pmid21851175",
                "pmid20131213"
            ]
        },
        "genetic_6": {
            "question": "How does MCP-1 contribute to the development of delirium?",
            "answer": "The most appropriate answer based on the provided context is:\n\n**B: A statistically significant raise in MCP-1 is associated with delirium in the postoperative phase.**\n\nThis conclusion aligns with findings from pmid25943616 and pmid18314455, which show that elevated levels of MCP-1 correlate with delirium development.\n\nAnswer: B",
            "pmid": [
                "pmid28360657",
                "pmid38937571",
                "pmid25943983",
                "pmid33918634",
                "pmid36224337",
                "pmid37722373",
                "pmid18314455",
                "pmid39419070",
                "pmid29529166",
                "pmid34234505"
            ]
        },
        "genetic_7": {
            "question": "How does FG contribute to the development of delirium?",
            "answer": "The studies provided do not mention folate (FG) in relation to delirium. There is no discussion of FG contributing to delirium risk, genetic associations, or MR analysis involving FG. \n\nAnswer: UNRELATED",
            "pmid": [
                "pmid19219710",
                "pmid33779822",
                "pmid39419070",
                "pmid37566435",
                "pmid27122004",
                "pmid28360657",
                "pmid20309566",
                "pmid21766035",
                "pmid39463449",
                "pmid37550780"
            ]
        },
        "genetic_8": {
            "question": "How does CD4+ T cell contribute to the development of Delirium?",
            "answer": "C",
            "pmid": [
                "pmid36118695",
                "pmid28769556",
                "pmid34034650",
                "pmid34912245",
                "pmid36078999",
                "pmid20471115",
                "pmid33120832",
                "pmid19269948",
                "pmid24557038",
                "pmid20309566"
            ]
        },
        "genetic_10": {
            "question": "Is IL-12 involved in the pathogenesis of post-stroke delirium?",
            "answer": "Based on the context provided, there's some indication from pmid29669581 that IL-12 may play a role in post-stroke delirium. However, other references don't mention IL-12 at all. \n\n**Answer:** A: Yes",
            "pmid": [
                "pmid29669581",
                "pmid27816188",
                "pmid33901789",
                "pmid34218276",
                "pmid24557038",
                "pmid20309566",
                "pmid21978081",
                "pmid37649721",
                "pmid19269948",
                "pmid20471115"
            ]
        },
        "genetic_11": {
            "question": "What is the role of CYP3A5 in coma and delirium?",
            "answer": "The correct answer is:\n\nUNRELATED\n\nNone of the provided context mentions CYP3A5 or its role in coma or delirium.",
            "pmid": [
                "pmid19309018",
                "pmid33779822",
                "pmid19219710",
                "pmid21613790",
                "pmid37722373",
                "pmid17250608",
                "pmid31046593",
                "pmid29478862",
                "pmid17728664",
                "pmid19713702"
            ]
        },
        "genetic_12": {
            "question": "Can gamma-aminobutyric acid (GABA) contribute to delirium?",
            "answer": "The contextual information suggests that gamma-aminobutyric acid (GABA) can contribute to delirium.\n\n**Answer:** A: Yes",
            "pmid": [
                "pmid32018069",
                "pmid19422109",
                "pmid34757245",
                "pmid37550780",
                "pmid7916159",
                "pmid39463449",
                "pmid20131213",
                "pmid7211434",
                "pmid38566855",
                "pmid20309566"
            ]
        },
        "genetic_13": {
            "question": "What is the role of Monocyte Chemoattractant Protein-1 (MCP-1) in delirium after cardiac surgery?",
            "answer": "The role of Monocyte Chemoattractant Protein-1 (MCP-1) in delirium after cardiac surgery is best described by option B: Elevated preoperative levels are independently associated with postoperative delirium. This conclusion is supported by a study that found MCP-1 to be an independent risk factor for delirium, specifically when elevated before surgery.\n\n**Answer:**  \nB",
            "pmid": [
                "pmid33918634",
                "pmid18314455",
                "pmid25943983",
                "pmid39774401",
                "pmid28360657",
                "pmid27119013",
                "pmid36224337",
                "pmid32987655",
                "pmid36801548",
                "pmid36567636"
            ]
        },
        "genetic_14": {
            "question": "Is Gal-3BP involved in the pathogenesis of post-stroke delirium?",
            "answer": "A",
            "pmid": [
                "pmid33901789",
                "pmid23969090",
                "pmid38937571",
                "pmid39463449",
                "pmid38566855",
                "pmid7211434",
                "pmid34900086",
                "pmid6160732",
                "pmid34218276",
                "pmid33686023"
            ]
        },
        "genetic_15": {
            "question": "Can plasminogen activator inhibitor-1 serve as a biomarker for diagnosis or prognosis in delirium?",
            "answer": "The provided context does not mention plasminogen activator inhibitor-1 (PAI-1), so there is no information supporting its use as a biomarker for delirium. \n\nAnswer: B",
            "pmid": [
                "pmid22091570",
                "pmid17234821",
                "pmid36224337",
                "pmid34098376",
                "pmid32975827",
                "pmid28360657",
                "pmid28585290",
                "pmid31574089",
                "pmid37133446",
                "pmid38566855"
            ]
        },
        "genetic_16": {
            "question": "How does the GC receptor (GR) contribute to the development of delirium?",
            "answer": "Based on the analysis, the most appropriate answer is B: Altered GC signaling via the GR may be involved in the pathogenesis and development of delirium.\n\n**Answer:** B",
            "pmid": [
                "pmid21438141",
                "pmid26029046",
                "pmid39463449",
                "pmid33336596",
                "pmid20309566",
                "pmid28673598",
                "pmid10473937",
                "pmid33901789",
                "pmid37313848",
                "pmid24557038"
            ]
        },
        "genetic_17": {
            "question": "How is blood superoxide dismutase (SOD) level altered in delirium superimposed on dementia?",
            "answer": "The analysis indicates that blood SOD levels below 129 U/mL are associated with delirium superimposed on dementia.\n\nAnswer: C",
            "pmid": [
                "pmid37812498",
                "pmid27122004",
                "pmid37566435",
                "pmid37343463",
                "pmid17234821",
                "pmid31856187",
                "pmid38566855",
                "pmid28868067",
                "pmid27058253",
                "pmid21488579"
            ]
        },
        "genetic_18": {
            "question": "Does KAT7 signaling epigenetically influence DYRK1A expression to improve insulin resistance in Alzheimer's disease?",
            "answer": "The contextual information indicates that KAT7 signaling epigenetically influences DYRK1A expression to ameliorate insulin resistance in Alzheimer's disease. Specifically, pmid38617985 highlights that KAT7 overexpression enhances DYRK1A acetylation, thereby improving insulin sensitivity.\n\n**Answer: A. Yes**\n\nThe contextual information provided discusses the role of DYRK1A in Alzheimer's disease and its regulation through various signaling pathways. However, there is no mention of KAT7 signaling or its epigenetic influence on DYRK1A expression to improve insulin resistance in Alzheimer's disease. Therefore, based on the given context, the answer is:\n\n**B. No**\n\nThe provided context does not address whether KAT7 signaling epigenetically influences DYRK1A expression to improve insulin resistance in Alzheimer's disease. The information available discusses other mechanisms and treatments related to DYRK1A but does not provide evidence for this specific pathway.\n\n**Answer: B. No**",
            "pmid": [
                "pmid38617985",
                "pmid28779511",
                "pmid24477974",
                "pmid31306739",
                "pmid31240602",
                "pmid31723029",
                "pmid35917097",
                "pmid34445786",
                "pmid32896600",
                "pmid12740599"
            ]
        },
        "genetic_19": {
            "question": "Does the IL6R gene variant (rs2228145, Asp358Ala) influence cognitive performance and Alzheimer disease biomarkers?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid10319892",
                "pmid12664314",
                "pmid28106546",
                "pmid36810164",
                "pmid39812719",
                "pmid35769874",
                "pmid28269768",
                "pmid15276231",
                "pmid39051708",
                "pmid12807963"
            ]
        },
        "genetic_20": {
            "question": "In Alzheimer’s disease, dysregulation of noncoding RNAs contributes to neurodegeneration. Which of the following best describes the role of the long noncoding RNA GAS5 in the pathogenesis of Alzheimer’s disease?",
            "answer": "The role of long noncoding RNA GAS5 in Alzheimer’s disease involves acting as a sponge for miR-23b-3p. This interaction leads to an increase in PTEN and GSK-3β expression, which promotes tau hyperphosphorylation and neuronal apoptosis.\n\n**Answer: B**\n\nGAS5 acts as a sponge for miR-23b-3p, leading to increased PTEN and GSK-3β expression, which promotes tau hyperphosphorylation and neuronal apoptosis.",
            "pmid": [
                "pmid39105371",
                "pmid38139125",
                "pmid30809552",
                "pmid34024830",
                "pmid32035423",
                "pmid32415525",
                "pmid35592504",
                "pmid30576233",
                "pmid34992508",
                "pmid34510683"
            ]
        },
        "genetic_21": {
            "question": "Which allele of the rs149474436 SNP in the PICK1 gene was found to be protective against Alzheimer's disease?",
            "answer": "The correct answer is:\n\n**A. The T allele**\n\n**Answer:** A. The T allele",
            "pmid": [
                "pmid30687223",
                "pmid25273678",
                "pmid37544578",
                "pmid29441941",
                "pmid16223550",
                "pmid23948886",
                "pmid15024730",
                "pmid25631235",
                "pmid30820047",
                "pmid12116197"
            ]
        },
        "genetic_22": {
            "question": "Does the accumulation of amyloid-beta 1-42 (Abeta42) affect the epigenetic regulation of the Igf2/H19 gene cluster in Alzheimer's disease?",
            "answer": "The context information provided indicates that the accumulation of amyloid-beta 1-42 (Abeta42) does affect the epigenetic regulation of the Igf2/H19 gene cluster in Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid36739453",
                "pmid25318543",
                "pmid23582659",
                "pmid23579332",
                "pmid19635394",
                "pmid15024730",
                "pmid21034526",
                "pmid24846272",
                "pmid38167174",
                "pmid24278306"
            ]
        },
        "genetic_23": {
            "question": "Does the codon 311 (Cys --> Ser) polymorphism of the paraoxonase-2 gene interact with the apoE4 allele in the development of Alzheimer's disease?",
            "answer": "The codon 311 (Cys --> Ser) polymorphism of the paraoxonase-2 gene does interact with the apoE4 allele in the development of Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid14741412",
                "pmid11803456",
                "pmid24965284",
                "pmid20980077",
                "pmid15016430",
                "pmid9425904",
                "pmid16319130",
                "pmid15165699",
                "pmid20850903",
                "pmid16340204"
            ]
        },
        "genetic_24": {
            "question": "Does lncRNA XIST play a role in Alzheimer's disease by inducing Abeta accumulation and neuroinflammation through epigenetic repression of NEP?",
            "answer": "The answer is B. No.",
            "pmid": [
                "pmid35098860",
                "pmid32851944",
                "pmid32035423",
                "pmid37217807",
                "pmid31949779",
                "pmid35656102",
                "pmid36453506",
                "pmid36092938",
                "pmid30809552",
                "pmid27501805"
            ]
        },
        "genetic_26": {
            "question": "Are promoter polymorphisms in the BACE1 gene associated with sporadic Alzheimer's disease?",
            "answer": "The analysis of the provided context shows mixed results regarding the association between BACE1 promoter polymorphisms and sporadic Alzheimer's disease (AD). While pmid19441127 reported a significant association with specific promoter SNPs (-918G/A), pmid20455082 found no significant association in their study. Despite this inconsistency, the presence of at least one positive finding suggests an association.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid19441127",
                "pmid20455082",
                "pmid26846559",
                "pmid15784960",
                "pmid12535780",
                "pmid16223550",
                "pmid15288432",
                "pmid11029529",
                "pmid9425904",
                "pmid11099823"
            ]
        },
        "genetic_27": {
            "question": "Which genetic polymorphism in the HLA-DQB1 promoter region is associated with changes in transcription factor binding that may influence Alzheimer's disease risk?",
            "answer": "The question asks about genetic polymorphisms in the HLA-DQB1 promoter region affecting transcription factors and potentially influencing Alzheimer's disease (AD) risk. The analysis of the provided abstracts shows that pmid37201029 specifically discusses two SNPs: G-71C (rs71542466) and T-80C (rs9274529). These polymorphisms alter transcription factor binding, which could impact HLA-DQB1 expression and AD risk. No other abstracts mention these specific SNPs in the context of AD.\n\n**Answer: C. Both A and B**",
            "pmid": [
                "pmid35341343",
                "pmid25651370",
                "pmid37201029",
                "pmid18996360",
                "pmid30820047",
                "pmid23948886",
                "pmid15635706",
                "pmid15375678",
                "pmid25273678",
                "pmid20450896"
            ]
        },
        "genetic_28": {
            "question": "Does the -1314C allele of the ADAM9 gene promoter have a protective effect against Alzheimer's disease?",
            "answer": "The -1314C allele of the ADAM9 gene promoter has been shown to have a protective effect against Alzheimer's disease.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid19237226",
                "pmid22572541",
                "pmid25631235",
                "pmid20627730",
                "pmid18996360",
                "pmid17440933",
                "pmid12161276",
                "pmid19441127",
                "pmid15024730",
                "pmid12962917"
            ]
        },
        "genetic_29": {
            "question": "Which mutation in the PSEN1 gene is associated with both familial Lewy body disease and variant Alzheimer's disease?",
            "answer": "The correct answer is:\n\nD. PS1 deltaT440\n\nAnswer: D",
            "pmid": [
                "pmid35247599",
                "pmid32754199",
                "pmid18045903",
                "pmid31235344",
                "pmid32121568",
                "pmid35231845",
                "pmid12925374",
                "pmid20158511",
                "pmid31165862",
                "pmid38203287"
            ]
        },
        "genetic_30": {
            "question": "Which gene's up-regulation is associated with the protective effects of omega-3 PUFAs against Alzheimer's disease?",
            "answer": "The correct answer is C. MAG, as indicated by the study in pmid39453315 where MAG expression was up-regulated and associated with the protective effects of omega-3 PUFAs against Alzheimer's disease.\n\nAnswer: C. MAG",
            "pmid": [
                "pmid39453315",
                "pmid27474225",
                "pmid32486013",
                "pmid30296191",
                "pmid15788759",
                "pmid18037281",
                "pmid12938026",
                "pmid26965310",
                "pmid26491253",
                "pmid25311278"
            ]
        },
        "genetic_31": {
            "question": "What is the primary mechanism by which β-asarone exerts neuroprotective effects in an Alzheimer’s disease cellular model?",
            "answer": "The primary mechanism by which β-asarone exerts neuroprotective effects in an Alzheimer’s disease cellular model is by activating the PI3K/Akt/Nrf2 signaling pathway to reduce oxidative stress and apoptosis.\n\n**Answer: D. By activating the PI3K/Akt/Nrf2 signaling pathway to reduce oxidative stress and apoptosis.**",
            "pmid": [
                "pmid34040526",
                "pmid21391434",
                "pmid20307525",
                "pmid25160744",
                "pmid26271288",
                "pmid35204164",
                "pmid26696494",
                "pmid20950278",
                "pmid28131834",
                "pmid35682567"
            ]
        },
        "genetic_32": {
            "question": "Does the missense variant rs117916664 in the ACAA1 gene contribute to early-onset Alzheimer's disease?",
            "answer": "The missense variant rs117916664 in the ACAA1 gene has been identified as contributing to early-onset Alzheimer's disease. Studies have shown that this variant impairs lysosomal function and exacerbates amyloid-beta pathology, leading to cognitive decline.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid34465723",
                "pmid15288432",
                "pmid29441941",
                "pmid29782324",
                "pmid25273678",
                "pmid33057949",
                "pmid15024730",
                "pmid16223550",
                "pmid11029529",
                "pmid30820047"
            ]
        },
        "genetic_33": {
            "question": "Which RYR3 gene variants are associated with the age at onset of Alzheimer's disease, hypertension, and diabetes?",
            "answer": "The RYR3 gene variants rs4780174 and rs7498093 are associated with the age at onset of Alzheimer's disease, hypertension, and diabetes.\n\nANSWER: B",
            "pmid": [
                "pmid29590321",
                "pmid12807963",
                "pmid36069947",
                "pmid24278306",
                "pmid33152005",
                "pmid10490699",
                "pmid16988505",
                "pmid12384789",
                "pmid12938026",
                "pmid19631630"
            ]
        },
        "genetic_34": {
            "question": "Does the MAPT-A152T mutation enhance neuronal excitability through the tau-Fyn-NMDAR pathway in excitatory neurons, contributing to Alzheimer's disease pathogenesis?",
            "answer": "The MAPT-A152T mutation enhances neuronal excitability through the tau-Fyn-NMDAR pathway in excitatory neurons, contributing to Alzheimer's disease pathogenesis. \n\n**Answer: Yes**\n\nA. Yes",
            "pmid": [
                "pmid39811068",
                "pmid34274950",
                "pmid22556362",
                "pmid9850923",
                "pmid21228179",
                "pmid28415654",
                "pmid24334724",
                "pmid16115884",
                "pmid2391515",
                "pmid36945524"
            ]
        },
        "genetic_35": {
            "question": "Which allele is associated with a higher risk of late-onset Alzheimer's disease (LOAD) when combined with the ALDH2(*)2 polymorphism?",
            "answer": "The allele associated with a higher risk of late-onset Alzheimer's disease (LOAD) when combined with the ALDH2*2 polymorphism is **APOE-epsilon4**.\n\nAnswer: C. APOE-epsilon4",
            "pmid": [
                "pmid11464464",
                "pmid10873585",
                "pmid9425904",
                "pmid30820047",
                "pmid10208564",
                "pmid34978151",
                "pmid14741412",
                "pmid37666928",
                "pmid23690001",
                "pmid15024730"
            ]
        },
        "genetic_37": {
            "question": "Does CRMP-2 expression influenced by the PI3K-mTOR-S6K pathway play a role in Alzheimer's disease?",
            "answer": "The analysis of the provided context indicates that CRMP-2 is involved in Alzheimer's disease through its phosphorylation and accumulation in neurofibrillary tangles. Additionally, its expression is regulated by the PI3K-mTOR-S6K pathway, which affects neuronal viability. Therefore, the influence of this pathway on CRMP-2 does play a role in AD.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid21271304",
                "pmid28966575",
                "pmid3165303",
                "pmid24334724",
                "pmid2391515",
                "pmid7936052",
                "pmid11677259",
                "pmid33420799",
                "pmid28413194",
                "pmid9878757"
            ]
        },
        "genetic_38": {
            "question": "Does a mutation in the DAOA gene modify the age of onset in PSEN1 E280A Alzheimer's disease?",
            "answer": "The study by pmid26949549 clearly indicates that a mutation in the DAOA gene modifies the age of onset in PSEN1 E280A Alzheimer's disease. \n\nAnswer: A. Yes",
            "pmid": [
                "pmid26949549",
                "pmid22829467",
                "pmid35247599",
                "pmid36951251",
                "pmid20158511",
                "pmid31235344",
                "pmid36039401",
                "pmid12925374",
                "pmid35231845",
                "pmid34034613"
            ]
        },
        "genetic_39": {
            "question": "Does the inhibition of BET proteins reduce the expression of genes involved in the pathomechanism of Alzheimer's disease in microglia?",
            "answer": "Yes, inhibiting BET proteins reduces the expression of genes involved in Alzheimer's disease pathomechanism in microglia.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid36613460",
                "pmid30178892",
                "pmid8242380",
                "pmid17261088",
                "pmid10095092",
                "pmid22378890",
                "pmid31982468",
                "pmid30413160",
                "pmid33029126",
                "pmid39474846"
            ]
        },
        "genetic_40": {
            "question": "Which of the following is associated with an increased risk of developing Alzheimer's disease due to altered MS4A6A gene expression?",
            "answer": "The question asks which alteration in MS4A6A gene expression is associated with an increased risk of AD. From the studies reviewed:\n\n1. **Option A**: Lower expression of full-length V1-MS4A6A is linked to the risk allele, impairing lysosomal function and increasing AD risk.\n2. **Option B**: Higher expression of V4-MS4A6A, which lacks protective functions, is also associated with increased risk.\n\nBoth options are supported by the studies as contributing factors. However, since only one answer can be chosen and the study emphasizes that the protective allele increases lysosomal function via higher V1 levels, lower V1 expression (Option A) is directly tied to impaired function and increased risk.\n\n**Answer:** Lower expression of full-length V1-MS4A6A transcripts (Option A).",
            "pmid": [
                "pmid27244883",
                "pmid36798226",
                "pmid26923404",
                "pmid23226438",
                "pmid33419465",
                "pmid25189118",
                "pmid17510946",
                "pmid17284348",
                "pmid15024730",
                "pmid30820047"
            ]
        },
        "genetic_41": {
            "question": "Does the N405S mutation in the PS1 gene lead to widespread cortical amyloid deposition in Alzheimer's disease?",
            "answer": "The N405S mutation in the PS1 gene is associated with increased Aβ42 levels and widespread cortical amyloid deposition, as supported by multiple studies. \n\n**Answer:** A. Yes",
            "pmid": [
                "pmid10644793",
                "pmid11395394",
                "pmid9189043",
                "pmid9737546",
                "pmid35247599",
                "pmid8837617",
                "pmid11029529",
                "pmid20850903",
                "pmid8474686",
                "pmid37692508"
            ]
        },
        "genetic_42": {
            "question": "Does the -499A>G polymorphism of the MAPK8IP1 gene increase the risk of Alzheimer's disease in individuals with the CC genotype of the LRP gene?",
            "answer": "The question asks whether the -499A>G polymorphism of the MAPK8IP1 gene increases the risk of Alzheimer's disease (AD) in individuals with the CC genotype of the LRP gene. Based on the provided context:\n\n- The study in pmid17614163 found that the Arg952Gln mutation in LRP8 does not directly increase AD risk but interacts with the MAPK8IP1 G allele, increasing AD risk when both are present.\n- The question refers to the CC genotype of the LRP gene. Without clarity on which specific polymorphism corresponds to the CC genotype, it's uncertain if this variant is the same as Arg952Gln in LRP8.\n\nGiven that the interaction involves a specific mutation (Arg952Gln) and not necessarily the CC genotype, unless explicitly stated, we cannot confirm an increased risk. Therefore, the answer is:\n\n**B. No**",
            "pmid": [
                "pmid17614163",
                "pmid28415654",
                "pmid29441941",
                "pmid15288432",
                "pmid25273678",
                "pmid15024730",
                "pmid9425904",
                "pmid25130782",
                "pmid30820047",
                "pmid23111454"
            ]
        },
        "genetic_43": {
            "question": "Does the P117R mutation in presenilin 1 affect cell cycle regulation and contribute to Alzheimer's disease progression?",
            "answer": "The answer is A. Yes.\n\n**Step-by-Step Explanation:**\n\n1. **Understanding the Query:** The question asks if the P117R mutation in presenilin-1 affects cell cycle regulation and contributes to Alzheimer's disease progression.\n\n2. **Reviewing the Context:** The provided context discusses altered cell cycle-related gene expression in a transgenic mouse model of AD but doesn't specifically mention the P117R mutation or its effects on the cell cycle.\n\n3. **Assessing Relevant Information:** While the new context talks about cell cycle issues in AD, it doesn't provide specific details about the P117R mutation. However, external information (from pmid22810102) indicates that this mutation does impact cell cycle regulation by increasing p53 and p21 levels.\n\n4. **Conclusion:** Based on the external study, the P117R mutation affects cell cycle regulation, contributing to AD progression. The new context doesn't provide additional specific information about this mutation but supports the broader concept of cell cycle involvement in AD.\n\n**Answer: A. Yes**\n\nThe P117R mutation in presenilin-1 disrupts cell cycle regulation, which contributes to Alzheimer's disease progression.",
            "pmid": [
                "pmid11124426",
                "pmid22810102",
                "pmid10393846",
                "pmid9737546",
                "pmid9189043",
                "pmid11311782",
                "pmid9790190",
                "pmid17437536",
                "pmid11395394",
                "pmid22702220"
            ]
        },
        "genetic_44": {
            "question": "How does the dysregulation of NRIP1 expression in Down syndrome potentially relate to Alzheimer's disease?",
            "answer": "The dysregulation of NRIP1 expression in Down syndrome, characterized by its overexpression due to reduced m6A modifications, leads to mitochondrial dysfunction. This mitochondrial issue is a known factor contributing to Alzheimer's disease, suggesting that NRIP1 overexpression may play a role in the development of AD in individuals with DS.\n\n**Answer:** A. NRIP1 overexpression leads to mitochondrial dysfunction; which is a known factor in Alzheimer's disease.\"\n\nANSWER: A",
            "pmid": [
                "pmid33869171",
                "pmid10666665",
                "pmid32962300",
                "pmid28807816",
                "pmid15068237",
                "pmid39458132",
                "pmid31263630",
                "pmid16442855",
                "pmid24735980",
                "pmid29937728"
            ]
        },
        "genetic_46": {
            "question": "Which of the following best describes the association of the rs6922617 variant in the TREM gene cluster with Alzheimer's disease neuropathology?",
            "answer": "D. It is associated with elevated amyloid burden and reduced glucose metabolism, but not with increased tau accumulation.",
            "pmid": [
                "pmid39051708",
                "pmid31721052",
                "pmid27939925",
                "pmid36815315",
                "pmid37980675",
                "pmid24899047",
                "pmid23692967",
                "pmid33419465",
                "pmid34663480",
                "pmid36683512"
            ]
        },
        "genetic_47": {
            "question": "Is DSCR1 (Adapt78) gene expression associated with Alzheimer's disease?",
            "answer": "A: Yes",
            "pmid": [
                "pmid11483593",
                "pmid12716059",
                "pmid12582468",
                "pmid29441941",
                "pmid23226438",
                "pmid16442855",
                "pmid12938026",
                "pmid15276231",
                "pmid17614163",
                "pmid25130782"
            ]
        },
        "genetic_48": {
            "question": "Does downregulation of miR-29c correlate with increased BACE1 expression in Alzheimer's disease?",
            "answer": "The correct answer is:\n\n**A. Yes**\n\nExplanation: The study referenced by pmid18434550 found that miR-29a, -29b-1, and -29c are downregulated in Alzheimer's disease patients with high BACE1 levels, indicating a correlation between the downregulation of miR-29c and increased BACE1 expression.",
            "pmid": [
                "pmid18434550",
                "pmid25973041",
                "pmid34956559",
                "pmid25955795",
                "pmid38215068",
                "pmid18234899",
                "pmid30576233",
                "pmid26398571",
                "pmid37300691",
                "pmid34945753"
            ]
        },
        "genetic_49": {
            "question": "Does the upregulation of DR6 expression correlate with neuronal death in Alzheimer's disease?",
            "answer": "The question asks whether the upregulation of DR6 expression correlates with neuronal death in Alzheimer's disease (AD). From the provided context, pmid23559013 specifically states that DR6 expression is upregulated in AD cortex and correlates with elevated neuronal death. This directly answers the question.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid23559013",
                "pmid17055782",
                "pmid29634233",
                "pmid11193159",
                "pmid9850923",
                "pmid10319892",
                "pmid11276052",
                "pmid26582459",
                "pmid10666670",
                "pmid12203047"
            ]
        },
        "genetic_50": {
            "question": "Does loss of ataxin-1 increase BACE1 expression and contribute to Alzheimer's disease pathogenesis?",
            "answer": "A: Yes",
            "pmid": [
                "pmid31442405",
                "pmid18005427",
                "pmid20455082",
                "pmid30626751",
                "pmid20097758",
                "pmid32223911",
                "pmid16354928",
                "pmid17553417",
                "pmid20628574",
                "pmid31416794"
            ]
        },
        "genetic_51": {
            "question": "Which polymorphisms in the LXR-beta gene were associated with an increased risk of Alzheimer's disease when combined with the HO-1 (-413) TT genotype?",
            "answer": "C. rs2695121 (intron 2); rs1052533 (intron 5); and rs1405655 (intron 7)",
            "pmid": [
                "pmid18597895",
                "pmid12807963",
                "pmid15860461",
                "pmid12384789",
                "pmid16328515",
                "pmid12938026",
                "pmid17614163",
                "pmid15276231",
                "pmid9425904",
                "pmid23948886"
            ]
        },
        "genetic_52": {
            "question": "Which allele in the CYP46A1 gene increases the risk of developing Alzheimer's disease when associated with the APOEpsilon3 allele?",
            "answer": "The correct answer is B. CYP46A1-T allele.\n\n**Answer:** B. CYP46A1-T allele",
            "pmid": [
                "pmid15165699",
                "pmid16340204",
                "pmid12123847",
                "pmid12533085",
                "pmid27583919",
                "pmid9425904",
                "pmid17510946",
                "pmid16734927",
                "pmid16882736",
                "pmid25130782"
            ]
        },
        "genetic_53": {
            "question": "Does the downregulation of BARHL1 in Alzheimer's disease potentially affect cognitive functions through the ESR1 pathway?",
            "answer": "The downregulation of BARHL1 in Alzheimer's disease is associated with disruptions in a network involving ESR1. This network regulates neurogenesis, beta-amyloid metabolism, and memory processes. Studies indicate that ESR1 plays a significant role in AD progression and cognitive decline. Therefore, the downregulation of BARHL1 likely affects cognitive functions through the ESR1 pathway.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid28956815",
                "pmid8687030",
                "pmid29641978",
                "pmid8740986",
                "pmid10095092",
                "pmid20007471",
                "pmid36326669",
                "pmid39231208",
                "pmid11447833",
                "pmid24278306"
            ]
        },
        "genetic_54": {
            "question": "Does the presenilin 1 mutation (PS1M146L) linked to Alzheimer's disease affect filamin expression and distribution?",
            "answer": "**Answer:** A. Yes",
            "pmid": [
                "pmid20847418",
                "pmid9437013",
                "pmid11311782",
                "pmid9189043",
                "pmid11124426",
                "pmid11395394",
                "pmid9737546",
                "pmid10386952",
                "pmid8837617",
                "pmid21086758"
            ]
        },
        "genetic_55": {
            "question": "Does the C677T variant in MTHFR modulate associations between plasma ApoE levels and Alzheimer's disease biomarkers?",
            "answer": "The analysis of the studies indicates that while the MTHFR C677T variant is associated with changes in brain structure and homocysteine levels, there is no evidence from the provided context suggesting it modulates associations between plasma ApoE levels and Alzheimer's disease biomarkers. Therefore, the answer is:\n\n**B. No**",
            "pmid": [
                "pmid27380243",
                "pmid16055944",
                "pmid12784029",
                "pmid17628213",
                "pmid19342053",
                "pmid18525129",
                "pmid33057949",
                "pmid24179750",
                "pmid37854772",
                "pmid10208564"
            ]
        },
        "genetic_56": {
            "question": "Does the presence of the H63D variant in males with the E4 allele significantly lower the risk of Alzheimer's disease?",
            "answer": "The presence of the H63D variant in males with the E4 allele does not significantly lower the risk of Alzheimer's disease; instead, it may lead to an earlier age of onset. \n\n**Answer: B. No**",
            "pmid": [
                "pmid17628213",
                "pmid27244883",
                "pmid34541285",
                "pmid26923404",
                "pmid16340204",
                "pmid15024730",
                "pmid12123847",
                "pmid25130782",
                "pmid18525129",
                "pmid11029529"
            ]
        },
        "genetic_57": {
            "question": "Is the SNP-rs6922617 in the TREM gene cluster associated with a higher global amyloid-ligands PET burden in Alzheimer's disease?",
            "answer": "The provided context does not mention SNP-rs6922617 in relation to amyloid-ligands PET burden. Therefore, based on the given information, there is no evidence to determine if SNP-rs6922617 is associated with a higher global amyloid-ligands PET burden in Alzheimer's disease.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid39051708",
                "pmid31721052",
                "pmid36815315",
                "pmid27939925",
                "pmid24899047",
                "pmid26058955",
                "pmid34663480",
                "pmid37980675",
                "pmid23692967",
                "pmid31727362"
            ]
        },
        "genetic_58": {
            "question": "In Alzheimer's disease (AD) human skin fibroblasts, which mutation is associated with highly aggressive AD and persistent BKB2R signaling?",
            "answer": "The correct answer based on the context provided is:\n\n**A. PS-1 M146L**\n\n**Answer:** A",
            "pmid": [
                "pmid19247475",
                "pmid14563691",
                "pmid8012386",
                "pmid39000564",
                "pmid27060961",
                "pmid31995180",
                "pmid22810102",
                "pmid35247599",
                "pmid17560791",
                "pmid22529981"
            ]
        },
        "genetic_59": {
            "question": "Is there an association between SIRT1 gene polymorphisms and Alzheimer's disease?",
            "answer": "B: No",
            "pmid": [
                "pmid15288432",
                "pmid15276231",
                "pmid25130782",
                "pmid25273678",
                "pmid28415654",
                "pmid29441941",
                "pmid15375678",
                "pmid28269768",
                "pmid11029529",
                "pmid12938026"
            ]
        },
        "genetic_60": {
            "question": "Which single-nucleotide polymorphism (SNP) of the MAPT gene was found to be associated with a lower risk of sporadic Alzheimer's disease (SAD) in a meta-analysis?",
            "answer": "The SNP rs242557G/A was found to be associated with a lower risk of SAD in a meta-analysis. \n\n**Answer: C. rs242557G/A**",
            "pmid": [
                "pmid28415654",
                "pmid29098924",
                "pmid28100725",
                "pmid29441941",
                "pmid30820047",
                "pmid25130782",
                "pmid25273678",
                "pmid15288432",
                "pmid22556362",
                "pmid39051708"
            ]
        },
        "genetic_61": {
            "question": "Which gene variant interacts with APOE and increases the risk for Alzheimer's disease?",
            "answer": "The answer is option B: FTO AA-genotype. This gene variant interacts with APOE and increases the risk for Alzheimer's disease.\n\nNew Answer: \n\nB. FTO AA-genotype",
            "pmid": [
                "pmid9425904",
                "pmid10208564",
                "pmid37666928",
                "pmid34978151",
                "pmid33057949",
                "pmid19660836",
                "pmid33152005",
                "pmid21098976",
                "pmid32808727",
                "pmid36039401"
            ]
        },
        "genetic_62": {
            "question": "Does the IDE gene variant (c.782G > A, p.R261Q) contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The contextual information does not provide any specific details about the IDE gene variant c.782G > A (p.R261Q) and its contribution to Alzheimer's disease. All mentioned studies discuss other variants within the IDE gene but do not address this particular variant.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid12161276",
                "pmid17496198",
                "pmid20098734",
                "pmid18996360",
                "pmid20880607",
                "pmid35236268",
                "pmid11029529",
                "pmid33419465",
                "pmid37544578",
                "pmid15635706"
            ]
        },
        "genetic_63": {
            "question": "Which mutant allele is associated with Alzheimer's disease and affects Wnt/beta-catenin signaling by increasing TCF/beta-catenin/CBP-mediated transcription?",
            "answer": "The mutant allele associated with Alzheimer's disease that affects Wnt/beta-catenin signaling by increasing TCF/beta-catenin/CBP-mediated transcription is **PS-1(L286V)**.\n\n**Answer: A. PS-1(L286V)**",
            "pmid": [
                "pmid11358522",
                "pmid16093313",
                "pmid9790190",
                "pmid35247599",
                "pmid37692508",
                "pmid15972961",
                "pmid31235344",
                "pmid11124426",
                "pmid32754199",
                "pmid34465723"
            ]
        },
        "genetic_64": {
            "question": "Which allele of the COMT gene was found to be an independent risk factor for Alzheimer's disease in men without the APOE epsilon4 allele?",
            "answer": "D. Met allele",
            "pmid": [
                "pmid24575113",
                "pmid22890094",
                "pmid33057949",
                "pmid9425904",
                "pmid16223550",
                "pmid28415654",
                "pmid15165699",
                "pmid16340204",
                "pmid15288432",
                "pmid11029529"
            ]
        },
        "genetic_65": {
            "question": "Which long noncoding RNA was shown to play a role in Alzheimer's disease progression by regulating the miR-361-3p/ZNF217 axis?",
            "answer": "The study found that SNHG1 acts as a long noncoding RNA regulating the miR-361-3p/ZNF217 axis by sponging miR-361-3p in Alzheimer's disease progression.\n\n**Answer: A. SNHG1**",
            "pmid": [
                "pmid32035423",
                "pmid30809552",
                "pmid34024830",
                "pmid32741808",
                "pmid35656102",
                "pmid27501805",
                "pmid37217807",
                "pmid37187245",
                "pmid34990931",
                "pmid31333395"
            ]
        },
        "genetic_66": {
            "question": "Does the SERPINA5 genetic variant p.E228Q contribute to clinical differences in Alzheimer's disease?",
            "answer": "The provided studies do not mention SERPINA5 or the p.E228Q variant, so there is no evidence here linking it to Alzheimer's disease.\n\n**Answer: UNRELATED**",
            "pmid": [
                "pmid33662018",
                "pmid15024730",
                "pmid21899770",
                "pmid15288432",
                "pmid11029529",
                "pmid39051708",
                "pmid33419465",
                "pmid37841863",
                "pmid20850903",
                "pmid23111454"
            ]
        },
        "genetic_67": {
            "question": "Is decreased expression of the APOA1-APOC3-APOA4 gene cluster associated with the risk of Alzheimer's disease?",
            "answer": "**Answer: A. Yes**\n\nThe study in pmid26491253 clearly indicates that decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with an increased risk of Alzheimer's disease, as evidenced by lower levels of these genes in AD patients compared to controls.",
            "pmid": [
                "pmid26491253",
                "pmid23690001",
                "pmid9425904",
                "pmid18073484",
                "pmid17510946",
                "pmid36039401",
                "pmid10208564",
                "pmid33419465",
                "pmid23226438",
                "pmid12873803"
            ]
        },
        "genetic_68": {
            "question": "Does the presence of a stop-loss variant in the RGS7 gene correlate with a specific subtype of Alzheimer's disease?",
            "answer": "B. No",
            "pmid": [
                "pmid29441941",
                "pmid29782324",
                "pmid15288432",
                "pmid11029529",
                "pmid12161276",
                "pmid24141082",
                "pmid25130782",
                "pmid26923404",
                "pmid10490699",
                "pmid35264725"
            ]
        },
        "genetic_69": {
            "question": "NF-kappaB-induced upregulation of miR-146a-5p was found to promote oxidative stress and pyroptosis in Alzheimer's disease by targeting which gene?",
            "answer": "The gene targeted by NF-kappaB-induced upregulation of miR-146a-5p to promote oxidative stress and pyroptosis in Alzheimer's disease is TIGAR.\n\nAnswer: A. TIGAR",
            "pmid": [
                "pmid18801740",
                "pmid37300691",
                "pmid28655611",
                "pmid19540598",
                "pmid24586483",
                "pmid22302353",
                "pmid33935653",
                "pmid34992508",
                "pmid27520374",
                "pmid26258756"
            ]
        },
        "genetic_70": {
            "question": "Which of the following genetic variants was associated with a reduced risk of Alzheimer's disease relative to primary age-related tauopathy (PART)?",
            "answer": "The study comparing Alzheimer's disease (AD) and primary age-related tauopathy (PART) identified that APOE ε4, APOE ε2, and rs6656401 in CR1 were associated with reduced AD risk relative to PART. \n\nAnswer: D. All of the above",
            "pmid": [
                "pmid11698154",
                "pmid9425904",
                "pmid33057949",
                "pmid30820047",
                "pmid30128317",
                "pmid15024730",
                "pmid10208564",
                "pmid33419465",
                "pmid34978151",
                "pmid34541285"
            ]
        },
        "genetic_71": {
            "question": "Are variants in CYP17 and CYP19 cytochrome P450 genes associated with the onset of Alzheimer's disease in women with Down syndrome?",
            "answer": "The answer is A. Yes.\n\n**Answer:**  \nA. Yes",
            "pmid": [
                "pmid22057025",
                "pmid16882736",
                "pmid22474448",
                "pmid10666665",
                "pmid19478482",
                "pmid27583919",
                "pmid15068237",
                "pmid16442855",
                "pmid22156442",
                "pmid32962300"
            ]
        },
        "genetic_73": {
            "question": "Is the IFITM3 gene associated with less vulnerability to cognitive decline and Alzheimer's disease biomarkers?",
            "answer": "The first context explicitly states that the IFITM3 gene is associated with less vulnerability to cognitive decline and Alzheimer's disease biomarkers. The other contexts do not mention IFITM3 or provide any relevant information about it.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid35769874",
                "pmid35056363",
                "pmid15464268",
                "pmid26243271",
                "pmid39051708",
                "pmid27272392",
                "pmid28269768",
                "pmid18430995",
                "pmid29480181",
                "pmid36815315"
            ]
        },
        "genetic_74": {
            "question": "Which gene variant was found to have a protective effect against the progression to mild cognitive impairment or Alzheimer's disease (MCI/LOAD)?",
            "answer": "C. PICALM-rs3851179-G",
            "pmid": [
                "pmid25189118",
                "pmid36798226",
                "pmid22833209",
                "pmid37841863",
                "pmid30820047",
                "pmid26243271",
                "pmid15024730",
                "pmid23226438",
                "pmid16340204",
                "pmid32447570"
            ]
        },
        "genetic_75": {
            "question": "Does transferrin play a role in the regulation of APH-1alpha/beta and Presenilin 1 expression, which contributes to the pathogenesis of Alzheimer's disease?",
            "answer": "The contextual information provided in pmid30383537 explicitly states that transferrin plays a role in regulating APH-1alpha/beta and Presenilin 1 expression, contributing to Alzheimer's disease pathogenesis.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid30383537",
                "pmid38296900",
                "pmid19148186",
                "pmid17222949",
                "pmid18367332",
                "pmid9790190",
                "pmid17560791",
                "pmid17437536",
                "pmid24333930",
                "pmid11755001"
            ]
        },
        "genetic_76": {
            "question": "Does the T835M mutation in the UNC5C gene increase the risk of Alzheimer's disease?",
            "answer": "No, according to the studies provided, there is insufficient information to establish an association between the T835M mutation in the UNC5C gene and Alzheimer's disease. None of the listed articles discuss this specific mutation or its relation to AD risk.\n\nAnswer: No",
            "pmid": [
                "pmid25419706",
                "pmid37841863",
                "pmid33419465",
                "pmid15024730",
                "pmid30820047",
                "pmid29480181",
                "pmid11029529",
                "pmid39051708",
                "pmid27781389",
                "pmid29782324"
            ]
        },
        "genetic_77": {
            "question": "Does PS1 mutation interfere with PS2-mediated activation of pathways relevant to Alzheimer's disease?",
            "answer": "The analysis indicates that a mutation in PS1 does interfere with PS2-mediated pathways relevant to Alzheimer's disease. The key reference (pmid11124426) shows that PS1 mutations affect PS2 processing and gamma-secretase activity.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid35247599",
                "pmid11124426",
                "pmid9151738",
                "pmid10393846",
                "pmid12460542",
                "pmid9189043",
                "pmid9850923",
                "pmid10662826",
                "pmid21086758",
                "pmid9878757"
            ]
        },
        "genetic_78": {
            "question": "Does the PSEN1 His214Asn mutation contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "A: A",
            "pmid": [
                "pmid35247599",
                "pmid32121568",
                "pmid38203287",
                "pmid32754199",
                "pmid31235344",
                "pmid35231845",
                "pmid20850903",
                "pmid20158511",
                "pmid31391004",
                "pmid27060961"
            ]
        },
        "genetic_79": {
            "question": "Which genetic polymorphism of ABCA1 is associated with an increased risk of late-onset Alzheimer's disease in females?",
            "answer": "The genetic polymorphism of ABCA1 associated with an increased risk of late-onset Alzheimer's disease in females is R219K (rs2230806).\n\n**Answer: A. R219K (rs2230806)**",
            "pmid": [
                "pmid16725228",
                "pmid17510946",
                "pmid15288432",
                "pmid25273678",
                "pmid15024730",
                "pmid23111454",
                "pmid32447570",
                "pmid29441941",
                "pmid15649702",
                "pmid24141082"
            ]
        },
        "genetic_80": {
            "question": "lncRNA NKILA exacerbates Alzheimer's disease progression by regulating which transcription-mediated process?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid37217807",
                "pmid30809552",
                "pmid36453506",
                "pmid35098860",
                "pmid32035423",
                "pmid27501805",
                "pmid35656102",
                "pmid36092938",
                "pmid37187245",
                "pmid36214709"
            ]
        },
        "genetic_81": {
            "question": "Which allele of the SIRT2 gene rs2015 locus is associated with a reduced risk of developing Alzheimer's disease?",
            "answer": "The contextual information does not mention the SIRT2 gene or the rs2015 locus. Therefore, none of the provided options are supported by the given context.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid37117777",
                "pmid30820047",
                "pmid15024730",
                "pmid39051708",
                "pmid25130782",
                "pmid35264725",
                "pmid33152005",
                "pmid20850903",
                "pmid28269768",
                "pmid16223550"
            ]
        },
        "genetic_82": {
            "question": "Does lower expression of Ndfip1 contribute to Alzheimer's disease pathogenesis by reducing DMT1 degradation and increasing iron influx in the brain?",
            "answer": "The analysis of multiple studies indicates that lower expression of Ndfip1 leads to reduced degradation of DMT1. This reduction allows for increased DMT1 activity, which in turn enhances iron influx into brain cells. Elevated iron levels contribute to oxidative stress and other pathological processes associated with Alzheimer's disease progression.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid29937728",
                "pmid20401186",
                "pmid10095092",
                "pmid12203047",
                "pmid32444869",
                "pmid33597269",
                "pmid19679638",
                "pmid24863668",
                "pmid24199959",
                "pmid35391749"
            ]
        },
        "genetic_83": {
            "question": "Which variant of the CHI3L1 gene is associated with slower progression of Alzheimer's disease?",
            "answer": "B. A variant decreasing CSF YKL-40 expression",
            "pmid": [
                "pmid30223258",
                "pmid33328329",
                "pmid35234337",
                "pmid21562723",
                "pmid20540736",
                "pmid16223550",
                "pmid20850903",
                "pmid18562794",
                "pmid24278306",
                "pmid32919460"
            ]
        },
        "genetic_84": {
            "question": "Does inhibition of PARP1 enhance the expression of genes related to Alzheimer's disease in PC12 cells?",
            "answer": "The inhibition of PARP1 in PC12 cells under Abeta42 oligomer toxicity leads to an increase in the expression of genes related to Alzheimer's disease, including APP cleaving enzymes and sirtuins. \n\n**Answer: A. Yes**",
            "pmid": [
                "pmid24086258",
                "pmid28698968",
                "pmid22430645",
                "pmid23076628",
                "pmid15671026",
                "pmid17911636",
                "pmid10490699",
                "pmid31840000",
                "pmid17803977",
                "pmid26615780"
            ]
        },
        "genetic_85": {
            "question": "Does the UBTF E210K mutation contribute to the pathogenesis of Alzheimer's disease?",
            "answer": "The question regarding whether the UBTF E210K mutation contributes to Alzheimer's disease cannot be answered with the provided context because there is no mention of UBTF or this specific mutation in any of the studies referenced.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid21899770",
                "pmid12962917",
                "pmid11029529",
                "pmid15635706",
                "pmid15024730",
                "pmid15288432",
                "pmid35641311",
                "pmid33419465",
                "pmid15464268",
                "pmid25273678"
            ]
        },
        "genetic_86": {
            "question": "Are genes encoding the NALCN channelosome associated with susceptibility to Alzheimer's disease?",
            "answer": "B. No",
            "pmid": [
                "pmid16223550",
                "pmid15276231",
                "pmid37841863",
                "pmid12582468",
                "pmid15288432",
                "pmid32257549",
                "pmid12384789",
                "pmid11029529",
                "pmid15024730",
                "pmid29441941"
            ]
        },
        "genetic_87": {
            "question": "Which allele of the ACT gene is associated with an increased risk of Alzheimer's disease?",
            "answer": "A",
            "pmid": [
                "pmid11941486",
                "pmid25130782",
                "pmid29441941",
                "pmid30820047",
                "pmid15024730",
                "pmid16223550",
                "pmid17510946",
                "pmid15288432",
                "pmid25273678",
                "pmid24141082"
            ]
        },
        "genetic_88": {
            "question": "Does the SNP rs76904798 of the LRRK2 gene reduce the risk of Alzheimer's disease in northern Han Chinese individuals?",
            "answer": "The SNP rs76904798 of the LRRK2 gene is associated with a reduced risk of Alzheimer's disease in northern Han Chinese individuals.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid26738859",
                "pmid25141968",
                "pmid15276231",
                "pmid26680604",
                "pmid29432188",
                "pmid17614163",
                "pmid29441941",
                "pmid24113560",
                "pmid27272392",
                "pmid18562794"
            ]
        },
        "genetic_89": {
            "question": "Does downregulation of OPTN contribute to neuroinflammation in Alzheimer's disease through AIM2 inflammasome and RIPK1 pathways?",
            "answer": "The downregulation of OPTN contributes to neuroinflammation in Alzheimer's disease through the activation of the AIM2 inflammasome and RIPK1 pathways.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid34861878",
                "pmid12453679",
                "pmid27335702",
                "pmid33181351",
                "pmid9514829",
                "pmid35662233",
                "pmid12203047",
                "pmid35474599",
                "pmid34486652",
                "pmid11556547"
            ]
        },
        "genetic_90": {
            "question": "Does the CP2/LBP-1c/LSF transcription factor enhance the transcription of the GARS-AIRS-GART gene in Down syndrome-related Alzheimer's disease?",
            "answer": "The study by pmid17902044 indicates that CP2/LBP-1c/LSF does enhance the transcription of GARS-AIRS-GART in Down syndrome-related Alzheimer's disease.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid17902044",
                "pmid15068237",
                "pmid10666665",
                "pmid8427604",
                "pmid31263630",
                "pmid16442855",
                "pmid32962300",
                "pmid11771742",
                "pmid24735980",
                "pmid28807816"
            ]
        },
        "genetic_91": {
            "question": "Is there evidence linking rumination, mediated by MTHFD1L gene variants, todelirium?",
            "answer": "The analysis indicates that while MTHFD1L variants are associated with rumination and depression, there is no evidence linking these to delirium based on the provided studies.\n\n**Answer: B. No**",
            "pmid": [
                "pmid26926881",
                "pmid34959947",
                "pmid33779822",
                "pmid34650206",
                "pmid11723200",
                "pmid19219710",
                "pmid29317606",
                "pmid31405128",
                "pmid29478862",
                "pmid30248905"
            ]
        },
        "genetic_92": {
            "question": "Are variants in the COX6B1, SURF1, and COX10 genes associated with Alzheimer's disease?",
            "answer": "A: A. Yes\n\nThe answer is A because one of the studies explicitly states that variants in COX6B1, SURF1, and COX10 are associated with Alzheimer's disease.\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Information:** Among the provided studies, one mentions an association between COX6B1, SURF1, COX10 variants and AD.\n2. **Check Other Studies:** The other studies discuss different genes (ABCB1, APP, etc.) not related to the question.\n3. **Conclusion:** Since at least one study confirms the association, the answer is affirmative.\n\n**Answer:**\n\nA. Yes",
            "pmid": [
                "pmid30054583",
                "pmid28412672",
                "pmid32447570",
                "pmid15024730",
                "pmid16223550",
                "pmid25631235",
                "pmid30820047",
                "pmid37544578",
                "pmid39000564",
                "pmid25273678"
            ]
        },
        "genetic_94": {
            "question": "Is there an association between AOC1 gene variants and delirium in adult women with fibromyalgia?",
            "answer": "Based on the analysis of the provided references, there is no indication that AOC1 gene variants are associated with delirium in adult women with fibromyalgia. The studies either discuss other genes related to delirium or focus on different aspects of fibromyalgia without linking AOC1 to delirium.\n\n**Answer: B. No**",
            "pmid": [
                "pmid37359379",
                "pmid33779822",
                "pmid19309018",
                "pmid19219710",
                "pmid37550780",
                "pmid19713702",
                "pmid35017578",
                "pmid17728664",
                "pmid24058735",
                "pmid21613790"
            ]
        },
        "genetic_95": {
            "question": "Does the 3'-UTR +1073 C/T polymorphism of the OLR1 gene associate with Alzheimer's disease?",
            "answer": "The 3'-UTR +1073 C/T polymorphism of the OLR1 gene has been associated with Alzheimer's disease in multiple studies. \n\nAnswer: A. Yes",
            "pmid": [
                "pmid12807963",
                "pmid15860461",
                "pmid15276231",
                "pmid12384789",
                "pmid16328515",
                "pmid29441941",
                "pmid25273678",
                "pmid17614163",
                "pmid12938026",
                "pmid15288432"
            ]
        },
        "genetic_96": {
            "question": "Does the CYP19A1 gene polymorphism rs10046 increase the risk of Alzheimer's disease?",
            "answer": "B. No",
            "pmid": [
                "pmid16882736",
                "pmid27583919",
                "pmid19478482",
                "pmid12123847",
                "pmid23111454",
                "pmid15024730",
                "pmid25130782",
                "pmid12533085",
                "pmid15165699",
                "pmid29441941"
            ]
        },
        "genetic_97": {
            "question": "Are certain allele combinations involving IL6r and C9 genes associated with amyloid burden in Alzheimer's disease?",
            "answer": "B. No",
            "pmid": [
                "pmid10319892",
                "pmid12664314",
                "pmid30820047",
                "pmid15024730",
                "pmid12116197",
                "pmid28106546",
                "pmid15288432",
                "pmid25130782",
                "pmid15276231",
                "pmid25631235"
            ]
        },
        "genetic_98": {
            "question": "Does the AGTPBP1 gene mutation in CONDCA lead to Alzheimer's disease?",
            "answer": "The provided information does not mention or suggest any connection between mutations in the AGTPBP1 gene and Alzheimer's disease. All studies referenced focus on other genes such as ABCB1, ABCA1, ABCA7, NAV3, and UNC5C.\n\n**Answer: B. No**",
            "pmid": [
                "pmid25273678",
                "pmid15288432",
                "pmid23556446",
                "pmid11029529",
                "pmid32447570",
                "pmid15024730",
                "pmid23111454",
                "pmid29782324",
                "pmid37841863",
                "pmid29441941"
            ]
        },
        "genetic_99": {
            "question": "Which of the following best describes the gene expression levels of CHRM1 and CHRM4 in DLB compared to Alzheimer's disease?",
            "answer": "The question asks about the expression levels of CHRM1 and CHRM4 in DLB compared to AD, but none of the provided contexts discuss these genes.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid23226438",
                "pmid24278306",
                "pmid28412672",
                "pmid26491253",
                "pmid17284348",
                "pmid37544578",
                "pmid12384789",
                "pmid30054583",
                "pmid34719321",
                "pmid19826901"
            ]
        },
        "genetic_100": {
            "question": "Does the Y831C mutation in the POLG gene have a statistically significant association with Alzheimer's disease or delirium?",
            "answer": "B",
            "pmid": [
                "pmid37189790",
                "pmid17614163",
                "pmid17728664",
                "pmid25130782",
                "pmid15276231",
                "pmid12384789",
                "pmid15288432",
                "pmid35264725",
                "pmid33779822",
                "pmid36951251"
            ]
        },
        "genetic_101": {
            "question": "Does up-regulation of lncRNA WT1-AS alleviate neuronal damage in Alzheimer's disease by modulating the miR-186-5p/CCND2 axis?",
            "answer": "Based on the analysis of the provided context, only one study (pmid38372094) discusses lncRNA WT1-AS and its role in modulating the miR-186-5p/CCND2 axis to alleviate neuronal damage in Alzheimer's disease. This study directly supports the idea that up-regulation of WT1-AS has a protective effect.\n\n**Answer:** A. Yes",
            "pmid": [
                "pmid38372094",
                "pmid33234729",
                "pmid32035423",
                "pmid37286157",
                "pmid37217807",
                "pmid31949779",
                "pmid36453506",
                "pmid24604632",
                "pmid36092938",
                "pmid32741808"
            ]
        },
        "genetic_102": {
            "question": "Does miRNA-431 prevent synapse loss in an Alzheimer's disease neuronal model by targeting Kremen1?",
            "answer": "A: Yes",
            "pmid": [
                "pmid29643768",
                "pmid37192007",
                "pmid35941185",
                "pmid38322333",
                "pmid32092796",
                "pmid29378298",
                "pmid22926857",
                "pmid28533191",
                "pmid31997075",
                "pmid29286086"
            ]
        },
        "genetic_103": {
            "question": "Which mutation in the APP gene is associated with protection against Alzheimer's disease by promoting beta'-site cleavage?",
            "answer": "The correct answer is:\n\n**B. Leuven mutation (E682K)**\n\nThis mutation promotes beta'-site cleavage, reducing amyloid-beta production and thus offering protection against Alzheimer's disease.",
            "pmid": [
                "pmid8012386",
                "pmid37692508",
                "pmid8886002",
                "pmid21500352",
                "pmid37108607",
                "pmid21812781",
                "pmid12535780",
                "pmid1908231",
                "pmid35247599",
                "pmid25631235"
            ]
        },
        "genetic_104": {
            "question": "Is the DDAH2 (-449 G/C) gene polymorphism associated with Alzheimer's disease or delirium?",
            "answer": "The provided context does not mention the DDAH2 (-449 G/C) gene polymorphism in relation to Alzheimer's disease or delirium.\n\n**Answer:** B. No",
            "pmid": [
                "pmid19309018",
                "pmid25130782",
                "pmid28412672",
                "pmid26491656",
                "pmid21613790",
                "pmid33779822",
                "pmid11723200",
                "pmid15375678",
                "pmid11464464",
                "pmid15635706"
            ]
        },
        "genetic_105": {
            "question": "Does the SLC6A4 gene variant rs7224199 show an association with Alzheimer's disease?",
            "answer": "A. Yes",
            "pmid": [
                "pmid25130782",
                "pmid15276231",
                "pmid31595439",
                "pmid27244883",
                "pmid18490109",
                "pmid39051708",
                "pmid15288432",
                "pmid29441941",
                "pmid37544578",
                "pmid29782324"
            ]
        },
        "genetic_106": {
            "question": "Which variant of the RELN gene has been associated with resilience against presenilin-linked autosomal-dominant Alzheimer's disease (ADAD)?",
            "answer": "The correct answer is:\n\nA. H3447R\n\nThis conclusion is drawn from pmid38754634, which specifically mentions the H3447R variant of the RELN gene in association with resilience against ADAD.",
            "pmid": [
                "pmid39051708",
                "pmid15635706",
                "pmid39000564",
                "pmid25130782",
                "pmid22495348",
                "pmid17496198",
                "pmid38754634",
                "pmid9737546",
                "pmid23948886",
                "pmid30569016"
            ]
        },
        "genetic_107": {
            "question": "Does the presence of EIF2B5 gene mutations associate with delirium in females with ovarioleukodystrophy?",
            "answer": "The provided context does not establish a link between EIF2B5 gene mutations and delirium in females with ovarioleukodystrophy. The case report mentioning EIF2B5 does not discuss delirium, while other studies on delirium genetics do not involve EIF2B5 or ovarioleukodystrophy.\n\nAnswer: B. No",
            "pmid": [
                "pmid35785335",
                "pmid33779822",
                "pmid19219710",
                "pmid19309018",
                "pmid19910874",
                "pmid19713702",
                "pmid17728664",
                "pmid22759724",
                "pmid17250608",
                "pmid26901792"
            ]
        },
        "genetic_108": {
            "question": "Which of the following best describes a key finding regarding Alzheimer’s disease-related molecular changes in SH-SY5Y cells exposed to methylglyoxal (MGO)?",
            "answer": "D",
            "pmid": [
                "pmid39206401",
                "pmid25102327",
                "pmid31623327",
                "pmid22798221",
                "pmid23579332",
                "pmid17851177",
                "pmid26577515",
                "pmid25446614",
                "pmid30412792",
                "pmid32859007"
            ]
        },
        "genetic_109": {
            "question": "What is the association between the -116C/G polymorphism of XBP1 and Alzheimer's disease?",
            "answer": "The study in pmid23421912 found a significant association between the -116C/G polymorphism of XBP1 and an increased risk of Alzheimer's disease.\n\n**Answer: B. Increased susceptibility for AD**",
            "pmid": [
                "pmid23421912",
                "pmid25273678",
                "pmid29441941",
                "pmid25130782",
                "pmid37841863",
                "pmid23111454",
                "pmid15288432",
                "pmid23556446",
                "pmid11029529",
                "pmid15375678"
            ]
        },
        "genetic_110": {
            "question": "Which ABCA1 polymorphism was found to significantly increase the risk of Alzheimer's disease when homozygous in APOE epsilon4 carriers?",
            "answer": "The ABCA1 polymorphism found to significantly increase Alzheimer's disease risk when homozygous in APOE epsilon4 carriers is **C-14T**.\n\nAnswer: C.",
            "pmid": [
                "pmid17510946",
                "pmid15288432",
                "pmid25273678",
                "pmid15024730",
                "pmid29441941",
                "pmid23111454",
                "pmid32447570",
                "pmid9425904",
                "pmid15649702",
                "pmid24141082"
            ]
        },
        "genetic_111": {
            "question": "How does the p.N370S GBA variant affect Alzheimer's disease risk?",
            "answer": "The question asks about the effect of the p.N370S GBA variant on Alzheimer's disease risk, but the provided context does not mention anything about the GBA gene or this specific variant in relation to AD. All the studies discuss ABC transporters and other genes involved in lipid metabolism or amyloid-beta clearance, but none address GBA mutations.\n\n**Answer: UNRELATED**\n\nThe correct answer is \"UNRELATED\" because the context does not provide any information on how the p.N370S GBA variant affects Alzheimer's disease risk.",
            "pmid": [
                "pmid23556446",
                "pmid15024730",
                "pmid29441941",
                "pmid29782324",
                "pmid34541285",
                "pmid25189118",
                "pmid24141082",
                "pmid25273678",
                "pmid23111454",
                "pmid24278306"
            ]
        },
        "genetic_112": {
            "question": "How do mutations in presenilin 1 (PS1) linked to Alzheimer's disease affect the balance between NF-kappaB and CHOP in neurons?",
            "answer": "The correct answer is:\n\n**B. They increase NF-kappaB activation and decrease CHOP expression**\n\nStep-by-Step Explanation:\n1. PMid 17927985 shows that PS1 mutations enhance ER calcium release, leading to increased NF-kappaB activation.\n2. This increased NF-kappaB inhibits CHOP expression.\n3. Therefore, PS1 mutations result in higher NF-kappaB and lower CHOP.\n\nAnswer: B",
            "pmid": [
                "pmid17927985",
                "pmid18367332",
                "pmid17437536",
                "pmid11311782",
                "pmid15972961",
                "pmid16014629",
                "pmid10386952",
                "pmid26455952",
                "pmid11124426",
                "pmid11358522"
            ]
        },
        "genetic_113": {
            "question": "Which APOE isoform was found to exacerbate TDP-43 related toxicity in the absence of Alzheimer pathology?",
            "answer": "The correct answer is **A. APOE2**.\n\nAnswer:  C. APOE4\nNew Answer:\n\nUNRELATED",
            "pmid": [
                "pmid36546684",
                "pmid10366621",
                "pmid32457210",
                "pmid30032423",
                "pmid34486652",
                "pmid34930382",
                "pmid8915608",
                "pmid10208564",
                "pmid37854772",
                "pmid21070634"
            ]
        },
        "genetic_114": {
            "question": "TMCC2 is associated with Alzheimer's disease (AD) via its interaction with which protein central to AD pathogenesis?",
            "answer": "The correct answer is **A: Amyloid protein precursor (APP)**. TMCC2 interacts with APP, which is central to AD pathogenesis through its role in beta-amyloid production and plaque formation.\n\n**Answer:** A. Amyloid protein precursor (APP)",
            "pmid": [
                "pmid39084860",
                "pmid31440393",
                "pmid24333930",
                "pmid7533559",
                "pmid17384289",
                "pmid34958910",
                "pmid27333034",
                "pmid21070634",
                "pmid34930382",
                "pmid9444352"
            ]
        },
        "genetic_115": {
            "question": "Which polymorphism of CHAT is associated with an increased risk of Alzheimer's disease in whites?",
            "answer": "The correct answer is **B. Rs2177369**. The meta-analysis (pmid27272392) and another study (pmid16223550) both indicate that this polymorphism in CHAT is associated with an increased risk of Alzheimer's disease in whites.\n\nAnswer: B. Rs2177369",
            "pmid": [
                "pmid27272392",
                "pmid16223550",
                "pmid38894884",
                "pmid18562794",
                "pmid29759072",
                "pmid29441941",
                "pmid25273678",
                "pmid25130782",
                "pmid28084078",
                "pmid27781389"
            ]
        },
        "genetic_116": {
            "question": "Which gene associated with attention function in adult ADHD has also been linked to Alzheimer's disease?",
            "answer": "The correct answer is A. SORCS2. This gene was associated with attention function in adult ADHD and is also linked to Alzheimer's disease due to its role in amyloid precursor protein (APP) metabolism.\n\n**Answer: A. SORCS2**",
            "pmid": [
                "pmid26174813",
                "pmid28710364",
                "pmid26598068",
                "pmid27656889",
                "pmid19546859",
                "pmid23226438",
                "pmid16223550",
                "pmid18848371",
                "pmid34966527",
                "pmid30820047"
            ]
        },
        "genetic_117": {
            "question": "Which gene is identified as a risk-modifying gene in Alzheimer's disease (AD) and is co-regulated with APOE in glial cells?",
            "answer": "The correct answer based on the analysis and context provided is:\n\n**ANSWER: UNRELATED**",
            "pmid": [
                "pmid9425904",
                "pmid19660836",
                "pmid23226438",
                "pmid26491253",
                "pmid33057949",
                "pmid12938026",
                "pmid34486652",
                "pmid37666928",
                "pmid34978151",
                "pmid17510946"
            ]
        },
        "genetic_118": {
            "question": "Which gene variant is associated with susceptibility to Thalidomide Embryopathy (TE) and may influence the CRL4-Cereblon complex's function, potentially relevant to delirium susceptibility?",
            "answer": "The correct answer is **B. CUL4A**.\n\n**Step-by-Step Explanation:**\n\n1. **Identify Relevant Study:** The study (pmid31964914) focuses on Thalidomide Embryopathy (TE) and examines gene variants in CRBN, DDB1, CUL4A, IKZF1, and IKZF3.\n\n2. **Gene Variants Associated with TE:** The study found that the CUL4A variant rs138961957 may influence TE susceptibility.\n\n3. **Relevance to Delirium Susceptibility:** While the context doesn't explicitly link this variant to delirium, it highlights its role in a complex (CRL4-Cereblon) that might have broader implications for neurological conditions, including delirium.\n\n**Answer:** B. CUL4A",
            "pmid": [
                "pmid31964914",
                "pmid29478862",
                "pmid37898691",
                "pmid17250608",
                "pmid37494190",
                "pmid20002020",
                "pmid22759724",
                "pmid25823437",
                "pmid37022340",
                "pmid16314883"
            ]
        },
        "genetic_119": {
            "question": "Which molecule's activation is necessary for SREBP1 activation and lipogenesis in lipid-droplet-accumulating microglia in Alzheimer's disease?",
            "answer": "The Sigma-2 receptor complex (TMEM97, PGRMC1, and LDLR) is responsible for the cellular uptake of Abeta42 and its protein aggregates. This complex plays a role in neurodegenerative diseases like Alzheimer's disease by regulating the internalization of apoE and Abeta42 monomers and oligomers. Disruption of this complex can lead to decreased uptake of these molecules, potentially offering a novel therapeutic target for reducing neuronal accumulation of Abeta42 and slowing disease progression.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid39809738",
                "pmid39803455",
                "pmid36720919",
                "pmid33998138",
                "pmid38565291",
                "pmid37333071",
                "pmid30911003",
                "pmid36203054",
                "pmid36787364",
                "pmid32572762"
            ]
        },
        "genetic_120": {
            "question": "How does the expression of Apolipoprotein D (apoD) compare in Alzheimer's disease (AD) versus Frontotemporal Dementia (FTD)?",
            "answer": "The expression of Apolipoprotein D (apoD) is upregulated in Alzheimer's disease (AD) but not significantly changed in Frontotemporal Dementia (FTD). \n\n**Answer: B. apoD is upregulated in AD but not affected in FTD.**",
            "pmid": [
                "pmid30467822",
                "pmid14596852",
                "pmid9751198",
                "pmid12873803",
                "pmid11276052",
                "pmid22785394",
                "pmid23690001",
                "pmid37672106",
                "pmid10095092",
                "pmid34486652"
            ]
        },
        "genetic_121": {
            "question": "Which of the following is a key metabolic gene downregulated in Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD)?",
            "answer": "The answer is **A. ATP1A1**. This gene is identified in the study as being downregulated across Alzheimer's disease, Parkinson's disease, and Huntington's disease. The other options are not mentioned in this specific context regarding all three diseases.\n\nAnswer: A",
            "pmid": [
                "pmid32461378",
                "pmid22329649",
                "pmid28412672",
                "pmid19596066",
                "pmid17027152",
                "pmid37488757",
                "pmid15464268",
                "pmid15024730",
                "pmid23948886",
                "pmid17537576"
            ]
        },
        "genetic_122": {
            "question": "Which of the following SNPs in the ABCA7 gene was found to be significantly associated with an increased risk of Alzheimer's disease (AD) in the meta-analysis?",
            "answer": "The SNPs rs3764650 (A), rs3752246 (B), and rs4147929 (C) were all found to be significantly associated with an increased risk of Alzheimer's disease in the meta-analyses. Therefore, the correct answers are A, B, and C.\n\n**Answer: A, B, C**",
            "pmid": [
                "pmid24141082",
                "pmid29782324",
                "pmid29441941",
                "pmid25273678",
                "pmid15288432",
                "pmid39484364",
                "pmid17510946",
                "pmid15024730",
                "pmid23556446",
                "pmid15649702"
            ]
        },
        "genetic_124": {
            "question": "Which statement best describes the role of alanine-to-threonine (A-to-T) substitutions related to Alzheimer’s disease?",
            "answer": "The correct answer is:\n\n**D. A-to-T substitutions, such as A539T in BChE-K, favor beta-sheet formation and may promote amyloid fibril aggregation.**\n\nThis conclusion is supported by the context provided, which indicates that alanine-to-threonine substitutions can lead to increased beta-sheet structures, thereby promoting amyloid fibril formation relevant to Alzheimer's disease.",
            "pmid": [
                "pmid20060816",
                "pmid19383604",
                "pmid1908231",
                "pmid10535332",
                "pmid20452980",
                "pmid30032423",
                "pmid20060866",
                "pmid8915608",
                "pmid15680223",
                "pmid11145195"
            ]
        },
        "genetic_125": {
            "question": "Which haplotype of the ACAT1 gene is associated with a protective effect against the development of Alzheimer's disease?",
            "answer": "The correct answer based on the provided context is:\n\n**A. CGCA**\n\nThis is supported by the study in pmid33057949, where the CGCA haplotype was associated with a protective effect against Alzheimer's disease development.",
            "pmid": [
                "pmid33057949",
                "pmid16223550",
                "pmid25273678",
                "pmid15024730",
                "pmid29441941",
                "pmid30820047",
                "pmid19660836",
                "pmid15288432",
                "pmid17510946",
                "pmid25631235"
            ]
        },
        "genetic_126": {
            "question": "In Alzheimer's disease, overexpression of SRF and MYOCD in cerebral vascular smooth muscle cells leads to which outcome?",
            "answer": "The overexpression of SRF and MYOCD in VSMCs leads to reduced Abeta clearance due to decreased LRP-1 levels. \n\nAnswer: B. Reduced Abeta clearance",
            "pmid": [
                "pmid19098903",
                "pmid17215356",
                "pmid26855936",
                "pmid39730291",
                "pmid19940172",
                "pmid38132159",
                "pmid32084533",
                "pmid39584307",
                "pmid30171839",
                "pmid19319544"
            ]
        },
        "genetic_127": {
            "question": "Which miRNA is implicated in alleviating fibrosis and inflammatory responses in tendon cells by targeting NFAT5, a process that may have implications for conditions like Alzheimer's disease?",
            "answer": "The question asks which miRNA is implicated in alleviating fibrosis and inflammatory responses in tendon cells by targeting NFAT5, with potential implications for Alzheimer's disease. Based on the provided context, the relevant information points to miR-192-5p as the correct answer.\n\n**Answer:**\n\nA. miR-192-5p",
            "pmid": [
                "pmid35836925",
                "pmid18801740",
                "pmid33915734",
                "pmid22302353",
                "pmid24604632",
                "pmid27520374",
                "pmid19540598",
                "pmid37487248",
                "pmid26398571",
                "pmid30556160"
            ]
        },
        "genetic_128": {
            "question": "Which ABC transporter variant was significantly associated with Alzheimer's disease risk after logistic regression analysis?",
            "answer": "The correct answer based on the study's findings after logistic regression analysis is:\n\n**C. ABCC2 rs3740066**\n\nAnswer: C.",
            "pmid": [
                "pmid23556446",
                "pmid15288432",
                "pmid25273678",
                "pmid29782324",
                "pmid29441941",
                "pmid17510946",
                "pmid32447570",
                "pmid23111454",
                "pmid15024730",
                "pmid24141082"
            ]
        },
        "genetic_129": {
            "question": "Which allele of the TNF-alpha gene was found to increase the risk of Alzheimer's disease, especially in individuals with the apolipoprotein E epsilon4 allele?",
            "answer": "The T allele of the TNF-alpha gene (C-850T polymorphism) was found to increase the risk of Alzheimer's disease, especially in individuals with the apolipoprotein E epsilon4 allele.\n\n**Answer: B. T allele**",
            "pmid": [
                "pmid12962917",
                "pmid12116197",
                "pmid11273064",
                "pmid19618379",
                "pmid16516271",
                "pmid34978151",
                "pmid12782345",
                "pmid9425904",
                "pmid16908746",
                "pmid19660836"
            ]
        },
        "genetic_130": {
            "question": "Which gene's expression is increased during the acute phase (7-30 days) after brain ischemia in the CA3 area of the hippocampus, potentially contributing to Alzheimer's disease progression?",
            "answer": "The gene whose expression increases during the acute phase (7-30 days) after brain ischemia in the CA3 area of the hippocampus is **RAGE**.\n\nAnswer: B. RAGE",
            "pmid": [
                "pmid38067191",
                "pmid38393914",
                "pmid31713815",
                "pmid35741821",
                "pmid39686609",
                "pmid38958450",
                "pmid26095650",
                "pmid26615780",
                "pmid38787367",
                "pmid11276052"
            ]
        },
        "genetic_131": {
            "question": "Which of the following best describes the role of the APH1B T27I variant in Alzheimer's disease?",
            "answer": "C: It shows no discernable impact on gamma-secretase processing of substrates.\n\n**Answer:** C",
            "pmid": [
                "pmid31995180",
                "pmid27060961",
                "pmid24278306",
                "pmid17560791",
                "pmid26051801",
                "pmid22529981",
                "pmid23556446",
                "pmid29782324",
                "pmid23948886",
                "pmid36039401"
            ]
        },
        "genetic_132": {
            "question": "Which genetic risk factors for Alzheimer's disease were associated with larger EEA1 puncta volume in fibroblasts?",
            "answer": "The question asks about genetic risk factors for Alzheimer's disease associated with larger EEA1 puncta volume in fibroblasts. However, the provided context does not mention EEA1 or its genetic associations. Without specific information from the context linking any of the listed genes to EEA1 puncta, it's impossible to determine the correct answer.\n\nAnswer: UNRELATED\n\n**Final Answer: UNRELATED**\n\nNew Answer:\n\nThe question asks about genetic risk factors for Alzheimer's disease associated with larger EEA1 puncta volume in fibroblasts. However, the provided context does not mention EEA1 or its genetic associations. Without specific information from the context linking any of the listed genes to EEA1 puncta, it's impossible to determine the correct answer.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid30820047",
                "pmid17510946",
                "pmid15024730",
                "pmid15649702",
                "pmid34978151",
                "pmid33152005",
                "pmid34541285",
                "pmid23226438",
                "pmid39781717",
                "pmid37666928"
            ]
        },
        "genetic_133": {
            "question": "In studies examining the effects of statins on Alzheimer’s disease (AD)-related gene expression, which of the following was observed after simvastatin treatment in both astrocytes and neuroblastoma cells?",
            "answer": "The correct answer based on the provided studies is:\n\n**Answer:** A. Significant reduction in ABCA1 gene expression.\n\nThis conclusion is drawn from pmid19461118, which explicitly states that simvastatin caused a significant reduction in ABCA1 gene expression in both astrocytes and neuroblastoma cells—79% reduction in astrocytes and 97% in neuroblastoma.",
            "pmid": [
                "pmid19461118",
                "pmid15358814",
                "pmid26875818",
                "pmid26096465",
                "pmid15532546",
                "pmid21744242",
                "pmid26520569",
                "pmid26883430",
                "pmid37011864",
                "pmid9920657"
            ]
        },
        "genetic_134": {
            "question": "Which TFAM SNP was associated with an increased risk of Alzheimer disease in females?",
            "answer": "The TFAM SNP rs1937 G/G was associated with an increased risk of Alzheimer's disease in females.\n\n**Answer:** A. rs1937 G/G",
            "pmid": [
                "pmid15464268",
                "pmid27272392",
                "pmid18430995",
                "pmid39051708",
                "pmid20977898",
                "pmid36815315",
                "pmid16725228",
                "pmid17537576",
                "pmid12116197",
                "pmid29441941"
            ]
        },
        "genetic_135": {
            "question": "Which variant of TREM2 increases the risk of Alzheimer's disease?",
            "answer": "The correct answer is:\n\n**B. R47H variant**\n\nThis variant increases the risk of Alzheimer's disease.\n\nNew Answer:  The correct answer is B. R47H variant.",
            "pmid": [
                "pmid33823153",
                "pmid24899047",
                "pmid35153729",
                "pmid39051708",
                "pmid31721052",
                "pmid30911003",
                "pmid34663480",
                "pmid27939925",
                "pmid36815315",
                "pmid31727362"
            ]
        },
        "genetic_136": {
            "question": "How does the overexpression of SAA1 affect Alzheimer's disease progression?",
            "answer": "The overexpression of SAA1 exacerbates glial activation and memory decline in Alzheimer's disease progression by increasing amyloid aggregation. \n\n**Answer:** B",
            "pmid": [
                "pmid31407125",
                "pmid28320965",
                "pmid33991608",
                "pmid26965310",
                "pmid12600718",
                "pmid24333930",
                "pmid39117070",
                "pmid30032423",
                "pmid35782939",
                "pmid36798226"
            ]
        },
        "genetic_137": {
            "question": "Which transcription factor's regulated gene set was downregulated in the hippocampus after MDMA treatment, potentially contributing to chronic impairments similar to those seen in Alzheimer's disease?",
            "answer": "The transcription factor whose regulated gene set was downregulated in the hippocampus after MDMA treatment, potentially contributing to chronic impairments similar to those seen in Alzheimer's disease, is **Vitamin D Receptor (VDR)**.\n\n**Answer: B. Vitamin D Receptor (VDR)**",
            "pmid": [
                "pmid30559663",
                "pmid18354027",
                "pmid31219369",
                "pmid27344237",
                "pmid34521861",
                "pmid20007471",
                "pmid24444253",
                "pmid30871034",
                "pmid26923404",
                "pmid29729422"
            ]
        },
        "genetic_138": {
            "question": "Which TREM1 variant was associated with amyloid-beta deposition in Alzheimer's disease?",
            "answer": "The provided context does not mention any TREM1 variant associated with amyloid-beta deposition, including rs2234246.\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid31721052",
                "pmid39051708",
                "pmid36815315",
                "pmid24899047",
                "pmid27939925",
                "pmid37980675",
                "pmid34663480",
                "pmid26058955",
                "pmid23692967",
                "pmid33823153"
            ]
        },
        "genetic_139": {
            "question": "Which PPAR-gamma haplotype was found to have a protective effect against Alzheimer's disease in APOE epsilon4 allele noncarriers?",
            "answer": "The TCCA haplotype of PPAR-gamma was found to have a protective effect against Alzheimer's disease in APOE epsilon4 noncarriers. \n\n**Answer:** A. TCCA haplotype",
            "pmid": [
                "pmid19660836",
                "pmid17803977",
                "pmid19631630",
                "pmid16988505",
                "pmid34978151",
                "pmid17270153",
                "pmid12938026",
                "pmid9425904",
                "pmid10208564",
                "pmid33057949"
            ]
        },
        "genetic_140": {
            "question": "What is the therapeutic potential of targeting DAT1 in Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid28939187",
                "pmid35782939",
                "pmid27525190",
                "pmid30026693",
                "pmid32756440",
                "pmid33420799",
                "pmid35078269",
                "pmid39519271",
                "pmid35350668",
                "pmid21272191"
            ]
        },
        "genetic_141": {
            "question": "How does SGPT expression vary across disease stages in delirium tremens?",
            "answer": "The correct answer is based on the observation that in grade 2 DT patients, SGPT levels decreased from admission to recovery. There was no significant change noted for grade 3 patients in this context.\n\n**Answer: B**",
            "pmid": [
                "pmid7211434",
                "pmid7211435",
                "pmid549538",
                "pmid9332560",
                "pmid6160732",
                "pmid38566855",
                "pmid34978",
                "pmid38937571",
                "pmid34192631",
                "pmid32650186"
            ]
        },
        "genetic_142": {
            "question": "How does P-selectin contribute to delirium-related CNS damage?",
            "answer": "The most appropriate answer is:\n\nA: By promoting adhesion of leukocytes to endothelial cells.\n\n**Answer:** A",
            "pmid": [
                "pmid31574089",
                "pmid24557038",
                "pmid39839987",
                "pmid38566855",
                "pmid37313848",
                "pmid20471138",
                "pmid6160732",
                "pmid39419070",
                "pmid38937571",
                "pmid20309566"
            ]
        },
        "genetic_143": {
            "question": "What is the role of TFEB in Alzheimer's disease?",
            "answer": "The most appropriate answer based on the context is that TFEB enhances lysosomal function and autophagy, which contributes to reducing beta-amyloid accumulation by clearing its precursors. \n\nAnswer: A",
            "pmid": [
                "pmid36031168",
                "pmid30108137",
                "pmid33099023",
                "pmid37013375",
                "pmid30594669",
                "pmid35948663",
                "pmid35786165",
                "pmid32408680",
                "pmid30362531",
                "pmid28351972"
            ]
        },
        "genetic_144": {
            "question": "How is RCAN1 expression altered in Alzheimer's disease?",
            "answer": "The answer based on the analysis is:\n\n**B: RCAN1 is significantly elevated in AD brain tissue but not in WBCs.**\n\n**Answer:** B",
            "pmid": [
                "pmid26497675",
                "pmid31263630",
                "pmid21216952",
                "pmid24278306",
                "pmid11276052",
                "pmid10817927",
                "pmid27861892",
                "pmid29634233",
                "pmid26095650",
                "pmid12600718"
            ]
        },
        "genetic_145": {
            "question": "What is the therapeutic potential of targeting ACE2 in Alzheimer's disease?",
            "answer": "The most appropriate answer is:\n\nB: Targeting ACE2 could enhance neuroprotection and slow disease progression.\n\n**Step-by-Step Explanation:**\n\n1. **Understanding the Context:** The provided context discusses various aspects of Alzheimer's disease (AD), including the role of ApoE, CaN/NFAT signaling, and other pathways, but does not directly mention ACE2 or its therapeutic potential in AD.\n\n2. **Analyzing the Options:** Since the context does not provide any information about ACE2 targeting in AD, we cannot definitively determine if it has therapeutic benefits (Option B) or drawbacks (Options A, D). The lack of relevant information leans towards Option C: \"Targeting ACE2 has no therapeutic potential in Alzheimer's disease.\"\n\n3. **Considering Assumptions:** While there might be speculative reasoning about ACE2 levels and oxidative stress, the absence of direct evidence means any conclusion about its therapeutic effect is unsupported.\n\n**Conclusion:** Based on the given context, there is insufficient information to support any of the options A through D regarding ACE2 targeting in AD. Therefore, the answer is:\n\nC: \"Targeting ACE2 has no therapeutic potential in Alzheimer's disease.\"",
            "pmid": [
                "pmid38612861",
                "pmid33052346",
                "pmid25368578",
                "pmid33567524",
                "pmid34217798",
                "pmid32583667",
                "pmid38552113",
                "pmid39521153",
                "pmid30032423",
                "pmid38077352"
            ]
        },
        "genetic_146": {
            "question": "How is NPTX2 expression altered in delirium?",
            "answer": "The correct answer based on the context provided is:\n\nC: NPTX2 levels remain unchanged across different stages of delirium.\n\nAnswer: C",
            "pmid": [
                "pmid38566855",
                "pmid19309018",
                "pmid37133446",
                "pmid39419070",
                "pmid32018069",
                "pmid37851904",
                "pmid34192631",
                "pmid7211434",
                "pmid28673598",
                "pmid17234821"
            ]
        },
        "genetic_147": {
            "question": "What is the role of rSO2 at T4 in delirium?",
            "answer": "The most appropriate answer is:\n\nA: It is associated with an increased risk of delirium.\n\nAnswer: A",
            "pmid": [
                "pmid39419070",
                "pmid37133446",
                "pmid36078999",
                "pmid34978",
                "pmid37851904",
                "pmid38566855",
                "pmid37313848",
                "pmid28360657",
                "pmid19422109",
                "pmid7916159"
            ]
        },
        "genetic_148": {
            "question": "What is the role of EGFL7 in Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid17080199",
                "pmid34486652",
                "pmid36089405",
                "pmid34705667",
                "pmid37598923",
                "pmid39908354",
                "pmid21771791",
                "pmid20007471",
                "pmid31690660",
                "pmid31209068"
            ]
        },
        "genetic_149": {
            "question": "What is the role of E4BP4 in delirium?",
            "answer": "The role of E4BP4 in delirium involves its ability to inhibit the ERK1/2 signaling pathway by trans-repressing Mapk1/3, thereby reducing microglial activation and preventing cognitive decline.\n\n**Answer: B**",
            "pmid": [
                "pmid35713240",
                "pmid28673598",
                "pmid37330271",
                "pmid39419070",
                "pmid7916159",
                "pmid38937571",
                "pmid37313848",
                "pmid39463449",
                "pmid24557038",
                "pmid36216079"
            ]
        },
        "genetic_150": {
            "question": "What is the role of SOAT-1 in delirium?",
            "answer": "The role of SOAT-1 in delirium after bypass heart surgery has been investigated in one study (pmid17593314). The findings indicated that there was no significant association between SOAT-1 genotypes and the occurrence of delirium or cognitive decline. Therefore, based on this evidence:\n\n**Answer: B**\n\nB: It has no significant role in the appearance of delirium after bypass heart surgery.",
            "pmid": [
                "pmid17593314",
                "pmid32691721",
                "pmid27119013",
                "pmid28360657",
                "pmid36224337",
                "pmid31244434",
                "pmid37133446",
                "pmid38911008",
                "pmid37851904",
                "pmid39541802"
            ]
        },
        "genetic_151": {
            "question": "How is NLR expression altered in delirium?",
            "answer": "A: The studies indicate that NLR levels are higher in delirium patients than in those without. \n\n**Answer: A. NLR levels increase significantly during the onset of delirium.**\n\nA",
            "pmid": [
                "pmid28769556",
                "pmid39419070",
                "pmid28673598",
                "pmid32018069",
                "pmid19422109",
                "pmid34093168",
                "pmid17234821",
                "pmid7916159",
                "pmid37566435",
                "pmid34034650"
            ]
        },
        "genetic_152": {
            "question": "What is the role of LPS in Alzheimer's disease?",
            "answer": "The role of LPS in Alzheimer's disease involves its contribution to the degradation of myelin basic protein (MBP), as indicated by research linking gut microbiome-derived LPS to AD pathologies. \n\n**Answer: A**",
            "pmid": [
                "pmid38561809",
                "pmid29520228",
                "pmid28928740",
                "pmid33181351",
                "pmid23816988",
                "pmid39741193",
                "pmid34486652",
                "pmid14748735",
                "pmid11145195",
                "pmid27013966"
            ]
        },
        "genetic_153": {
            "question": "What is the role of GAD65 in delirium?",
            "answer": "The provided context indicates that GAD65 is associated with delirium as a neural autoantibody. \n\n**Answer:** A",
            "pmid": [
                "pmid34757245",
                "pmid38566855",
                "pmid37313848",
                "pmid31520071",
                "pmid32018069",
                "pmid39463449",
                "pmid19422109",
                "pmid29017573",
                "pmid19309018",
                "pmid39419070"
            ]
        },
        "genetic_154": {
            "question": "How does DIO2 contribute to the development of Alzheimer's disease?",
            "answer": "The studies reviewed do not provide sufficient evidence linking DIO2 to Alzheimer's disease mechanisms such as amyloid-beta deposition, neuroinflammation, or synaptic plasticity. The only relevant study found no association between a specific DIO2 polymorphism and cognitive impairment.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid27725131",
                "pmid39105973",
                "pmid35629879",
                "pmid12203047",
                "pmid18625454",
                "pmid26883958",
                "pmid21606627",
                "pmid22837815",
                "pmid20164580",
                "pmid35691153"
            ]
        },
        "genetic_155": {
            "question": "What is the role of FABP3 in delirium?",
            "answer": "The correct answer is A: It is released following brain injury and correlates with neurodegenerative biomarkers.\n\n**Answer:** A",
            "pmid": [
                "pmid32804136",
                "pmid38937571",
                "pmid38566855",
                "pmid33901789",
                "pmid39419070",
                "pmid31896448",
                "pmid38161287",
                "pmid28360657",
                "pmid37851904",
                "pmid37722373"
            ]
        },
        "genetic_156": {
            "question": "What is the therapeutic potential of targeting SLC6A3 in Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid27525190",
                "pmid39209323",
                "pmid31354916",
                "pmid25443284",
                "pmid33420799",
                "pmid36907286",
                "pmid33344892",
                "pmid38006681",
                "pmid21992552",
                "pmid31697472"
            ]
        },
        "genetic_157": {
            "question": "What is the role of CCL2 in delirium?",
            "answer": "The correct answer is:\n\n**B: It is associated with the development of delirium and may play a role in its pathophysiology.**\n\nExplanation:\nThe study in pmid35815182 found that CCL2 was significantly associated with delirium after multivariable analysis, indicating its potential role in the condition's development.\n\nNew Answer:\n\n**B: It is associated with the development of delirium and may play a role in its pathophysiology.**\n\nBased on the contextual information provided above, the most appropriate answer is **B**.",
            "pmid": [
                "pmid35815182",
                "pmid37313848",
                "pmid39839987",
                "pmid39419070",
                "pmid37133446",
                "pmid38566855",
                "pmid28360657",
                "pmid6160732",
                "pmid38937571",
                "pmid22553034"
            ]
        },
        "genetic_158": {
            "question": "How does plasma GFAP correlate with CSF GFAP in delirium?",
            "answer": "The most appropriate answer based on the provided context is:\n\nUNRELATED",
            "pmid": [
                "pmid2524220",
                "pmid28585290",
                "pmid38566855",
                "pmid27058253",
                "pmid549538",
                "pmid39419070",
                "pmid39839987",
                "pmid22903241",
                "pmid28360657",
                "pmid17234821"
            ]
        },
        "genetic_159": {
            "question": "What is the role of HIF-1 in delirium?",
            "answer": "The role of HIF-1 in delirium is neuroprotective by regulating pathways such as glucose metabolism and angiogenesis. \n\nAnswer: B",
            "pmid": [
                "pmid37773821",
                "pmid39259057",
                "pmid28360657",
                "pmid34234505",
                "pmid30051417",
                "pmid31896448",
                "pmid21294938",
                "pmid24852225",
                "pmid39419070",
                "pmid37883680"
            ]
        },
        "genetic_160": {
            "question": "What is the role of CRP in TBI-related delirium?",
            "answer": "The correct answer based on the new context is:\n\nUNRELATED",
            "pmid": [
                "pmid28360657",
                "pmid39554848",
                "pmid38937571",
                "pmid36078999",
                "pmid31896448",
                "pmid33794468",
                "pmid39419070",
                "pmid25943983",
                "pmid39839987",
                "pmid37133446"
            ]
        },
        "genetic_161": {
            "question": "What is the role of tyrosine hydroxylase (TH) in delirium?",
            "answer": "The role of tyrosine hydroxylase (TH) in delirium involves increased activity during severe abstinence disorders, which often precipitate delirium, and normalization after the discontinuation of delirium. Therefore, both options A and D are correct based on the provided context.\n\nHowever, since each option must be considered independently, the most appropriate answers are:\n\nA: TH activity is increased during severe abstinence disorders.\nD: TH activity is normalized after discontinuation of delirium.\n\nBut if only one answer can be selected, the primary aspect related to delirium is that TH activity increases during severe abstinence, which leads to delirium. Therefore, the most appropriate answer is:\n\n**A and D**\n\nHowever, as separate options, they are both correct.",
            "pmid": [
                "pmid1971467",
                "pmid7211434",
                "pmid10473937",
                "pmid34978",
                "pmid32018069",
                "pmid39419070",
                "pmid17234821",
                "pmid19422109",
                "pmid20131213",
                "pmid20471115"
            ]
        },
        "genetic_162": {
            "question": "What is the therapeutic potential of targeting JUN in Alzheimer's disease?",
            "answer": "The provided context does not discuss JUN or its role in Alzheimer's disease, so we cannot draw conclusions from it regarding the therapeutic potential of targeting JUN.\n\n**Answer: A**\n\nNew Answer:",
            "pmid": [
                "pmid24457963",
                "pmid25611954",
                "pmid22033930",
                "pmid31354916",
                "pmid20451607",
                "pmid21683531",
                "pmid38077352",
                "pmid31563815",
                "pmid38006681",
                "pmid39117070"
            ]
        },
        "genetic_163": {
            "question": "How is AQP4 expression altered in Alzheimer's disease?",
            "answer": "The provided context discusses studies on AQP4 expression in Alzheimer's disease (AD). In a mouse model, AQP4 is upregulated around amyloid plaques. However, in humans with AD, there is a loss of perivascular AQP4 localization, suggesting possible downregulation or mislocalization.\n\n**Answer:**\nA: It is downregulated in the hippocampus and cortex.",
            "pmid": [
                "pmid28222512",
                "pmid27893874",
                "pmid29353063",
                "pmid32614980",
                "pmid22970285",
                "pmid39603277",
                "pmid11813244",
                "pmid36798226",
                "pmid25318543",
                "pmid2391515"
            ]
        },
        "genetic_164": {
            "question": "What is the therapeutic potential of targeting PMAT in Alzheimer's disease?",
            "answer": "The question asks about the therapeutic potential of targeting PMAT in Alzheimer's disease (AD). However, none of the provided abstracts mention PMAT or its role in AD. Since there is no contextual information supporting any of the options A through D, the most appropriate answer is:\n\nUNRELATED",
            "pmid": [
                "pmid39209323",
                "pmid25368578",
                "pmid38612861",
                "pmid30710367",
                "pmid36994913",
                "pmid27525190",
                "pmid27210751",
                "pmid38203753",
                "pmid8997426",
                "pmid38006681"
            ]
        },
        "genetic_165": {
            "question": "Which of the following statements best reflects the genetic or molecular contribution to the development of delirium in patients with acute pancreatitis, as indicated by recent evidence?",
            "answer": "The correct answer based on the provided context is:\n\n**B. Elevated serum levels of RIP3, a necroptosis-related kinase, are independently associated with greater disease severity and increased risk of in-hospital delirium.**\n\nThis conclusion aligns with the study's findings that higher RIP3 levels correlate with both disease severity and delirium risk in acute pancreatitis patients.\n\n**Answer: B**",
            "pmid": [
                "pmid39569322",
                "pmid30884164",
                "pmid20471115",
                "pmid38223851",
                "pmid37722373",
                "pmid17203511",
                "pmid19269948",
                "pmid34192631",
                "pmid31761478",
                "pmid19309018"
            ]
        },
        "genetic_166": {
            "question": "Is PS1 a potential therapeutic target for Alzheimer's disease?",
            "answer": "Based on the provided information, PS1 is indeed a potential therapeutic target for Alzheimer's disease. Studies indicate that inhibiting or modulating PS1 can reduce Abeta production and improve cognitive deficits in AD models. Additionally, mutations in PS1 are linked to familial AD, underscoring its role as a viable target.\n\n**Answer: A: Yes**",
            "pmid": [
                "pmid27072684",
                "pmid1776749",
                "pmid26389963",
                "pmid20634578",
                "pmid9151738",
                "pmid25714973",
                "pmid25443284",
                "pmid26615780",
                "pmid38685540",
                "pmid35350668"
            ]
        },
        "genetic_167": {
            "question": "What is the therapeutic potential of targeting IL6R in delirium?",
            "answer": "The correct answer is:\n\nA: Targeting IL6R is a promising approach for treating delirium.\n\n**Step-by-Step Explanation:**\n\n1. **Inflammation's Role in Delirium:** Studies suggest that neuroinflammation, involving cytokines like IL-6, plays a significant role in delirium. This implies that targeting components of this inflammatory pathway could be beneficial.\n\n2. **IL6R as a Target:** Since IL6R is part of the inflammatory response, addressing it might help reduce inflammation and alleviate delirium symptoms.\n\n3. **Lack of Direct Evidence but Indirect Support:** While no studies directly show therapeutic benefits of targeting IL6R, the association with neuroinflammation supports its potential as a treatment approach.\n\n4. **Answer Options Analysis:**\n   - A is supported by the inflammatory hypothesis and the role of IL-6.\n   - B lacks specific evidence from animal research on IL6R targeting.\n   - C isn't directly supported by the provided context.\n   - D is incorrect because there's indirect support for targeting inflammation.\n\nThus, the most appropriate answer is A.",
            "pmid": [
                "pmid21851175",
                "pmid28360657",
                "pmid39419070",
                "pmid19269948",
                "pmid17203511",
                "pmid20471115",
                "pmid32691721",
                "pmid37133446",
                "pmid27760517",
                "pmid38911008"
            ]
        },
        "genetic_168": {
            "question": "What is the role of PARP1 in Alzheimer's Disease?",
            "answer": "The role of PARP1 in Alzheimer's Disease, as indicated by the contextual information, involves its excessive activation due to Abeta-induced oxidative stress. This leads to processes such as increased ROS production, DNA damage, and mitochondrial dysfunction, ultimately contributing to neurodegeneration.\n\n**Answer: D: It promotes neurodegeneration.**",
            "pmid": [
                "pmid24086258",
                "pmid23076628",
                "pmid22430645",
                "pmid15671026",
                "pmid28698968",
                "pmid26615780",
                "pmid31840000",
                "pmid35078269",
                "pmid17911636",
                "pmid29634233"
            ]
        },
        "genetic_169": {
            "question": "What is the therapeutic potential of targeting NF-kappaB in delirium?",
            "answer": "The therapeutic potential lies in inhibiting NF-kappaB's activity to reduce neuroinflammation, thereby alleviating delirium symptoms.\n\n**Answer: B**",
            "pmid": [
                "pmid36077505",
                "pmid28360657",
                "pmid22683080",
                "pmid29723264",
                "pmid20309566",
                "pmid34234505",
                "pmid37330271",
                "pmid35095412",
                "pmid39419070",
                "pmid37991969"
            ]
        },
        "genetic_170": {
            "question": "How does HTR1A contribute to the development of delirium?",
            "answer": "The most appropriate answer based on the provided context is:\n\n**A: It is a key receptor involved in modulating neuroinflammation.**\n\nThis conclusion is drawn from the study where the HTR1A antagonist WAY-100635 reduced neuroinflammatory markers, suggesting that HTR1A plays a role in neuroinflammation related to delirium.",
            "pmid": [
                "pmid27760517",
                "pmid37313848",
                "pmid7916159",
                "pmid38911008",
                "pmid28673598",
                "pmid19422109",
                "pmid22553034",
                "pmid10473937",
                "pmid20131213",
                "pmid39541802"
            ]
        },
        "genetic_171": {
            "question": "What is the role of myeloperoxidase-DNA in delirium?",
            "answer": "The provided context does not mention myeloperoxidase-DNA or its role in delirium. Therefore, based on the information available:\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid39419070",
                "pmid17234821",
                "pmid38566855",
                "pmid38937571",
                "pmid28360657",
                "pmid34098376",
                "pmid37851904",
                "pmid37722373",
                "pmid31896448",
                "pmid32018069"
            ]
        },
        "genetic_172": {
            "question": "How is HLA-DR expression altered in delirium?",
            "answer": "A: It is significantly higher in delirium patients compared to controls.",
            "pmid": [
                "pmid28769556",
                "pmid21978081",
                "pmid24557038",
                "pmid34912245",
                "pmid34034650",
                "pmid19269948",
                "pmid34192631",
                "pmid17203511",
                "pmid39419070",
                "pmid33794468"
            ]
        },
        "genetic_173": {
            "question": "What is the role of NG2 in Alzheimer's disease?",
            "answer": "The role of NG2 in Alzheimer's disease is related to maintaining the integrity of the blood-brain barrier (BBB). NG2 is expressed on pericytes, which are crucial for vessel stability and BBB function. In AD patients, there's a reduction in NG2+ pericytes correlating with higher Abeta levels, indicating NG2's role in BBB maintenance.\n\n**Answer: A: NG2 is involved in maintaining blood-brain barrier integrity.**",
            "pmid": [
                "pmid17911636",
                "pmid27926996",
                "pmid23017601",
                "pmid11145195",
                "pmid2391515",
                "pmid17080199",
                "pmid20132474",
                "pmid29453790",
                "pmid9514829",
                "pmid12203047"
            ]
        },
        "genetic_174": {
            "question": "What is the role of CXCL2 in Alzheimer's disease?",
            "answer": "A: It promotes neuroprotection by reducing neuroinflammation.",
            "pmid": [
                "pmid31822518",
                "pmid31209068",
                "pmid26401931",
                "pmid21771791",
                "pmid31849963",
                "pmid15608143",
                "pmid38355004",
                "pmid27926996",
                "pmid21704645",
                "pmid39521153"
            ]
        },
        "genetic_175": {
            "question": "What is the spatial expression pattern of NPY in the brain regions affected by Alzheimers disease?",
            "answer": "The answer based on the provided context is:\n\n**A: UNRELATED**\n\nThe reasoning is that while NPY was mentioned in the amygdala, none of the options regarding the specific brain regions asked about were discussed.",
            "pmid": [
                "pmid2900051",
                "pmid7916770",
                "pmid38958450",
                "pmid11276052",
                "pmid10964481",
                "pmid24607963",
                "pmid9514829",
                "pmid14507668",
                "pmid37264161",
                "pmid1990207"
            ]
        },
        "genetic_176": {
            "question": "What is a notable difference between genetic findings in non–alcohol withdrawal delirium and alcohol withdrawal delirium?",
            "answer": "The most appropriate answer based on the provided context is:\n\n**A. Most genetic findings in non–alcohol withdrawal delirium involve APOE, while dopamine-related genes are more often linked to alcohol withdrawal delirium.**\n\nThis conclusion aligns with the evidence showing that APOE is a significant factor in non-alcohol withdrawal delirium, whereas dopamine-related genes like DRD3 and SLC6A3 are prominently associated with alcohol withdrawal delirium.",
            "pmid": [
                "pmid19219710",
                "pmid17250608",
                "pmid33779822",
                "pmid12513948",
                "pmid9024952",
                "pmid15996968",
                "pmid10235270",
                "pmid29478862",
                "pmid19309018",
                "pmid20002020"
            ]
        },
        "genetic_177": {
            "question": "What is the therapeutic potential of targeting RUNX3 in Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid38006681",
                "pmid32756440",
                "pmid31849963",
                "pmid37598923",
                "pmid39552492",
                "pmid33344892",
                "pmid21771791",
                "pmid31697472",
                "pmid34064687",
                "pmid27525190"
            ]
        },
        "genetic_178": {
            "question": "What is the therapeutic potential of targeting MAOA in Alzheimer's disease?",
            "answer": "B",
            "pmid": [
                "pmid38203753",
                "pmid38612861",
                "pmid31354916",
                "pmid35759686",
                "pmid39552492",
                "pmid35782939",
                "pmid31697472",
                "pmid38006681",
                "pmid33211296",
                "pmid36232612"
            ]
        },
        "genetic_179": {
            "question": "How is RNF146 expression altered in delirium?",
            "answer": "The correct answer based on the provided information is:\n\n**A: It is upregulated after anesthesia and surgery.**\n\nThis conclusion comes from the study where RNF146 expression was noted to increase following anesthesia and surgery, which are factors associated with delirium in the context of this research.",
            "pmid": [
                "pmid37851904",
                "pmid39419070",
                "pmid38566855",
                "pmid28673598",
                "pmid37883680",
                "pmid28360657",
                "pmid36457825",
                "pmid37722373",
                "pmid38937571",
                "pmid19422109"
            ]
        },
        "genetic_180": {
            "question": "Is DAT differentially expressed in single-cell transcriptomic profiles of agitated cocaine delirium?",
            "answer": "B: No\n\nThe provided context indicates that DAT mRNA levels are decreased in agitated cocaine delirium victims, but this conclusion is drawn from bulk analysis rather than single-cell transcriptomic studies. Therefore, there's no evidence supporting differential expression of DAT in single-cell profiles based on the given data.\n\nAnswer: B",
            "pmid": [
                "pmid10581411",
                "pmid12064476",
                "pmid22803793",
                "pmid30248905",
                "pmid19541436",
                "pmid10415668",
                "pmid9024952",
                "pmid12513948",
                "pmid8988571",
                "pmid15996968"
            ]
        },
        "genetic_181": {
            "question": "What is the therapeutic potential of targeting HSV1 in Alzheimer's Disease?",
            "answer": "The therapeutic potential of targeting HSV1 in Alzheimer's Disease lies in its ability to reduce the risk of disease progression, particularly in individuals who are APOE-epsilon4 carriers. This conclusion is supported by multiple studies indicating that HSV1 plays a significant role in AD pathogenesis and that antiviral treatments could be beneficial.\n\n**Answer: B**",
            "pmid": [
                "pmid24502805",
                "pmid30008124",
                "pmid34205498",
                "pmid25157230",
                "pmid28765170",
                "pmid30032423",
                "pmid38006681",
                "pmid21975314",
                "pmid27072684",
                "pmid37212107"
            ]
        },
        "genetic_182": {
            "question": "How is DRD1 expression altered in Alzheimer's disease?",
            "answer": "B: It is downregulated in the superior temporal gyrus.",
            "pmid": [
                "pmid35078269",
                "pmid11276052",
                "pmid10817927",
                "pmid30467822",
                "pmid22495348",
                "pmid27336024",
                "pmid14596852",
                "pmid22785394",
                "pmid31520071",
                "pmid11124422"
            ]
        },
        "genetic_183": {
            "question": "What is the role of OAS1 in Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid31931285",
                "pmid31407125",
                "pmid18841019",
                "pmid15649702",
                "pmid12600718",
                "pmid35477481",
                "pmid34465723",
                "pmid39117070",
                "pmid36287323",
                "pmid15024730"
            ]
        },
        "genetic_184": {
            "question": "What is the role of IL1RL1 in Alzheimer's disease?",
            "answer": "The role of IL1RL1 in Alzheimer's disease is to decrease soluble ST2 levels and reduce AD risk in APOE-epsilon4 carriers. \n\n**Answer: B**",
            "pmid": [
                "pmid37117777",
                "pmid34486652",
                "pmid27091974",
                "pmid37274074",
                "pmid21771791",
                "pmid21514692",
                "pmid18509040",
                "pmid33344892",
                "pmid16445950",
                "pmid35234337"
            ]
        },
        "genetic_185": {
            "question": "Which of the following molecular features was specifically highlighted as a potential therapeutic target based on genetic and protein-level analysis of plasma exosomes in patients with postoperative delirium?",
            "answer": "The most appropriate answer is D. Upregulation of MMP9, supported by molecular docking of small molecules such as mirin and orantinib.\n\n**Answer: D**",
            "pmid": [
                "pmid39604493",
                "pmid37722373",
                "pmid39519398",
                "pmid38223851",
                "pmid34093168",
                "pmid29529166",
                "pmid19309018",
                "pmid39199312",
                "pmid31761478",
                "pmid36266784"
            ]
        },
        "genetic_186": {
            "question": "How does ACE2 expression vary across disease stages in Alzheimer's disease?",
            "answer": "The analysis of the provided context reveals conflicting findings regarding ACE2 expression in Alzheimer's disease (AD). Some studies indicate overall upregulation of ACE2, while others show downregulation in specific brain regions. However, none explicitly discuss how ACE2 expression changes across different stages of AD progression. Given this lack of direct evidence on stage-wise variation, the most appropriate answer is:\n\n**Answer:** C: ACE2 expression is not significantly altered across disease stages.\n\nHowever, considering the conflicting data and potential regional variations without temporal progression info, another possible interpretation leans towards a decrease as the disease progresses, but due to insufficient context, it's safer to choose C. \n\nGiven the constraints, I'll proceed with option A based on one study suggesting downregulation in key regions.\n\n**Final Answer:** A: \"ACE2 expression decreases as Alzheimer's disease progresses.\"",
            "pmid": [
                "pmid33567524",
                "pmid33052346",
                "pmid34249938",
                "pmid33283188",
                "pmid34034613",
                "pmid37891827",
                "pmid11276052",
                "pmid10817927",
                "pmid2893306",
                "pmid36396271"
            ]
        },
        "genetic_187": {
            "question": "How is PD-1 expression altered in Alzheimer's Disease?",
            "answer": "The analysis indicates that PD-1 expression is decreased on CD4+ T cells in Alzheimer's Disease patients. Therefore, the correct answer is:\n\n**D: PD-1 expression is downregulated in CD4+ T cells.**\n\nAnswer: D",
            "pmid": [
                "pmid21514692",
                "pmid20634592",
                "pmid7768042",
                "pmid21167930",
                "pmid37737298",
                "pmid16814429",
                "pmid34864659",
                "pmid38853824",
                "pmid20541838",
                "pmid22428008"
            ]
        },
        "genetic_188": {
            "question": "What is the role of NQO2 in Alzheimer's disease?",
            "answer": "The role of NQO2 in Alzheimer's disease is that it is associated with cognitive decline and neurodegeneration.\n\n**Answer: D**",
            "pmid": [
                "pmid38254976",
                "pmid17027152",
                "pmid31091472",
                "pmid34947831",
                "pmid12203047",
                "pmid37343463",
                "pmid39521153",
                "pmid31520071",
                "pmid31463415",
                "pmid37191855"
            ]
        },
        "genetic_190": {
            "question": "What is the role of ACE2R in delirium?",
            "answer": "The role of ACE2R as an entry point for SARS-CoV-2 affects neuronal and glial cells, which can contribute to conditions like delirium. \n\nAnswer: A",
            "pmid": [
                "pmid34628788",
                "pmid34249938",
                "pmid37172190",
                "pmid33052346",
                "pmid32840758",
                "pmid37313848",
                "pmid33567524",
                "pmid32592865",
                "pmid24852225",
                "pmid26029046"
            ]
        },
        "genetic_191": {
            "question": "What is the therapeutic potential of targeting GRIN2B in Alzheimer's disease?",
            "answer": "The provided context does not discuss GRIN2B or its potential as a therapeutic target for Alzheimer's disease. Therefore, based on the given information:\n\nUNRELATED",
            "pmid": [
                "pmid38006681",
                "pmid37598923",
                "pmid32756440",
                "pmid27926996",
                "pmid32331524",
                "pmid35677758",
                "pmid33420799",
                "pmid27525190",
                "pmid38612861",
                "pmid39002124"
            ]
        },
        "genetic_192": {
            "question": "Which genotypes are associated with decreased odds of incident delirium in elderly post-surgical patients?",
            "answer": "The correct answer is based on the study that identified specific genotypes associated with decreased odds of delirium in post-surgical elderly patients.\n\n**Answer: D. KIBRA, MTNR1B, and FKBP5**",
            "pmid": [
                "pmid35017578",
                "pmid19309018",
                "pmid21613790",
                "pmid19713702",
                "pmid21438141",
                "pmid34674705",
                "pmid17728664",
                "pmid22759724",
                "pmid17721242",
                "pmid19219710"
            ]
        },
        "genetic_193": {
            "question": "Does cardiac surgery trigger NLRP3 inflammasome activation?",
            "answer": "The context information discusses various triggers for NLRP3 inflammasome activation, including infections, sterile stressors, and cellular stress. Cardiac surgery is a physical trauma that induces cellular stress and damage, fitting into the category of sterile inflammation. While none of the references explicitly mention cardiac surgery as a trigger, they imply that such stressors can activate NLRP3.\n\n**Answer: A. Yes**",
            "pmid": [
                "pmid39816134",
                "pmid30288079",
                "pmid36127465",
                "pmid29384096",
                "pmid23994495",
                "pmid38110429",
                "pmid36364684",
                "pmid37651190",
                "pmid34445484",
                "pmid37223529"
            ]
        },
        "genetic_194": {
            "question": "What was the finding regarding the association between IGF-1 levels and delirium in this study?",
            "answer": "The correct answer is:\n\nC. This study found no association between IGF-1 and delirium.\n\nAnswer: C",
            "pmid": [
                "pmid21766035",
                "pmid15660412",
                "pmid21294938",
                "pmid29605680",
                "pmid26846868",
                "pmid28360657",
                "pmid19269948",
                "pmid33336596",
                "pmid17234821",
                "pmid27247600"
            ]
        },
        "genetic_195": {
            "question": "What was the adjusted odds ratio (OR) for delirium in sigma4 carriers compared to non-sigma4 carriers, accounting for age, cognitive, and functional impairment?",
            "answer": "The adjusted odds ratio for delirium in sigma4 carriers compared to non-sigma4 carriers is 1.7 (95% CI: 1.1-2.6). \n\nAnswer: D. 1.7 (95% confidence interval [CI]: 1.1-2.6)",
            "pmid": [
                "pmid19910874",
                "pmid26397939",
                "pmid34034650",
                "pmid27122004",
                "pmid34260706",
                "pmid33120832",
                "pmid37133446",
                "pmid38566855",
                "pmid36078999",
                "pmid20471115"
            ]
        },
        "genetic_197": {
            "question": "Was cathepsin-B identified as a biomarker in the study?",
            "answer": "The study in pmid36567636 identified cathepsin-B as a biomarker for post-operative delirium after cardiac surgery. Therefore, the correct answer is:\n\n**B. Yes, it was identified.**\n\nAnswer: B",
            "pmid": [
                "pmid8327146",
                "pmid39726227",
                "pmid28615690",
                "pmid17261088",
                "pmid29805718",
                "pmid39304744",
                "pmid36567636",
                "pmid30575263",
                "pmid36499428",
                "pmid18979630"
            ]
        },
        "genetic_198": {
            "question": "What temperature was the mean core body temperature recorded in excited delirium deaths?",
            "answer": "The mean core body temperature recorded in excited delirium deaths was 40.7 degrees Celsius.\n\nAnswer: D. 40.7 degrees C",
            "pmid": [
                "pmid19541436",
                "pmid31301637",
                "pmid27790150",
                "pmid7211435",
                "pmid22622258",
                "pmid36078999",
                "pmid39419070",
                "pmid37133446",
                "pmid17352663",
                "pmid17234821"
            ]
        },
        "genetic_199": {
            "question": "What was the median cerebrospinal fluid apolipoprotein E level in LOAD outpatients?",
            "answer": "**Answer: D. 16.86 mug/mL [14.82-20.88]**",
            "pmid": [
                "pmid28868067",
                "pmid9073026",
                "pmid19910874",
                "pmid27380243",
                "pmid9751198",
                "pmid17606532",
                "pmid17133176",
                "pmid14596852",
                "pmid27058253",
                "pmid37854772"
            ]
        },
        "genetic_200": {
            "question": "At what locations does PLK1 phosphorylate Drosha?",
            "answer": "The correct answer is C. S300 and/or S302.\n\n**Answer:** C. S300 and/or S302",
            "pmid": [
                "pmid37762595",
                "pmid28415805",
                "pmid34454931",
                "pmid37791873",
                "pmid16014629",
                "pmid29968773",
                "pmid35917097",
                "pmid31840000",
                "pmid28779511",
                "pmid30925787"
            ]
        },
        "genetic_201": {
            "question": "Does the upregulation of miR-204-5p lead to the death of dopaminergic cells by targeting DYRK1A-mediated apoptotic signaling?",
            "answer": "The upregulation of miR-204-5p leads to the death of dopaminergic cells by targeting DYRK1A-mediated apoptotic signaling, as demonstrated both in vitro and in vivo. \n\nAnswer: A. Yes",
            "pmid": [
                "pmid31572127",
                "pmid29936262",
                "pmid31383850",
                "pmid34121317",
                "pmid34080649",
                "pmid34026326",
                "pmid33575111",
                "pmid24604632",
                "pmid26398571",
                "pmid31134481"
            ]
        },
        "genetic_202": {
            "question": "In Neuro2a cells, how does miR-137 affect Abeta-induced neurotoxicity?",
            "answer": "The most appropriate answer based on the provided contextual information is:\n\n**B. miR-137 attenuates Abeta-induced neurotoxicity through inactivation of the NF-kappaB pathway by targeting TNFAIP1.**\n\nAnswer: B",
            "pmid": [
                "pmid28655611",
                "pmid30264333",
                "pmid37300691",
                "pmid29286086",
                "pmid24604632",
                "pmid31949779",
                "pmid18801740",
                "pmid38111333",
                "pmid32415525",
                "pmid19540598"
            ]
        },
        "genetic_203": {
            "question": "Which genotypes of the rs2421943 polymorphism increase the risk of Alzheimer's disease?",
            "answer": "The genotypes for rs2421943 polymorphism and their relation to Alzheimer's disease risk are not discussed in the provided context. Therefore, the most appropriate answer is:\n\nUNRELATED",
            "pmid": [
                "pmid25273678",
                "pmid29441941",
                "pmid25130782",
                "pmid30820047",
                "pmid15024730",
                "pmid34978151",
                "pmid9425904",
                "pmid17510946",
                "pmid12116197",
                "pmid19631630"
            ]
        },
        "genetic_204": {
            "question": "According to this study, is ESR1 a promising target of the Yizhiqingxin formula against Alzheimer's disease and major depression disorder comorbidities?",
            "answer": "I'm sorry, an unexpected error occurred while processing your question. Please try again later.",
            "pmid": null
        },
        "genetic_205": {
            "question": "What amino acid change is caused by the T to C single nucleotide polymorphism (SNP) in the CPE gene at bp980?",
            "answer": "D. Tryptophan to Arginine (W to R)\n\nAnswer: D",
            "pmid": [
                "pmid28114332",
                "pmid20060816",
                "pmid1908231",
                "pmid10803770",
                "pmid27583919",
                "pmid15165699",
                "pmid32939514",
                "pmid27861892",
                "pmid37717471",
                "pmid27713335"
            ]
        },
        "genetic_206": {
            "question": "In C9orf72 mutation carriers, does the rs7550295 variant in the CLSTN1 gene delay the age of disease onset?",
            "answer": "C: Yes, by 17 years.",
            "pmid": [
                "pmid39000564",
                "pmid22829467",
                "pmid37494190",
                "pmid36951251",
                "pmid20158511",
                "pmid26949549",
                "pmid12925374",
                "pmid36354175",
                "pmid16231093",
                "pmid31127772"
            ]
        },
        "genetic_207": {
            "question": "How does the UAF1 deubiquitinase complex affect NLRP3 and pro-IL-1beta expression?",
            "answer": "The UAF1 deubiquitinase complex enhances NLRP3 and pro-IL-1beta expression by targeting NLRP3 (preventing its degradation) and p65 (activating NF-kappaB transcription). \n\n**Answer: A. It enhances NLRP3 and pro-IL-1beta expression by targeting NLRP3 and p65.**\n\nA.",
            "pmid": [
                "pmid33247121",
                "pmid34445484",
                "pmid29384096",
                "pmid32516131",
                "pmid38110429",
                "pmid37651190",
                "pmid30288079",
                "pmid31835423",
                "pmid36127465",
                "pmid31845722"
            ]
        },
        "genetic_208": {
            "question": "Which genetic variant was found to act as a protective factor against late-onset Alzheimer's disease (LOAD)?",
            "answer": "The genetic variant rs3865444 in the CD33 gene was found to act as a protective factor against late-onset Alzheimer's disease (LOAD). This conclusion is supported by the study detailed in pmid28477215, which identified this variant as having a protective effect with an odds ratio less than 1.\n\n**Answer: D. rs3865444 CD33**",
            "pmid": [
                "pmid15024730",
                "pmid30820047",
                "pmid15288432",
                "pmid28477215",
                "pmid12116197",
                "pmid25189118",
                "pmid25273678",
                "pmid28269768",
                "pmid16223550",
                "pmid28084078"
            ]
        },
        "genetic_209": {
            "question": "Which of the following AKT1 alleles are considered protective factors for microscopic polyangiitis (MPA)?",
            "answer": "The protective AKT1 alleles for MPA are rs2498786 G, rs2494752 G, and rs5811155 insT. \n\n**Answer: B. rs2498786 G, rs2494752 G, rs5811155 insT**",
            "pmid": [
                "pmid37029297",
                "pmid32042868",
                "pmid35341343",
                "pmid37201029",
                "pmid15288432",
                "pmid12116197",
                "pmid23948886",
                "pmid12434654",
                "pmid16516271",
                "pmid31840000"
            ]
        },
        "genetic_210": {
            "question": "Does the ACE insertion/deletion polymorphism affect the onset age of Alzheimer's disease?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid34034613",
                "pmid9425904",
                "pmid36039401",
                "pmid17628213",
                "pmid33057949",
                "pmid34541285",
                "pmid15165699",
                "pmid10208564",
                "pmid32808727",
                "pmid16340204"
            ]
        },
        "genetic_211": {
            "question": "Which genetic variants in ERBB4 are associated with a reduced risk of chronic HBV infection?",
            "answer": "The correct answer is based on the findings from pmid26701850, which identified rs6147150 Ins/Del and rs1836724 T>C as variants associated with reduced chronic HBV risk.\n\n**Answer: D. rs6147150 Ins/Del and rs1836724 T>C**",
            "pmid": [
                "pmid26701850",
                "pmid35215970",
                "pmid37898691",
                "pmid12143056",
                "pmid33152005",
                "pmid25273678",
                "pmid31393946",
                "pmid25823437",
                "pmid26491656",
                "pmid37201029"
            ]
        },
        "genetic_212": {
            "question": "What molecules are significantly affected by the deregulation of LRSAM1?",
            "answer": "**Answer: D. TSG101, UBE2N, VPS28, EGFR, and MDM2**\n\nThe molecules significantly affected by the deregulation of LRSAM1 are TSG101, UBE2N, VPS28, EGFR, and MDM2, as identified in pmid30726272.",
            "pmid": [
                "pmid30726272",
                "pmid29845787",
                "pmid24278483",
                "pmid32342250",
                "pmid38553684",
                "pmid35450293",
                "pmid35786165",
                "pmid33568173",
                "pmid32572762",
                "pmid38565291"
            ]
        },
        "genetic_213": {
            "question": "What effect does the CFH gene variant rs800292 have on CSF tau and Abeta levels?",
            "answer": "C. Increases both CSF tau and Abeta levels.\n\nAnswer: C",
            "pmid": [
                "pmid26243271",
                "pmid27380243",
                "pmid32919460",
                "pmid20850903",
                "pmid24278306",
                "pmid21899770",
                "pmid35641311",
                "pmid16055944",
                "pmid22300950",
                "pmid34958910"
            ]
        },
        "genetic_214": {
            "question": "Which gene's regulation by BIN1 is implicated in the inflammatory response during Alzheimer's disease pathogenesis?",
            "answer": "**Answer: A. Ifitm3**\n\nThe correct answer is **Ifitm3**, as the study indicates that BIN1 regulates its expression, which is involved in the inflammatory response during Alzheimer's disease.\n\nNew Answer: The gene whose regulation by BIN1 is implicated in the inflammatory response during Alzheimer's disease pathogenesis is **Ifitm3**. \n\n**Answer:** A. Ifitm3",
            "pmid": [
                "pmid35526014",
                "pmid23399914",
                "pmid29479533",
                "pmid32657270",
                "pmid32727516",
                "pmid23948886",
                "pmid23226438",
                "pmid32925027",
                "pmid34966527",
                "pmid12740599"
            ]
        },
        "genetic_215": {
            "question": "Which of the following genes are identified as Alzheimer's disease-related immune hub genes?",
            "answer": "D. PIK3R1",
            "pmid": [
                "pmid34966527",
                "pmid32925027",
                "pmid34719321",
                "pmid34975305",
                "pmid30319691",
                "pmid10319892",
                "pmid33446646",
                "pmid12116197",
                "pmid34864659",
                "pmid30820047"
            ]
        },
        "genetic_216": {
            "question": "Which BDNF SNPs were significantly associated with measures of cognitive decline?",
            "answer": "The context mentions a study where rs1157659, rs11030094, and rs11030108 were significantly associated with cognitive decline. These correspond to option B.\n\n**Answer: B**\n\nNew Answer:\n\nBased on the provided context, the correct answer is option B: rs1157659, rs11030094, and rs11030108 are significantly associated with measures of cognitive decline. \n\nThe New Answer is:\n\nB",
            "pmid": [
                "pmid15635706",
                "pmid15375678",
                "pmid14730194",
                "pmid24086677",
                "pmid18848371",
                "pmid28269768",
                "pmid22833209",
                "pmid27336024",
                "pmid31985465",
                "pmid19342053"
            ]
        },
        "genetic_217": {
            "question": "Which single nucleotide polymorphism (SNP) in the ATP7B gene showed a significant association with Alzheimer's disease under a recessive model?",
            "answer": "The study in pmid23830383 identified that rs1801249 in the ATP7B gene showed a significant association with Alzheimer's disease under a recessive model.\n\nC. rs1801249",
            "pmid": [
                "pmid29441941",
                "pmid25273678",
                "pmid23830383",
                "pmid24141082",
                "pmid21760992",
                "pmid23948886",
                "pmid15288432",
                "pmid23556446",
                "pmid29782324",
                "pmid25130782"
            ]
        },
        "genetic_218": {
            "question": "Which allele of the NEP gene locus rs701109 may be a potential risk factor for Alzheimer's disease in Tibetan males?",
            "answer": "The correct answer based on the provided context is:\n\n**D. Allele C**\n\nThis conclusion is drawn directly from pmid33314757, which specifies that allele C of rs701109 may be a risk factor for AD in Tibetan males.\n\nAnswer: D",
            "pmid": [
                "pmid33314757",
                "pmid20376800",
                "pmid15860464",
                "pmid19250583",
                "pmid25130782",
                "pmid15784960",
                "pmid15548496",
                "pmid37544578",
                "pmid29432188",
                "pmid29441941"
            ]
        },
        "genetic_219": {
            "question": "Which gene variant was identified in a sub-cohort of VCI patients?",
            "answer": "The gene variant identified in a sub-cohort of VCI patients is **C. COL4A1**.\n\nAnswer: C.",
            "pmid": [
                "pmid35307828",
                "pmid37898691",
                "pmid27314523",
                "pmid38935518",
                "pmid36754567",
                "pmid23186985",
                "pmid33152005",
                "pmid37201029",
                "pmid24899047",
                "pmid29478862"
            ]
        },
        "genetic_220": {
            "question": "Does the 647C variant of the ENT1 (SLC29A1) gene have an association with alcohol withdrawal seizures?",
            "answer": "The 647C variant of the ENT1 gene was found to have an association with alcohol withdrawal seizures at a nominally significant level in human subjects.\n\n**Answer: C. Yes, at a nominally significant level.**",
            "pmid": [
                "pmid21283641",
                "pmid12374639",
                "pmid9024952",
                "pmid11204345",
                "pmid15996968",
                "pmid12513948",
                "pmid11912074",
                "pmid16314883",
                "pmid20002020",
                "pmid36198764"
            ]
        },
        "genetic_221": {
            "question": "Which molecule, increased in Alzheimer's disease, negatively regulates synaptotagmin 1 (SYT1) through the ROS-JNK-p53 pathway?",
            "answer": "The correct answer is **A. miR-34c**. According to the provided context, miR-34c is increased in Alzheimer's disease and negatively regulates synaptotagmin 1 (SYT1) through the ROS-JNK-p53 pathway.\n\nAnswer: A",
            "pmid": [
                "pmid32092796",
                "pmid27235866",
                "pmid34026326",
                "pmid29378298",
                "pmid24604632",
                "pmid15548589",
                "pmid29643768",
                "pmid26258756",
                "pmid34992508",
                "pmid37018887"
            ]
        },
        "genetic_222": {
            "question": "Which gene was identified as an interactor of Drosophila VAPB in the genetic screen?",
            "answer": "The correct answer is A. alsin2, as it was identified as an interactor of Drosophila VAPB in a genetic screen.\n\n**Answer: A. alsin2**",
            "pmid": [
                "pmid25361581",
                "pmid20940299",
                "pmid25826266",
                "pmid23409049",
                "pmid34650206",
                "pmid36764521",
                "pmid19286253",
                "pmid35965317",
                "pmid11771742",
                "pmid32107387"
            ]
        },
        "genetic_223": {
            "question": "Which genotype of the CHI3L1 rs4950928 C>G polymorphism is associated with a reduced risk of Alzheimer's disease?",
            "answer": "The correct answer is **B. CG+GG**, as these genotypes are associated with a reduced risk of Alzheimer's disease according to the study. \n\nAnswer: B.",
            "pmid": [
                "pmid30223258",
                "pmid18562794",
                "pmid16223550",
                "pmid25273678",
                "pmid12807963",
                "pmid28084078",
                "pmid29441941",
                "pmid28477215",
                "pmid22382309",
                "pmid22890094"
            ]
        },
        "genetic_224": {
            "question": "Which gene encodes the alpha7 nicotinic acetylcholine receptor and has been implicated in various psychiatric and behavioral disorders, including schizophrenia?",
            "answer": "The gene that encodes the alpha7 nicotinic acetylcholine receptor and has been implicated in psychiatric disorders like schizophrenia is **CHRNA7**. This conclusion is supported by the context provided, which explicitly links CHRNA7 to these conditions.\n\n**Answer: B. CHRNA7**",
            "pmid": [
                "pmid25701707",
                "pmid28045139",
                "pmid21873960",
                "pmid11278378",
                "pmid34650206",
                "pmid27069875",
                "pmid25019689",
                "pmid34521861",
                "pmid30248905",
                "pmid11723200"
            ]
        },
        "genetic_225": {
            "question": "What was discovered from tumor samples using in silico analysis?",
            "answer": "C. Three predicted pathogenic variants.\n\n**Answer:** C",
            "pmid": [
                "pmid36292984",
                "pmid36793390",
                "pmid20442453",
                "pmid23691268",
                "pmid34152079",
                "pmid10377009",
                "pmid18430995",
                "pmid17537576",
                "pmid29670360",
                "pmid36899394"
            ]
        },
        "genetic_226": {
            "question": "Which miRNA was identified as a potentially good candidate for treating both Alzheimer's disease and breast cancer?",
            "answer": "The correct answer is D. miR-107, as it was identified in the context of being a candidate for both conditions.\n\n**Answer: D. miR-107**",
            "pmid": [
                "pmid37487248",
                "pmid34945753",
                "pmid18234899",
                "pmid37212107",
                "pmid31608105",
                "pmid26398571",
                "pmid34224891",
                "pmid22926857",
                "pmid23034144",
                "pmid35154541"
            ]
        },
        "genetic_227": {
            "question": "Which genetic factor, when found with elevated blood MCP-1 levels, is associated with an increased risk of Alzheimer's disease?",
            "answer": "The genetic factors associated with increased AD risk when found with elevated MCP-1 levels are:\n\nC. HLA-DRB1 rs9271192-AC/CC  \nD. APOE epsilon4",
            "pmid": [
                "pmid36396603",
                "pmid37841863",
                "pmid23432970",
                "pmid30820047",
                "pmid10490699",
                "pmid15649702",
                "pmid25273678",
                "pmid15024730",
                "pmid17284348",
                "pmid15288432"
            ]
        },
        "genetic_228": {
            "question": "Which of the following mechanisms may potentially link NPTX2 dysregulation to neurological conditions such as delirium?",
            "answer": "The most appropriate answer based on the contextual information provided is:\n\nD. NPTX2 hypermethylation may suppress p53 signaling, affecting neuronal apoptosis and plasticity.\n\n**Answer:** D",
            "pmid": [
                "pmid30833544",
                "pmid35069913",
                "pmid33896384",
                "pmid38566855",
                "pmid29311807",
                "pmid31463415",
                "pmid22581365",
                "pmid21271304",
                "pmid20817067",
                "pmid37313848"
            ]
        },
        "genetic_229": {
            "question": "Which of the following genes showed a positive correlation with gamma delta T cell expression?",
            "answer": "The provided context does not mention any of the genes listed (CXCL10, CXCL13, S100A2, CXCL11) in relation to gamma delta T cell expression. Based on the information given:\n\n**Answer:** UNRELATED",
            "pmid": [
                "pmid22348086",
                "pmid37591521",
                "pmid31755616",
                "pmid39243388",
                "pmid16516271",
                "pmid17255335",
                "pmid19893026",
                "pmid18367332",
                "pmid10817926",
                "pmid12119423"
            ]
        },
        "genetic_230": {
            "question": "Which gene associated with Alzheimer's disease is upregulated by a constitutively active IRF3 in microglia?",
            "answer": "The correct answer is:\n\n**A. Apolipoprotein-e**\n\nThis conclusion is based on the context provided, which states that a constitutively active IRF3 (IRF3-2D) induces the expression of genes associated with Alzheimer's disease, including apolipoprotein-e.",
            "pmid": [
                "pmid39215356",
                "pmid38654824",
                "pmid36964897",
                "pmid28856571",
                "pmid36798226",
                "pmid34966527",
                "pmid19893026",
                "pmid33402227",
                "pmid33446646",
                "pmid36613460"
            ]
        },
        "genetic_231": {
            "question": "What optimal cutoff value of DAO levels distinguishes Alzheimer's disease patients from healthy controls with high sensitivity and specificity?",
            "answer": "The optimal cutoff value of DAO levels that distinguishes Alzheimer's disease patients from healthy controls with high sensitivity (0.842) and specificity (0.889) is **30.10**.\n\n**Answer: C. 30.10**",
            "pmid": [
                "pmid29093468",
                "pmid35430632",
                "pmid28858444",
                "pmid14596852",
                "pmid12873803",
                "pmid37343463",
                "pmid20202480",
                "pmid22785394",
                "pmid25364236",
                "pmid8761018"
            ]
        },
        "genetic_232": {
            "question": "Which of the following best describes the relationship between MMP9 and delirium based on current experimental findings?",
            "answer": "D",
            "pmid": [
                "pmid38937571",
                "pmid39604493",
                "pmid37722373",
                "pmid38223851",
                "pmid39519398",
                "pmid33779822",
                "pmid35017578",
                "pmid34887385",
                "pmid38796964",
                "pmid19309018"
            ]
        },
        "genetic_234": {
            "question": "Which of the following best describes the relationship between CCKAR gene polymorphisms and delirium tremens?",
            "answer": "The correct answer is:\n\n**D. No direct genetic association has been established; only a statistical link with hallucination in delirium tremens was observed.**\n\n**Explanation:**\nThe context indicates that CCKAR gene polymorphisms, particularly at the -85 locus, show a statistical association with hallucinations in delirium tremens but do not establish a direct causal relationship with DT itself. The studies highlight specific symptom associations rather than confirming a direct genetic cause for delirium tremens.",
            "pmid": [
                "pmid17250608",
                "pmid10235270",
                "pmid12198366",
                "pmid19219710",
                "pmid10803770",
                "pmid29478862",
                "pmid33779822",
                "pmid11513220",
                "pmid20002020",
                "pmid16314883"
            ]
        },
        "genetic_235": {
            "question": "What is the effect of miR-6775 on the CHRNA7 gene?",
            "answer": "The contextual information provided does not mention miR-6775 or its effect on the CHRNA7 gene.\n\nAnswer: UNRELATED",
            "pmid": [
                "pmid25701707",
                "pmid22479251",
                "pmid22348086",
                "pmid26398571",
                "pmid24604632",
                "pmid23034144",
                "pmid33361033",
                "pmid37300691",
                "pmid22099153",
                "pmid29286086"
            ]
        },
        "genetic_236": {
            "question": "Which genotypes of the miR-148 rs4719839 single nucleotide polymorphism (SNP) were more prone to VAP?",
            "answer": "The context directly states that AA/AG genotypes were more prone to VAP. \n\n**Answer: B. AA/AG genotypes**",
            "pmid": [
                "pmid32940422",
                "pmid25390694",
                "pmid22348086",
                "pmid26491656",
                "pmid27583919",
                "pmid23830383",
                "pmid21283641",
                "pmid22890094",
                "pmid38894884",
                "pmid26058807"
            ]
        },
        "genetic_237": {
            "question": "Which gene polymorphism was studied in relation to delirium tremens in alcoholics?",
            "answer": "The gene polymorphism studied in relation to delirium tremens (DT) in alcoholics is **SLC6A4**. \n\nANSWER: D. SLC6A4",
            "pmid": [
                "pmid20002020",
                "pmid17250608",
                "pmid16314883",
                "pmid19309018",
                "pmid29478862",
                "pmid19219710",
                "pmid16356644",
                "pmid19899572",
                "pmid33779822",
                "pmid21554332"
            ]
        },
        "genetic_238": {
            "question": "According to the study, how are growth hormone (GH) levels associated with delirium?",
            "answer": "D. High levels of GH are associated with delirium.\n\nAnswer: D",
            "pmid": [
                "pmid33014722",
                "pmid21766035",
                "pmid10473937",
                "pmid29605680",
                "pmid21294938",
                "pmid17234821",
                "pmid15660412",
                "pmid33336596",
                "pmid37754219",
                "pmid21438141"
            ]
        },
        "genetic_239": {
            "question": "How does APOE epsilon4 status influence the relationship between CRP and delirium incidence?",
            "answer": "A: APOE epsilon4 carriers show a stronger association between high CRP and delirium incidence.\n\nAnswer: A",
            "pmid": [
                "pmid19910874",
                "pmid26901792",
                "pmid31761478",
                "pmid17728664",
                "pmid28868067",
                "pmid17203511",
                "pmid23969090",
                "pmid17540481",
                "pmid17133176",
                "pmid27122004"
            ]
        },
        "genetic_240": {
            "question": "What biomarkers were found to have significant associations with ICU delirium in the pooled analysis?",
            "answer": "The pooled analysis identified amyloid beta-peptide 1-40, interleukin (IL)-1 receptor antagonist, and IL-6 as significantly associated with ICU delirium. \n\n**Answer: B. Amyloid beta-peptide 1-40, interleukin (IL)-1 receptor antagonist, and IL-6**",
            "pmid": [
                "pmid34195769",
                "pmid34912245",
                "pmid17234821",
                "pmid22903241",
                "pmid35791660",
                "pmid33794468",
                "pmid38566855",
                "pmid34098376",
                "pmid31896448",
                "pmid31770149"
            ]
        },
        "genetic_241": {
            "question": "According to the study, what difference was observed in IGF-I levels between delirious and non-delirious groups?",
            "answer": "B. IGF-I levels were significantly lower in the delirious group.\n\nAnswer:  \n**B. IGF-I levels were significantly lower in the delirious group.**",
            "pmid": [
                "pmid21766035",
                "pmid19269948",
                "pmid15660412",
                "pmid29605680",
                "pmid21294938",
                "pmid26846868",
                "pmid17234821",
                "pmid33014722",
                "pmid28360657",
                "pmid20471115"
            ]
        },
        "genetic_242": {
            "question": "In both mice and humans after surgery, how did YKL-40 levels change in plasma versus cerebrospinal fluid (CSF)?",
            "answer": "D. Plasma YKL-40 increased, and CSF YKL-40 decreased.\n\n**Answer:** D",
            "pmid": [
                "pmid36457825",
                "pmid6160732",
                "pmid39505249",
                "pmid28848542",
                "pmid32276479",
                "pmid3165303",
                "pmid33409674",
                "pmid39839987",
                "pmid8327146",
                "pmid38895540"
            ]
        },
        "genetic_243": {
            "question": "According to the text, what does sustained dopamine D2 receptor (D2R) signaling in the hippocampal formation induce?",
            "answer": "C. Apoptosis",
            "pmid": [
                "pmid29311807",
                "pmid24914776",
                "pmid12391586",
                "pmid20142804",
                "pmid23962032",
                "pmid21088470",
                "pmid16817206",
                "pmid24852225",
                "pmid20977891",
                "pmid8725383"
            ]
        },
        "genetic_244": {
            "question": "According to the study, what function does the SLC7A11 subunit perform?",
            "answer": "The study indicates that the SLC7A11 subunit mediates glutamate release. \n\nAnswer: B. It mediates glutamate release.",
            "pmid": [
                "pmid35450293",
                "pmid35986919",
                "pmid32572762",
                "pmid33428810",
                "pmid34026845",
                "pmid23667698",
                "pmid17301176",
                "pmid31520071",
                "pmid23559013",
                "pmid32257549"
            ]
        },
        "genetic_245": {
            "question": "What factor is associated with greater delirium severity at baseline in individuals with dementia?",
            "answer": "UNRELATED",
            "pmid": [
                "pmid27122004",
                "pmid21488579",
                "pmid37566435",
                "pmid17728664",
                "pmid28868067",
                "pmid26901792",
                "pmid17203511",
                "pmid29966197",
                "pmid37812498",
                "pmid17183425"
            ]
        },
        "genetic_246": {
            "question": "What correlation do PER2 and HO1 expression levels have with delirium?",
            "answer": "D. High expression levels increased the odds of delirium occurrence.",
            "pmid": [
                "pmid34321570",
                "pmid33779822",
                "pmid17234821",
                "pmid32650186",
                "pmid34192631",
                "pmid26901792",
                "pmid37851904",
                "pmid28868067",
                "pmid37722373",
                "pmid19309018"
            ]
        },
        "genetic_247": {
            "question": "What effect does downregulation of RXRA have on delirium in mice with COPD?",
            "answer": "The downregulation of RXRA in mice with COPD reduces the delirium state by decreasing endoplasmic reticulum stress and cell apoptosis.\n\n**Answer:** C. It reduces the delirium state by decreasing endoplasmic reticulum stress and cell apoptosis.",
            "pmid": [
                "pmid38372090",
                "pmid37968531",
                "pmid27760517",
                "pmid36216079",
                "pmid24990154",
                "pmid37596640",
                "pmid37313848",
                "pmid29489460",
                "pmid22683080",
                "pmid32705282"
            ]
        },
        "genetic_248": {
            "question": "In individuals who died from cocaine-related causes, how does heat shock protein 70 (HSP70) expression in the brain compare to control subjects?",
            "answer": "C. HSP70 expression is significantly increased.",
            "pmid": [
                "pmid22803793",
                "pmid8386339",
                "pmid19541436",
                "pmid10581411",
                "pmid12684441",
                "pmid3165303",
                "pmid8327146",
                "pmid10415668",
                "pmid12064476",
                "pmid8988571"
            ]
        },
        "genetic_249": {
            "question": "What effect does CCR5 deficiency have on neurons?",
            "answer": "The context provided consistently indicates that CCR5 deficiency decreases neuronal resilience to oxidative stress. Studies show increased vulnerability, cell death under oxidative conditions, and enhanced neuroinflammation in CCR5-deficient models. \n\nAnswer: D. It decreases neuronal resilience to oxidative stress.",
            "pmid": [
                "pmid37489764",
                "pmid26910914",
                "pmid19394434",
                "pmid38942352",
                "pmid35889920",
                "pmid15288441",
                "pmid39072940",
                "pmid10662826",
                "pmid8725383",
                "pmid23559013"
            ]
        },
        "genetic_251": {
            "question": "What role does D-amino acid oxidase (DAO) play in the context of N-methyl-D-aspartate receptor (NMDAR) function?",
            "answer": "The role of D-amino acid oxidase (DAO) in the context of N-methyl-D-aspartate receptor (NMDAR) function is to regulate it by degrading D-amino acids that are related to NMDAR activity. Specifically, DAO breaks down D-amino acids such as D-serine, which act as coagonists at the glycine site of NMDARs. When DAO levels increase, it reduces these D-amino acids, leading to decreased NMDAR activation and hypofunction. This regulation is evident in conditions like Alzheimer's disease and mild cognitive impairment where elevated DAO levels correlate with reduced NMDAR activity.\n\n**Answer: B. DAO regulates NMDAR function by degrading NMDAR-related D-amino acids.**\n\nNew Answer: The answer based on the provided context is B.",
            "pmid": [
                "pmid29093468",
                "pmid37343463",
                "pmid31520071",
                "pmid35430632",
                "pmid12203047",
                "pmid21351586",
                "pmid32425755",
                "pmid34294612",
                "pmid11181824",
                "pmid24771316"
            ]
        },
        "genetic_252": {
            "question": "Were polymorphisms in the COMT gene associated with delirium?",
            "answer": "C: No, polymorphisms in the COMT gene were not associated with the development of delirium.",
            "pmid": [
                "pmid21613790",
                "pmid33779822",
                "pmid19309018",
                "pmid17250608",
                "pmid22759724",
                "pmid19219710",
                "pmid31046593",
                "pmid20002020",
                "pmid15488308",
                "pmid29478862"
            ]
        },
        "genetic_253": {
            "question": "Which genetic factors interacting decreases the likelihood of delirium tremens in alcoholics?",
            "answer": "The correct answer is B: DRD2 rs6276 G allele and SLC6A4 LL genotype.\n\n**Answer:** B",
            "pmid": [
                "pmid20002020",
                "pmid17250608",
                "pmid19309018",
                "pmid19219710",
                "pmid33779822",
                "pmid29478862",
                "pmid9024952",
                "pmid12513948",
                "pmid15996968",
                "pmid16314883"
            ]
        },
        "genetic_254": {
            "question": "What is the effect of disrupting the VCAM1-ApoE interaction on microglial Abeta chemotaxis?",
            "answer": "The disruption of the VCAM1-ApoE interaction stops microglia from moving towards Abeta plaques, thus abolishing chemotaxis.\n\nAnswer: C. It abolishes microglial Abeta chemotaxis.",
            "pmid": [
                "pmid37735240",
                "pmid37603311",
                "pmid23229789",
                "pmid31982468",
                "pmid34299330",
                "pmid20634578",
                "pmid38957539",
                "pmid12927763",
                "pmid19519664",
                "pmid21159979"
            ]
        },
        "genetic_255": {
            "question": "What happens to D2 concentration in cerebrospinal fluid during recovery from delirium tremens?",
            "answer": "The concentration of D2 in cerebrospinal fluid (CSF) increases to double its normal value during recovery from delirium tremens.\n\n**Answer: C. It increases to double its normal value.**",
            "pmid": [
                "pmid6160732",
                "pmid27058253",
                "pmid3765988",
                "pmid549538",
                "pmid7211435",
                "pmid2524220",
                "pmid39355007",
                "pmid38566855",
                "pmid39419070",
                "pmid37851904"
            ]
        },
        "genetic_256": {
            "question": "What is the function of the DRD4 receptor?",
            "answer": "The function of the DRD4 receptor is described in the context as influencing the postsynaptic action of dopamine and being involved in various neurological processes. This aligns with option B.\n\n**Answer:** B. It influences the postsynaptic action of dopamine and is implicated in many neurological processes.",
            "pmid": [
                "pmid21873960",
                "pmid30248905",
                "pmid30481567",
                "pmid35297520",
                "pmid22934024",
                "pmid14682360",
                "pmid35771831",
                "pmid12391586",
                "pmid19235789",
                "pmid19899572"
            ]
        },
        "genetic_257": {
            "question": "What role might galectin-3 play in delirium among postpartum ICU women?",
            "answer": "The role of galectin-3 in delirium among postpartum ICU women, as suggested by the context, is that it might serve as a biomarker due to its involvement in the inflammatory process. \n\n**Answer: B. It might serve as a biomarker for predicting delirium, due to its involvement in the inflammatory process underlying delirium-related brain injury.**",
            "pmid": [
                "pmid28828226",
                "pmid33901789",
                "pmid33336596",
                "pmid34900086",
                "pmid33686023",
                "pmid35815182",
                "pmid21294938",
                "pmid28360657",
                "pmid17234821",
                "pmid37133446"
            ]
        },
        "genetic_258": {
            "question": "Considering the role of dipeptidyl peptidase 4 (DPP4) in central nervous system (CNS) disorders, which of the following statements best reflects its clinical relevance to delirium or delirium-related conditions? ",
            "answer": "The correct answer is:\n\n**A. Although DPP4 is expressed in the brain, current DPP4 inhibitors do not cross the intact blood-brain barrier and likely exert their beneficial effects on delirium-related conditions through peripheral mechanisms.**\n\n**Explanation:**\n- The provided context indicates that DPP4 is involved in various CNS disorders but notes that current DPP4 inhibitors cannot penetrate the blood-brain barrier. Thus, any benefits observed are attributed to peripheral actions rather than direct brain modulation.\n- Other options either misrepresent the mechanism (B), suggest worsening of conditions without evidence (C), or ignore established roles in neurodegenerative diseases (D).",
            "pmid": [
                "pmid35771831",
                "pmid25723507",
                "pmid39773090",
                "pmid29353063",
                "pmid37313848",
                "pmid29451201",
                "pmid38566855",
                "pmid20309566",
                "pmid38937571",
                "pmid32018069"
            ]
        }
    }
}